

17th International Congress on Infectious Diseases

HYDERABAD • INDIA • MARCH 2~5, 2016



Organized by the
International Society for Infectious Diseases

Supported By



Final Program



ProMED mail

Program for Monitoring Emerging Diseases



What is ProMED?

- ☐ A global expert network of infectious disease and public health specialists.
- ☐ The organization that first reported the outbreak of SARS in 2003 and another new coronavirus in 2012.
- ☐ A FREE emerging diseases alert system that reaches 65,000 subscribers in 190 countries worldwide in multiple languages.
- ☐ The world's first infectious disease social network, with its own website, Twitter feed, and Facebook pages.




ALL OF THE ABOVE

For a FREE subscription to ProMED-mail email alerts, go to www.promedmail.org and click on subscribe.



Sponsored by the International Society for Infectious Diseases



17th International Congress on Infectious Diseases

HYDERABAD, INDIA

MARCH 2~5, 2016

FINAL PROGRAM



Table of Contents

Welcome by the ISID	1
Welcome by the National Organizing Committee	2
Time Schedule	3
International Society for Infectious Diseases (ISID)	4
ISID Governance	5
Members of the ISID Council	5
Congress Committees	6
Congress Information	6
In Memoriam ~ Dr. Suniti Solomon	7
Awards	8
Acknowledgements	11
General Information	12
ISID Business Meeting	14
Slide Preview Room	14
Poster Presentations	14
Meet-the-Expert	16
CME Accreditation	16
Commercial Exhibition	17
Plenary Lectures	18
Trainee Track	20
Pre-Congress Workshops	21
Schedule at-a-Glance	22
Floorplans	24
Opening Ceremony	27
Scientific Program	26
Wednesday, March 2, 2016	26
Thursday, March 3, 2016	28
Friday, March 4, 2016	33
Saturday, March 5, 2016	38
Poster Presentations	42
Thursday, March 3, 2016	42
Friday, March 4, 2016	60
Saturday, March 5, 2016	78
Index of Authors and Co-Authors	95
Disclosures	109
Notes	125



Welcome by the ISID



Dear Members, Colleagues, Sponsors and Friends,

It is with great pleasure that I welcome you to Hyderabad and to the 17th International Congress on Infectious Diseases. This meeting is especially noteworthy as it is the very first time that the meeting has been held in India, a country of 1.25 billion people with all the healthcare challenges that that implies, and I am really pleased that we will have an opportunity to share knowledge and experience with colleagues from right across South Asia, as well as representatives from more than 160 countries worldwide.

I would also like to take this opportunity to express my profound thanks to Prof. Ramanan Laxminarayan and his colleagues on the National Organizing Committee. Together with Dr. Britta Lassmann, our Program Director, and the International Committee, they have put together a truly outstanding program.

One of the things that struck me when I came to my first ICID, and which persuaded me to become involved with the Society, was the genuine sense of friendship and collegiality that existed between colleagues from hugely diverse backgrounds and experiences. This is what helps to make this meeting unique, and I urge you to take advantage of the opportunity to speak to friends and colleagues, junior and senior, and share your experiences and knowledge.

But also—don't miss out on the city of Hyderabad, a fascinating, vibrant place with an extraordinary history. There is much to see and do and I hope you find your time here enjoyable and interesting as well as intellectually fulfilling.

Welcome to Hyderabad and the 17th ICID!

Jon Cohen

President, International Society for Infectious Diseases (ISID)





Welcome by the National Organizing Committee



Dear Friends,

My colleagues on the National Organizing Committee and I are delighted to welcome you to the 17th ICID from March 2nd to the 5th in the stately city of Hyderabad. We are grateful to the International Society for Infectious Diseases for bringing the International Congress on Infectious Diseases to the Indian sub-continent for the very first time.

The sub-continent is host to both a range of infectious diseases and of active research to combat them. We have an exciting scientific program to offer at this meeting that covers a range of issues of particular relevance to the Indian sub-continent including malaria, typhoid, dengue, tuberculosis, antimicrobial resistance and health-care associated infections, as well as global infectious disease threats.

We hope you enjoy your time in Hyderabad, a city that blends the ancient and stately, best characterized by the Charminar and the Golconda Fort; and the new, as represented by the many of the world's leading information technology and biotech companies that call the city home.

We welcome you to India! We hope you have a wonderful experience and are tempted to return soon.

Warm wishes,

Ramanan Laxminarayan

Distinguished Professor, Public Health Foundation of India (PHFI)

Director and Senior Fellow, Center for Disease Dynamics, Economics & Policy





Time Schedule

Congress Registration and Information	9:00 – 19:00	Wednesday March 2, 2016
	8:00 – 18:00	Thursday March 3, 2016
	8:00 – 18:00	Friday March 4, 2016
	8:00 – 18:00	Saturday March 5, 2016
Pre-Congress Workshops	13:00 – 17:00	Wednesday March 2, 2016
Opening Ceremony	18:30 – 20:00	Wednesday March 2, 2016
Welcome Reception	20:00 – 21:30	Wednesday March 2, 2016
Scientific Sessions	9:00 – 17:45	Thursday March 3, 2016 through Saturday March 5, 2016
Poster Sessions	12:45 – 14:15	Thursday March 3, 2016 through Saturday March 5, 2016
Meet-the-Expert Sessions	7:45 – 8:45	Thursday March 3, 2016 through Saturday March 5, 2016
Business Meeting (<i>lunch provided</i>)	12:45 – 13:45	Saturday March 5, 2016
Commercial Exhibition	9:00 – 16:30	Thursday March 3, 2016
	9:00 – 16:30	Friday March 4, 2016
	9:00 – 16:00	Saturday March 5, 2016



The **International Society for Infectious Diseases**—with more than 70,000 members representing every country in the world—is a non-profit organization committed to the control of infectious diseases around the globe with an emphasis on countries that disproportionately bear the burden of infectious diseases. www.isid.org

Recognizing that infectious diseases cross all national and regional boundaries and that effective solutions require international scientific exchange and cooperation, ISID's goals are to:

- Promote the exchange of information and the sharing of knowledge amongst the international infectious diseases community;
- Focus the attention of the international infectious diseases community on countries that disproportionately bear the burden of infectious diseases;
- Foster a global perspective among members of the international community as they set infectious disease priorities;
- Increase our understanding of infectious diseases by supporting scientific investigation and disseminating the results of research;
- Provide opportunities that enhance the professional development of individuals in the discipline; and
- Create and promote international partnerships for the control and management of infectious diseases around the world.

Any individual interested in international infectious diseases may become a member of the Society. There is no membership fee. www.isid.org/membership/index.shtml

The Society's wide range of activities include:

- The **International Congress on Infectious Diseases (ICID)** that takes place every two years in a different region of the world. www.isid.org/icid/
- The **International Meeting on Emerging Diseases and Surveillance (IMED)**. www.imed.isid.org/
- Fellowship and grant programs, including the **ISID Research Grant Program** to fund pilot research projects or training of young investigators from resource-limited countries; the **ISID Travel Grants** to support young investigators to present their work at the ICID or IMED; the **ISID/ESCMID Fellowship Program**, in collaboration with the European Society of Clinical Microbiology and Infectious Diseases, to enable multidisciplinary clinical and laboratory training abroad; and the **SSI/ISID Fellowship Program**, in collaboration with the Swiss Society for Infectious Diseases, to support infectious disease physicians and scientists from low- and middle-income countries through multidisciplinary clinical and laboratory training at select biomedical institutions in Switzerland. www.isid.org/grants/grants.shtml
- ISID's **Emerging Leaders in International Infectious Diseases** are promising early career colleagues who join one of ISID's committees to get familiar with ISID's work and to connect with colleagues around the world.
- The **International Journal of Infectious Diseases (IJID)**, a peer-reviewed, open access journal that publishes original clinical and laboratory-based research, together with reports of clinical trials, reviews, and case reports dealing with the epidemiology, clinical diagnosis, treatment, and control of infectious diseases with particular emphasis placed on those diseases that are most common in under-resourced countries. www.ijidonline.com
- The **Guide to Infection Control in the Hospital** contains up-to-date principles and interventions designed to reduce the rate of nosocomial infections, explain key principles and guidelines for reducing the rate of nosocomial infections and practical measures intended to improve quality of care, minimize risk, save lives, and reduce costs. www.isid.org/publications/guide_infection_contr.shtml
- The **Program for Monitoring Emerging Diseases (ProMED)** is one of the largest publicly available emerging disease and outbreak alert systems in the world. ProMED publishes real-time, around the clock reports of infectious disease outbreaks and toxic exposure incidents with commentaries from a worldwide staff of expert moderators. ProMED follows the One Health concept of covering emerging diseases and toxin exposures in plant, animal, wildlife and humans. One of the early innovators in using non-traditional/informal information sources to identify unusual health events around the world, ProMED-mail emphasizes transparency, is open to all sources, is free of political constraints, and is available to anyone free of charge. ProMED currently reaches over 70,000 subscribers in more than 185 countries. In addition to the generally focused English version, ProMED is also available in several languages and as regional networks. www.promedmail.org



ISID Governance

The Society is governed by a Council that is elected by the membership. The Council is organized according to geographic regions to ensure representation from all areas of the world. The membership, upon the recommendation of the Council, also approves the composition of the Executive Committee and its officers. The Executive Committee of the Society is charged with overall responsibility for the Society's activities. Executive Committee and council members serve on the Research, Education and Publication, External Affairs, ProMED, Finance and Nominations Sub-Committees.

Members of the ISID Council:

Laith J. Abu-Raddad, *Qatar*
 Mohannad A.A. Al-Nsour, *Jordan*
 Zeinab Hassan Al-Wahsh, *Jordan*
 Ramy Karam Aziz, *Egypt*
 Zulfiqar Bhutta, *Pakistan*
 Paul Brown, *Jamaica*
 Philippe Buchy, *Singapore*
 Francois Caron, *France*
 Sergio Cimerman, *Brazil*
 Onder Ergonul, *Turkey*
 Teshome Gebre, *Ethiopia*
 Maria G. Guzman, *Cuba*
 Nii Hanson-Nortey, *Ghana*
 Aikichi Iwamoto, *Japan*
 Gagandeep Kang, *India*
 Sasisopin Kiertiburanakul, *Thailand*
 Vladimir Krčmery, *Slovak Republic*
 Claudio Lanata, *Peru*
 S.S. Lee, *Hong Kong*
 Hsieh-Shong Leu, *Taiwan*
 Poh Lian Lim, *Singapore*
 Shabir A. Madhi, *South Africa*
 Neelika Malavige, *Sri Lanka*
 Francois-Xavier Mbopi-Keou, *Cameroon*
 Shaheen Mehtar, *South Africa*
 Paul Newton, *Laos*
 Hanna Nohynek, *Finland*
 Alaine Umubyeyi Nyaruhirira, *Rwanda*
 Miguel O'Ryan, *Chile*
 Didier Pittet, *Switzerland*
 Ranjan Premaratna, *Sri Lanka*
 Guillermo Ruiz Palacios, *Mexico*
 Samir Saha, *Bangladesh*
 Papa Salif Sow, *Senegal*
 Roberto Salvino, *Philippines*
 Eduardo Savio, *Uruguay*
 Patricia Schlagenhauf, *Switzerland*
 Yupin Suputtamongkol, *Thailand*
 Sally Roberts, *New Zealand*
 Paul Anantharajah Tambyah, *Singapore*
 Ursula Theuretzbacher, *Austria*

2014–2016

ISID Executive Committee:

Jonathan Cohen, *United Kingdom*
 Ron Dagan, *Israel*
 Rana Hajjeh, *USA*
 Alison Holmes, *United Kingdom*
 Adeeba Kamarulzaman, *Malaysia*
 Keith Klugman, *USA*
 Ramanan Laxminarayan, *India*
 Ziad Memish, *Saudi Arabia*
 Marc Mendelson, *South Africa*

ISID's Emerging Leaders in International Infectious Diseases

Seif Al-Abri, *Oman*
 Jaffar Al-Tawfiq, *Saudi Arabia*
 Elizabeth Ashley, *United Kingdom*
 Ruanna Barnabas, *South Africa/US*
 Andre Bulabula, *Democratic Republic of Congo*
 Enrique Castro-Sanchez, *United Kingdom*
 Veasna Duong, *Vietnam*
 Eyal Leshem, *South Africa*
 Ada Lin, *Hong Kong*
 Ira Praharaj, *India*
 Rajiv Sarkar, *India*
 Ly Sowath, *Cambodia*
 Sean Wasserman, *South Africa*



17th INTERNATIONAL CONGRESS ON INFECTIOUS DISEASES

Congress Committees

National Organizing Committee

Ramanan Laxminarayan, *New Delhi, Chair*
Virander S. Chauhan, *New Delhi*
Rajesh S. Gokhale, *New Delhi*
Gagandeep Kang, *Vellore*
Arti Kapil, *New Delhi*
Sanjay Madhav Mehendale, *New Delhi*
Neelika Malavige, *Sri Lanka*
Dilip Mathai, *Hyderabad*
G. Balakrish Nair, *Gurgaon*
Suneetha Narreddy, *Hyderabad*
Ranjan Premaratna, *Sri Lanka*
R.K. Ratho, *Chandigarh*
Camilla Rodrigues, *Mumbai*
Samir K. Saha, *Bangladesh*
Anita Shet, *Bangalore*
Suniti Solomon, *Chennai*
Rajeev Soman, *Mumbai*
Shyam Sundar, *Varanasi*
Soumya Swaminathan, *Chennai*
George M. Varghese, *Vellore*

International Organizing Committee

Jonathan Cohen, *United Kingdom, President*
Ron Dagan, *Israel*
Rana Hajjeh, *USA*
Alison Holmes, *United Kingdom*
Adeeba Kamarulzaman, *Malaysia*
Keith Klugman, *USA*
Britta Lassmann, *USA*
Ramanan Laxminarayan, *India*
Ziad Memish, *Saudi Arabia*
Marc Mendelson, *South Africa*



17th INTERNATIONAL CONGRESS ON INFECTIOUS DISEASES

Congress Information

Congress Site

Hyderabad International
Convention Centre (HICC), India

Official Language

The official language of the Congress is English.
No translation will be provided.

Important Information

Please visit our website www.isid.org/ucid/ for
detailed and updated information on the Congress.

International Society for Infectious Diseases (ISID)

Norman R. Stein, *Executive Director*
Britta Lassmann, *Program Director*
International Society for Infectious Diseases
9 Babcock Street, Unit 3
Brookline, MA 02446, USA
Phone: (617) 277-0551
Fax: (617) 278-9113
Email: info@isid.org
website: www.isid.org

17th ICID Congress Secretariat

Registration & Housing

MCI India
4th Floor, Building No. 18, Sector 44
122003 Gurgaon Haryana
India
Phone: (+91) 124 4974160
Fax: (+91) 124 4108917
Email: ucid16@mci-group.com

Exhibition Management

Media Plan
Freyung 6
1010 Vienna, Austria
Phone: (+43 1) 536 63 0
Fax: (+43 1) 535 60 16
Email: mp@media.co.at

Congress Management Consultant

MTM Meetings Tourism Management
Walter Straub
Dr. Rudolf Streckergerasse 6
2345 Brunn am Gebirge, Austria
Telephone: (+43 2236) 37 99 07
E-mail: w.straub@kabsi.at



Dr. Suniti Solomon ~ 1938–2015

Dr. Suniti Solomon, an eminent physician and microbiologist from India, and a member of the National Organizing Committee of the 17th International Congress on Infectious Diseases passed away on July 28, 2015 in Chennai, India.

Dr. Solomon's name is synonymous with pioneering HIV and AIDS research in the country. In 1986, she and her team at Madras Medical College in Chennai, India, documented for the first time the extent of HIV infection in the country. Her efforts in this area facilitated several policy and programme actions. Dr. Solomon established one of India's first voluntary HIV counselling and testing facilities in 1993 at the Y. R. Gaitonde Centre for AIDS Research and Education, a premier HIV/AIDS care and support centre in Chennai. She was actively involved in the work of the YRG Centre and in HIV education to the end of her life.

With an MD in Microbiology from Madras University, Dr. Solomon trained in pathology in the UK, the USA, and Australia before returning to Chennai in 1973. Her experience covered a wide range of aspects linked to HIV infection, biomedical parameters to socio-economics. She published extensively on HIV epidemiology, prevention, care, support and related gender issues. In 2009, the Ministry of Science and Technology conferred the National Award for Women Bioscientists on Dr. Solomon in recognition of her contributions to the field of HIV/AIDS research in India.

Dr. Solomon will always be remembered for her groundbreaking research and significant contributions towards care and support work in the area of HIV and AIDS in India.



Awards

More than 1,000 abstracts were considered for the award programs. The abstract review process was blinded, which means that authors' names, affiliation and country were not disclosed to the reviewers. Each abstract was reviewed and scored by at least two reviewers - 80 reviewers from 35 countries were involved in the review process. Abstracts were then ranked according to combined reviewer scores and highest scoring abstracts were forwarded to the respective awards committees for consideration. The award winning scientists were selected according to the criteria described on the 17th ICID web page www.isid.org/icid/awards.shtml.

Winners of the Sanofi Pasteur Awards for Communicable Disease Epidemiology



Antonia Ho ~ Institute of Infection and Global Health, University of Liverpool, UK ~ abstract #21.002

Antonia Ho is an infectious diseases physician from Glasgow, Scotland. She holds an MSc in Epidemiology from the London School of Hygiene and Tropical Medicine and an MRes in Clinical Sciences from the University of Liverpool. She was awarded a Wellcome Trust Clinical PhD Fellowship in 2011. Her research focuses on the epidemiology of influenza in sub-Saharan Africa, particularly the impact of HIV infection on the burden and severity of influenza infection in adults in Malawi.



Van Minh Tu Hoang ~ Children's Hospital 2 ~ Ho Chi Minh City, Vietnam ~ abstract #14.001

Van Hoang is a pediatrician who worked in the Infectious Diseases ward and Scientific Research Department, Children's Hospital 2 – Hso Chi Minh City, Vietnam for over 5 years. She participated in studies of dengue fever and hand, foot and mouth disease as a study coordinator before she received a scholarship from the Oxford Clinical Research Unit (OUCRU). She has been a PhD student of the Oxford University since 2014 and currently works on her thesis on hand, foot and mouth disease in the South of Vietnam.

The Sanofi Pasteur Awards will be officially presented during the Opening Ceremony on Wednesday, March 2, 2016 at 18:30hrs.

The ISID gratefully acknowledges the support of SANOFI PASTEUR, which made these awards possible.

Winner of the ISID New Investigator Award



Arunachalam Ramaiah ~ Indian Institute of Science ~ Bangalore, India ~ abstract #21.006

Dr. Ramaiah is presently a Postdoctoral Research Associate working with Prof. Annapurna Vyakarnam at the Centre for Infectious Disease Research, Indian Institute of Science (IISc), Bangalore, India and received a Ph.D. in Bioinformatics (2012) from Manonmaniam Sundaranar University, Tirunelveli, India.

He is actively collaborating with both Indian and Overseas scientists from National Institute for Research in Tuberculosis, Broad Institute, Kings College London, St. John's Research Institute, UCLA and Cedars-Sinai Medical Center. He was admitted as a Visiting Scholar at Abo Akademi University, Finland to pursue part of his Ph.D research as well as to participate in an ongoing major research project under Indo-Finnish Cultural Exchange Programme, followed by his first Postdoctoral research at MS University, India.

The broad goal of his research is to employ bioinformatic and immunological approaches to study the host-pathogen interactions by analyzing the high-throughput sequences generated from pathogens isolated in India, as it is crucial in the context of effective vaccine design and testing.

The ISID New Investigator Award will be officially presented during the Opening Ceremony on Wednesday, March 2, 2016 at 18:30hrs.

Wellcome Trust/DBT India Alliance Poster Awards

The Wellcome Trust/DBT India Alliance Poster Awards recognize high quality research presented in poster format. Finalists were selected based on combined abstract reviewer scores. Each finalist's poster and presentation is judged by two judges at the Congress based on the following criteria:



1. Originality and significance of the research
2. Methods employed
3. Content and layout of the poster
4. Presentation by lead author

Of fifteen poster finalists (see page 15) each day, five will be selected for the **Wellcome Trust/DBT India Alliance Poster Awards**. Each awardee receives an award certificate and a INR 5,000 stipend. Prof. Anita Shet, Poster Competition Coordinator, presents Wellcome Trust/DBT India Alliance Poster Awards to the presenting authors after the afternoon plenary talk each day.



Awards

Elsevier Foundation Travel Grants for Early Career Women Scientists from Low or Lower-Middle Income Countries

The Society gratefully acknowledges the generous support from the Elsevier Foundation.



Enoka Corea
University of Colombo
SRI LANKA
~ abstract # 41.214



Refath Farzana
Khwaja Yunus Ali
Medical College
BANGLADESH
~ abstract # 41.045



Felana Ihantamalala
Pasteur Institute of
Madagascar
MADAGASCAR
~ abstract # 35.003



Hemadri Jayaratne
University of
Sri Jayewardenepura
SRI LANKA
~ abstract # 43.196



Yetunde Oke
Malaria Consortium
NIGERIA
~ abstract # 35.004



Faith Onditi
Institute of Primate
Research (IPR)
KENYA
~ abstract # 35.011



Eniyou Oriero
Medical Research
Council Unit
THE GAMBIA
~ abstract # 41.181



Isatou Sarr
Medical Research
Council Unit
THE GAMBIA
~ abstract # 41.008



Minu Sharma
National Zoonoses and Food
Hygiene Research Centre
(NZFHRC) ~ NEPAL
~ abstract # 43.263



Hiruni Wijesooriya
University of Colombo
SRI LANKA
~ abstract # 43.085

Winners of the ProMED Awards in Emerging Infectious Diseases

The ProMED Awards recognize high quality abstracts submitted in the area of Emerging Infectious Diseases.



Idriss Bomo
Nigeria Field Epidemiology
and Laboratory Training
Program, NIGERIA
~ abstract # 14.008




Micky Mwamuye
University of Nairobi
KENYA
~ abstract # 35.006



Ananda Wijewickrama
Infectious Diseases Hospital
SRI LANKA
~ abstract # 14.003

ISID Research Grantee Travel Award



John Libwea
Expanded Programme
on Immunization,
Central Technical Group,
Department of Planning,
Monitoring & Evaluation
CAMEROON
~ abstract # 42.059

ISID Emerging Leaders in International Infectious Diseases Travel Grants

Andre Bulabula
Provincial Hospital of Bukavu
DEMOCRATIC REPUBLIC OF CONGO
~ abstract #43.097

Sean Wasserman
University of Cape Town
SOUTH AFRICA
~ abstract #42.232



Travel Grant Awards for Young Investigators from India and Southeast Asia

**BILL & MELINDA
GATES foundation**

The Society gratefully acknowledges the generous support from the Bill & Melinda Gates Foundation that enabled these grants.

Sonu Agrawal – Chandigarh, India
Rajiv Ahlawat – Chandigarh, India
Asma Ahmed – Bangalore, India
Harishchander Anandaram – Chennai, India
Shamma Athalye Shetye – Mumbai, India
Priyantha Balasooriya – Colombo, Sri Lanka
Nargis Bali – Soura, India
Kuldeep Bhardwaj – Mumbai, India
Saurabh Bhargava – Kanpur, India
Manisha Biswal – Chandigarh, India
Priyanka Chahar – Rohtak, India
Salesh Chandran – Indore, India
Somdatta Chatterjee – Kolkota, India
Ravi Kumar Chaudhary – Greater Noida, India
Sumi Chetry – Dibrugarh, India
Swathirajan Chinnambedu Ravichandran – Chennai, India
Nargis Choudhury – Silchar, India
Betsy Dass – Chennai, India
Saswati Majumder Datta – Kolkata, India
Akhilandeswarre Dharmaprakash – Thiruvananthapuram, India
Thongadi Ramesh Dinesh – Chennai, India
Pham Doanh – Hanoi, Vietnam
Prasanna Duvvuri – Hyderabad, India
Rajkumari Elizabeth – Silchar, India
Geetanjali Ganguli – Bhubaneswar, India
Ramesh Geetharani – Chennai, India
Selvamurthi Gomathi – Chennai, India
Vishal Goyal – New Delhi, India
M Gunasekaran – Chennai, India
Sonal Gupta – New Delhi, India
Vivek Gupta – Wardha, India
Parakriti Gupta – Chandigarh, India
Anand Ignatius – Mangalore, India
Zhahirul Islam – Dhaka, Bangladesh
Evangeline Jayakumar – Chennai, India
Bharath K Sundararaj – Bangalore, India
Bhuvanesh Kalal – Mangalore, India
Sivasangeetha Kanagasabai – Chennai, India
Ravi Kant – New Delhi, India
Debarshi Kar Mahapatra – Segunderabad, India
Manjeri Kaushik – Rohtak, India
Vidya Krishna – Chennai, India
D R Naveen Kumar – Vellore, India
Manochitra Kumar – Pondicherry, India
Dinesh Kumar – Varanasi, India
Prawin Kumar – New Delhi, India
Raman Mahajan – New Delhi, India
Anirban Mandal – Kolkata, India
Selvin Sundar Raj Mani – Vellore, India
Anand Kumar Maurya – Jodhpur, India

Kayur Mehta – Hyderabad, India
Anshul Mishra – Patna, India
Richa Misra – Lucknow, India
Mayank Modi – Vadodara, India
Lavanya Mohanam – Chennai, India
Sarita Rath Mohapatra – New Delhi, India
Aman Moudgil – Palampur, India
Prashant Mudaliar – Trivandrum, India
Shyam Lal Mudavath – Mohali, India
Swati Mudshingkar – Pune, India
Kalamathy Murugananthan – Kandy, Sri Lanka
Mitha Naik – Trivandrum, India
Nishant Nandanwar – Hyderabad, India
Mukti Nayak – Kolkata, India
Avinash Padhi – Bhubaneswar, India
Kesavaram Padmavathy – Chennai, India
Shashiraja Padukone – Puducherry, India
Apoorva Patel – Bangalore, India
Deepjyoti Paul – Silchar, India
Nagaraj Perumal – Madras, India
Agila Kumari Pragasam – Vellore, India
KV Pramina – Hebbal, India
Asim Priyendu – Mangalore, India
Siva Raghavendhar – New Delhi, India
Niharika Rajnala – Bangalore, India
Srabanti Rakshit – Bangalore, India
Subhasree Roy – Kolkata, India
Mani Sankar – New Delhi, India
Paramita Sarkar – Kolkata, India
Srabasti Sengupta – Bhubaneswar, India
Nasheed Shaikh – Mumbai, India
Priyanka Sharma – New Delhi, India
Irshad Ali Sheikh – Kolkata, India
Namita Singh – New Delhi, India
Ravinder Singh – New Delhi, India
Neetu Singh – Varanasi, India
Taru Singh – New Delhi, India
Kuljit Singh – Patna, India
Bhawana Singh – Varanasi, India
Harkaran Singh – Amritsar, India
Om Prakash Singh – Varanasi, India
Jyotsana Singh – Tiruvalla, India
Ruchi Singh – New Delhi, India
Abhishek Kumar Singh – Varanasi, India
Jitendra Singh – New Delhi, India
Nadeera Siriseena – Kandy, Sri Lanka
Sinosh Skariyachan – Bangalore, India
Dhakshinamoorthy Subashini – Chennai, India
Beula Subashini – Vellore, India
Puja Tiwary – Varanasi, India
Supriya Upadhyay – Shillong, India
Sheetal Verma – Lucknow, India
Ashish Vyas – New Delhi, India



Acknowledgements



The International Organizing Committee would like to take this opportunity to acknowledge the following Benefactors, Sponsors, Contributors, and Cooperating Organizations:

CONGRESS BENEFACTORS



PREMIER SPONSORS



SPONSORS

Bill & Melinda Gates Foundation
Bharat Biotech
Japanese Association for Infectious Disease (JAID)
The Elsevier Foundation
GSK
Sanofi Pasteur
Skoll Global Threats Fund
Takeda Pharmaceutical International
Etihad Airways

CONTRIBUTORS

B. Braun
Sociedade Brasileira de Infectologia (SBI)
British Society for Antimicrobial Chemotherapy (BSAC)
Center for Disease Dynamics, Economics & Policy (CDDEP)
DRIVE-AB — A project of the Innovative Medicines Initiative
The Lancet Infectious Diseases
Nato Grant on Refugee and Migrant Health
South African Field Epidemiology Training Programme (SAFETP)
SLS Cell Cure Technologies
Wellcome Trust/DBT India Alliance

COOPERATING ORGANIZATIONS

Clinical Infectious Disease Society (CIDS), India
Department of Biotechnology, Ministry of Science & Technology, India
European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
Infection Control Africa Network (ICAN)
Indian Academy of Pediatrics (IAP)
Indian Association of Medical Microbiologists (IAMM)
International Society for Diseases Surveillance (ISDS)
Public Health Foundation of India (PHFI)



General Information



Badges

All registrants have been issued badges, which must be worn to gain admission to the convention facilities and social program. Badges are color-coded as follows:

Delegates – blue

Staff – red

Press – purple

Exhibitors – yellow

A fee of USD 150 will be charged for the replacement of lost or forgotten badges.

Only delegates with blue and purple badges will be admitted to the scientific sessions.

Congress Venue

The 17th ICID takes place at the Hyderabad International Convention Center (HICC). No smoking is allowed. Mobile phones must be switched off in the meeting rooms. Your cooperation will be appreciated. Unauthorized recording (video and/or audio) and photography are not allowed.

Congress Language

The official language of the Congress is English.



Congress Mobile App

The Congress Mobile App (**sponsored by Takeda**) includes the program, abstracts, floor plans, sponsors and exhibition information. It can be downloaded from the Apple App Store and Google Play Store.

Search for keyword 17thICID. The App will also work offline once downloaded. In order to update the App with any program changes you will have to connect to the Internet.



Lunch, Snack Bar and Restaurants

A cash lunch and snack bar area will be available to Congress delegates. This area is located in the Exhibit Hall 3 (Ground Floor).

Only limited number of lunch vouchers are available for those who did not pre-order lunch when registering. These may be purchased at the registration counter.

Other possible options for Lunch include: The SQUARE restaurant, La Cantina, Le Café, all located in the adjoining NOVOTEL.

Internet Access

Congress delegates are invited to the internet area which is located in the exhibit area in Hall 3 (Ground Level). The HICC offers wi-fi internet service (**sponsored by Bharat Biotech**) in the public areas and foyers which is ideal for basic web search and checking web based email. A coupon per day will be necessary to access the wi-fi internet service. **One coupon per person and day** will be available and can be collected from the registration desk each day.



About Hyderabad

Hyderabad is India's fifth largest city and the state capital of Telangana. Hyderabad is a major center for Business, Information Technology and Biotechnology, as well as a fascinating tourist destination with a rich cultural history and stunning architecture. Also known as the City of Pearls, Hyderabad is located in the heart of India and is noted for its natural beauty, bazaars, hills, lakes, mosques and minarets. It is clean, green, and progressive and is endowed with culturally rich tourist attractions in addition to an encouraging Business climate. It is a place that offers the contemporary along with the traditional and its 400-year old history is contrasted with the offices of global giants such as Microsoft, Google, Citibank, and Dell.



General Information



Tipping

Tipping is common practice in India for a range of services. In restaurants the accepted standard is around 7% to 10% of the bill, although sometimes a service charge will be included. Small notes INR 10 to INR 30 are a good tip for small tasks.

Credit Cards & Changing Money

Major credit cards are accepted in most hotels, shops and restaurants. Banking hours vary, but most banks are open weekdays from 9:00hrs to 16:30hrs. Banks offer the best foreign-exchange rates.

Currency

India's unit of currency is the Indian Rupee (INR). Banknotes in circulation come in denominations of INR 5, INR 10, INR 20, INR 50, INR 100, INR 500 and INR 1000. Rupee coins are available in denominations of INR 1, INR 2, INR 5, INR 10.

Shopping

Hyderabad has centuries-old bazaars offering exquisite crafts like *bidri* and local products such as *ittar*, as well as chic boutiques and designer stores. Often called the City of Pearls, Hyderabad is one of the largest centres of pearl trade in India.

Electrical Current

India uses 230 Volts, 50 Hz alternating current as the power source. Plugs and sockets have either grounded / earthed 3 Pin connections (Type D) or ungrounded 2 pin connections (Type C).

Official Carrier

Ethihad was appointed official carrier for the 17th International Congress on Infectious Diseases.

Taxis

Taxis are not readily available. For those delegates who choose to avail taxi services may either contact the Novotel Concierge or may use local radio/mobile taxi services like Uber or Ola. Their apps are readily available on the App Store and Google Play Store.

Tours

Tours can be booked through the Tours Counter in the registration area on the ground level.

Safety Precautions

As in most places, it is advisable to take the following precautions while in Hyderabad

- Do not leave luggage or valuables unattended.
- Use the safety deposit boxes provided by most hotels.
- Carry only the cash, credit cards, and identification that you need.

Insurance

The Organizing Committee, ISID and MCI India accept no liability for personal injuries sustained by or for loss or damage to property belonging to Congress participants, either during or as a result of the Congress or during tours. It is therefore recommended that delegates and accompanying persons arrange for appropriate travel and health insurance before traveling.

Emergencies

For emergencies, dial tel. 100 from any landline phones. No coins are needed for this call.





17th INTERNATIONAL CONGRESS ON INFECTIOUS DISEASES

ISID Business Meeting

The ICID, held every 2 years, is the main opportunity for the Society's membership to come together. It is then that members can actively exchange ideas concerning the ISID and its activities with representatives of the Executive Committee and Council. Your input is important and your contributions are appreciated. We would like to invite all members to participate in the Business Meeting, which will take place on **Saturday, March 5, 2016 at 12:45hrs Room G.05-06 (Ground Floor)**. During this meeting, members will vote on the composition of the Executive Committee and Council for the period 2016–2018. You will hear reports from various officers concerning the ongoing activities of the Society, and you will be able to voice your suggestions and concerns. A light lunch will be provided. We hope you will attend this important meeting.



17th INTERNATIONAL CONGRESS ON INFECTIOUS DISEASES

Slide Preview Room

An LCD projector and laptop for MS Powerpoint presentations are provided in all meeting rooms. All presenters are requested to take their presentations on a memory stick to the slide preview room in **Room G.04 (Ground Floor)**. All presentations must be received as early as possible, but no later than two hours before the presentation. Please use the meeting room laptop computer rather than your personal computer for your presentation. No videos are allowed.

A technician will be available to assist the presenters. Any questions regarding presentations should be directed to the slide preview room located in **Room G.04 (Ground Floor)**.



17th INTERNATIONAL CONGRESS ON INFECTIOUS DISEASES

Poster Presentations

Exhibition

Hall 3

Ground Floor

9:45 – 10:15hrs

12:45 – 14:15hrs

15:15 – 15:45hrs

Posters are displayed in the exhibition area in **Hall 3 (Ground Level)**. Each poster board is marked with the number assigned to each abstract, which can be found in the program book. Authors are requested to affix their posters at the number assigned to them (as listed in the program) on the morning of their designated date of presentation between 8:00 and 9:30hrs. At least one author of each poster must be present for discussion and questions during the official poster sessions **each day from 12:45 to 14:15hrs** and, if possible, during the coffee breaks.

All posters must be removed at the end of the day of the poster session, but no later than 17:45hrs. Posters not removed by this time will be dismantled by the Congress staff and may be claimed from the poster attendant. The Congress assumes no responsibilities for the condition of posters not removed by the presenter. All posters not collected by 17:45hrs on **Saturday, March 5**, will be disposed of.

Abstracts of poster presentations are published on the conference App and as a supplement to the International Journal of Infectious Diseases (IJID). Abstracts accepted for "International Scientific Exchange" are not presented but published on the Congress web page.



Poster Presentations

**Exhibition
Hall 3
Ground Floor**
9.45 – 10:15hrs
12:45 – 14:15hrs
15:15 – 15:45hrs

Thursday, March 3, 2016	Exhibition / Hall 3	41.001 - 41.284
Friday, March 4, 2016	Exhibition / Hall 3	42.001 - 42.278
Saturday, March 5, 2016	Exhibition / Hall 3	43.001 - 43.271

Thursday, March 3, 2016

41.001 - 41.015	Poster Prize Finalists (Thursday)
41.016 - 41.023	Animal Models, Pathogenesis and Host Defenses
41.024 - 41.107	Antimicrobial Resistance
41.108 - 41.115	Antimicrobials: Adherence and Stewardship
41.116 - 41.118	Antimicrobials: Clinical Trials
41.119 - 41.122	Antimicrobials: Mechanisms and Spectrum
41.123 - 41.130	Antimicrobials: Pharmacology
41.131 - 41.168	Bacterial Infections
41.169 - 41.189	Diagnostics
41.190 - 41.199	Economics, Health Policy and Implementation
41.200 - 41.265	Emerging Infectious Diseases
41.266 - 41.266	Geriatric Infections
41.267 - 41.275	Immunocompromised Host (Non-HIV)
41.276 - 41.281	Sexually Transmitted Diseases
41.282 - 41.285	Travel Medicine and Travel Health

Friday, March 4, 2016

42.001 - 42.015	Poster Prize Finalists (Friday)
42.016 - 42.091	Epidemiology and Public Health
42.092 - 42.138	HIV/AIDS and Other Retroviruses
42.139 - 42.173	Infection Control
42.174 - 42.216	Infectious Disease Surveillance and Notification
42.217 - 42.233	Mycology, Fungal Infections and Antifungal Drugs
42.234 - 42.250	Nosocomial Infections and Critical Care
42.251 - 42.268	Other
42.269 - 42.278	Pediatric and Perinatal Infections

Saturday, March 5, 2016

43.001 - 43.015	Poster Prize Finalists (Saturday)
43.016 - 43.086	Parasitology and Parasitic Infections
43.087 - 43.151	Tuberculosis and other Mycobacterial Infections
43.152 - 43.172	Vaccines and Vaccine Development
43.173 - 43.244	Virology and Viral Infections (Non-HIV)
43.245 - 43.271	Zoonoses and Infections in Animals

Of fifteen poster finalists, each day five will be selected for the **Wellcome Trust/DBT India Alliance Poster Awards**. Each awardee will receive an award certificate and a **INR 5,000** stipend. Prof. Anita Shet, Poster Competition Coordinator, will present the Wellcome Trust/DBT India Alliance Poster Awards to the presenting authors at the end of the afternoon plenary talk each day.



17th INTERNATIONAL CONGRESS ON INFECTIOUS DISEASES

Meet-the-Expert

Meet-the-Expert Sessions are scheduled from Thursday, March 3 to Saturday, March 5, 2016, from **07:45 to 08:45hrs**. Delegates are invited to meet informally with leading scientists. Meet-the-Expert Sessions will be held in **Hall 2, Room G.01-03, G.05-06 on the Ground Floor**. A light breakfast will be provided for participants in the Meet-the-Expert sessions.

THURSDAY, MARCH 3, 2016

Clinical Case Discussions for Trainees
Room: Hall 2

- V. Gant (UK)

Why Isn't Mathematical Modeling Being Utilized to Inform Infectious Disease Public Health Policy?

Room: G.01-03

- M. Roberts (USA)

The Value of Adult Vaccination

In collaboration with MSD

Room: G.05-06

- Herpes Zoster Management
 - J. Litt (Australia)
- Pneumococcal Disease in Adults
 - D. Fedson (France)

FRIDAY, MARCH 4, 2016

How to Publish Your Work—Insights from the Editors

In collaboration with Elsevier

Room: G.01-03

- E. Petersen (Denmark)
Editor-in-chief of the *International Journal of Infectious Diseases*
- J. McConnell (United Kingdom)
Editor of *The Lancet Infectious Diseases*

CME

CME

CME

FRIDAY, MARCH 4, 2016

Strengthening Disease Surveillance, Emergency Preparedness and Risk Communication for Health Security in India

In Collaboration with the International Society for Disease Surveillance (ISDS)

Room: G.05-06

- V. Singh (India)
- P. Murthy (India)

CME

SATURDAY, MARCH 5, 2016

Clinical Cases in Tropical Dermatology

Room: G.01-03

- A. Sethi (USA)

CME

Clinical Management of Anti-Fungal Resistance—Interactive Cases

Room: G.05-06

- F. Menichetti (Italy)

CME



17th INTERNATIONAL CONGRESS ON INFECTIOUS DISEASES

CME Accreditation

The 17th International Congress on Infectious Diseases is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The 17th ICID is designated for a maximum of 21 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits.™ Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

EACCME evaluation forms can be accessed online: <https://isid.typeform.com/to/dnd1kM>, the Congress App and will be emailed to registered attendees at the end of the Congress. All sessions meeting CME criteria are designated **CME**.

CME



Commercial Exhibition

The exhibits and coffee break areas are located in Hall 3 on the Ground Level.

All delegates are encouraged to visit the exhibits.

Thursday, March 3, 2016 09:00 – 16:30 hrs

Friday, March 4, 2016 09:00 – 16:30 hrs

Saturday, March 5, 2016 09:00 – 16:00 hrs

Exhibitors

(as per printing date)

Aerte

Alere

B.Braun Medical

bioMerieux

Bruker Physik

Cepheid

Copan

DNA Genotek

elife

Elsevier

EpiCore

Fast-track Diagnostics

GeneReach

Longhorn Vaccines & Diagnostics

Mabtech

MP Biomedicals

MSD

Pfizer

Public Health Foundation of India (PHFI)

Public Library of Science (PLOS)

Takeda

Taylor & Francis Group

Telangana Tourism

Time Research

Exhibition Management

Media Plan

International Exhibitions and Advertising

Helferstorferstr. 2

1010 Vienna, Austria

Phone: (43 1) 536 63-34

Fax: (43 1) 535 60 16

E-mail: mp@media.co.at



Plenary Lectures



SHIRANEE SRISKANDAN

Streptococcal Lymphatic Metastasis: Bacterial Close Encounters of the Fourth Kind

Thursday, March 3, 2016 • 09:00–09:45hrs

Shiranee Sriskandan is Professor of Infectious Diseases at Imperial College London and an Infectious Diseases clinical consultant. She leads the Gram Positive Pathogenesis research group, in addition to the molecular bacteriology work of the NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, in partnership with Public Health England, and Imperial's Biomedical Research Centre. Her research group addresses the mechanisms by which *Streptococcus pyogenes* causes extreme clinical phenotypes in individuals and populations, examining the interface between pathogen molecular microbiology and host immune response.

Having trained in medicine at Cambridge University, she obtained her PhD in London, then held MRC and GSK postdoctoral research fellowships. She has held expert advisory roles in relation to maternal sepsis, use of intravenous immunoglobulin, streptococcal vaccines, and streptococcal prevention in healthcare and household settings.



CHING-LUNG LAI


Challenges and Opportunities in the Management of Chronic Hepatitis B Infection

Thursday, March 3, 2016 • 14:30–15:15hrs

Ching-Lung Lai is the Simon KY Lee Professor in Gastroenterology and the Chair Professor of Medicine and Hepatology at the Department of Medicine, University of Hong Kong, where he has been working since his graduation.

For the last three decades he has been extensively involved in research into various aspects of HBV, including hepatocellular carcinoma. He is one of the lead investigators in the pivotal trials of various nucleos(t)ide analogues which have revolutionised the treatment of chronic hepatitis B. He and his colleagues have also been investigating the still emerging field of the natural history of chronic hepatitis B, with findings which have an important bearing on the treatment end-points for chronic hepatitis B.

Professor Lai has published over 450 peer-reviewed papers and reviews in international journals. His publications have been widely cited and he is one of top scientists in the field of chronic hepatitis B infection. He has also been awarded multiple awards by the University of Hong Kong for his outstanding teaching.



NICHOLAS JOHN WHITE

Ronald Ross Memorial Plenary Lecture

Malaria: Past, Present and Future

Friday, March 4 2016 • 09:00–09:45hrs

Nick White, Professor of Tropical Medicine at the Faculty of Tropical Medicine, Mahidol University, Thailand and at Oxford University, UK, and Consultant Physician at the John Radcliffe Hospital, Oxford, is a Wellcome Trust Principal Research Fellow who chairs the Wellcome Trust Tropical Medicine Research Programmes in South East Asia. He trained in medicine in London at Guy's Hospital and he has lived and worked in Thailand since 1980. His research focus is the pathophysiology and treatment of malaria. He has concentrated on characterizing antimalarial pharmacokinetic-pharmacodynamic relationships to improve the treatment of malaria and to reduce the emergence of resistance. This led to artemisinin based combination treatment for falciparum malaria, and the change to artesunate for the treatment of severe malaria. He has authored over 900 scientific publications and 40 book chapters. He currently chairs the WorldWide Antimalarial Resistance Network and he co-chairs the WHO Global Malaria Programme technical expert group on the prevention and treatment of malaria, and the WHO antimalarial treatment guidelines committee.



Plenary Lectures



SOUMYA SWAMINATHAN

Tuberculosis: Challenges and Solutions in the 21st Century

Friday, March 4, 2016 • 14:30–15:15hrs

Soumya Swaminathan is a pediatrician by training, having completed her medical education at the Armed Forces Medical College and the All India Institute of Medical Sciences followed by a fellowship in pediatric pulmonology at the Children's Hospital of Los Angeles. She has spent over 24 years at the Tuberculosis Research Centre in Chennai, (now renamed the National Institute for Research in Tuberculosis), where she is currently the Director. She has over 200 peer-reviewed publications and serves on many national and international committees. Her major research interests are in pediatric and adult TB, their interaction with HIV and nutrition and the management of co-infections as well as pharmacokinetics and pharmacogenetics.

She is an elected Fellow of three of India's Science Academies and chaired the HIV section of the International Union against TB and Lung Diseases 2011–2013. She also served as Coordinator for Neglected Priorities Research at WHO/TDR, Geneva 2009–2011. She is the recipient of several awards for excellence in biomedical sciences. Dr. Swaminathan was appointed as Director General of the Indian Council of Medical Research (ICMR) and Secretary, Department of Health Research (Ministry of Health & Family Welfare) in August 2015. She will head a network of 32 research centres under ICMR, the apex body for coordination and promotion of biomedical research in India.



SALLY C. DAVIES

Antimicrobial Resistance: From Problem to Policy to Action

Saturday, March 5, 2016 • 09:00–09:45hrs

Dame Sally Davies is England's Chief Medical Officer (CMO), and the Chief Scientific Adviser for the Department of Health. As CMO she is the independent advisor to the Government on all medical matters, particularly Public Health. The CMO also advises the Health Secretary on medical matters and promoting the health and well being of the people of England. She carries the rank of Permanent Secretary and is the professional head of the Department's medical staff and head of the Medical Civil Service. Prof. Davies has been actively involved in NHS R&D from its establishment. As Director-General she established the National Institute for Health Research (NIHR) with a budget of £1 billion. Her own research interests focused on Sickle Cell disease.

Long an active participant in WHO, Prof. Davies led the UK delegation to the Ministerial Summit in November 2004 and the Forum on Health Research in November 2008. She spoke on R&D at the World Health Assembly in May 2005 and serves the WHO Global Advisory Committee on Health Research. She also chaired the Expert Advisory Committee for the development of the WHO research strategy. She is a member of the International Advisory Committee for A*STAR, Singapore and has advised many other organizations on research strategy and evaluation. Prof. Davies was awarded a DBE (Dame Commander of the British Empire) in the New Year Honours 2009 for services to medicine. In September 2011 she was conferred as Emeritus Professor at Imperial College London.



PAUL ANANTHARAJAH TAMBYAH

Zika, MERS, Ebola, SARS and H1N1: Local and Global Responses to Viral Threats

Saturday, March 5 2016 • 14:30–15:15hrs

Paul Anantharajah Tambyah is currently Professor of Medicine at the National University of Singapore and Senior Consultant Infectious Diseases Physician at the National University Hospital. He is also Research Director in the Division of Infectious Diseases of the National University Health System. After graduating from the National University of Singapore, he did his postgraduate training at the University of Wisconsin under Dr. Dennis Maki and since returning to Singapore in 1999 he has held a number of academic, professional and advisory appointments including Assistant Dean of the Yong Loo Lin School of Medicine. He is immediate past President of the Society of Infectious Diseases (Singapore) and Secretary-General of the Asia Pacific Society of Clinical Microbiology and Infection.



17th ICID Trainee Track

Brought to you by Prof. Alison Holmes, chair of ISID's Education & Publication Committee.

In accordance with ISID's mission to focus on the needs of trainees and investigators early in their careers, ISID has introduced a **Trainee Track** during the 17th ICID, highlighting interactive sessions and networking events. With generous assistance from the Bill & Melinda Gates Foundation and the Elsevier Foundation, ISID has been able to offer young investigators unprecedented financial support to attend the 17th ICID.

Trainee Track ~ Scientific Program

Interactive sessions are highlighted in the program schedule-at-glance on pages 22-23.

Trainees are encouraged to attend each of the six **Plenary Lectures** on areas of broad interest by renowned infectious diseases experts in their fields. They will address fundamental challenges in infectious diseases and give insights into specific fields of research, policy or clinical infectious diseases, highlight open questions and discuss future strategies. Trainees especially would benefit from the daily, early morning **Meet-the-Expert Sessions** that give attendees the opportunity to discuss relevant topics with leading experts in a more personal setting. And by choosing among the many **Symposia** presented as parallel break-out sessions, trainees will be able to explore the most pressing challenges in prevention, management and investigation of infectious diseases. Symposia are structured to include question and answers periods that will allow opportunity for trainees' participation.

Trainees who attend the **Poster Viewing sessions** will interact with colleagues from around the world to discuss topics of interest and possible collaborations. The **Wellcome Trust/DBT India Alliance Poster Award** recipients will be announced each day after the afternoon plenary talk.

Trainee Track – Networking

Trainees are invited to attend the **17th ICID Welcome Reception**, following the Opening Ceremony. During the hours of the 17th ICID, trainees can meet with colleagues and recharge with complimentary refreshments at the **Trainee Lounge**. A visit with staff at the **ISID** exhibit booth will present the opportunity to ask questions about ISID's grant programs, learn about the **International Journal of Infectious Diseases (IJID)**, and subscribe to **ProMED-mail**, ISID's outbreak reporting system. Find out about our new outbreak surveillance initiative at the **EpiCore Booth (Hall 3/Exhibition, Booth No. 10)** and discover how you can join an international network of health professionals who are changing the landscape of outbreak detection. You may join the **EpiCore Luncheon Workshop** on Saturday, March 5 from 12.30 to 14.15hrs in meeting room G.01-03 (Ground Floor). Pre-registration at EpiCore Booth necessary.



EpiCore Workshop

Pre-Registration necessary, limited attendance.

Pre-registration is **EpiCore Workshop**

necessary at the
EpiCore Booth

**(Booth #10) in the
Exhibition Hall 3
(Ground Level)**

Saturday, March 5, 2016, 12.30–14.15hrs, Room: G.01-03

Workshop Leader: Marjorie Pollack, MD

Nontraditional sources of information such as social and mass media can often alert public health officials to possible disease outbreaks faster than traditional surveillance methods. Field epidemiologists are learning how to leverage these new methods for disease detection through a new innovative disease surveillance initiative called EpiCore. This workshop will introduce participants to a newly developed platform for verification of outbreaks globally. EpiCore will help the global public health community to find outbreaks faster, allowing for speedier responses and control.

Workshop participants will learn about innovative disease surveillance methods and will have the opportunity to train in the use of the EpiCore platform. After completion of the workshop, qualified participants will be able to enroll as EpiCore volunteers and participate in this global effort to combat emerging infectious diseases. EpiCore is a collaboration of ISID's Program for Monitoring Emerging Diseases (ProMED), the Skoll Global Threats Fund, TEPHINET and HealthMap.



Pre-Congress Workshops

Pre-Registration necessary, limited attendance.

Antibiotic Stewardship in the Resource Limited Setting

CME

*In collaboration with the British Society for Antimicrobial Chemotherapy
Supported by an unrestricted educational grant from MSD*

Wednesday, March 2, 2016

13:00–17:00hrs, Room 1.06

The aim of the course is to provide trainers with the knowledge and skills to effectively deliver educational sessions for healthcare professionals involved in the development, delivery and measurement of antimicrobial stewardship within hospitals—"the training the trainer model." The emphasis on the material will be how this can be delivered in a resource limited setting.

Innovative Strategies in Hand Hygiene Promotion Around the World

CME

Wednesday, March 2, 2016

14:00–16:30hrs, Room: 1.05

The workshop will allow participants to learn and discuss the most recent evidence from the literature regarding the burden of healthcare-associated infections. Recent information regarding hand hygiene promotion, in particular through the multimodal strategy promoted by the World Health Organization (WHO), including caveats for promotion, dissemination, cultural adaptation and adoption at different levels of resources and commitment will be presented. Monitoring of healthcare institutions at large scale level, as well as their promotion and rewarding of excellence will be discussed with concrete examples worldwide..



Schedule-at-a-Glance

HYDERABAD INTERNATIONAL CONVENTION CENTRE (HICC)

			Hall 4 Ground Floor				
WEDNESDAY MARCH 2	Registration & Info 09:00 – 19:00	09:00–18:30hrs					
		18:30–20:00hrs	OPENING CEREMONY				
		20:00–21:30hrs	WELCOME RECEPTION (Novotel Garden/HICC)				
			Hall 4 Ground Floor	Hall 1 Ground Floor	Hall 2 Ground Floor	Hall 5 Ground Floor	
THURSDAY • MARCH 3	Registration & Info ~ 08:00 – 18:00	07:45–08:45hrs				TT Meet-the-Expert ~ Clinical Case Discussion for Trainees	
		09:00–09:45hrs	01 ~ PLENARY I ~ Streptococcus Pathogenesis ~ S. Sriskandan (UK)				
		09:45–10:15hrs	Coffee Break ~ Hall 3				
		10:15–12:15hrs		02 ~ Symposium Childhood Pneumonia	03 ~ Symposium Dengue	04 ~ Symposium ~ Carbapenem-Resistant Enterobacteriaceae	
		12:15–12:45hrs	Lunch Break (optional) & Poster Presentations (12:45 – 14:15hrs) ~ Hall 3				
		12:30–14:15hrs					
		14:30–15:15hrs	08 ~ PLENARY II ~ Chronic Hepatitis B Infection ~ C.L. Lai (China)				
		15:15–15:45hrs	Coffee Break ~ Hall 3				
		15:45–17:45hrs		09 ~ Symposium Antibiotic Resistance	10 ~ Symposium Epidemic Preparedness	11 ~ Symposium Drug Resistant Tuberculosis	
FRIDAY • MARCH 4	Registration & Info ~ 08:00 – 18:00	07:45–08:45hrs					
		09:00–09:45hrs	15 ~ PLENARY III ~ Malaria N. White (Thailand)				
		09:45–10:15hrs	Coffee Break ~ Hall 3				
		10:15–12:15hrs		16 ~ Symposium Infectious Encephalitis	17 ~ Symposium Future of ID Diagnosis	18 ~ Symposium Childhood Vaccinations	
		12:15–12:45hrs	Lunch Break (optional) & Poster Presentations (12:45 – 14:15hrs) ~ Hall 3				
		12:30–14:15hrs					
		14:30–15:15hrs	22 ~ PLENARY IV ~ Tuberculosis S. Swaminathan (India)				
		15:15–15:45hrs	Coffee Break ~ Hall 3				
		15:45–17:45hrs		23 ~ Symposium Intestinal Microbiota	24 ~ Symposium Pediatric Diarrhea	25 ~ Symposium ~ Dengue, Chikungunya & Zika Virus	
SATURDAY • MARCH 5	Registration & Info ~ 08:00 – 18:00	07:45–08:45hrs					
		09:00–09:45hrs	29 ~ PLENARY V ~ Antimicrobial Resistance ~ S. Davies (UK)				
		09:45–10:15hrs	Coffee Break ~ Hall 3				
		10:15–12:15hrs		30 ~ Symposium ~ Cancer, Transplants, New Biologics and IDs	31 ~ Symposium ~ New and Recently Approved Antibiotics	32 ~ Symposium ~ Hot Topics HIV - Antiretroviral Therapy	
		12:15–12:45hrs	Lunch Break (optional) & Poster Presentations (12:45 – 14:15hrs) ~ Hall 3				
		12:30–14:15hrs					
		14:30–15:15hrs	36 ~ PLENARY VI ~ Zika, MERS, Ebola, SARS, H1N1 ~ P. Tambyah (Singapore)				
		15:15–15:45hrs	Coffee Break ~ Hall 3				
		15:45–17:45hrs		37 ~ Symposium Infections in Critical Care		38 ~ Symposium ~ Enteric Fever Prevention & Control	

TT = Trainee Track Scientific Sessions Plenary Session Satellite Symposia Pre-Conference Workshops


HYDERABAD INTERNATIONAL CONVENTION CENTRE (HICC)

Meeting Room 1.05 First Floor		Meeting Room 1.06 First Floor			
TT	14:00–16:30 Pre-Congress Workshop Hand Hygiene	TT	13:00–17:00 Pre-Congress Workshop Antibiotic Stewardship		
				09:00–18:30hrs	WEDNESDAY MARCH 2
				18:30–20:00hrs	
WELCOME RECEPTION (Novotel Garden/HICC)				20:00–21:30hrs	
Hall 6 Ground Floor		Meeting Room G.01-03 Ground Floor		Meeting Room G.05-06 Ground Floor	
		TT	Meet-the-Expert Mathematical Modeling & ID	TT	Meet-the-Expert Value of Adult Vaccination
Coffee Break ~ Hall 3					
05 ~ Symposium Antifungal Prophylaxis & Treatment		06 ~ Symposium HIV-Management		07 ~ Symposium ~ One Health & Emerging Infectious Diseases	
Lunch Break (optional) & Poster Presentations (12:45 – 14:15hrs) ~ Hall 3					
Satellite Symposium Pertussis					
Coffee Break ~ Hall 3					
12 ~ Symposium Malaria – Hot Topics		13 ~ Symposium Rickettsial Infections		14 ~ Oral Presentations EID & One Health	
		TT	Meet-the-Editors How to Publish Your Work	TT	Meet-the-Expert ~ Surveillance & Emergency Preparedness
Coffee Break ~ Hall 3					
19 ~ Symposium ~ Managing Gram-Negative Bacterial Infections		20 ~ Symposium Meliodosis		21 ~ Oral Presentations HIV & Tuberculosis	
Lunch Break (optional) & Poster Presentations (12:45 – 14:15hrs) ~ Hall 3					
Satellite Symposium Pneumococcal Disease					
Coffee Break ~ Hall 3					
26 ~ Symposium Neglected Infectious Diseases		27 ~ Symposium Viral Hepatitis		28 ~ Oral Presentations Bacterial Infections & Vaccines	
Satellite Symposium MMRV					
		TT	Meet-the-Expert ~ Clinical Cases in Tropical Dermatology	TT	Meet-the-Expert ~ Interactive Cases—Anti-Fungal Resistance
Coffee Break ~ Hall 3					
33 ~ Symposium Visceral Leishmaniasis		34 ~ Symposium ~ Infectious Diseases in Refugees & Migrants		35 ~ Oral Presentations Tropical Infectious Diseases	
Lunch Break (optional) & Poster Presentations (12:45 – 14:15hrs) ~ Hall 3					
		TT	EpiCore Workshop 12:30 – 14.15hrs	ISID Business Meeting 12:30 – 13:30hrs	
Coffee Break ~ Hall 3					
39 ~ Symposium Protecting Healthcare Workers		40 ~ Symposium STDs: Global Challenges			

THURSDAY • MARCH 3	07:45–08:45hrs
	09:00–09:45hrs
	09:45–10:15hrs
	10:15–12:15hrs
	12:15–12:45hrs
	12:30–14:15hrs
	14:30–15:15hrs
	15:15–15:45hrs
	15:45–17:45hrs
FRIDAY • MARCH 4	07:45–08:45hrs
	09:00–09:45hrs
	09:45–10:15hrs
	10:15–12:15hrs
	12:15–12:45hrs
	12:30–14:15hrs
	14:30–15:15hrs
	15:15–15:45hrs
	15:45–17:45hrs
18:00–20:00hrs	
SATURDAY • MARCH 5	07:45–08:45hrs
	09:00–09:45hrs
	09:45–10:15hrs
	10:15–12:15hrs
	12:15–12:45hrs
	12:30–14:15hrs
	14:30–15:15hrs
	15:15–15:45hrs
	15:45–17:45hrs



GROUND FLOOR



MEETING ROOMS

Halls 1, 2, 5, 6 ~ Ground Floor
Rooms G.01–G.03 ~ Ground Floor
Rooms G.05–G.06 ~ Ground Floor

PLENARY HALL

Hall 4 ~ Ground Floor


SPEAKER PREVIEW ROOM

Room G.04 ~ Ground Floor


HALL 3 ~ GROUND FLOOR

Exhibition
Coffee Breaks
Poster Area
Internet Corner
Cash Snack Bar
Lunch

FIRST FLOOR



SECOND FLOOR





Pre-Congress Workshops

Antibiotic Stewardship in the Resource Limited Setting

CME

Room: 1.06
First Floor

13:00–17:00
Wednesday, March 2, 2016

**NO FEE – Limited Capacity,
Pre-registration necessary!**

*In collaboration with the British Society for
Antimicrobial Chemotherapy*

*Supported by an unrestricted educational
grant from MSD*

Course Objectives: The aim of the course is to provide trainers with the knowledge and skills to effectively deliver educational sessions for healthcare professionals involved in the development, delivery and measurement of antimicrobial stewardship within hospitals—"the training the trainer model." The emphasis on the material will be how this can be delivered in a resource limited setting.

Learning Outcomes: The main learning outcomes that have been identified are:

- 1) The need for stewardship, structures for implementing stewardship in resource limited settings.
- 2) Measuring [and interpreting through scientific methods] and auditing the quantity and quality of antibiotic use and infection care; methods for measuring and analyzing the cause and effect of interventions.
- 3) Methods: the types of interventions [toolkit] and evidence base to support the stewardship "toolkit".
- 4) Implementing stewardship and optimizing antibiotic use by improving the effectiveness of interventions through a range of implementation strategies that employ techniques such as guidelines, audit and feedback, social and behavioural science, improvement science, and change management.
- 5) The role of education in supporting these interventions.

Target Audience: Maximum 100 physicians, pharmacists, nurses involved/interested in developing/delivering or supporting stewardship programs.

PROGRAM

13:00–14:30

Plenary 1: What is Stewardship?
What Works and in What Setting?

Chair: Alison Holmes (United Kingdom)

- 1) What is Stewardship, Current Global Stewardship Activity and is it Effective?
Dilip Nathwani (United Kingdom)

- 2) Evidence of Stewardship Effectiveness and Challenges in Resource Limited Setting
Marc Mendelson (South Africa)

- 3) Stewardship "Tool Kits" in Hospital and Community Setting—A Global Perspective
Rana Hajjeh (USA)

- 4) Educational Opportunities in Stewardship—Including Role of E-Learning
Dilip Nathwani (United Kingdom)

14:15–14:30 Panel Discussion

14:30–14:50 Refreshments

14:50–15:50

Plenary 2: Implementing Stewardship

Chair: Tim Walsh (United Kingdom)

- 1) Basic Improvement Methods in Stewardship
Alison Holmes (United Kingdom)

- 2) The Role of Behavior and Culture Change in Effecting Change
Esmita Charani (United Kingdom)

- 3) The Stewardship Team—The Role of Nurses in Stewardship
Enrique Castro Sanchez (United Kingdom)

15:50–16:10 Panel Discussion

16:15–17:15 WORKSHOP 1 or WORKSHOP 2

WORKSHOP 1

Doing Stewardship

- 1) Surgical prophylaxis
Sanjeev Singh (India)
- 2) ICU
Chand Wattal (India)

WORKSHOP 2

Illustrative Studies of Stewardship in Different Healthcare Settings: Key Lessons

- 1) India: Stewardship in the community setting
Sijith Chandy (India)
- 2) South Africa
Marc Mendelson (South Africa)



Innovative Strategies in Hand Hygiene Promotion Around the World

CME

Room: 1.05 14:00–16:30
First Floor Wednesday, March 2, 2016

NO FEE – Limited Capacity
Pre-registration necessary!

Presenter/Discussant: Prof. Didier Pittet, MD, MS, CBE, Director, Infection Control Programme and WHO Collaborating Centre on Patient Safety, The University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland

Workshop Description: The workshop will allow participants to learn and discuss the most recent evidence from the literature regarding the burden of healthcare-associated infections. Recent information regarding hand hygiene promotion, in particular through the multimodal strategy promoted by the World Health Organization (WHO), including caveats for promotion, dissemination, cultural adaptation and adoption at different levels of resources and commitment will be presented. Monitoring of healthcare institutions at large scale level, as well as their promotion and rewarding of excellence will be discussed with concrete examples worldwide.

Target Audience: Physicians, nurses, public health professionals, whether expert or not in infectious diseases of infection control, as well as hospital administrators and ministry of health representatives.

Desired outcome: Knowledge and expertise in infection control and hand hygiene promotion and public health will improve among participants

14:00–15:10

- 1) Burden of Healthcare-Associated Infection: Worldwide Perspectives
- 2) Hand Hygiene Promotion Multimodal Strategy
- 3) Worldwide Dissemination of Hand Hygiene Promotion
- 4) Monitoring Healthcare Institutions at a Large Scale
- 5) Driving Excellence

15:10–15:30 Coffee Break

15:30–16:30 Round Table Discussion

Opening Ceremony

Room: Hall 4 18:30–20:00
Plenary Hall Wednesday, March 2, 2016

18:15hrs All guests to be seated

18:30hrs Welcome Remarks

19:30hrs Awards Presentation

Presentation of the Sanofi Pasteur Awards for Communicable Disease Epidemiology

Presentation of the
ISID New Investigator Award

20:00hrs Welcome Reception on the Lawn at the Novotel

Hosted by



For all delegates and registered accompanying persons
Dress code: Business Attire



Meet-the-Expert Sessions

Thursday, March 3, 2016

07:45–08:45

Clinical Case Discussions for Trainees

CME

– V. Gant, United Kingdom

Room: Hall 2

Why Isn't Mathematical Modeling Being Utilized to Inform Infectious Disease Public Health Policy?

CME

– M. Roberts, USA

Room: G.01–03

The Value of Adult Vaccination

In collaboration with MSD

– Herpes Zoster Management

Room: G.05–06

J. Litt, Australia

– Pneumococcal Disease in Adults

Room: G.05–06

D. Fedson, France

Session 01

Plenary I

CME

Streptococcal Lymphatic Metastasis: Bacterial Close Encounters of the Fourth Kind

Chair: Keith Klugman, USA

Room: Hall 4 (Plenary Hall)

09:00–09:45

Ground Floor

Thursday, March 3, 2016

01.001 Streptococcal lymphatic metastasis: Bacterial close encounters of the fourth kind

S. Sriskandan

London (United Kingdom)

Coffee Break

Exhibition/Hall 3

09:45–10:15

Ground Floor

Thursday, March 3, 2016

Session 02

Symposium

CME

Prevention of Childhood Pneumonia Through Vaccination

Co-Chairs: Keith Klugman, USA

N.K. Ganguly, India

Room: Hall 1

10:15–12:15

Ground Floor

Thursday, March 3, 2016

02.001 Global burden of pneumonia

K. Thomas

Vellore (India)

02.002 Community-acquired pneumonia in children under five years of age: An overview

S. Awashti

Lucknow (India)

02.003 Prevention of childhood pneumonia through vaccination

R. Dagan

Beer-Sheva (Israel)

02.004 The path to pneumonia prevention in India—Call to action

R. Kumar

New Delhi (India)

In collaboration with the

Bill & Melinda Gates Foundation

Session 03

Integrated Symposium

Potential Role of Dengue Vaccination in Integrated Disease Prevention and Control

Co-Chairs: Ashutosh Biswas, India

Gathsaurie Neelika Malavige, Sri Lanka

Room: Hall 2

10:15–12:15

Ground Floor

Thursday, March 3, 2016

03.001 The burden of dengue: Insights from large scale clinical studies

O. Brady

Oxford (United Kingdom)

03.002 Recent update on dengue vaccine development

P. Pitisuttithum

Bangkok (Thailand)

03.003 Dengue vaccination impact: Perspective from modeling

T. Hladish

Gainesville, FL (USA)

03.004 Roadmap for dengue vaccination introduction in Mexico

M. Betancourt-Cravioto

Mexico City (Mexico)

Developed in collaboration with and supported by an educational grant from Sanofi Pasteur



Session 04

Symposium

Diagnosis and Treatment of Carbapenem-resistant Enterobacteriaceae

Co-Chairs: Didier Pittet, Switzerland
Tetsuya Matsumoto, Japan

Room: Hall 5 **10:15–12:15**
Ground Floor **Thursday, March 3, 2016**

- 04.001** Non-molecular detection of carbapenemases in Enterobacteriaceae clinical isolates
L. Martinez-Martinez
Santander (Spain)
- 04.002** Molecular diagnosis of carbapenemase producing Enterobacteriaceae infection
Y. Ishii
Tokyo (Japan)
- 04.003** Control of carbapenem-resistant Enterobacteriaceae
S. Munoz-Price
Milwaukee, WI (USA)
- 04.004** Appropriate therapy for carbapenem-resistant Enterobacteriaceae (CRE)
O.C. Abraham
Vellore (India)

In collaboration with the Japanese Association for Infectious Diseases

Session 05

Integrated Symposium

Antifungal Prophylaxis or Treatment: Why, When & What?

Co-Chairs: Antonio Pagliuca, United Kingdom
Alok Srivastava, India

Room: Hall 6 **10:15–12:15**
Ground Floor **Thursday, March 3, 2016**

- 05.001** Making clinical sense of *Candida* and *Aspergillus* susceptibilities
N. Wiederhold
San Antonio, TX (USA)
- 05.002** Why prophylaxis for IFI?
A. Pagliuca
London (United Kingdom)
- 05.003** Risk stratification for treatment or prophylaxis of invasive fungal infections
M. Slavin
Melbourne (Australia)

CME

- 05.004** New options for prevention and treatment of IFI

R. Duarte

Madrid (Spain)

Sponsored by MSD

Session 06

Symposium

HIV-Management of Opportunistic Infections in Low- and Middle-Income Countries

Co-Chairs: Adeeba Kamarulzaman, Malaysia
N. Kumarasamy, India

Room: G.01–03 **10:15–12:15**
Ground Floor **Thursday, March 3, 2016**

- 06.001** Tuberculosis/HIV co-infection
S. Swaminathan
Chennai (India)
- 06.002** Cryptococcal meningitis and beyond—Management of select opportunistic infections in Sub-Saharan Africa
G. Meintjes
Cape Town (South Africa)
- 06.003** Challenges in the management of opportunistic infections: Focus on Southeast Asia
A. Kamarulzaman
Kuala Lumpur (Malaysia)
- 06.004** The challenge of opportunistic infections: Focus on South America
J. Torres
Caracas (Venezuela)

CME

Session 07

Symposium

One Health and Emerging Infectious Diseases

Co-Chairs: Larry Madoff, USA
Ali Benkirane, Morocco

Room: G.05–06 **10:15–12:15**
Ground Floor **Thursday, March 3, 2016**

- 07.001** Mers-CoV: From camels to humans
Z. Memish
Riyadh (Saudi Arabia)

CME



07.002 Climate change and other drivers of infectious diseases—Focus on Asia and the Pacific

D. Harley
Acton (Australia)

07.003 Viral hemorrhagic fevers: Ebola and beyond

L. Blumberg
Johannesburg (South Africa)

07.004 Rabies: One Health in action

P. Cowen
Raleigh, NC (USA)

Lunch Break *(optional)*

Exhibition/Hall 3 12:45–14:15
Ground Floor Thursday, March 3, 2016

A cash snack bar and lunch areas are available in Exhibition/Hall 3

Poster Presentations

Exhibition/Hall 3 12:45–14:15
Ground Floor Thursday, March 3, 2016

Sessions 41.001–41.284 (see pages 42–59)

Session 08

Plenary II

Challenges and Opportunities in the Management of Chronic Hepatitis B Infection

Chair: Adeeba Kamarulzaman, Malaysia

Room: Hall 4 (Plenary Hall) 14:30–15:15
Ground Floor Thursday, March 3, 2016

08.001 Challenges and opportunities in the management of chronic hepatitis B infection

C.-L. Lai
Hongkong (China)

Coffee Break

Exhibition/Hall 3 15:15–15:45
Ground Floor Thursday, March 3, 2016

Session 09

Symposium

Antibiotic Resistance: National Actions Contribute to a Global Solution

Co-Chairs: Ramanan Laxminarayan, India
Chand Wattal, India

Room: Hall 1 15:45–17:45
Ground Floor Thursday, March 3, 2016

09.001 India's perspective on antibiotic resistance

A. Prakash and **N.K. Ganguly**
New Delhi (India), Pondicherry (India)

09.002 South Africa's perspective on antibiotic resistance

M. Mendelson and **P. Matsoso**
Cape Town (South Africa), Pretoria (South Africa)

09.003 Kenya's perspective on antibiotic resistance

C. Mailu and **G. Revathi**
Nairobi (Kenya)

09.004 Nepal's perspective on antibiotic resistance

R. Chaudhary and **P. K. Pokharel**
Kathmandu (Nepal), Dharan (Nepal)

09.005 Mozambique's perspective on antibiotic resistance

B. Sigauque and **M. Saide**
Maputo (Mozambique)

09.006 Lessons learned

H. Gelband
Washington, DC (USA)

09.007 Panel Discussion

R. Laxminarayan
New Delhi (India)

In collaboration with the Center for Disease Dynamics, Economics & Policy

Session 10

Symposium

Ebola and Beyond: Preparing for the Next Pandemic

Co-Chairs: Daniel Lucey, USA
Mandeep Chadha, India

Room: Hall 2 15:45–17:45
Ground Floor Thursday, March 3, 2016

10.001 India—National disaster and epidemic preparedness

V. Menon
New Delhi (India)



10.002 Influenza preparedness including H1N1
M. Chadha
Pune (India)

10.003 Conducting clinical trials in the outbreak setting—MSF's perspective
H. De Clerck
Antwerp (Belgium)

10.004 WHO reforms and UN actions
D. Lucey
Washington, DC (USA)

Session 11 Symposium

CME

Advances and Understanding in the Management of Drug Resistant Tuberculosis

Co-Chairs: Rajesh Gokhale, India
Robert S. Wallis, USA

Room: Hall 5 **15:45–17:45**
Ground Floor **Thursday, March 3, 2016**

11.001 Diagnostic advances in assessing drug resistant tuberculosis
C. Rodrigues
Mumbai (India)

11.002 Translating genomics research into control of MDR tuberculosis: Lessons learned and future prospects
M. P. Nicol
Cape Town (South Africa)

11.003 Advances in the understanding and management of drug-resistant tuberculosis
R. S. Wallis
Johannesburg (South Africa)

11.004 Multidrug-resistant tuberculosis in children: Special considerations
F. Qamar
Karachi (Pakistan)

Member proposed symposium

Session 12 Symposium

CME

Malaria—Hot Topics

Co-Chairs: Nicholas White, Thailand
Virander S. Chauhan, India

Room: Hall 6 **15:45–17:45**
Ground Floor **Thursday, March 3, 2016**

12.001 The threat of antimalarial drug resistance
E. Ashley
London (United Kingdom)

12.002 Declining efficacy of mefloquine-artesunate combination and relative role of drug-resistant molecular markers: Thai-Myanmar Border 2003–2013
A. P. Physo
Maesot Tak (Thailand)

12.003 Malaria prevention strategies
L. Von Seidlein
Bangkok (Thailand)

12.004 Management of relapsing *Plasmodium vivax* malaria
C. Chu
Bangkok (Thailand)

Session 13 Symposium

CME

New Insights on Rickettsial Infections

Co-Chairs: Dilip Mathai, India
Ranjan Premaratna, Sri Lanka

Room: G.01–03 **15:45–17:45**
Ground Floor **Thursday, March 3, 2016**

13.001 Epidemiology and ecology of rickettsial infections
R. Premaratna
Ragama (Sri Lanka)

13.002 Challenges and opportunities in the diagnosis and management of rickettsial infections in Southeast Asia
G. M. Varghese
Vellore (India)

13.003 Current understanding of scrub typhus immunity and vaccine development: The way ahead
D. H. Walker
Galveston, TX (USA)

13.004 *Rickettsia felis* burden in the tropics
E. Angelakis
Marseille (France)



Session 14

Oral Presentations

Emerging Infectious Diseases & One Health

Co-Chairs: Marjorie Pollack, USA
Stuart Handsides, United Kingdom

Room: G.05-06
Ground Floor

15:45-17:45
Thursday, March 3, 2016

CME

14.001 Expression of glycoprotein gene of rabies virus and evaluation of recombinant protein for seromonitoring of vaccinal antibodies in dogs

R. Sharada¹, S. I. Isloor², V. Balamurugan², B. Veeresh², V. Suryanarayana², R. Manisha², D. Rathnamma², M. Satyanarayana²

¹Hassan (India), ²Bangalore (India)

14.002 The EpiCore project: Using innovative surveillance methods to verify outbreaks of emerging infectious diseases

Z. Haddad¹, L. Madoff², E. Cohn², J. Olsen³, A. Crawley³, J. Brownstein², M. Smolinski³, J. Shao³, M. Pollack⁴, D. Herrera-Guibert⁵
¹Brookline, MA (USA), ²Boston, MA (USA), ³San Francisco, CA (USA), ⁴New York, NY (USA), ⁵Atlanta, GA (USA)

14.003 Effect of non-steroidal anti-inflammatory drugs (NSAIDS) on bleeding and liver in dengue infection

A. Wijewickrama, G. Abeyrathna, S. Gunasena, D. Idampitiya
Colombo (Sri Lanka)

14.004 Clinical features and virology of hand foot mouth disease in Southern Vietnam, July 2013–March 2015

V. M. T. Hoang, T. A. Nguyen, T. T. Tran, M. T. Ha, V. Do, V. Ho, T. H. Nguyen, K. Truong Huu, N. Le, C. Nguyen Van Vinh, Q. Phan, L. Thwaites, S. Sabanthan, T. Le, H. R. van Doorn
Ho Chi Minh City (Viet Nam)

14.005 Functional Dipeptidyl Peptidase 4 (DPP4) in mink supports entry and replication of Middle East respiratory syndrome coronavirus: American Mink (Neovision vision), a novel in vivo model of MERS-CoV infection

S. K. Naveen, C. Kannadka, M.-C. Chen, S.-C. Lin, G. J. N. Nichols, M. Patterson, M. Kappes, T. G. Voss
Harrisonburg, VA (USA)

14.006 Multiple introductions of MERS-CoV in a 2014 hospital outbreak in Riyadh, Saudi Arabia

S. Fagbo¹, L. Skakni¹, D. K. Chu², M. Garbati¹, M. Peiris², A. M. Hakawi¹

¹Riyadh (Saudi Arabia), ²Hong Kong (China)

14.007 Moving *Leptospira* to the focus of One Health epidemiology: Lessons from large scale genome analysis of pathogenic species

N. Ahmed, K. Nalam
Hyderabad (India)

14.008 Integrated human and animal vaccination delivery to nomadic Fulani communities in Northern Nigeria 2015

I. M. Bomo, N. E. Waziri, P. Nguku, A. Tsofo
Abuja (Nigeria)

14.009 A synthetic consensus anti-Spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in non-human primates

K. Muthumani¹, D. Falzarano², E. L. Reuschel¹, K. Kraynyak³, K. Ugen⁴, P. Kim⁵, J. Maslow⁵, J. J. Kim³, N. Y. Sardesai³, G. Kobinger⁶, H. Feldmann⁷, D. Weiner¹

¹Philadelphia, PA (USA), ²Saskatoon, SK (Canada), ³Plymouth Meeting, PA (USA), ⁴Tampa, FL (USA), ⁵Seoul (Republic of Korea), ⁶Winnipeg, MB (Canada), ⁷Hamilton, MT (USA)

14.010 Identification of host genes leading to West Nile virus encephalitis in mice brain using RNA-Seq analysis

M. Kumar, M. Belciad, **V. Nerurkar**
Honolulu, HI (USA)

14.011 Climate change and disease dynamics—A big data perspective
D. Lopez, **G. Sekaran**
Vellore (India)



Meet-the-Expert Sessions

Friday, March 4, 2016

07:45–08:45

How to Publish Your Work— Insights from the Editors

CME

In collaboration with Elsevier

- **E. Petersen**, Denmark **Room: G.01–03**
Editor-in-chief of the *International Journal of Infectious Diseases*
- **J. McConnell**, United Kingdom **Room: G.01–03**
Editor of *The Lancet Infectious Diseases*

Strengthening Disease Surveillance, Emergency Preparedness and Risk Communication for Health Security in India

CME

*In Collaboration with the International Society
for Disease Surveillance (ISDS)*

- **V. Singh**, India **Room: G.05–06**
- **P. Murthy**, India **Room: G.05–06**

Session 15

Ronald Ross Memorial Plenary Lecture Plenary III

CME

Malaria: Past, Present and Future

Co-Chairs: Ramanan Laxminarayan, India
Neena Valecha, India

Room: Hall 4 (Plenary Hall) 09:00–09:45
Ground Floor Friday, March 4, 2016

- 15.001** Malaria: Past, present and future
N. White
Bangkok (Thailand)

The Ronald Ross Memorial Lecture recognizes the contributions of Dr. Ronald Ross in discovering the mosquito transmission of malaria. Ross was awarded the Nobel Prize in Medicine in 1902 for his work on malaria and he has laid the foundation for successful research on this disease and methods of combating it. His groundbreaking research was conducted in Hyderabad in what is today called the Sir Ronald Ross Institute of Parasitology.

Coffee Break

Exhibition/Hall 3 09:45–10:15
Ground Floor Friday, March 4, 2016

Session 16

CME

Symposium

Infectious Encephalitis: Advances and Unknown

Co-Chairs: John McConnell, United Kingdom
Laura Kramer, USA

Room: Hall 1 10:15–12:15
Ground Floor Friday, March 4, 2016

- 16.001** Flavivirus encephalitis and other neurological syndromes (Japanese encephalitis, WNV, Tick Borne encephalitis Virus, Dengue, Zika Virus)
T. Solomon
Liverpool (United Kingdom)
- 16.002** Enterovirus encephalitis including enterovirus 71 and D68
T. Wong
Kuala Lumpur (Malaysia)
- 16.003** Acute encephalitis syndrome of unknown etiology
A. Desai
Bangalore (India)
- 16.004** Rabies encephalitis
A. Jackson
Winnipeg, MB (Canada)

In collaboration with the Lancet Infectious Diseases

Session 17

CME

Symposium

The Future of Infectious Diseases Diagnostics

Co-Chairs: Jayaraman Shanmugam, India
Paul Brown, Jamaica

Room: Hall 2 10:15–12:15
Ground Floor Friday, March 4, 2016

- 17.001** MALDI-TOF
A. Chakrabarti
Chandigarh (India)
- 17.002** Microbial culturomics
E. Angelakis
Marseille (France)
- 17.003** Point of care testing for global health
V. Gant
London (United Kingdom)
- 17.004** Whole genome sequencing in diagnostic microbiology
T. Peto
Oxford (United Kingdom)

*In collaboration with the Indian Association of
Medical Microbiologists*



Session 18

Symposium

**Childhood Vaccinations:
The Old and the New**

Co-Chairs: Vijay Yewale, India
Anita Shet, India

CME

Room: Hall 5
Ground Floor

10:15–12:15
Friday, March 4, 2016

- 18.001** Polio eradication: End game and beyond
T. J. John
Vellore (India)
- 18.002** Haemophilus influenza type B (Hib) vaccines: A looming success. Lessons learned from the Hib initiative
R. Hajjeh
Atlanta, GA (USA)
- 18.003** Pneumococcal conjugate vaccines
S. K. Saha
Dhaka (Bangladesh)
- 18.004** Prevention of enteric infections: Spotlight on Asia
G. Kang
Vellore (India)

In collaboration with the Indian Academy of Pediatrics

Session 19

Integrated Symposium

**Managing the Most Problematic
Gram-Negative Bacterial
Infections**

Co-Chairs: Matteo Bassetti, Italy
Venkatsubramanian Ramasubramanian, India

Room: Hall 6
Ground Floor

10:15–12:15
Friday, March 4, 2016

- 19.001** Antibiotic use and global trends of gram-negative resistance
C. Rodrigues
Mumbai (India)
- 19.002** Risk stratification: Identifying the right patient for the right treatment
M. Bassetti
Udine (Italy)
- 19.003** Strategic options for management of severe gram-negative infections
A. Shorr
Washington, DC (USA)

- 19.004** The role of antimicrobial stewardship in developing strategies for appropriate therapy

G. H. Karam

New Orleans, LA (USA)

Sponsored by MSD

Session 20

Symposium

**Melioidosis: A South Asian Disease
Emerging Globally**

Co-Chairs: Enoka Corea, Sri Lanka
Ivo Steinmetz, Germany

CME

Room: G.01–03
Ground Floor

10:15–12:15
Friday, March 4, 2016

- 20.001** Melioidosis endemicity in India
C. Mukhopadhyay
Manipal (India)
- 20.002** Predicted distribution of *B. pseudomallei* and burden of melioidosis in South Asia and worldwide
D. Limmathurotsakul
Bangkok (Thailand)
- 20.003** Why is melioidosis difficult to treat? Insights into pathogenesis
J. Wiersinga
Amsterdam (Netherlands)
- 20.004** Challenges in diagnosis and management of melioidosis
D. A. B. Dance
Vientiane (People's Democratic Republic of Lao)

Member proposed Symposium

Session 21

Oral Presentations

HIV & Tuberculosis

Co-Chairs: Leo Liu, USA
Rama Rao Amara, USA

CME

Room: G.05–06
Ground Floor

10:15–12:15
Friday, March 4, 2016

- 21.001** Pattern of HIV-1 drug resistance mutations among patients failing thymidine analogue and non-thymidine analogue based first-line failure in South India
S. Sivamalar, **T. R. Dinesha**, S. Gomathi, J. Boobalan, A. Pradeep, S. Poongulali, S. S. Solomon, S. Solomon, P. Balakrishnan, S. Saravanan
Chennai (India)



- 21.002** The impact of HIV infection on the burden and severity of influenza illness in Malawian adults
A. Ho¹, S. Aston², H. Jary¹, M. Alaerts¹, M. Menyere¹, J. Mallewa¹, M. Nyirenda¹, D. Everett¹, N. French², R. Heyderman¹
¹Blantyre (Malawi), ²Liverpool (United Kingdom)

- 21.003** Attenuated resting memory B cell compartment in HIV infected children despite highly active antiretroviral therapy (HAART)
R. Singh, A. Mukherjee, S. Kumar Kabra, R. Lodha, B. K. Das
New Delhi (India)

- 21.004** Evaluation of novel rapid bead based method for capturing of Mycobacterium tuberculosis in sputum
S. Verma, T. Dhole, S. Kashyap, M. Kumar
Lucknow (India)

- 21.005** Comparative evaluation of in-house real time IS 6110, nested MPT 64 PCR and Roche AMPLICOR 16s rRNA PCR for diagnosing tuberculous meningitis
R. Gupta, R. Thakur, N. Jalan, R. Pumanshi, M. Paul, S. Kushwaha
New Delhi (India)

- 21.006** Evolutionary patterns of T cell epitopes in Mycobacterium tuberculosis strains isolated in India
A. Ramaiah¹, S. Nayak¹, S. Rakshit¹, A. McGuire², S. Shanmugam³, J. Chandrabose³, S. Narayanan³, A. EarL², S. Swaminathan³, A. Vyakarnam¹
¹Bangalore (India), ²Cambridge (USA), ³Chennai (India)

- 21.007** Molecular evidence of melioidosis among patients suspected for tuberculosis
E. Jayakumar, R. Barani, M. Mani, V. Seshan, S. Muthiah Kothandaramanujam, R. Balakrishnan, P. Srikanth
Chennai (India)

- 21.008** Missed pulmonary TB screening opportunities at primary healthcare facilities: An exit study, Eastern Cape Province, South Africa
P. F. Kweza¹, N. Abraham¹, M. M. Claassens², C. Van Schalkwyk², A. Medino-Marino¹
¹Pretoria (South Africa), ²Cape Town (South Africa)

- 21.009** Performance evaluation of AnyplexII MTB/MDR/XDR for detection of first and second-line drug resistance in Mycobacterium tuberculosis
L. A. Malinga, B. Sibandze, R. Tsireledzo, N. Makhado, C. Maluleka, B. Magazi
Pretoria (South Africa)

- 21.010** Impact of Type I IFN dysregulation in M. tuberculosis infection on T cell responses
A. Ahmed¹, S. Nayak¹, S. Babu², A. Vyakarnam¹
¹Bangalore (India), ²Chennai (India)

- 21.011** Ps20: A novel correlate of inflammation and infection in tuberculosis?
B. K. Sundararaj¹, G. D'Souza¹, A. Jesuraj¹, C. Johnson², W. Bonam², L. E. Hannah³, S. Swaminathan³, M. Thakkar⁴, A. Vyakarnam¹
¹Bangalore (India), ²Madanapalle (India), ³Chennai (India), ⁴Pune (India)

Lunch Break

(optional)

Exhibition/Hall 3 12:45–14:15
Ground Floor Friday, March 4, 2016

A cash snack bar and lunch areas are available in Exhibition/Hall 3.

Poster Presentations

Exhibition/Hall 3 12:45–14:15
Ground Floor Friday, March 4, 2016

Sessions 42.001 – 42.278 (see pages 60–77)

Session 22

CME

Plenary IV

Tuberculosis: Challenges and Solutions for the 21st Century

Chair: Marc Mendelson, South Africa

Room: Hall 4 (Plenary Hall) 14:30–15:15
Ground Floor Friday, March 4, 2016

- 22.001** Tuberculosis: Challenges and Solutions for the 21st Century
S. Swaminathan
Chennai (India)

Coffee Break

Exhibition/Hall 3 15:15–15:45
Ground Floor Friday, March 4, 2016

Session 23

CME

Symposium

Intestinal Microbiota in Health and Disease

Co-Chairs: Makedonka Mitreva, USA
Ilan Youngster, USA

Room: Hall 1 15:45–17:45
Ground Floor Friday, March 4, 2016



- 23.001** The healthy human antibiotic resistome:
A multi-body habitat analysis
M. Mitreva
St. Louis, MO (USA)
- 23.002** Fecal microbiota transplants—
The clinical perspective
I. Youngster
Boston, MA (USA)
- 23.003** Neonatal microbiota in health and disease
P. Panigrahi
Omaha, NE (USA)
- 23.004** Beneficial modulation of the gut microbiota
P. Cotter
Cork (Ireland)

Session 24

Symposium

Pediatric Diarrhea in Low Income Countries: Rotavirus and Beyond

Co-Chairs: Miguel O'Ryan, Chile
Gagandeep Kang, India

Room: Hall 2 **15:45–17:45**
Ground Floor **Friday, March 4, 2016**

- 24.001** Rotavirus vaccines—A promise kept
J. E. Tate
Atlanta, GA (USA)
- 24.002** Norovirus infection and vaccine development: Where are we?
M. O'Ryan
Chile (Chile)
- 24.003** The outcomes of cryptosporidial infections in Indian children
G. Kang
Vellore (India)
- 24.004** Molecular diagnostics and the aetiology of diarrhea in low-income countries
J. Platts-Mills
Charlottesville, VA (USA)

Session 25

Symposium

Dengue, Chikungunya and Zika Virus Go Global

Co-Chairs: Tom Yuill, USA
Philippe Buchy, Singapore

Room: Hall 5 **15:45–17:45**
Ground Floor **Friday, March 4, 2016**

- 25.001** Dengue, Chikungunya and Zika Virus:
Global emergence
K. G. Luz
Natal (Brazil)
- 25.002** Pathogenesis of severe dengue infection
G. N. Malavige
Nugegoda (Sri Lanka)
- 25.003** Management of severe dengue
Y. S. Leo
Singapore (Singapore)
- 25.004** Zika virus: What you need to know
T. Yuill¹, R. Hajjeh², K. G. Luz³, T. Solomon⁴
¹Madison, WI (USA), ²Atlanta, GA (USA), ³Natal (Brazil), ⁴Liverpool (United Kingdom)

In collaboration with the Brazilian Society of Infectious Diseases

Session 26

Symposium

Neglected Infectious Diseases Around the World

Co-Chairs: George K. Varghese, India
Daniel Lew, Switzerland

Room: Hall 6 **15:45–17:45**
Ground Floor **Friday, March 4, 2016**

- 26.001** Leptospirosis
D. Diament
Sao Paulo (Brazil)
- 26.002** Leprosy: Is it a disease to be neglected?
J. Muliylil
Vellore (India)
- 26.003** Parasitic infections and allergies
P. Cooper
London (United Kingdom)
- 26.004** Infectious disease pathology in India: Interactive cases
R. Gopalakrishnan
Chennai (India)

In collaboration with the Clinical Infectious Diseases Society India (CIDS)

Session 27

Symposium

The Silent Epidemic of Hepatitis

Co-Chairs: Fatma Amer, Egypt
R.K. Ratho, India

Room: G.01–03 **15:45–17:45**
Ground Floor **Friday, March 4, 2016**



27.001 Hepatitis C infection in people who inject drugs

T. Azim

Dhaka (Bangladesh)

27.002 HCV state of the art:

Who, when and how to treat

J. Koirala

Springfield, IL (USA)

27.003 HIV and hepatitis C co-infection

G. Matthews

Sydney (Australia)

27.004 Hepatitis E vaccine—Where are we today?

P. Abraham

Vellore (India)

28.006 Identification of biofilm-stage specific

proteins associated with multidrug resistance and quorum sensing pathway in a pandemic strain of *Vibrio parahaemolyticus* isolated from India

A. Dharmaprakash, S. Thomas

Thiruvananthapuram (India)

28.007 Acquired 16s methyl transferase associated high level aminoglycoside resistance in *Acinetobacter baumannii* recovered from ICU patients from a tertiary referral hospital of northeast India

S. Upadhyay, S. R. Joshi, A. B. Khryiem, P. Bhattacharyya

Shillong (India)

28.008 *Helicobacter pylori* infection: Correlation to disease severity and Clarithromycin resistance in a Sri Lankan setting

N. L. Ubhayawardana, M. Weerasekera, C. Gunasekera, D. Weerasekera, K. Samarasinghe, N. Fernando
Colombo (Sri Lanka)

28.009 Recurrent spontaneous abortion: Significance of early non-invasive detection of Chlamydia trachomatis infection

N. Singh, P. PRASAD, B. Das, S. Rastogi
New Delhi (India)

28.010 Zinc restores altered intestinal ion-transport, barrier functions and counteract inflammatory mediators induced by *Shigella* infection in T84 cells

P. Sarkar¹, I. A. Sheikh, T. Saha, J. Aoun, M. H. Kazi
Kolkata (India)

28.011 Performance of the matrix assisted laser desorption / ionization time of flight mass spectrometry (MALDI-TOF MS) for accurate identification of routine gram negative bacteria—A reference laboratory experience from Mumbai

S. Athalye Shetye
Mumbai (India)

28.012 Challenges and opportunities in antibacterial drug discovery

K. P. Purnapatre, S. Dube
Gurgaon (India)

Session 28

Oral Presentations

Bacterial Infections & Vaccines

Co-Chairs: Eskild Petersen, Oman

Natalia Pshenichnaya, Russian Federation

CME

Room: G.05–06

15:45–17:45

Ground Floor

Friday, March 4, 2016

28.001 Safety, immune lot-to-lot consistency and non-inferiority of a fully liquid pentavalent DTwP-HepB-Hib vaccine: Results from Phase III licensure study of Shan5™

A. Sil, B. N. Patnaik, V. J. Midde
Hyderabad (India)

28.002 Correlates of county-level non-viral sexually transmitted infection hot spots in the US

B. Chang¹, W. Pearson², K. Owusu-Edusei Jr.²
¹New York, NY (USA), ²Atlanta, GA (USA)

28.003 Recombinant accessory cholera enterotoxin of *Vibrio cholerae* activate ANO6 via RhoA-ROCK-PIP2 signaling to induce secretory diarrhea

I. A. Sheikh, J. Aoun, P. Sarkar, T. Saha, M. H. Kazi
Kolkata (India)

28.004 A decade of antimicrobial stewardship at the University of Florida—Challenges, strategies and outcomes

K. Cherabuddi, K. Klinker
Gainesville, FL (USA)

28.005 Guillain-Barré syndrome in Bangladesh: The role TLR4 Asp299Gly and Thr399Ile polymorphisms

I. Jahan¹, R. U. Ahammad¹, M. M. Khalid¹, S. K. Sarker¹, M. B. Islam¹, H. P. Endtz²,
Z. Islam¹

¹Dhaka (Bangladesh), ²Rotterdam (Netherlands)



Meet-the-Expert Sessions

Saturday, March 5, 2016

07:45–08:45

Clinical Cases in Tropical Dermatology

CME

– A. Sethi, USA

Room: G.01-03

Clinical Management of Anti-Fungal Resistance—Interactive Cases

CME

– F. Menichetti, Italy

Room: G.05-06

Session 29

Plenary V

CME

Antimicrobial Resistance: From Problem to Policy to Action

Chair: Jon Cohen, United Kingdom

Room: Hall 4 (Plenary Hall)

09:00–09:45

Ground Floor

Saturday, March 5, 2016

- 29.001** Antimicrobial resistance:
From problem to policy to action
S. Davies
London (United Kingdom)

Coffee Break

Exhibition/Hall 3

09:45–10:15

Ground Floor

Saturday, March 5, 2016

Session 30

Symposium

CME

Infections in the Era of Cancer Treatments, Transplants and New Biologics

Co-Chairs: Suneetha Narreddy, India
Steven Opal, USA

Room: Hall 1

10:15–12:15

Ground Floor

Saturday, March 5, 2016

- 30.001** Fungal infections after transplant
S. Swaminathan
Chennai (India)
- 30.002** Neutropenic sepsis
F. Menichetti
Pisa (Italy)

- 30.003** Infectious complications of biologic therapeutics

S. Opal

Providence, RI (USA)

- 30.004** Cytomegalovirus

P. Ljungman

Huddinge (Sweden)

In collaboration with the Clinical Infectious Diseases Society India and the European Society of Clinical Microbiology and Infectious Diseases

Session 31

Symposium

CME

New and Recently Approved Antibiotics: Challenges and Opportunities

Co-Chairs: Ursula Theuretzbacher, Austria
Radha Rangarajan, India

Room: Hall 2

10:15–12:15

Ground Floor

Saturday, March 5, 2016

- 31.001** New antibiotics: What do we need?
D. Morgan
Baltimore, MD (USA)
- 31.002** The antibiotic pipeline: What can we expect?
U. Theuretzbacher
Vienna (Austria)
- 31.003** Incentivizing antibiotic innovation
C. Årdal
Oslo (Norway)
- 31.004** Basic improvement methods in stewardship
A. H. Holmes
London (United Kingdom)

In collaboration with DRIVE-AB—A project of the Innovative Medicines Initiative

Session 32

Symposium

CME

HIV—Hot Topics in Antiretroviral Therapy and its Consequences

Co-Chairs: Dilip Mathai, India
Nguyen Quoc, Viet Nam

Room: Hall 5

10:15–12:15

Ground Floor

Saturday, March 5, 2016

- 32.001** Update on HIV Prevention
K. Mayer
Boston, MA (USA)



32.002 The good, the bad and the beautiful:
Anti-retroviral therapy considerations in
children and adolescents

A. Shet

Bangalore (India)

32.003 Manifestations and management of IRIS

G. Meintjes

Cape Town (South Africa)

32.004 The long-term impact of antiretroviral
therapy in resource-limited settings

N. K. Kumarasamy

Chennai (India)

Session 33

Symposium

Update on Visceral Leishmaniasis in South Asia

Co-Chairs: Suman Rijal, India
Shyam Sundar, India

Room: Hall 6
Ground Floor

10:15–12:15
Saturday, March 5, 2016

33.001 Active case finding of kala-azar

P. Das

Patna (India)

33.002 Treatment of visceral leishmaniasis

S. Sundar

Varanasi (India)

33.003 Post kala-azar dermal leishmaniasis: Burden,
diagnosis and treatment challenges

V. Ramesh

New Delhi (India)

33.004 Combination treatment for visceral
leishmaniasis patients co-infected with
human immunodeficiency virus in India

S. Burza

London (United Kingdom)

*In collaboration with the Drugs for Neglected
Diseases Initiative*

Session 34

Symposium

Infectious Diseases in Refugees, Migrants and Internally Displaced Persons

Co-Chairs: Vladimir Krčmery, Slovak Republic
Mustafa Mubarak, Sudan

Room: Hall G.01–03
Ground Floor

10:15–12:15
Saturday, March 5, 2016

34.001 The health of refugees and displaced persons
in South Sudan

J. Wamala

Juba (Uganda/South Sudan)

34.002 Managing health and infections in refugees:
Turkey's experience

H. Leblebicioglu

Samsun (Turkey)

34.003 Rapid diagnostic point of care tests in
resource limited settings

J. Kafkova

Nairobi (Kenya)

34.004 Infectious diseases in refugees and migrants
during the European Migrant Crisis 2015

V. Krčmery

Bratislava (Slovakia)

*Supported in part with a NATO grant on
Refugee and Migrant Health*

Session 35

Oral Presentations

Tropical Infectious Diseases

Co-Chairs: Ravi Kiran Barigala, India
Larry Lutwick, USA

Room: Hall G.05–06
Ground Floor

10:15–12:15
Saturday, March 5, 2016

35.001 From evidence to impact: Improving
treatment for kala-azar patients in India

R. Mahajan¹, T. Sunyoto¹, K. Malakyan¹,
G. Mitra¹, D. Kumar², M. A. Lima³,
P. Mathew¹, S. Burza¹

¹New Delhi (India), ²Hajipur (India),

³Barcelona (Spain)

35.002 In silico and experimental studies of
Plasmodium serpentine receptor predicts
its role as putative purinergic receptor

S. Gupta¹, N. Joshi¹, S. Singh²

¹Dadri (India), ²Noida (India)

35.003 Spatiotemporal epidemiology of malaria
in Madagascar between 2006 and 2015

F. A. Ithantamalala¹, V. Herbreteau²,
J. M. Rakotondramanga¹, G. Pennober²,
B. Rahoilijaona¹, C. J. E. Metcalf³,
C. O. Buckee⁴, F. Rakotomanana¹, C. Rogier¹,
A. Wesolowski⁴

¹Antananarivo (Madagascar), ²Saint-Pierre-
La Réunion (France), ³Princeton, NJ (USA),

⁴Boston, MA (USA)



- 35.004** Assessment of effect of intermittent preventive treatment of malaria in pregnancy on birth weight of babies in Nigeria: Life-saving dynamics
Y. F. Oke, M. Salihu
Abuja (Nigeria)
- 35.005** Rickettsial disease IFA-IgG titres in auto-immune diseases: What do they imply?
P. Balasooriya, N. B. Bandara,
T. Chandrasena, **R. Premaratna**
Ragama (Sri Lanka)
- 35.006** Novel tick-borne Rickettsia sp. from wild ticks of Kenya: Implications for emerging vector-borne disease outbreaks
M. M. Mwamuye, E. Kariuki, D. Omondi,
J. Kabii, D. Odongo, D. Masiga, J. Villinger
Nairobi (Kenya)
- 35.007** Twelve months outcome in kala-azar patients treated with 3 novel regimens, at public health care facilities in Bihar
V. Goyal¹, R. Mahajan¹, B. Sharma¹,
N. Strub-Wourgaft³, M. Balasegaram³,
S. Rijal¹, S. Ellis², F. Alves², S. Burza¹,
T. Sunyoto¹, N. Lima³, K. Pandey⁴,
V. N. Rabi Das⁴, P. Das⁴, J. Alvar²
¹New Delhi (India), ²Geneva (Switzerland),
³Barcelona (Spain), ⁴Patna (India)
- 35.008** Post kala-azar dermal leishmaniasis treated with liposomal amphotericin B (AmBisome)
S. Burza¹, M. D. Boer², R. Mahajan¹, A. K.
Das³, G. Mitra¹, P. Almeida³, M. A. Lima⁴,
B.-N. Ahmed³, T. Sunyoto¹, K. Ritmeijer²
¹New Delhi (India), ²Amsterdam
(Netherlands), ³Dhaka (Bangladesh),
⁴Barcelona (Spain)
- 35.009** Multilocus sequence typing of seven genetic loci to discriminate strains of *L. donovani* isolated from Bangladesh
S. S. Banu
Westmead (Australia)
- 35.010** The effect of TNF-Alpha neutralization on parasite load and cytokine production in human visceral leishmaniasis
N. Singh¹, R. Kumar², S. Nylén³, D. Sacks⁴,
S. Sundar¹
¹Varanasi (India), ²New Delhi (India),
³Stockholm (Sweden), ⁴Bethesda, MD (USA)
- 35.011** The baboon (*Papio anubis*)-*Plasmodium knowlesi* model of placental malaria
F. I. Onditi
Nairobi (Kenya)

Lunch Break

(optional)

Exhibition/Hall 3 12:45–14:15
Ground Floor Saturday, March 5, 2016

A cash snack bar and lunch areas are available in Exhibition/Hall 3.

Poster Presentations

Exhibition/Hall 3 12:45–14:15
Ground Floor Saturday, March 5, 2016

Sessions 43.001 – 43.271 (see pages 78–94)

Session 36

CME

Plenary VI

**Zika, MERS, Ebola, SARS and H1N1:
Local and Global Responses
to Viral Threats**

Chair: Rana Hajjeh, USA

Room: Hall 4 (Plenary Hall) 14:30–15:15
Ground Floor Saturday, March 5, 2016

- 36.001** Zika, MERS, Ebola, SARS and H1N1:
Local and global responses to viral threats
P. A. Tambyah
Singapore (Singapore)

Coffee Break

Exhibition/Hall 3 15:15–15:45
Ground Floor Saturday, March 5, 2016

Session 37

CME

Symposium

**Sepsis and Other Infections
in Critical Care**

Co-Chairs: Balaji Veeraraghavan, India
Jon Cohen, United Kingdom

Room: Hall 2 15:45–17:45
Ground Floor Saturday, March 5, 2016

- 37.001** Intensive care considerations in epidemics
P. A. Tambyah
Singapore (Singapore)
- 37.002** Epidemiology of sepsis in low- and middle-income countries
V. Ramasubramanian
Chennai (India)



37.003 Antibiotic use in the ICU
J. Cohen
Brighton (United Kingdom)

37.004 New therapeutics for sepsis
S. Opal
Providence, RI (USA)

In collaboration with the Clinical Infectious Diseases Society India

Session 38 Symposium

CME

Enteric Fever Prevention and Control Strategies

Co-Chairs: Anita Zaidi, USA
Matar Ghassan, Lebanon

Room: Hall 5
Ground Floor 15:45–17:45
Saturday, March 5, 2016

38.001 The surveillance for enteric fever in Asia project (SEAP): Estimating the community burden of enteric fever

D. Garrett
Washington, DC (USA)

38.002 Development status of typhoid conjugate vaccines globally

S. Sahastrabuddhe
Seoul (Republic of Korea)

38.003 Strategies on containing and treating drug resistant typhoid in low and middle-income countries

A. Arjyal
Lalitpur (Nepal)

38.004 Global typhoid policy recommendations

A. Zaidi
Seattle, WA (USA)

Session 39 Symposium

CME

Protecting the Healthcare Worker Around the World

Co-Chairs: Alison Holmes, United Kingdom
Arti Kapil, India

Room: Hall 6
Ground Floor 15:45–17:45
Saturday, March 5, 2016

39.001 Protecting the healthcare worker around the world

R. Gallagher
London (United Kingdom)

39.002 Technologies for hospital disinfection and textiles for bioburden reduction

G. Bearman
Richmond, VA (USA)

39.003 The impact of education on reducing Ebola virus disease transmission in healthcare facilities

S. Mehtar
Cape Town (South Africa)

39.004 Protecting the health care worker during outbreaks—The case of viral hemorrhagic fever outbreaks

H. De Clerck
Antwerp (Belgium)

Session 40 Symposium

CME

Sexually Transmitted Infections: Global Challenges

Co-Chairs: Sanjay Mehendale, India
Helen Rees, South Africa

Room: G.01–03
Ground Floor 15:45–17:45
Saturday, March 5, 2016

40.001 HIV and syphilis

K. Mayer
Boston, MA (USA)

40.002 Prostatitis: Challenges in diagnosis and treatment

K. G. Naber
Munich (Germany)

40.003 Global challenges of implementing human papillomavirus vaccines

H. Rees
Johannesburg (South Africa)

40.004 Prospects of untreatable gonorrhea and ways forward

Speaker to be confirmed



Session 41

Poster Presentations

Poster Session I

Room: Hall 3

12:45–14:15

(Posters & Exhibition)

Thursday, March 3, 2016

Poster Prize Finalists (Thursday)

- 41.001** Antimicrobial resistance, phylogenetic distribution and molecular docking of integrons in multidrug resistant diarrheagenic *E. coli* isolates from children under five in Delhi, India
T. Singh, S. Das, V. Ramachandran, K. Maroof, A. Rai
New Delhi (India)
- 41.002** Correlation of beta-lactam resistance with over expression of efflux pumps among neonatal septicemic isolates of *Acinetobacter baumannii* from India
S. Roy, S. Basu
Kolkata (India)
- 41.003** Assessment of anti-bacterial activity of silver ions in infected diabetic foot ulcers—An answer to antibiotic resistance
A. P. Ignatius, R. Tellis
Mangalore (India)
- 41.004** Antimicrobial susceptibility pattern and sequence analysis of DNA gyrase and DNA topoisomerase IV in *Salmonella enterica* serovars typhi and paratyphi A at a tertiary care centre in North India
R. Misra
Lucknow (India)
- 41.005** Is Moxifloxacin a secret weapon or simply a trump card to treat methicillin resistant staphylococcal infections? A study from Egypt
A. A. Y. Abouelfetouh¹, M. Naguib², S. Magdy², M. Kassem¹, M. El-Nakeeb¹
¹Alexandria (Egypt), ²Damanhour (Egypt)
- 41.006** Emergence, spread and exchange of bla_{NDM-1} gene among enterobacteriaceae in septicemic neonates
S. Datta, S. Mitra, S. Chatterjee, S. Basu
Kolkata (India)
- 41.007** Comparison of antimicrobial resistance determinants and Staphylococcal Cassette Chromosome mec elements of Staphylococci isolated from human and veterinary origin
N. Perumal, P. Krishnan
Chennai (India)
- 41.008** The impact of pre-hospital antibiotics on blood culture yields in a low resource setting
I. Sarr, S. Jarju, N. kebbeh, G. Sey, M. Saidykhan, G. Thomas, F. Seck, M. Antonio, K. Bojang
¹Banjul (Gambia)
- 41.009** Vaccination of stray dogs against rabies is an effective strategy to reduce the risk of human rabies
V. K. Jayasundara
Dehiwala (Sri Lanka)
- 41.010** Mosquito infection with dengue and Yellow Fever in Bayelsa and Benue States, Nigeria
C. Isaac¹, **E. J. Agwu**²
¹Ekpoma (Nigeria), ²Nsukka (Nigeria)
- 41.011** High prevalence of *Schistosoma mansoni* and other intestinal parasites among elementary school children in Southwest Ethiopia: A cross-sectional study
Z. Mengistie
Addis Ababa (Ethiopia)
- 41.012** Efficacy, safety and cost-effectiveness of thermotherapy for *L. donovani*-induced cutaneous leishmaniasis: A randomized controlled clinical trial
W. Refai¹, N. Madarasingha¹, S. Weerasingha¹, U. Senarath¹, A. De Silva¹, R. Fernandopulle¹, A. Satoskar², N. Karunaweera¹
¹Colombo (Sri Lanka), ²Columbus, OH (USA)
- 41.013** Identification and functional validation of a biomarker for the diagnosis of miltefosine relapse during visceral leishmaniasis
P. Tiwary, D. Kumar, S. Sundar
Varanasi (India)
- 41.014** Endoscopic nodular gastritis with *Helicobacter pylori* infection: An indicator of high-grade bacterial colonization and severe gastritis in children
K. K. Prasad, S. B. Lal, B. R. Thapa, U. Debi, A. K. Sharma
Chandigarh (India)
- 41.015** Microarray-based assay for simultaneous identification and drug resistance detection of microorganisms causing sexually transmitted diseases
A. Leinsoo, B. Shaskolskiy, E. Dementieva, A. Runina, D. Vorobyev, X. Plakhova, A. Kubanov, D. Gryadunov
Moscow (Russian Federation)



Animal Models, Pathogenesis and Host Defenses

- 41.016** Temperature and oxidative stress as triggers for virulence gene expression in pathogenic *Leptospira spp*
T. Fraser, **P. Brown**
Kingston (Jamaica)
- 41.017** Prevalence of virulence determinants among HA-MRSA and CA-MRSA isolates and pathogenicity testing using caenorhabditis elegans model
B. S. Dass¹, P. Udayakumar², J. Malaiyan¹, B. Krishnaswamy², P. Krishnan¹
¹Chennai (India), ²Karaikudi (India)
- 41.018** Modeling of cerebral tuberculosis in BALB/c mice using clinical strain from patients with CNS-TB infection
U. Gupta
Agra (India)
- 41.019** Genome wide differential host response to highly or low pathogenic H5N1 avian influenza virus infection in ducks
A. Kumar, P. Vijayakumar, P. N. Gandhale, P. B. Ranaware, S. B. Sudhakar, H. Kumar, D. D. Kulkarni, A. A. Raut, **A. Miishra**
Bhopal (India)
- 41.020** Differential dendritic cells responses to infection with various serotypes of *Shigella*
C. Narayan, B. R. Thapa, J. K. Mahajan, V. Kant, B. Mohan, N. Taneja
Chandigarh (India)
- 41.021** Genome wide host gene expression analysis in chicken lungs infected with avian influenza viruses
P. B. Ranaware, A. Mishra, P. Vijayakumar, P. N. Gandhale, S. B. Sudhakar, H. Kumar, D. D. Kulkarni, **A. A. Raut**
Bhopal (India)
- 41.022** Murine model of tuberculous meningitis: New insight into understanding pathological complications of the disease
S. Majeed, B. Radotra, **S. Sharma**
Chandigarh (India)
- 41.023** Cleavage site and ectodomain of HA2 sub-unit sequence of three equine influenza virus isolated in Morocco
M. Boukharta¹, **F. Zakham**², N. Touil³, M. Elharrak³, M. M. Ennaji¹
¹Mohammedia (Morocco), ²Hodeidah (Yemen), ³Rabat (Morocco)

Antimicrobial resistance

- 41.024** Nasal carriage of methicillin resistant *Staphylococcus aureus* among health workers in high risk units in a tertiary hospital in north western Nigeria
M. M. Abdulaziz¹, A. Olayinka²
¹Zaria (Nigeria), ²Shika-Zaria (Nigeria)
- 41.025** Antibiotic sensitivity and resistance patterns of *Salmonella typhi* isolates from Nigerian malnourished children
U. I. Abdullahi
Kano (Nigeria)
- 41.026** Comparison of bacterial characteristics (MICs) of Gram negative bacteria isolated from patients with neutropenic sepsis pre and post-Levofloxacin prophylaxis
H. M. W. Abeywardena¹, N. Perera²
¹Nuwara Eliya (Sri Lanka), ²Leicester (United Kingdom)
- 41.027** Prevalence and antibiotic sensitivity profiles of bacteria causing community acquired pneumonia
R. Adhikari, S. Shrestha
Kathmandu (Nepal)
- 41.028** Antibiotic resistance pattern of HA-MRSA strains isolated from leukemia patients in Baghdad, Iraq
N. Al-Azawi¹, K. Mohammed Ali², A. Alwan¹, **S. B. I. Al-rifai**¹, A. Al-bayati¹
¹Baghdad (Iraq), ²Tikrit (Iraq)
- 41.029** Prevalence and risk factors for intestinal colonization with vancomycin-resistant enterococci among patients admitted to intensive care units of a large teaching hospital in Southern India
R. Amberpet, S. Sistla, S. Parija, M. M. Thabab, R. Ramachandra
Pondicherry (India)
- 41.030** Carbapenem resistance in clinical isolates of multi drug resistance *E.coli*
T. Ananthabalrajurs
Mysore (India)
- 41.031** A study of 24 patients with colistin resistant gram negative isolates in a tertiary care hospital in South India
R. Arjun, R. Gopalakrishnan, V. Ramasubramanian, S. Nambi, S. Durairajan
Chennai (India)



- 41.032** Genotypic and phenotypic characterization of antimicrobial resistance in *Staphylococcus aureus* strains isolated from wound infections in Mardin, Southeastern Turkey
C. Demir¹, M. Demirci², A. Yigin³,
H. Bahar Tokman²
¹Mardin (Turkey), ²Istanbul (Turkey),
³Sanliurfa (Turkey)
- 41.033** Frequent resistant gram negative rod stool colonization among patients admitted with acute febrile illness in Pune, India
R. S. Bharadwaj¹, M. Robinson²,
I. Marbaniang¹, A. Kagal¹, P. A. Raichur¹,
V. Kulkarni¹, U. Balasubramanian¹,
P. Onawale¹, S. Kanade¹, G. Nelson³,
A. Gupta², V. Mave¹
¹Pune (India), ²Baltimore, MD (USA),
³Nashville, TN (USA)
- 41.034** Molecular characterization of *Escherichia coli* isolated from hospital acquired infections from two different geographical areas, Ujjain and Bangalore
S. Chandran
Ujjain (India)
- 41.035** Transcriptional response of AcrAB-TolC conferring carbapenems resistance within *Escherichia coli* associated with community acquired infection
S. Chetri, A. Bhattacharjee, D. Dhar Chanda,
A. Chakravarty
Silchar (India)
- 41.036** Beta-lactam resistance among enterobacteriaceae: Follow-up 7 years
R. Chheang, P. NOP, S. Heng, A. Tarantola,
A. Kerléguer
Phnom Penh (Cambodia)
- 41.037** Expansion of diverse inc F type plasmids within enterobacteriaceae conferring multidrug resistant trait in tertiary referral hospital in North East India
N. A. Choudhury, A. Bhattacharjee,
D. Dhar Chanda, A. Chakravarty
Silchar (India)
- 41.038** Bacteriological profile of ablood culture isolates in a cancer hospital with special reference to *E.coli* and its Antibiotic susceptibility pattern in patients with haematological malignancies
R. R. Dandamudi
Hyderabad (India)
- 41.039** Analysis of quinolone resistance due to mutational changes in *Escherichia coli* associated with urinary tract infections: A study from North East India
N. Dasgupta, D. Paul, D. Dhar Chanda,
A. Chakravarty, A. Bhattacharjee
Silchar (India)
- 41.040** Microbiological profile of aerobic bacterial isolates causing complicated intra-abdominal infections managed at a tertiary level health care providing facility in northern India
A. Deep, S. Marwah, S. Pandey,
U. Chaudhary
Rohtak (India)
- 41.041** Antibiotics susceptibility pattern of *Vibrio cholerae* O1 Ogawa, isolated during Cholera outbreak investigations in Mozambique from 2014 to 2015
L. C. Dengo Baloi
Maputo (Mozambique)
- 41.042** Evidence of carriage of minimal form of resistance island in clinical isolates of multidrug-resistant *Acinetobacter baumannii*
M. Douraghi, S. Jasemi, M. A. Boroumand,
M. Rahbar
Tehran (Iran)
- 41.043** Antibiotic susceptibility patterns of prevalent anaerobic gram negative bacilli in Lagos, Nigeria: A 20 year survey
L. O. Egwari¹, N. Nwokoye², O. Olubi²
¹Ota (Nigeria), ²Lagos (Nigeria)
- 41.044** Transcriptional response of *arnA* and *pmrB* in relation to polymyxin resistance in *Pseudomonas aeruginosa* associated with surgical wound infection: A study from North East India
R. Elizabeth¹, S. Roy², D. Paul², D. Dhar²,
A. Chakravarty², A. Bhattacharjee²
¹Manipur (India), ²Silchar (India)
- 41.045** Molecular epidemiology and spread dynamics of multi-drug resistant in *A. baumannii* isolated from patients and hospital environment in Bangladesh
R. Farzana¹, T. Mozumder², B. Hasan³
¹Enayetpur (Bangladesh), ²Dhaka (Bangladesh), ³Uppsala (Sweden)
- 41.046** Genotyping of *Mycobacterium tuberculosis* strains isolated from patients with pulmonary drug-resistant tuberculosis in Ukraine
O. Konstantynovska, A. Rogozhin,
A. Gerilovych, S. Sapko, P. Poteiko,
O. Liashenko, V. Bolotin, O. Solodiankin
Kharkiv (Ukraine)



- 41.047** Of bugs and drugs: have carbapenems met their doom?
M. Gupta¹, V. Agarwal², R. Surpam²
¹Lucknow (India), ²Nagpur (India)
- 41.048** Serotype distribution and antibiotic resistance among isolates of *Streptococcus pneumoniae* causing invasive pneumococcal disease in adults in Turkey: 2005–2015
G. Hasçelik¹, N. Gürler², M. Ceyhan¹, C. Özakin³, G. Bayramoglu⁴, Z. Gülay⁵, G. Söyletir², A. Yaman⁶, L. Oksuz², D. Perçin⁷, S. Aydemir⁵, K. Yanık⁸, M. Gültekin⁹, B. Sancak¹
¹Ankara (Turkey), ²Istanbul (Turkey), ³Bursa (Turkey), ⁴Trebizond (Turkey), ⁵Izmir (Turkey), ⁶Adana (Turkey), ⁷Kayseri (Turkey), ⁸Samsun (Turkey), ⁹Antalya (Turkey)
- 41.049** Antibiotic susceptibility pattern of *Brucella melitensis* clinical isolates in Hamedan, west of Iran
S. H. Hashemi, M.-Y. Alikhani, F. Torkaman Asadi, Z. Naseri
Hamedan (Iran)
- 41.050** In-vitro activity of Fosfomycin against clinical isolates of carbapenem resistant *Acinetobacter baumannii* complex and *Pseudomonas aeruginosa* at a South African academic hospital
A. A. Hoosen, K. Baba
Bloemfontein (South Africa)
- 41.051** pncA mutations in mycobacterium tuberculosis is a strong predictor of poor treatment outcome in the therapy of multidrug resistant tuberculosis
D. Li, **Y. Hu**
Shanghai (China)
- 41.052** Antimicrobial resistance of methicillin-resistant staphylococci isolated from food producing animal
A. Beshiru, I. Igbinosa, **E. Igbinosa**
Benin City (Nigeria)
- 41.053** Antibioqram characterization of *Salmonella serovars* isolated from food-animal and abattoir effluents
I. Igbinosa¹, V. Chigor², E. Igbinosa¹
¹Benin City (Nigeria), ²Nsukka (Nigeria)
- 41.054** AmpC beta-lactamase producing *Escherichia coli* associated with urinary tract infection from a tertiary health care centre in North East India
B. Ingti, D. Dhar (Chanda), A. Chakravarty, A. Bhattacharjee
Silchar (India)
- 41.055** Antibiotic resistance among hospitalized patients in Mauritius in 2014
M. Issack
Quatre-Bornes (Mauritius)
- 41.056** In vitro antimicrobial susceptibility of ceftriaxone/sulbactam/ethylenediaminetetraacetic acid and comparison to other beta-lactam/beta-lactamase inhibitors, carbapenems and colistin against gram negative bacteria
S. Jain, A. Gupta, V. Khare
New Delhi (India)
- 41.057** Antimicrobial susceptibility and serotype distribution of invasive and non-invasive *Streptococcus pneumoniae* isolates and comparison from healthy carriers
S. Jain, B. K. Das, S. Tyagi, A. Kapil, R. Chaudhry, S. Sood, S. K. Kabra, D. Nair
New Delhi (India)
- 41.058** Healthy carriage of drug-resistant enterobacteriaceae in the community
V. M. Joy, S. Bansal, N. Batra, G. Didwal, A. Thakur, V. Gautam, P. Ray, M. Gupta
Chandigarh (India)
- 41.059** Epidemiology of extended-spectrum beta-lactamase- and carbapenemase-producing bacteria in stool from apparently healthy children, South Africa
M. Kaba, R. I. Manenzhe, C. Moodley, H. J. Zar, M. P. Nicol
Cape Town (South Africa)
- 41.060** Characterization of carbapenem resistance in clinical isolates of enterobacteriaceae
V. Kalwaje Eshwara¹, P. Sahai², C. Tellapragada², C. Mukhopadhyay²
¹Udupi (India), ²Manipal (India)
- 41.061** Multidrug resistant blood culture isolates: An experience from a tertiary care hospital in Eastern Nepal
B. Khanal, A. Yadav, T. Pandit, L. B. Shrestha, B. Narayan Raj
Dharan (Nepal)
- 41.062** Bacterial species and antimicrobial susceptibility of wound culture, obtained from diabetic gangrene patients who went limb amputation at a Japanese University Hospital
S. I. Kimura, H. Yamaguchi, A. Takuma, E. Fukuoka, S. Fukuoka, A. Minemura, K. Suzuki, T. Soga, T. Ebara, M. Nakamura
Yokohama (Japan)



- 41.063** The species distribution and resistance pattern of vancomycin resistance *Enterococci* from bloodstream infections in Istanbul, Turkey
F. Koksall Cakirlar, M. Günaydin, N. Gonullu, N. Kiraz
Istanbul (Turkey)
- 41.064** Detection of carbapenemase genes OXA-48, VIM, IMP, KPC and NDM in carbapenemase-producing *Pneumoniae klebsiella* isolates from blood cultures of hospitalized patients in Istanbul, Turkey
F. Koksall Cakirlar, N. Gonullu, F. Kalayci, N. Kiraz
Istanbul (Turkey)
- 41.065** Detection of IMP, VIM and NDM metallo-betalactamase carbapenemase genes in carbapenem resistant *Pseudomonas* strains from bloodstream infections in Istanbul, Turkey
F. Yilmaz Yucel, **F. Koksall Cakirlar**, E. Koyuncu, R. Ozturk
Istanbul (Turkey)
- 41.066** Carbapenemase producing enterobacteriaceae from chronic hemodialysis and renal transplant patients from a tertiary care centre in Chennai, South India
P. Krishnan, G. Kaushik, P. Gnana Soundari, R. Vijayakumar
Chennai (India)
- 41.067** Synthesis and biological evaluation of indole-based 2-Aryl-2,3-epoxy-1,4-naphthoquinones as methicillin-resistant *Staphylococcus aureus* (MRSA) inhibitors
A. Kulkarni¹, I. Soni², A. Dharmaraja¹, R. Sankar¹, R. Thakare², S. Chopra², H. Chakrapani¹
¹Pune (India), ²Lucknow (India)
- 41.068** Susceptibility pattern of healthcare-associated methicillin resistant *Staphylococcus aureus* to Vancomycin and Daptomycin
J. Kumari, S. Shenoy, C. Mahabala, K. Vidyaxshmi, G. Bhat K
Mangalore (India)
- 41.069** Prevalence and antibiotic sensitivity of *Staphylococcus aureus* and *Pseudomonas aeruginosa* in middle ear fluids of chronic suppurative otitis media and chronic rhinosinusitis patients undergoing ear surgery
J. Madhavi, M. Santoshi, K. R. Meghanadh, A. Jyothy
Hyderabad (India)
- 41.070** The emergence of cotrimoxazole and quinolone resistance in *Shigella sonnei*
J. Mandal, A. Das, M. Natarajan
Puducherry (India)
- 41.071** Carriage of multiple gene cassettes mediated extended spectrum cephalosporinase within diverse incompatibility (Inc) plasmid groups among gram negative rods in a tertiary referral hospital of India
A. P. Maurya¹, D. Dhar Chanda², A. Chakravarty², A. Bhattacharjee²
¹Dehradun (India), ²Silchar (India)
- 41.072** Beta-lactamases in a Nepalese hospital: Wake up before the "biological quake" destroys you
S. K. Mishra, G. P. Sapkota, S. Adhikari, M. Lakhey
Kathmandu (Nepal)
- 41.073** Fecal carriage of carbapenem resistant enterobacteriaceae (CRE) and risk factor analysis in hospitalised patients: A single centre study from India
B. Mohan, A. Prasad, H. Kaur, V. Hallur, N. Gautam, N. Taneja
Chandigarh (India)
- 41.074** Molecular mechanisms of efflux pump mediated resistance in clinical isolates of multidrug resistant *Pseudomonas aeruginosa*
L. Mohanam¹, L. Priya¹, E. M. Selvam¹, S. S. Shivekar², T. Menon¹
¹Chennai (India), ²Puducherry (India)
- 41.075** Identification of erm and msrA genes in inducible clindamycin resistance of clinical isolates of *Staphylococcus aureus* by polymerase chain reaction and D-test in Iran
M. Moosavian¹, S. Shoja², S. Rostami³, M. Torabipour¹, Z. Farshadzadeh⁴
¹Ahvaz (Iran), ²Bandar Abbas (Iran), ³Isfahan (Iran), ⁴Tehran (Iran)
- 41.076** An issue of Public Health concern due to emerging drug resistance against *Toxascaris leonina* (Linstow, 1909) in Asiatic lions (*Panthera leo persica*)
A. D. Moudgil¹, L. D. Singla¹, M. P. Singh²
¹Ludhiana (India), ²Chhatbir (India)
- 41.077** Prevalence of plasmid-mediated quinolone resistance determinants in enterobacteriaceae strains in West-Iran
M.-Y. Alikhani, R. Yousefi Mashouf, **A. S. Mozaffari Nejad**, A. Majlesi, R. K. Kakhki, A. Roointan, M. Abazari
Hamedan (Iran)



- 41.078** Blood stream infections: Changing trends in etiology and susceptibility pattern
S. S. Mudshingkar, M. Palewar, V. Dohe, R. S. Bharadwaj
Pune (India)
- 41.079** Emergence of multidrug resistant and non-vaccine serotypes of *Streptococcus pneumoniae* in a tertiary care hospital, Southern India
P. S. R. Murthy, S. Sistla
Pondicherry (India)
- 41.080** Molecular serogrouping of serologically atypical *Shigella* isolates from South India
D. P. Muthuirulandi Sethuvel, S. Anandan, D. N. Kumar, B. Veeraraghavan
Vellore (India)
- 41.081** Profile of genes coding for Carbapenemases among resistant *Acinetobacter* species from a tertiary care centre: A laboratory based study
S. Nagaraj¹, S. Chandran², R. Yoganand¹, R. Macaden¹
¹Bangalore, Karnataka (India), ²Ujjain (India)
- 41.082** Detection of antimicrobial resistance genes in Diarrhoeagenic *Escherichia coli* from children less than 5 years
M. Natarajan, D. Manjunathan, J. Mandal, B. Harish
Pondicherry (India)
- 41.083** Safety and therapeutic efficacy of *Staphylococcus aureus* specific lytic phage against multidrug-resistant *S. aureus* (MDRSA) in BALB/c mice: A prospective study
J. M. O. Oduor, W. Nyamongo Onkoba, F. Maloba, W. Ouma Arodi, N. Atunga,
F. I. Onditi
Nairobi (Kenya)
- 41.084** Molecular characterization of high level aminoglycoside resistant non-urinary isolates of *Enterococcus* species
K. Padmavathy, A. Kiruthiga, S. Praveen
Chennai (India)
- 41.085** Tracking trends in antibiotic effectiveness using the drug resistance index
S. Pant¹, E. Klein¹, S. Gandra³, R. Laxminarayan³
¹Washington, DC (USA), ²New Delhi (India)
- 41.086** Concentration dependent carbapenem exposure alters the plasmid copy number within nosocomial isolates of *Escherichia coli* harboring bla_{NDM-1}: A study from Northeast India
D. Paul, D. Dhar, A. Bhattacharjee
Silchar (India)
- 41.087** Surveillance of bloodstream infection and antibiotic resistance in Phnom Penh, Cambodia 2007–2014
T. Phe¹, E. Vlieghe², K. Lim¹, C. Veng¹, S. Thai¹, L. Leng¹, C. Kham¹, J. Jacobs²
¹Phnom Penh (Cambodia), ²Antwerp (Belgium)
- 41.088** Antibiotic sensitivity patterns among ESBL UTIs in Sri Lanka
N. Luke, S. Wickramasinghe, B. Sebastiampillai, M. Gunathilake, N. Miththinda, S. Fernando, S. Silva,
R. Premaratna
Ragama (Sri Lanka)
- 41.089** Direct costs and length of stay in Carbapenem resistant versus Carbapenem sensitive *Klebsiella pneumoniae* infections in a tertiary care hospital
A. Priyendu, Z. Ahmed, A. Nagappa, V. Eshwara, M. Varma
Manipal (India)
- 41.090** Development, optimization, standardization and validation of a simple in-house agar gradient method to determine vancomycin MIC's for *Staphylococcus aureus*
S. Rai, M. Tandon, N. Singh, I. Kaur
New Delhi (India)
- 41.091** Multidrug-resistant *Acinetobacter baumannii*—Plasmid-borne carbapenem and aminoglycoside co-resistance causing outbreak in Southwest Virginia
J. Rao¹, D. Susanti², M. C. Mitkos³, J. K. Brima³, A. Baffoe-Bonnie³, M. J. F. Cotarelo³, T. M. Kerkering¹, B. Mukhopadhyay²
¹Roanoke, VA (USA), ²Blacksburg (USA), ³Madrid (Spain)
- 41.092** Biofilm formation by *Staphylococcus* species on exposure of sub-lethal concentration of vancomycin
K. Shrestha, S. Mishra, S. Sharma, H. Kattel, N. Shah, K. Parajuli, J. Sherchand, B. M. Pokhrel, **B. P. Rijal**
Kathmandu (Nepal)
- 41.093** Influence of variation in the sequence(s) of factors essential for methicillin resistance (fem genes) on the expression of resistance to lysostaphin and secretion of DNase.
R. C. Rosy
Hyderabad (India)
- 41.094** Comparison of genotype MTBDRsl and BACTEC MGIT960 in detecting second line drug resistance among *Mycobacterium tuberculosis* clinical isolates
S. B. Rufai, J. Singh, P. Kumar, S. Singh
New Delhi (India)



- 41.095** Lower respiratory tract infection in two tertiary hospitals of Kolkata and carbapenem resistance
A. Banerjee¹, M. Ghosh¹, K. Karak¹, S. Basu¹, B. B. Mukhopadhyay², S. Mallik¹, B. Saha¹
¹Kolkata (India), ²Agartala (India)
- 41.096** Characterization of multidrug-resistant *escherichia coli* and salmonella isolated from food producing animals in Northeastern India
R. Sanjukta¹, J. B. Dutta², A. Sen¹, I. Shakuntala¹, S. Ghatak¹, A. K. Puro¹, S. Das¹, S. Huidrom¹, T. K. Dey¹, D. Purkait¹, A. Dutta¹, B. C. Das²
¹Ribhoi (India), ²Guwahati (India)
- 41.097** Correlation of carbapenem resistance and hypermucoviscosity in *K.pneumoniae* isolated from blood culture at a tertiary hospital in South India
C. Shankar, S. Anandan, P. Babu, E. Munusamy, B. Veeraraghavan
Vellore (India)
- 41.098** Prevalence and antibiogram of *Pseudomonas aeruginosa* isolated from clinical specimens in a Teaching Hospital, Kathmandu
S. Shrestha, R. Amatya, R. P. Adhikari
Kathmandu (Nepal)
- 41.099** Risk Factors for acquisition of invasive infections with NDM-1 + *K. pneumoniae*
B. M. Snyder¹, S. Anandan², A. Madabhushi¹, A. prakasam², V. P. Verghese², V. Balaji², **E. A. F. Simoes**¹
¹Denver, CO (USA), ²Vellore (India)
- 41.100** Assessment of antibiotic resistance patterns of the fecal coliforms isolated from Cauvery River and screening of novel herbal lead molecules against probable drug targets of MDR pathogens by computational virtual screening
S. Skariyachan
Bangalore (India)
- 41.101** Antibiotic use increases risk of acquiring ESBLs and enterobacteriaceae-resistant to ciprofloxacin in a prospective cohort of Dutch travelers
E. A. Reuland¹, **G. J. B. Sonder**¹, I. G. Stolte¹, N. al Naiemi², A. Koek¹, G. B. Linde¹, T. J. van de Laar¹, C. M. Vandenbroucke-Grauls¹, A. P. van Dam¹
¹Amsterdam (Netherlands), ²Hengelo (Netherlands)
- 41.102** Incidence of penicillin resistant *Streptococcus pneumoniae* in sputum among children and elderly pneumonic patients attending two major hospitals in Khartoum
S. M. Sulieman, A. El-Nimair
Khartoum (Sudan)
- 41.103** High rate of antimicrobial resistance in bloodstream infections among infants and children in India
S. Sundaresan, S. Nagaraj, S. Rao, A. Shet
Bangalore (India)
- 41.104** Investigating the distribution of integrons among clinical isolates of *Acinetobacter baumannii* and their association to carbapenem resistance
C. Swathi
Hyderabad (India)
- 41.105** In-vitro assessment of antibiotic combinations against multidrug resistant gram negative bacilli in South India: A save carbapenem campaign
R. Tellis
Mangalore (India)
- 41.106** Prevalence of plasmid-mediated quinolone resistance genes among ciprofloxacin-resistant clinical isolates of enterobacteriaceae over four years: A descriptive study
Y. Thiagarajan, B. Harish
Pondicherry (India)
- 41.107** Towards a national action plan for antimicrobial resistance: The Kenyan experience
E. Wesangula, R. Kamau, V. Kamau, F. Kiberenge
Nairobi (Kenya)

Antimicrobials: Adherence and Stewardship

- 41.108** Antimicrobial use in children at a tertiary teaching hospital in New Zealand
N. Ghoreishi¹, T. Graham², L. McDermott², S. Gardiner², T. Walls²
¹Mashhad (Iran), ²Christchurch (New Zealand)
- 41.109** Antimicrobial prescribing patterns in a tertiary care hospital in India: Role of persuasive intervention for changing antibiotic prescription behavior
C. Wattal, **S. Khanna**, N. Goel
New Delhi (India)
- 41.110** Newer trends in microbes and antibiotic sensitivity pattern of community acquired pneumonia in a tertiary care hospital in India
M.V. Anjana¹, C.P. Jafer²
¹Malappuram (India), ²Perinthalmanna (India)



- 41.111** Empiric antimicrobial therapy for different types of gall bladder pathologies based on bacterial etiology
A. Poojary, K. Balsara, S. Rohra, V. Waigankar, K. Kapadia, T. Udwadia
Mumbai (India)
- 41.112** Missed opportunities for shared decision making in antimicrobial stewardship: The potential consequences of a lack of patient engagement in secondary care
T. M. Rawson, L. S. P. Moore, B. Hernandez, E. Castro-Sánchez, E. Charani, R. Ahmad, A. H. Holmes
London (United Kingdom)
- 41.113** Microbial profile of prosthetic joint infections and effectiveness of cefuroxime prophylaxis: Experience from a tertiary care hospital
S. Sebastian, B. Dhawan, R. Malhotra, A. Kapil, R. Chaudhry, V. Sreenivas, V. Kumar
New Delhi (India)
- 41.114** Antibiotic prescribing to the inpatients diagnosed with malaria and viral fever in two tertiary care hospitals in Madhya Pradesh India
K. Landstedt Nilsson¹, A. Sharma², C. Stålsby Lundborg¹, **M. Sharma**²
¹Stockholm (Sweden), ²Ujjain (India)
- 41.115** Adherence to antiretroviral drug treatment ARV among people living with HIV/AIDS: A study from Eastern Nepal
D. K. Yadav, P. Karki, S. Yadav, N. Jha
Dharan (Nepal)

Antimicrobials: Clinical Trials

- 41.116** The antimicrobial and phytochemical analysis of the leaves of *Aspilia africana* on clinical isolates
O. R. Ezeigbo
Aba (Nigeria)
- 41.117** Randomized equivalence trial of amoxicillin versus placebo for fast breathing pneumonia (RETAPP)
S. Kerai, I. Nisar, B. Balouch, F. Aziz, F. Jehan
Karachi (Pakistan)
- 41.118** Colistin PK-PD (pharmacokinetic-pharmacodynamics) in Indian patients
V. Gautam¹, **M. Sharma**¹, N. Shafiq¹, J. W. Mouton², S. Malhotra¹, P. Ray¹
¹Chandigarh (India), ²Rotterdam (Netherlands)

Antimicrobials: Mechanisms and Spectrum

- 41.119** The sensitivity to antibiotics of nosocomial strains of *Acinetobacter baumannii* isolated in the tertiary hospitals in the Central Kazakhstan
I. Azizov¹, A. Lavrinenko², D. Babenko¹, N. Bisenova², Y. Zakharova³, A. Cheska⁴, S. Kolesnichenko¹
¹Karaganda (Kazakhstan), ²Astana (Kazakhstan), ³Almaty (Kazakhstan), ⁴Brasov (Romania)
- 41.120** Computer assisted rational design and synthesis of some novel 2,4-di-substituted thiazole derivatives and their metal complexes (copper, cobalt, and nickel) as inhibitor of bacterial metabolic enzymes
D. Kar Mahapatra, S. K. Bharti
Bilaspur (India)
- 41.121** Incidence of SHV and CTX-M Extended spectrum beta-lactamases producing gram negative bacterial isolates from antenatal mother with asymptomatic bacteriuria
K. Ramakrishnan
Pondicherry (India)
- 41.122** Molecular detection of azithromycin resistance mechanisms in typhoidal salmonellae
P. Sharma, S. Dahiya, S. Sood, B. K. Das, A. Kapil
New Delhi (India)

Antimicrobials: Pharmacology

- 41.123** In vitro and in vivo activity of "compound A" against gram-positive and -negative pathogens including MDR strains
T. K. Burman, P. Bhateja, S. Dube
Gurgaon (India)
- 41.124** A small molecule that inhibits FtsZ with potent in vitro and in vivo activity against *Staphylococcus aureus*
S. Dube, T. Mathur, M. Kumar
Gurgaon (India)
- 41.125** BBIL-5: An investigational new biotherapeutic for treating drug resistant *S. aureus* infections
S. Kandaswamy, K. Ella
Hyderabad (India)



41.126 In-vivo efficacy of a novel Leu-t-RNA synthetase inhibitor compound against MDR *Pseudomonas aeruginosa* 1594965 in a foreign body associated urinary tract infection model

M. Kumar, M. Rao, T. K. Barman, M. Pandya, S. Dube
Gurgaon (India)

41.127 Activity of a novel ketolide A against *Haemophilus influenzae* using in vitro and in vivo pharmacodynamic models

M. Pandya, M. Rao, T. K. Barmana, R. Sood, S. Dube
Gurgaon (India)

41.128 Synthesis and antibacterial activity of novel 3'-N-alkyl ketolide and fluoro-ketolide carbamates against community acquired respiratory pathogens

R. Venkataramanan, R. Kumar, S. Dube
Gurgaon (India)

41.129 Pharmacokinetic endeavors for antimalarial therapeutics

M. Wahajuddin, I. Taneja, K. Raju, M. Rashid
Lucknow (India)

41.130 Designing new antimalarial hits from African medicinal plants at the University of Buea (Cameroon); Part I: Isolation, in vitro activity, in silico "drug-likeness" and Pharmacokinetic profiles

D. Zofou
Buea (Cameroon)

Bacterial Infections

41.131 Distribution of emm types of beta hemolytic streptococci associated with necrotizing fasciitis: Clinical profile and outcome

T. Abraham, S. Sistla, S. Chandra Sistla
Pondicherry (India)

41.132 Cholera outbreak—IDP camps in Maiduguri, northern Nigeria, September 2015

A. T. Abubakar, M. Dalhat, P. Nguku
Abuja (Nigeria)

41.133 A spate of Lemierre syndrome cases: Causes other than *Fusobacterium spp*

R. K. C. Raymond, M. L. H. Oh, H. Shafi, **A. P. Acosta**
Singapore (Singapore)

41.134 Analysis of IL-10 and IL-6 gene polymorphisms and their serum levels in patients with brucellosis: A case control study

M.-Y. Alikhani
Hamedan (Iran)

41.135 Transcriptome analysis of *Salmonella enterica* subspecies enterica serotype typhi biofilm

K. Anbalagan¹, V. S. Chinni², K. K. Phua¹
¹Pulau Pinang (Malaysia), ²Bedong (Malaysia)

41.136 Aerobic bacteria in infected breast of Turkish woman: Prevalence and antimicrobial resistance evaluated in cases with lactational mastitis, periductal mastitis and granulomatous mastitis

Z. Taner, **H. Bahar Tokman**, M. Velidedeoglu, E. Göksoy, V. Çelik, M. Demirci, F. Dal, Y. Küçük, B. Mete, M. Yemisen, S. Vehid, B. Kocazeybek, M. Günaydın, N. Kiraz
Istanbul (Turkey)

41.137 Role of bacteria in Inflammatory bowel disease (IBD)

R. S. Bharadwaj
Pune (India)

41.138 The gene expression of *Helicobacter pylori* neutrophil-activating protein (HP-NAP), an immunomodulator in allergic asthma: The first case-control study conducted in children living in Istanbul-Turkey

R. Caliskan, H. Bahar Tokman, S. Nepesov, A. Karakullukcu, M. Demirci, G. Ayaz, S. Saribas, O. Dinc, Z. Taner, S. Vehid, H. Kırkoyun Uysal, E. Bonabi, H. Çokugras, B. Kocazeybek
Istanbul (Turkey)

41.139 A case of *Actinomyces meyeri* empyema: Still a challenging entity management

V. Clerigo, L. S. C. S. Fernandes, A. Feliciano, L. Carvalho
Lisbon (Portugal)

41.140 Detection of (hld) gene from staphylococcus epidermidis strains isolated from ICU of Rasul-e Akram hospital, Tehran-Iran

A. Ebrahimzadeh Namvar, **A. Gholami**
Babol (Iran)

41.141 Single-domain antibody selected from the phage display library neutralizes *Escherichia coli* endotoxin-induced effects on leukocytes in vitro and in Swiss albino mice

A. K. Gupta, A. Singh
Hisar (India)

41.142 Study on the frequency of spa gene in *Staphylococcus aureus* isolates from human infections and its relationship with mecA gene

M. Haghighi, Z. Lotfi
Shiraz (Iran)



- 41.143** Meningococcal pneumonia in Japan: A case report and review of the literatures
J. Hirai, T. Kinjo, T. Tome, K. Uechi, M. Nakamatsu, S. Haranaga, J. Fujita
Okinawa (Japan)
- 41.144** Neonatal sepsis and antibiotic resistance in low-income countries
B.-T. Huynh¹, P. Herindrainy², M. Padget¹, P. Piola², J.-M. collard², B. Garin², E. kermorvant¹, E. Delarocque-Astagneau¹, D. Guillemot¹
¹Paris (France), ²Antananarivo (Madagascar)
- 41.145** Phenotypic and genotypic characterization of *V.cholerae* O1 strains isolated in Democratic Republic of Congo in sanctuaries areas
G. Kamwiziku¹, M. L. Quilici², D. Bompangue¹, J. J. Muyembe¹
¹Kinshasa (Democratic Republic of Congo), ²Paris (France)
- 41.146** Clinico-microbiological spectrum of infective endocarditis at a tertiary care centre
P. Kanne, L. Vemu, S. Sudhaharan, N. Mamidi
Telangana (India)
- 41.147** Risk factors associated with persistence of *Staphylococcus aureus* bacteremia
T. Kitazawa, K. Seo, I. Koga, Y. Ota
Tokyo (Japan)
- 41.148** Comparison of the outcome of *Clostridium difficile* infection between patients treated with metronidazole and patients treated with vancomycin: A multi-center retrospective cohort study in Japan
K.-I. Kobayashi¹, Y. Ainoda¹, N. Sekiya¹, H. Kurai², A. Imamura¹
¹Tokyo (Japan), ²Shizuoka (Japan)
- 41.149** Clinical profile, susceptibility patterns, treatment and outcomes of Melioidosis in India
M. Koshy, M. Jagannati, T. David, S. Jasmine, J. Punitha, B. Veeraraghavan, G. M. Varghese
Vellore (India)
- 41.150** Emerging trends in the antibiotic susceptibility pattern of *Vibrio cholerae* in North Karnataka
S. R. Kulkarni, C. Chillarge
Bidar (India)
- 41.151** Bacteriological profile of chronic Osteomyelitis in a tertiary care hospital in South India
V. Lakshmi, S. Sudhaharan, P. Chavali, N. Mamidi
Hyderabad (India)
- 41.152** Characterization of diarrhoeogenic *Escherichia coli* using a novel multiplex PCR
D. Manjunathan, M. Natarajan, J. Mandal, N. Parameshwaran, S. Kar
¹Pondicherry (India)
- 41.153** Spontaneous bacterial peritonitis in patients of cirrhosis of liver with ascites
T. P. Manohar, A. Shejpal
Nagpur (India)
- 41.154** Tropical pyomyositis—Outcomes and clinical profile
V. K. N. Marimuthu, G. Midha, C. Mukhopadhyay, K. Saravu
Manipal (India)
- 41.155** Virulence gene profile and SCCmec types of clinical MRSA isolates: Is there a fitness cost involved?
N. Nagasundaram, S. Sistla
Pondicherry (India)
- 41.156** The human microbiome research in Africa—A systematic review
M. R. Ngwarai, L. E. Ah Tow, M. P. Nicol, M. Kaba
Cape Town (South Africa)
- 41.157** Nocardiosis-a clinicoepidemiological profile over 10 years
M. M. Ninan, P. Rupali, P. Mohanraj, J. S. Michael
Vellore (India)
- 41.158** Cholera outbreak investigation, Gajala community, Birnin Kudu Local Government Area (LGA), Jigawa State, Nigeria, September 2015
R. N. Nnaji¹, O. Ajumobi¹, U. Bala², A. Oladimeji¹, M. Sarki¹, R. usman¹, M. Buba¹, F. Sale¹, U. Osigwe¹, P. Nguku¹
¹Abuja (Nigeria), ²Dutse (Nigeria)
- 41.159** *Clostridium difficile* infection at outpatient clinic without known risk factors—CDI can be antibiotic-unassociated diarrhea in outpatient setting
G. Ohji, S. Okumoto, S. Nishimura, K. Iwata
Kobe (Japan)
- 41.160** *Salmonella* manipulation of host signalling pathways promotes cellular transformation and cancer of infected tissues
C. B. Pratap¹, T. Scanu², R. M. Spaapen², J. M. Bakker², L.-E. Wu², I. Hofland², A. Broeks², V. K. Shukla¹, M. Kumar¹, H. Janssen², J.-Y. Song², H. T. Riele², D. W. Holden³, G. Nath¹, J. Neefjes²
¹Varanasi (India), ²Amsterdam (Netherlands), ³London (United Kingdom)



41.161 Factors associated with Urinary tract infections caused by extended spectrum beta-lactamase (ESBL) producing organisms in Sri Lanka
S. Fernando, N. Luke, S. Wickramasinghe, B. Sebastianpillai, M. Gunathilake, N. Miththinda, S. Silva, **R. Premaratna**
Ragama (Sri Lanka)

41.162 Pathogenetic significance of macrophage inflammatory protein-1A in patients with erysipelas of the lower extremities
T. Moskovaya, **N. Pshenichnaya**, I. Kucherenko
Rostov-on-Don (Russian Federation)

41.163 Elevated expression of miR-223 and miR-21 in *Helicobacter pylori* induced gastric cancer patients
R. P. Rai, K. Prasad, J. Khatoon, S. Mohindra, U. Ghoshal, N. Krishnani
Lucknow (India)

41.164 Clinical spectrum of *Aeromonas* infections in hospitalized patients
P. V. Rao, R. Gopalakrishnan, V. Ramasubramanian, S. Nambi, D. Sureshkumar
Chennai (India)

41.165 Clinico-Microbiological study of diabetic foot ulcers
S. Seal
Bhubaneswar (India)

41.166 Mycobacterial esat-6 like protein alters antigen presentation and mediates intracellular survival in a NO and P38 dependent manner
S. Sengupta, A. Sonawane
Bhubaneswar (India)

41.167 Umbilical stump infections in neonates with special reference to MRSA
R. Vanisree
Hyderabad (India)

41.168 Molecular serotyping of *Klebsiella pneumoniae* capsular types, sequencing of positives and its epidemiology in the Eastern Cape Province, South Africa
S. D. Vasaikar¹, L. Obi², I. Morobe³, M. Bisi Johnson⁴
¹Mthatha (South Africa), ²East London (South Africa), ³Gaborone (Botswana), ⁴Lagos (Nigeria)

Diagnostics

41.169 Effective diagnosis of hydatidosis (*Echinococcus granulosus*) by immunomagnetic bead ELISA technique using paramagnetic nanoparticles
I. R. Aly
Cairo (Egypt)

41.170 Nano-Gold Sandwich ELISA: A key for *G. duodenalis* early diagnosis in patient's stool and serum samples of infected patients
I. R. Aly
Cairo (Egypt)

41.171 Dried cerebrospinal fluid spots for diagnosing Japanese Encephalitis Virus (JEV) infection by Anti-JEV IgM antibody capture enzyme-linked immunosorbent assay: Harnessing the potential of a fully saturated pre-cut filter paper disc
T. Bharucha¹, O. Sengvilaipaseuth², A. Chanthongthip², E. Phuangpanom², O. Phonemixay², M. Vongsouvath², S. Lee¹, P. Newton¹, A. Dubot-Peres¹
¹London (United Kingdom), ²Vientiane (People's Democratic Republic of Lao)

41.172 Development of a rapid point of care immuno-filtration assay for serodiagnosis of cutaneous anthrax in India
A. K. Goel, N. Ghosh, N. Puranik, A. Varshney, M. Kumar
Gwalior (India)

41.173 Molecular biology technique combined with Fine needle aspiration cytology revealing the diagnostic dilemma in tubercular lymphadenitis cases
V. Gupta, A. Bhake
Wardha (India)

41.174 Baseline titres of *Salmonella agglutinins* in the healthy population in Sri Lanka
C. Illapperuma¹, S. Agampodi², **E. M. Corea**¹
¹Colombo (Sri Lanka), ²Saliyapura (Sri Lanka)

41.175 Fetuin-A as a biomarker to predict invasive pneumococcal disease in children
R. P. Janapatla, M.-H. Hsu, W.-T. Liao, C.-H. Chiu
Taoyuan (Taiwan)

41.176 Next generation sequencing targeting drug resistance conferring genes in rapid detection of Multi-drug resistant tuberculosis
E. Jayakumar, M. Mani, G. Sarangan, R. Barani, R. Balakrishnan, T. Dhanasekar, S. Muthiah Kothandaramnujam, S. Lekha, S. Ramasubramanian, R. K Goyal, P. Srikanth
Chennai (India)



- 41.177** Association of serum procalcitonin and C-reactive protein levels with CURB-65 criteria among patients with acute community acquired pneumonia
F. Karamat, H. Ghasemibasir, E. Abdoli, J. Poorolajal, A. Shafiee Aghdam
Hamadan (Iran)
- 41.178** Using peptidoglycan associated lipoprotein of *Legionella pneumophila* as a urinary antigen for development of an indirect sandwich ELISA
M. Moosavian¹, A. Gholipour², M. Makvandi¹, H. Galehdari¹, A. Alvandi³, S. A. Mard¹
¹Ahvaz (Iran), ²Shahrekord (Iran), ³Kermanshah (Iran)
- 41.179** Studies on incidence of malaria and comparative efficacy of diagnostic test methods for *Plasmodium falciparum* and *Plasmodium vivax*
G. I. Olasehinde
Ota (Nigeria)
- 41.180** Mild encephalitis/encephalopathy with a reversible splenial lesion caused by Legionnaires' disease presenting with cerebellar ataxia symptoms and impaired consciousness
D. Ono¹, Y. Shibue², M. Kurokawa², H. Oka²
¹Omori (Japan), ²Tokyo (Japan)
- 41.181** Field evaluation of a novel loop mediated isothermal amplification (LAMP) assay for molecular diagnosis of asymptomatic malaria in a field setting in sub-Saharan Africa
E. C. Oriero¹, J. Jacobs², J.-P. Van Geertruyden², D. C. Nwakanma¹, U. D'Alessandro¹
¹Banjul (Gambia), ²Antwerp (Belgium)
- 41.182** Diagnosis of Iranian MSMD patients in a proliferation and cytokine production setting
S. A. Sarrafzadeh, M. Mahloojirad, M. Nourizadeh, Z. Pourpak, M. Moin
Tehran (Iran)
- 41.183** Comparative evaluation of Xpert® Carba-R assay with conventional methods for detection of carbapenemase producing enterobacteriaceae
N. Shaikh, L. Drego, A. Shetty, C. Rodrigues
Mumbai (India)
- 41.184** Identification of B cell epitopes of in vivo expressed RD proteins in pulmonary tuberculosis (PTB) patients
S. Sharma¹, D. Suri¹, S. Ramamurthy², M. Ryndak², S. Laal², I. Verma¹
¹Chandigarh (India), ²New York, NY (USA)
- 41.185** Role of fine needle aspiration cytology in the diagnosis of cutaneous leishmaniasis
M. Hoseinzadeh¹, **M. Shokripour**¹, N. Omidifar², O. Eilami²
¹Shiraz (Iran), ²Yasouj (Iran)
- 41.186** SLA-ELISA: A comparison with DAT & rK39 ELISA for identification of seroconverters
A. K. Singh¹, O. P. Singh¹, M. Boelaert², B. Ostyn², M. Rai¹, S. Sundar¹
¹Varanasi (India), ²Antwerp (Belgium)
- 41.187** Comparative analysis of syndromic and PCR-based diagnostics assay reveals misdiagnosis/over treatment for trichomoniasis based on subjective judgment in symptomatic patients
S. C. Sonkar
New Delhi (India)
- 41.188** Determination of absolute accuracy of diagnostic tests using bayesian LCMs: A re-evaluation of diagnostic tests for Adenovirus
R. Sundaramurthy, D. Rahul, K. Subashini, B. Harish
Pondicherry (India)
- 41.189** PCR-RFLP for identification of Mucorales from clinical specimens
K. Zaman, S. Rudramurthy, A. Das, N. Panda, A. Chakrabarti
Chandigarh (India)

Economics, Health Policy and Implementation

- 41.190** Economic evaluation of influenza vaccine intervention
K. Abbas, N. Dorratoltaj, A. Marathe, S. Swarup, B. Lewis, S. Eubank
Blacksburg, VA (USA)
- 41.191** Attitude toward quoting research evidence in technical guidelines on the Nigeria HIV/AIDS program
O. V. Akinmade, J. Enegele, O. Akinmade, O. Olaiya, A. Effiong
Abuja (Nigeria)
- 41.192** Equipping India's community health worker supervisors with a mobile phone based supervisory application
F. Ali
Jhunjhunu (India)
- 41.193** An economic evaluation of a livestock anthrax vaccination program in high-risk regions of the country of Georgia
C. Campbell¹, S. V. Shadomy¹, K. E. Stauffer², H. T. Walke¹, L. Avaliani², I. Kalandadze², M. I. Meltzer¹
¹Atlanta, GA (USA), ²Tbilisi (Georgia)



- 41.194** Ending the neglect: The role of global policy advocacy in addressing neglected tropical diseases (NTDs)
N. Mistry, N. Pillai, **A. Cashwell**, S. Vaite
Washington, DC (USA)
- 41.195** Potential impact and economic value of dengue vaccination in 10 endemic countries
L. Coudeville¹, N. Baurin¹, D. Shepard², Y. Halasa²
¹Lyons (France), ²Waltham, MA (USA)
- 41.197** Improving HIV service delivery in detention centers and ART facility in Odessa, Ukraine
N. A. Rakhmanova¹, U. Snidevich², I. Semenenko²
¹Silver Spring, MD (USA), ²Kiev (Ukraine)
- 41.198** Policy options for state-based PCV roll-out in India: The evidence base
M. Sauer¹, A. Singh², L. Privor-Dumm¹
¹Baltimore, MD (USA), ²New Delhi (India)
- 41.199** Case management of childhood diarrhoea in low-and-middle-income countries: Time trends and country-wise changes during 1985-2012
C. Sreeramareddy¹, L. Yue-Peng², B. Forsberg³
¹Bangalore (India), ²Kuala Lumpur (Malaysia), ³Stockholm (Sweden)
- 41.203** The role of diabetes in the severity of 2009 influenza A (H1N1) and the Middle East respiratory syndrome coronavirus (MERS-CoV): A systematic review and meta-analysis
A. Badawi, S. Ryoo
Toronto (Canada)
- 41.204** Concurrent dengue and malaria coinfection: Observations from a central Mumbai hospital
A. Barua, M. E. Yeolekar
Mumbai (India)
- 41.205** Melioidosis: An underdiagnosed entity in Odisha. A series of four cases over a two months period
B. Behera, S. Mohanty, B. Mishra, A. K. Praharaj
Bhubaneswar (India)
- 41.206** Genetic diversity of *Orientia tsutsugamushi* strains from patients in North India
M. Biswal, A. Kumar, N. Sharma, A. Bhalla, S. Singhi, S. Sethi
Chandigarh (India)
- 41.207** Emerging rickettsioses in Northeast India
T. Bora, S. A. Khan
Dibrugarh (India)
- 41.208** Predictors of severity in Dengue infection
A. Bswas, P. Sohal, K. Baruah, P. Singla, N. Wig, P. Aggarwal, L. Dar
New Delhi (India)
- 41.209** A qualitative risk assessment of emerging infectious diseases of Bangladesh
S. Chakma, K. Islam, S. Mahmood
Dhaka (Bangladesh)
- 41.210** Group B *Streptococcus*: An emerging infection in South Asia
M. Chaudhary, M. S. Edwards
Houston, TX (USA)
- 41.211** Comparative risk factors for nosocomial non-carbapenemase producing (NCP) and carbapenemase producing (CP) carbapenem resistant Enterobacteriaceae (CRE) intestinal colonization
P. Y. Chia, B. F. Poh, C. Y. Toh, K. Marimuthu, B. Ang
Singapore (Singapore)
- 41.212** Molecular identification of non-tuberculous mycobacteria in humans in Zimbabwe
N. Chin'ombe, B. Muzividzi, E. Munemo, P. Nziramasanga
Harare (Zimbabwe)

Emerging Infectious Diseases

- 41.200** Adverse reactions to field vaccination against lumpy skin disease in cattle
S. M. Abutarbush
Al Ain (United Arab Emirates)
- 41.201** Maximizing detection of dengue virus serotypes by a modified reverse transcription-polymerase chain reaction assay in India: Presence of co-infection with multiple serotypes
S. F. Ahmed¹, R. Vivek¹, S. Kotabagi¹, K. Nayak², A. Chandele², M. K. Kaja², A. Shet¹
¹Bangalore (India), ²New Delhi (India)
- 41.202** The first two (2) laboratory confirmed Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection managed in the Philippines
R. N. Aniceto
Muntinlupa (Philippines)



- 41.213** Ethio-nosologic opportunism in tropical, emergency and re-emergency diseases in Albania
N. Como, E. Meta, M. Qato, N. Gjermeni, M. Kokici, A. Harxhi, P. Pipero, S. Bino, D. Kraja
Tirana (Albania)
- 41.214** Sri Lanka: Nationwide epidemiology of Melioidosis
E. M. Corea¹, J. Masakorala¹, S. Sivam¹, H. Sathkumara¹, D. De Silva¹, V. Thevanesam², T. Inglis³
¹Colombo (Sri Lanka), ²Peradeniya (Sri Lanka), ³Perth (Australia)
- 41.215** Identification of *Bartonella* spp and *Rickettsia* spp of human body lice from homeless people of Bogota D.C, Colombia
A. C. Marquez, A. A. Faccini-Martínez, C. A. López, M. Hidalgo, **C. L. Cuervo**
Bogota (Colombia)
- 41.216** Persistence of Japanese encephalitis virus infection in healthy children in JE Endemic Area
T. N. Dhole¹, M. Kakkar², S. Chaturvedi², V. Saxena², S. Abbas², A. Kumar³, A. Zia¹, S. Verma¹
¹Lucknow (India), ²New Delhi (India), ³Bareilly (India)
- 41.217** An outbreak of diphtheria in K'Bang District, Gia Lai, Vietnam, October 2013–July 2014
P. V. Doanh¹, D. Pham T¹, L. Vu N², T. Chu V³, H. Do T H², H. Nguyen T T¹, T. Ly T T¹, H. Nguyen L M¹, T. Pham N¹, N. Ha T³, H. Ralan T¹, T. Mounts⁴
¹Buon Ma Thuot, (Viet Nam), ²Ha Noi (Viet Nam), ³Ho Chi Minh (Viet Nam), ⁴Atlanta, GA (USA)
- 41.218** Ebola virus diseases signs, symptom and predicting death: A literature review
M. H. Ekat
Brazzaville (Congo, Republic of)
- 41.219** Drivers for MERS-CoV emergence in Qatar
E. Farag¹, R. Sikkema², C. B. E. M. Reusken², H. Ghobashy¹, H. Al-Romaihi¹, A. El-Sayed¹, M. Al Thani¹, M. nour¹, S. Al-Marri¹, M. Al-Hajri¹, M. P. G. Koopmans²
¹Doha (Qatar), ²Bilthoven (Netherlands)
- 41.220** *Corynebacterium diphtheriae*: An emerging cause of chronic suppurative otitis media
U. N. Gaikwad, R. Arora, N. Gade, S. Kombade, P. Das, S. S. Negi, A. Bhargava
Raipur (India)
- 41.221** Lessons learnt from a recent Ebola virus outbreak: A scoping study
M. GFrover, N. Bhatnagar, A. Kotwal, H. Chauhan
New Delhi (India)
- 41.222** Occurrence of dengue in 2013 and 2014 in northern Mozambique: Is Dengue an endemic disease in Mozambique ?
A. Muianga¹, G. Pinto¹, S. Ali¹, J. Oludele¹, V. Monteiro¹, A. Tivane¹, K. I. Falk², **E. S. Gudo**¹
¹Maputo (Mozambique), ²Solna (Sweden)
- 41.223** Fluoroquinolone resistance in *Shigella* over a decade In India: Do we have plasmid-mediated quinolone resistance?
P. Gupta, A. Kumar, G. Varma, A. Mewara, B. Mohan, N. Taneja
Chandigarh (India)
- 41.224** H1N1—Monster to be tamed
M. Hisham, M. Sivakumar, P. Vivekananthan, V. Ganesh, K. Muthulakshmi
Coimbatore (India)
- 41.225** Childhood deaths with a co-morbidity of diarrhea and severemalnutrition: A brief insight in an urban critical care ward in Dhaka, Bangladesh
S. Islam, M. S. Hossain, M. J. Chisti
Dhaka (Bangladesh)
- 41.226** *Campylobacter jejuni* infection and Guillain-Barré syndrome: An emerging cause of acute flaccid paralysis after the eradication of poliomyelitis in Bangladesh
Z. Islam¹, M. B. Islam¹, B. C. Jacobs², I. Jahan¹, Q. D. Mohammad¹, H. P. Endtz²
¹Dhaka (Bangladesh), ²Rotterdam (Netherlands)
- 41.227** Dengue sero-prevalence and serotype distribution among children near Hyderabad, India
G. R. Jammy¹, E. Ganguly², G. Oruganti², S. Garg³, A. Bhavsar⁴, J. Nealon⁵
¹Pittsburgh (USA), ²Hyderabad (India), ³New Delhi (India), ⁴Mumbai (India), ⁵Singapore (Singapore)
- 41.228** Human ocular dirofilariasis due to *Dirofilaria repens*: An underdiagnosed entity or emerging filarial disease?
L. G. Jessani, S. Patil, D. Annapurneshwari, S. Durairajan, R. Gopalakrishnan
Chennai (India)



- 41.229** Clinical profile and serological epidemiology of scrub typhus and spotted fever among hospitalized children at a tertiary hospital in South India
B. S. Kalal, P. Puranik, S. Nagaraj, S. Rego, A. Shet
Bangalore (India)
- 41.230** Seroprevalence of scrub typhus and coinfection with leptospirosis in Chennai, Tamil Nadu
S. Kanagasabai, G. Thatchinamoorthy, A. Ganesan, G. Pachiyappan, P. Gouthami, S. Valarmathi, S. Mini Jacob
Chennai (India)
- 41.231** Pharmacophore modeling, database mining and biological evaluation to identify novel structurally diverse compounds as potential anti-Ebola drugs
R. Kant
New Delhi (India)
- 41.232** West Nile Virus circulation and incrimination of mosquito vectors in North East India
S. A. Khan, S. Kakati, P. Chowdhury, P. Dutta
Dibrugarh (India)
- 41.233** Molecular phylogenetics of *Orientia tsutsugamushi* strains circulating in Assam based on 56-kilodalton type-specific antigen gene
S. A. Khan¹, T. Bora¹, A. Richards², S. Chattopadhyay², J. Jiang², B. Laskar¹, P. Dutta¹
¹Dibrugarh (India), ²Silver Spring, MD (USA)
- 41.234** Uganda national acute febrile illness agent detection serosurvey 2004–2005
G. Kharod¹, D. haberling¹, M. Person¹, A. Folkema², R. Galloway¹, M. Elrod¹, J. Perniciaro¹, W. Nicholson¹, N. Patel¹, J. Bwogi³, H. Bukenya³, C. Drakeley⁴, S. Mbulaiteye⁵, D. Blaney¹, S. Shadomy¹
¹Atlanta, (USA), ²Ontario (Canada), ³Entebbe (Uganda), ⁴London (United Kingdom), ⁵Bethesda, MD (USA)
- 41.235** Spotted fever group and typhus fever group rickettsiosis in South Western India
M. Koralur¹, I. Bairy¹, M. Varma¹, E. Athan², J. Stenos²
¹Manipal (India), ²Victoria (Australia)
- 41.236** Predictors of pediatric clinical outcomes and associated age-specific mortality in the West African Ebola epidemic, 2014–2015: A comparative secondary data analysis of two districts in Sierra Leone
H. Kyobe Bosa¹, J. T. Orikiiriza¹, F. Vairo², F. Mubiru¹, D. Bulwadda¹, C. Suleiman Kamara³, F. Sahr³
¹Kampala (Uganda), ²Rome (Italy), ³Freetown (Sierra Leone)
- 41.237** Molecular identification of human *Plasmodium knowlesi* infections in North Sumatra, Indonesia
I. N. D. Lubis¹, H. Wijaya¹, M. Lubis¹, C. P. Lubis¹, C. J. Sutherland²
¹Medan (Indonesia), ²London (United Kingdom)
- 41.238** *Cronobacter sakazakii*—An unrecognised food borne pathogen, India
J. Mahindroo¹, I. Shyam¹, B. Mohan¹, S. Thakur², N. Taneja¹
¹Chandigarh (India), ²Raleigh, NC (USA)
- 41.239** Crimean-Congo Hemorrhagic fever in former Soviet Union countries based on ProMED-RUS reports (2005–2015 years)
V. Melnik¹, N. A. Rakhmanova², N. Pshenichnaya³, B. Aslanov⁴
¹Dontesk (Ukraine), ²Silver Spring, MD (USA), ³Rostov-on-Don (Russian Federation), ⁴Saint-Petersburg (Russian Federation)
- 41.240** Clinical features and likely predictors of severity and fatality in dengue patients admitted to a tertiary care hospital in India
V. Menon, V. Menon, J. Jelitta, P. Umadevi, D. T S, R. Jayaprasad
Kochi (India)
- 41.241** GPI-anchored CCL28 as a strong mucosal immunostimulator with influenza VLPs
T. Mohan, R. W. Compans, B. Wang
Atlanta, GA (USA)
- 41.242** Serological and molecular investigation of Dengue, Chikungunya and Rift Valley Fever in febrile and non-febrile patients from northern Mozambique during Dengue outbreak, 2014
A. Muanga¹, K. Falk², J. Oludele¹, G. Pinto¹, S. Ali¹, A. T. Tivane¹, G. Galano³, E. Samo Gudo¹, N. Lagerqvist²
¹Maputo (Mozambique), ²Stockholm (Sweden), ³Cabo Delgado (Mozambique)



- 41.243** Leishmania disease gap analysis study—Pakistan
S. M. Mursalin
Islamabad (Pakistan)
- 41.244** Synthetic DNA encoded antibody prophylaxis confers rapid protective immunity in vivo against Chikungunya virus infection
K. Muthumani¹, P. Block¹, S. Flingai¹, N. Muruganantham², I. K. Chaaithanya², G. Sarangan³, P. Srikanth³, P. Vijayachari², N. Y. Sardesai⁴, J. J. Kim⁴, K. Ugen⁵, D. Weiner¹
¹Philadelphia, PA (USA), ²Port Blair (India), ³Chennai (India), ⁴Plymouth Meeting, PA (USA), ⁵Tampa, FL (USA)
- 41.245** Comparative analysis of spatial distribution of dengue in Asia-Pacific region
S. Naish
Brisbane (Australia)
- 41.246** Architectural suitability, designing achieving infection control and also the psychological comfort of the users: Isolation centre (IC) for especially dangerous pathogens
G. Nakibaala
Kampala (Uganda)
- 41.247** Cultural impact on the design for isolation centres for especially dangerous pathogens e.g. Ebola
G. Nakibaala
Kampala (Uganda)
- 41.248** Development and evaluation of a viral-specific random PCR and next-generation sequencing based assay for detection and sequencing of hand, foot, and mouth disease pathogens
A. T. Nguyen, N. Nghiem, T. Tran, V. Hoang, N. Le, Q. Phan, N. Le, V. Ho, V. Do, T. Ha, H. Nguyen, C. Nguyen Van Vinh, G. Thwaites, H. R. van Doorn, T. Le Ho Chi Minh (Viet Nam)
- 41.249** Could malaria re-emerge in Romania?
G. Nicolescu, V. Purcarea-Ciulacu, A. Vladimirescu, G. Dumitrescu, D. Saizu, E. Savin, I. Sandric, F. Mihai
Bucharest (Romania)
- 41.250** Co-occurrence of mosquito larval in natural and artificial habitats in Mazandaran Province, northern Iran
S. H. Nikookar, A.-A. Enayati, S. P. Ziapour, S. N. Mousavi Nasab, M. Fazeli-Dinan, J. Shojaei
Sari (Iran),
- 41.251** Evidence of presence of antibodies against selected arboviruses in Ijara and Marigat Districts, Kenya
V. O. Ofula¹, J. Oundo¹, Z. Irura¹, E. Chepkorir¹, C. Tigoi¹, J. Ongus¹, R. Coldren¹, R. Sang¹, R. Schoepp², C. Rossi²
¹Nairobi (Kenya), ²Washington, DC (USA)
- 41.252** Serological evidence of henipavirus among horses and pigs in Zaria and environs, Kaduna State Nigeria
O. T. Olufemi¹, J. U. Umoh², A. A. Dzikwi², L. Wang³, G. Crameri³, C. Morrissey³, J. Barr³, Y. O. Olufemi⁴
¹Wukari (Nigeria), ²Zaria (Nigeria), ³Geelong (Australia), ⁴Nottingham (United Kingdom)
- 41.253** Serosurveillance of leptospirosis among paddy field workers with febrile illness from Western Maharashtra, India
G. A. Potdar, S. Pol, R. S. Bharadwaj
Pune (India)
- 41.254** Novel allelic profile of the clinical strains of burkholderia pseudomallei on multi locus sequence typing from India
C. Tellapragada¹, **T. Shaw**¹, V. Kalwaje Eshwara², V. Bhat¹, S. Kumar³, C. Mukhopadhyay¹
¹Manipal (India), ²Udupi (India), ³Gwalior (India)
- 41.255** Modulations in HLA-DR expression in visceral leishmaniasis infection
B. Singh¹, M. Sudarshan¹, T. Singh¹, M. Fakiola², J. Oommen³, J. Blackwell⁴, S. Sundar¹
¹Varanasi (India), ²Cambridge (United Kingdom), ³Perth (Australia), ⁴Subiaco (Australia)
- 41.256** Severe *Plasmodium vivax* infections in children
V. Singh, P. Gupta, J. Chandra
New Delhi
- 41.257** Implementing a novel community engagement system during a clinical trial of a candidate Ebola vaccine within an outbreak setting
E. M. Smout¹, L. Enria¹, T. Mooney¹, S. Lees¹, D. Watson-Jones¹, B. Greenwood¹, B. Leigh², H. J. Larson¹
¹London (United Kingdom), ²Freetown (Sierra Leone)



- 41.258** Periodicity in the waxing and waning of Influenza A H1N1: A report from a tertiary care center in Chennai India

P. Srikanth, G. Sarangan, M. Mani, R. Barani, S. Reju, R. Annamalai, J. Damodharan
Chennai (India)

- 41.259** Clinical features, cytokine profiles and immune response in children with severe hand foot and mouth disease in Vietnam
N. T. Tran¹, H.M.T Van¹, L.A. Nguyet¹, D.Q. Ha¹, V.T.T. Hang¹, T.T. Thuy¹, D.C. Viet¹, D.T.N. Diep¹, H.L. Viet¹, H.M. Tuan¹, C.-A. Siegrist², T. L.V¹, L. Kaiser², C. Tapparel², H. R. van Doorn¹

¹Ho Chi Minh City (Viet Nam),

²Geneva (Switzerland)

- 41.260** Atypical presentation of epidemic typhus in South India: A case report

K. Vivek, Q. Anwar, S. Shampure
Bangalore (India)

- 41.261** Real-Time PCR studies regarding the *Borrelia burgdorferi*, *Francisella tularensis*, tick borne encephalitis virus (TBEv) and Crimean Congo hemorrhagic fever virus (CCHFv) occurrence in the Romanian ticks

A. Vladimirescu, G. Dumitrescu, L. Ionescu, M. Neculescu, V. Moraru, D. Popescu, S. Bicheru, D. Danes, D. Baraitareanu, V. Ciulacu-Purcarea, G. Nicolescu
Bucharest (Romania)

- 41.262** SPIDR-WEB: An NGS biotechnology platform for diagnostic and transcriptomic applications

A. Hatch, P. Chain, J. Gans, **M. Vuyisich**
Los Alamos, NM (USA)

- 41.263** Yellow Fever threat to Asia: A model national contingency plan

J. Woodall, **T. Yuill**
Rio de Janeiro (Brazil), Madison, WI (USA)

- 41.264** Eating raw liver, a potential risk factor of Crimean-Congo hemorrhagic fever (CCHF) occurrence in high-risk occupations in NUR County, Northern Iran

S. P. Ziapour, A. Enayati, S. H. Nikookar, F. Sahraei-Rostami, S. Kheiri, A. Charkameh, J. Shojaei
Sari (Iran)

- 41.265** Outbreak of *Prototheca wickerhamii* algaemia and sepsis in a tertiary care chemotherapy oncology unit

I. D. Khan
Kolkata (India)

Geriatric Infections

- 41.266** Serotyping of invasive *S. pneumoniae* in adults, more than fifty years old, at a tertiary care center

C. Wattal, N. Goel, S. Byotra
New Delhi (India)

Immunocompromised Host (Non-HIV)

- 41.267** Trying to understand infections in transplant patients in a private hospital in Buenos Aires, Argentina

C. Freuler, M. Garcia Posadas, A. V. Sanchez, M. Radosta, N. Garcia Allende, M. Mayer Wolf, V. Rodríguez, C. Ezcurra
Buenos Aires (Argentina)

- 41.268** Post renal transplant infections: Single center experience from Nigeria

G. Ilyasu, A. Abdu, F. M Dayyab, A. B Tiamiyu, Z. G Habib, B. Adamu, A. G Habib
Kano (Nigeria)

- 41.269** Infectious complications post liver transplant in a tertiary hospital

S. Katari, S. Narreddy, M. Varma, A. Shrima, R. K. Barigala, M. Balasubramaniam
Hyderabad (India)

- 41.270** A case of liver transplant in leptospirosis induced acute on chronic liver failure

S. Katari, S. Narreddy, M. Varma, A. Shrima, R. K. Barigala, M. Balasubramaniam, R. Rao, M. Ratnamani
Hyderabad (India)

- 41.271** An unusual presentation of invasive aspergillosis—Diagnostic and management dilemmas

M. M. Naik¹, M. Prabhu², D. Nayak², K. V. Rajagopal²
¹Trivandrum (India), ²Manipal (India)

- 41.272** Rare case of amphotericin-B resistant cryptococcal meningitis in HIV non reactive patient

S. Singhal, P. Gupta, B. S. Lamba, P. Singh, M. I. Chouhan, D. Meher
New Delhi (India)

- 41.273** Mother T follicular helper cells prevent vertical transmission of Hepatitis B to their babies

A. K. Vyas, P. David, S. Patra, S. K. Sarin, N. Trehanpati
New Delhi, (India)



- 41.274** Significance of preservation fluid cultures in solid organ transplantation
H. Nam¹, K. Galen¹, M. Campara¹, N. Perni², R. Garcia-Roca¹, **V. Yeldandi**¹
¹Chicago, IL (USA), ²Saginaw (USA)
- 41.275** *Plasmodium falciparum* GLURP 2 clones on the Jos Plateau, Nigeria, possibly indicates that the region is a low endemic area
O. I. Ita¹, K. I. Onyedibe², F. Odey¹, E. Banwat², D. Z. Egah²
¹Calabar (Nigeria), ²Jos-Plateau (Nigeria)

Sexually Transmitted Diseases

- 41.276** Secondary syphilis manifesting as annular lichenoid plaques
K. Bhardwaj, R. Gadkare, A. Dandale, S. Ghate, R. Dhurat
Mumbai (India)
- 41.277** Is there a correlation between *Chlamydia trachomatis* detection and development of disease in reactive arthritis/ undifferentiated spondyloarthropathy patients
P. Kumar, D. S. Bhakuni, S. Rastogi
New Delhi (India)
- 41.278** The evaluation and risk assessment of sexually transmitted disease in Korean adolescents at risk
J. Lee, Y. B. Seo, J. J. Park, S. K. Jeong
Seoul (Republic of Korea)
- 41.279** Screening for chlamydia trachomatis in reproductive age group women by real time PCR assay in a semi-urban area of South India
M. Malathi, V. Sowmya, A. Vijayalakshmi
Chengalpattu (India)
- 41.280** Differential expression of superoxide dismutases in early aborters infected with *Chlamydia trachomatis*
P. Prasad, N. Singh, B. Das, S. Raisuddin, M. Dudeja, S. Rastogi
New Delhi (India)
- 41.281** Hepatitis B and Human immunodeficiency virus co-infection among pregnant women in resource limited high endemic setting, Addis Ababa, Ethiopia: Implications for current and emerging prevention and control measures
Z. D. Woldesonbet
Addis Ababa (Ethiopia)

Travel Medicine and Travel Health

- 41.282** Yellow fever vaccine associated neurotropic disease (YEL-AND)
P. Doke, B. Purandare, D. Bhosle, P. Dave, S. Jagtap, M. Gupta
Pune (India)
- 41.283** Mathematical modelling of the effects of prebiotic concentration on *Lactobacillus casei* growth
V. S. Shankar Kumar, U. J. Anantharaj, M. Sakthioli, R. Vinnakota, K. Krishnamurthy
Chennai (India)
- 41.284** Low and declining attack rates of imported typhoid fever in the Netherlands despite restrictive vaccination policy
G. J. B. Sonder, F. Suryapranata
Amsterdam (Netherlands)
- 41.285** Novel synthetic antimicrobial peptides against *Streptococcus pneumoniae*
H. Jindal, S. Devi, R. Devi
Kuala Lumpur (Malaysia)



Session 42

Poster Presentations

Poster Session II

Room: Hall 3
(Posters & Exhibition)

12:45–14:15
Friday, March 4, 2016

Poster Prize Finalists (Friday)

42.001 Investigation of diverse carbapenem resistance mechanisms in *Pseudomonas aeruginosa* isolated from a tertiary care centre in India

A. K. Prakasam, S. Anandan, N. Hadibasha, R. Gopi, B. Veeraraghavan
Vellore (India)

42.002 Demonstration of horizontal gene transfer of fluoroquinolone resistance by plasmids in clinical isolates of *Shigella spp.* and *Salmonella spp.*

D. N. Kumar, D. P. Muthuirulandi Sethuvel, S. Anandan, B. Veeraraghavan
Vellore (India)

42.003 Molecular binding analysis of aminoglycoside N-acetyltransferase aac(6')-Ib and its bi-functional fluoroquinolone active variant aac(6')-Ib-cr active-site with ciprofloxacin and kanamycin: An in-silico approach

B. Harish¹, **Y. Thiagarajan**¹, P. Jenardhanan¹, P. Mathur²
¹Pondicherry (India), ²Bhubaneswar (India)

42.004 Combination of NS1 antigen and anti-NS1 IgA assays in the diagnosis of Dengue infection in Asia

V. Valverde¹, C. Delaroche¹, E. Smal¹, R. Chhoeung², V. Duong², P. Buchy²
¹Steenvoorde (France), ²Phnom Penh (Cambodia)

42.005 Atypical presentation and nosocomial spread—Intensifying the MERS mystery and misery

S. Fagbo, A. M. Hakawi, M. Mukahal, L. Skakni, A. Santos, M. Garbati, K. Alao
Riyadh (Saudi Arabia)

42.006 The impact of increased use of ASHAs on rural immunization coverage in India

A. Wagner, D. Bettampadi, J. Porth, M. Boulton
Ann Arbor, MI (USA)

42.007 Tracking the emergence of multidrug resistant, extraintestinal pathogenic *Escherichia coli* in India

N. Ahmed
Hyderabad (India)

42.008 Infection prevention and control (IPC) and ebola virus disease (EVD) infection among health care workers in Sierra Leone and Nigeria

F. C. Umenze¹, Z. Onyancha², M. Syethii², E. Compes³

¹Lagos (Nigeria), ²Nairobi (Kenya),

³Madrid (Spain)

42.009 Healthcare worker exposure to solid organ recipients with rabies virus disease: An infection control perspective

T. A. Hayden, I. Koutlakis-Barron, T. Luckie, D. S. A. Aljumaah, D. A. H. Alkhenizan
Riyadh (Saudi Arabia)

42.010 Real time antimicrobial resistance surveillance in critical care: Identifying outbreaks of carbapenem-resistant gram negative bacteria from routinely collected data

L. S. P. Moore, R. Freeman, A. Charlett, J. A. Otter, H. Donaldson, **A. H. Holmes**
London (United Kingdom)

42.011 Relationships between flavivirus serological laboratory test results from Dengue endemic areas of India: Limitations and challenges

J. Nealon¹, A. Chakravarti², A. Moureau³, S. Kumar², L. Ochiai⁴, M. Bonaparte⁵, S. Garg²
¹Singapore (Singapore), ²New Delhi (India), ³Marcy l'Etoile (France), ⁴Lyons (United Kingdom), ⁵Swiftwater, PA (USA)

42.012 DPT vaccination rate in children ages 1 to 5 years old and associated factors in K'bang District, Gia Lai Province, Viet Nam in 2015

P. V. Doanh¹, D. Pham T¹, H. Do T H², N. Leisha³, K. Klein³, L. Vu N², V. Nguyen Q¹, O. Dang¹, T. Chu V², D. Tran V², T. Pham N¹, H. Nguyen L M¹, H. Nguyen T T¹, T. Hoang N¹, T. Mounts³

¹Buon Ma Thuot (Viet Nam), ²Ha Noi (Viet Nam), ³Atlanta, GA (USA)

42.013 Drug-resistant tuberculosis in children less than 5 years old with culture positive *Mycobacterium tuberculosis*

P. Mahabeer¹, M. Khan², K. Mlisana¹

¹Glenwood Durban (South Africa), ²Durban (South Africa)

42.014 Mycobacterial lipoprotein mediates mycobacterial survival by inhibiting antimicrobial peptide secretion and blocking phagosomal maturation pathway

A. Padhi, A. Sonawane
Bhubaneswar (India)



- 42.015** Synthesis, ADME and antimycobacterial studies of a novel series of 2-thiazolylimino-5-arylidene-4-thiazolidinone derivatives
A. Mital, **R. P. Burman**, S. S. Jhamb, R. Gour, M. S. Gill
Nagar (India)

Epidemiology and Public Health

- 42.016** Isolation and molecular characterisation of *Mycobacterium africanum* from the sputum of butchers in a municipal abattoir in Ibadan, Oyo State, Nigeria
C. A. Agada¹, S. I. B. Cadmus², D. Igwe²
¹Makurdi (Nigeria), ²Ibadan (Nigeria)
- 42.017** Antibiotic susceptibility profile of enteric organisms from healthy individuals in a tertiary institution in Nigeria
F. Agbaje-Daniels¹, A. Babalola², I. Akintayo², A. Adeleye³
¹Igbesa (Nigeria), ²Ogun (Nigeria), ³Lagos (Nigeria)
- 42.018** Socio-economic and demographic impact on malaria prevalence in Akoko South-west of Ondo state, Nigeria
F. R. Akanbi
Ibadan (Nigeria)
- 42.019** Prevalence of tuberculosis among pregnant women in high burden setting in Sudan using Interferon gamma (IFN- Alpha) releasing assay (IGRA)
K. Yassin¹, H. Zaki¹, A. Alzeini², T. M. Abdallah², **A. A. Ali**²
¹Khartoum (Sudan), ²Kassala (Sudan)
- 42.020** APAIDSON program evaluation of the largest private public partnership consortium for HIV/AIDS care and treatment in India
R. R. Allam¹, G. Oruganti¹, C. Uthappa¹, N. Simhachalam¹, J. Rajesh¹, V. Yeldandi²
¹Hyderabad (India), ²Chicago, IL (USA)
- 42.021** Use of contact isolation to prevent spread: Ebola outbreak in a healthworkers base camp, Port Loko District, Sierra Leone, March 2015
U. P. Anebonam, O. Ossai
Abuja (Nigeria)
- 42.022** Outbreak of methanol poisoning in a semi urban community, Ondo state, southern Nigeria, April-May 2015: A descriptive analysis
M. O. Anyanwu, F. Akinyode, A. Adewole
Ibadan (Nigeria)
- 42.023** Binomics of mosquitos in Anambra State, Nigeria
D. N. Aribodor
Awka, Anambra (Nigeria)
- 42.024** Hospital based surveillance for radiological pneumonia in children under 5 years of age in Uttar Pradesh and Bihar: Project protocol and preliminary results
S. Awasthi, J. V. Singh, C. M. Pandey, N. Kohli, M. Agarwal
Lucknow (India)
- 42.025** A cross sectional study on knowledge and perception about risk factors of selected vector borne diseases among the population of rural field practice areas of KSHEMA
N. Priyadarisini¹, **S. Badiger**¹, N. Udayakiran¹, A. K. Shetty²
¹Mangalore (India), ²Winston-Salem, NC (USA)
- 42.026** Meningococcal carriage in University freshmen in Kashmir, North India
N. K. Bali, H. Mir, R. Yusuf, V. Tantray, D. Kakru, P. Koul
Srinagar (India)
- 42.027** An evaluation of a 24 hour malaria mobile case reporting system compared to the paper-based case reporting system in South Africa, 2015
R. E. Baloyi
Johannesburg (South Africa)
- 42.028** Emergence of multidrug-resistance in tuberculosis cases: Role of risk factors
A. Bompelli, V. Konuru
Hanamkonda (India)
- 42.029** Waning maternal measles antibodies in infants
M. Boulton¹, X. Wang², B. Carlson¹, A. Wagner¹, J. Montgomery¹, Y. Zhang²
¹Ann Arbor, MI (USA), ²Tianjin (China)
- 42.030** Spatial analysis of patients with multi-drug resistant pulmonary tuberculosis between 2009 and 2012 in Eastern China
W. Chen¹, Z. Liu², X. Wang², W. Wang¹
¹Shanghai (China), ²Zhejiang (China)
- 42.031** Evaluation of malaria epidemiological surveillance system in Luanda Province between January 2008 January 2014
C. Samutondo, **C. G. Claudete**
Luanda (Angola)



- 42.032** Prevalence and characterization of group B *Streptococcus* among pregnant women at a tertiary hospital in South Africa
Y. Dangor¹, M. Said¹, G. Kwatra², S. Madhi², N. Mbelle², F. Ismail¹
¹Pretoria (South Africa), ²Johannesburg (South Africa)
- 42.033** Frequency of cutaneous leishmaniasis among patients referred to the Center for Disease Control in Kuhgiluyeh and Boyerahmad province 2009–2013
O. Eilami, R. S. Khalili
Yasuj (Iran)
- 42.034** Assessment of uptake of intermittent preventive therapy for malaria in pregnancy following a health facility based training approach in Akwa Ibom state, Nigeria
I. Elechi¹, O. Ifabiyi¹, K. Ugbene¹, I. Akpan¹, J. Uzim², A. A. Aisiri², O. Adeusi², B. Aiyenigba²
¹Uyo (Nigeria), ²Abuja (Nigeria)
- 42.035** To evaluate the level of oxidative and antioxidative parameters and its relationship with clinical symptoms in women with primary fibromyalgia syndrome
G. Fatima, S. Kumar Das, A. Ali Mahdi
Lucknow (India)
- 42.036** Hepatitis A outbreak due to contaminated public water in Tiruchirappalli Corporation, Tamil Nadu, India, 2015
R. Geetharani¹, M. Sree Kalpana², R. Mohan Kumar¹, M. Murhekar¹, S. Mehendale¹
¹Chennai (India), ²New Delhi (India)
- 42.037** Effect of behaviour change-intervention on hand washing practices and knowledge about hand washing among school students, Perambalur district, Tamil Nadu, India, 2014–2015
R. Geetharani¹, B. Tarun¹, M. Sree Kalpana², R. Mohan Kumar¹
¹Chennai (India), ²New Delhi (India)
- 42.038** Polio eradication initiatives, a critical data analysis, District Khairpur, Sindh Pakistan, 2014
A. Ghanghro¹, A. S. Phulpoto², A. A. Memon²
¹Islamabad (Pakistan), ²Khairpur (Pakistan)
- 42.039** Transporting snakebite victims to appropriate health facility to save lives through emergency ambulance service in India
A. Gimkala
Secunderabad (India)
- 42.040** Health status of industrial workforce in district Lahore Pakistan
A. Gohar
Lahore (Pakistan)
- 42.041** Bacteriological profile of street vended food
A. Guraza
Trichy (India)
- 42.042** The impact of short educational messages in motivating community-dwelling seniors to receive influenza and pneumococcal vaccines
H. J. A. Ho, A. Chow
Singapore (Singapore)
- 42.043** Characterization of antibiotic resistance in *Escherichia coli* isolates from abattoir drains
E. Igbiosa
Benin City (Nigeria)
- 42.044** Detection of clusters and geographical hotspot for Lassa fever in Edo Central Senatorial district of Nigeria: A step into a nation-wide mapping of Lassa fever
C. G. Ike, D. Asogun
Irrua (Nigeria)
- 42.045** Prevalence of hepatitis delta virus in Sindh and Punjab (Pakistan) epidemiological survey
A. R. Jamil
Karachi (Pakistan)
- 42.046** Outbreak of Measles in Bhelterghat, Ghanapara and Pekbeki, Goalpara, Assam, India, 2015
T. Jamir¹, S. Sodha¹, B. Bhagabati², B. Das³, A. Shrivastava¹, A. Kumar¹, S. Venkatesh¹
¹New Delhi (India), ²Guwahati (India), ³Goalpara (India)
- 42.047** The epidemiological survey of HPV infection in married women referring to Firoozgar hospital
M. Jamshidi Makiani, S. Aminimoqaddam, S. Minaeian, S. A. A. Moosavi, Z. Moeeni, M. Zangeneh
Tehran (Iran)
- 42.048** Prevalence of urinary tract infection among HIV patients in Aba, Nigeria
A. M. Kanu, N. Mgbajiaka, N. Abadom
Aba (Nigeria)
- 42.049** Outbreak investigation of acute viral hepatitis in Kangra valley, Himachal Pradesh, India, 2014–2015
V. Katoch
New Delhi (India)
- 42.050** Prevalence of severe rotavirus associated gastroenteritis among children under five years of age in Chennai, India
S. A. Naaraayan¹, **C. G. Kumar**¹, S. Sundari¹, S. Venkatasubramanian¹, S. Mehendale¹, G. Kang²
¹Chennai (India), ²Vellore (India)



- 42.051** Modelling of epidemic development caused by TB/HIV co-infection in Ukraine
I. Kuzin
Kiev (Ukraine)
- 42.052** The effect of hospital visit behavior on the outcome of severe hand, foot and mouth disease in middle China
L. Long¹, L. gao², S. Hu², K. Luo², Z. Chen¹, Y. Lan¹, D. Zhou¹
¹Chengdu (China), ²Changsha (China)
- 42.053** Community cases management of malaria in Tripura, India-MSF intervention in response to malaria epidemic
R. Mahajan¹, T. Sunyoto¹, K. Malakyan¹, G. Mitra¹, D. Kumar², P. Mathew¹, M. A. Lima³
¹New Delhi (India), ²Hajipur (India), ³Barcelona (Spain)
- 42.054** Morbidity by Influenza A (Novel H1N1) virus infection in relation to age and gender from January 01, 2015 to October 30, 2015 in Baroda, a city in Western India
M. Modi, K. Madhavani, N. Patel, T. Javadekar
Baroda (India)
- 42.055** Estimation of the chronic obstructive pulmonary disease from exposure to particulate matter in Ahvaz, Southwest Iran
M. J. Mohammadi, S. Geravandi, G. Goudarzi, R. Malihi, F. Yousefi, F. Soltani, A. Ghomeishi, S. Salmanzadeh
Ahvaz (Iran)
- 42.056** First molecular detection and genotyping of group A rotaviruses by semi-nested RT-PCR from Sewage in Nigeria
B. O. Motayo, A. Faneye, J. A. Adeniji
Ibadan (Nigeria)
- 42.057** Evaluation of risk factors that have the potential for the introduction and spread highly pathogenic avian influenza and Newcastle disease into two states of Nigeria
W. I. Musa, P. A. Abdu, L. Sa'idu, M. Bello Zaria (Nigeria)
- 42.058** What are the burden and spectrum of skin infections in Cameroonian prisons?
E. A. Kouotou¹, **J. R. N. Nansseu¹**, I. Sieleunou², L.-L. Moguieu Bogue³, H. Adegbidi⁴, J. Tameyi Tatsa³, A. Sangare⁵, R. Moyou Somo¹
¹Yaoundé (Cameroon), ²Montréal (Canada), ³Bangangté (Cameroon), ⁴Cotonou (Benin), ⁵Treichville (Cote d'Ivoire)
- 42.059** Assessing the baseline burden of otitis media in children 2 to 3 years of age for estimating the effects of 13-valent pneumococcal conjugate vaccine (PCV) on *Otitis media*
J. Njuma Libwea¹, M. Kobela², P. Koki Ndombo², R. Syrjänen¹, H. Huhtala¹, N. Fointama², K. Shiro², H. Nohynek¹, P. Nourti¹, A. Palmu¹
¹Tampere (Finland), ²Yaounde (Cameroon)
- 42.060** Staphylococcal foodborne illness outbreak, Tshwane District, Gauteng Province–South Africa, June 2015
T. Ntshiq¹, H. Mpangane², D. Mpambane¹, M. Moshime¹
¹Pretoria (South Africa), ²Johannesburg (South Africa)
- 42.061** Factors associated with high HIV related stigma among commuter populations in Johannesburg inner city, South Africa
P. S. Nyasulu, N. Tshuma, K. Muloongo, L. Chimoyi
Johannesburg (South Africa)
- 42.062** Development of saliva based diagnostic method for malaria
G. I. Olasehinde, I. Fadina, O. O. Ayepola, A. A. Ajayi, L. O. Egwari
Ota (Nigeria)
- 42.063** Outbreak investigation of Kaysanur Forest Disease (KFD) in Wayanad District, Kerala, India 2015
P. Padda¹, A. Shrivastava¹, S. Sodha¹, S. Venkatesh¹, V. KR²
¹New Delhi (India), ²Wayanad (India)
- 42.064** Molecular epidemiology of rabies virus in Nepal
G. R. Pant¹, Y. Feng², C. Tu², D. R. Bhatta³
¹Chitawn (Nepal), ²Changchun (China), ³Kathmandu (Nepal)
- 42.065** Typhoid fever surveillance in Africa program (TSAP): Constructing a geospatial sampling frame for random sampling of households
U. Panzner¹, G. D. Pak¹, C. G. Meyer², M. Ali³, S. Baker⁴, J. D. Clemens⁵, J. Fung Deerin¹, N. Gasmelseed⁶, J. Im¹, K. H. Keddy⁷, A. Gassama Sow⁸, A. Tall⁸, J. Park¹, T. F. Wierzb¹, F. Marks¹
¹Seoul (Republic of Korea), ²Tübingen (Germany), ³Baltimore, MD (USA), ⁴Ho Chi Minh City (Viet Nam), ⁵Dhaka (Bangladesh), ⁶Wadmedani (Sudan), ⁷Johannesburg (South Africa), ⁸Dakar (Senegal)



- 42.066** Genetic variability of the G-L intergenic region sequences of Indian rabies virus strains circulating in animals
K. Pramina¹, B. Veeresh¹, S. I. Isloor¹, D. Rathnamma¹, S. Yathiraj¹, M. Narayanswamy¹, R. Sharada², Y. Chaitra¹, N. R. Hegde³
¹Bangalore (India), ²Hassan (India), ³Hyderabad (India)
- 42.067** Prevalence of rickettsial infections in acute coronary syndromes in Sri Lanka: A case control study
C. D. Mettananda, **R. Premaratna**, D. Danansuriya, N. B. Bandara
Ragama (Sri Lanka)
- 42.068** Influence of Alpha thalassemia on the protective effect of sickle cell gene on severity of *P. falciparum* malaria
P. Purohit, S. Patel, P. K. Mohanty
Burla (India)
- 42.069** Role of medical colleges in TB control under RNTCP—Five years experience in Puducherry, S. India (2010–2014)
A. Purty, Z. Singh, M. Natesan, R. Chauhan, D. Ramachandran
Pondicherry (India)
- 42.070** Evaluation of Chikungunya virus infection and screening of antibodies
S. Raghavenhdar, S. K. Kabra, P. Ray
New Delhi (India)
- 42.071** Clinical, social, and meteorological factors associated with dengue and malaria diagnosis in adults in Pune, India
D. Kadam¹, **P. A. Raichur**¹, A. Chandanwale¹, S. Joshi¹, M. Robinson², I. Marbaniang¹, A. Kagal¹, R. S. Bharadwaj¹, V. Mave¹
¹Pune (India), ²Baltimore, MD (USA)
- 42.072** Decadal study of incidence and control of malaria in tribal population—With special reference to Khammam district of Telangana State
A. Rambabu
Khammam (India)
- 42.073** Genotypic, phenotypic and functional profiles of NDM harboring Carbapenem resistant *Escherichia coli* from India
A. Ranjan, N. Ahmed
Hyderabad (India)
- 42.074** Epidemiology of bluetongue virus in Australasia
P. P. Rao, V. Reddy, N. R. Hegde
Hyderabad (India)
- 42.075** Dengue seroprevalence in urban dwelling Indonesian children: A nationally-representative study
A. Prayitno¹, A.-F. C. Taurel², J. Nealon³, H. Irawan Satari¹, R. Mulya Karyanti¹, R. Sekartini¹, S. Soedjatmiko¹, H. Gunardi¹, B. Medise¹, T. Sasmono¹, M. Simmerman², A. Bouckennooghe³, **S. Rezeki Hadinegoro**¹
¹Jakarta (Indonesia), ²Bangkok (Thailand), ³Singapore (Singapore)
- 42.076** Earthquake related infections in Nepal
S. Mishra¹, R. Lama¹, H. Kattel¹, S. Ghimire¹, S. Sharma¹, N. Shah¹, K. Parajuli¹, J. Sherchand¹, J. Koirala², B. M. Pokhrel¹, **B. P. Rijal**¹
¹Kathmandu (Nepal), ²Springfield, IL (USA)
- 42.077** Assessment of fourteen days primaquine treatment efficacy in *Plasmodium vivax* malaria at primary and tertiary care centers in Southwestern India
K. Saravu, K. Rishikesh, V. Guddattu
Manipal (India)
- 42.078** Ethiopian dracunculiasis eradication, the end game challenges, 2015
A. S. Shilbe, G. E. Yembo, D. J. Wayesa, A. B. Woyessa, T. B. Anbessie, A. K. Habtemichael, Z. Z. Kebede, K. Haile
Addis Ababa (Ethiopia)
- 42.079** Factors associated with Ano-genital warts occurrence among Human Immunodeficiency Virus (HIV) infected patients in Gauteng, South Africa
Q. Sibanda¹, E. Musenge², P. Nyasulu², B. Muzah²
¹Pretoria (South Africa), ²Johannesburg (South Africa)
- 42.080** A multicentric surveillance of invasive pneumococcal disease (IPD) in children under five years in India
J. Singh, A. Manoharan
Tiruvalla (India)
- 42.081** An analytical study of behavioral risks and illness among camel keeper and non-camel keeper at zoo parks in Thailand 2014
S. Hinjoy¹, **P. Smithsuwan**², A. Wongkumma²
¹Bangkok (Thailand), ²Nonthaburi (Thailand)



- 42.082** Outbreak of suspected cholera associated with unprotected well water, Biral B village, Gulbarga district, Karnataka, 2015
M. SreeKalpana¹, S. Samir¹, R. Kamaraj², L. Kayla¹, K. Prakash Kumar³, M. Vijayashree⁴, K. Rajashree³, H. Nazneen³
¹New Delhi (India), ²Chennai (India), ³Bangalore (India), ⁴Gulbarga (India)
- 42.083** Hepatitis E outbreak among factory workers due to contaminated factory water, Mandya District, Karnataka, India, 2015
M. SreeKalpana¹, F. Asha², G. Kapil¹, M. Murhekar², P. Maruthi³, K. Prakash Kumar⁴, R. Doddamallappa⁴, M. Ravikumar³, H. Shwetha³, L. Manuja³, B. Ramrao³, R. Mohan Kumar², S. Venkatesh¹, A. Shrivastava¹
¹New Delhi (India), ²Chennai (India), ³Mandya (India), ⁴Bangalore (India)
- 42.084** Describing the interactive model design of avian influenza: Animal infection and human infection
T.N. Anand, S. Rajan, L.R. Aravind Trivandrum (India)
- 42.085** The impact of a SMS-based disease outbreak alert system (mSOS) in Kenya
M. Toda¹, I. Njeru¹, D. Zurovac¹, S. O-Tipo¹, D. Kareko¹, M. Mwau¹, K. Morita²
¹Nairobi (Kenya), ²Nagasaki (Japan)
- 42.086** Detection of mycobacteria in raw milk and assesment of risk factors among fulani herdsmen in Bwari Area Council, Abuja, Nigeria
A. M. Usman, J. Kwagga, K. Junaid, I. Abdulkadir Zaria (Nigeria)
- 42.087** Impact of outpatient neuraminidase inhibitor treatment on hospitalisation in patients infected with influenza A (H1N1)pdm09: An IPD analysis
S. Venkatesan, P. R. Myles, J. Leonardi-Bee, P. Consortium Investigators, J. S. Nguyen-Van-Tam Nottingham (United Kingdom)
- 42.088** Spatial and temporal dynamics of the cases of tuberculosis in the zone of farming health of Pendjwa, Province of Bandundu/RDC, 2009–2013
J. Wangi Bosila Besancon (France)
- 42.089** Prevalence and re-infection of *Schistosoma mansoni* among school children in Mekele town, North Ethiopia
H. H. Weldegebreal Dessie (Ethiopia)
- 42.090** Epidemiology of needle stick-sharp injuries (NSSIs) and potential high risk exposures among health professionals in Ethiopia: Neglected public health concern
Z. D. Woldesonbet Addis Ababa (Ethiopia)
- 42.091** Social, economic, and immunological impacts of TB treatment in Eastern rural China
X. Xiao¹, L. Yuan¹, L. Qiu², W. Lu³, W. Jiang¹, Q. Zhao¹
¹Shanghai (China), ²Jiangxi (China), ³Jiangsu (China)

HIV/AIDS and Other Retroviruses

- 42.092** Incidence and risk factors for Tenofovir induced nephrotoxicity among patients with HIV on stable combination antiretroviral therapy(c ART) in South India
B. Achappa Mangalore (India)
- 42.093** Variations in the elimination of new HIV infections among children in Africa
O. Adetokunboh Cape Town (South Africa)
- 42.094** Changing the content of Cl, Ca, K, Na in the hair of HIV-infected patients depending on the concentration of CD4 lymphocytes
Z. Akhmedjanova, Z. Akhmedova, E. Danilova, D. Akhmedjanov Tashkent (Uzbekistan)
- 42.095** Private public partnership for stigma free HIV service delivery in APAIDSCON network in India
R. R. Allam¹, G. Orugant¹, C. K. Uthappa¹, V. Yeldandi²
¹Hyderabad (India), ²Chicago, IL (USA)
- 42.096** Insilico analysis of micro RNA based target interaction associated with pharmacogenomics of acquired immune deficiency syndrome
H. Anandaram, D. Alex Anand Chennai (India)
- 42.097** The elements of paediatric HIV status disclosure: A qualitative study from Karnataka, India
N. K. Kodyalamoole¹, **S. Badiger**¹, A. K. Shetty²
¹Mangalore (India), ²Winston-Salem, NC (USA)
- 42.098** Development of engineered nanocarrier for controlled delivery of a protease inhibitor
G. Agarwal, **S. Bhargava** Kanpur (India)



- 42.099** Prevalence and risk factors associated with immunological non-response in HIV-1 infected patients treated with NNRTI based first line drugs in South India
J. Boobalan, T. R. Dinesha, P. Balakrishnan, S. Sivamalar, K. Murugavel, S. Poongulali, N. Kumarasamy, S. S. Solomon, S. Solomon, S. Saravanan
Chennai (India)
- 42.100** Prevalence of genital herpes in HIV positive patients attending STI clinic at a tertiary care hospital and its correlation with CD4 counts
L. Buddamakuntala, P. Moodambail
Bangalore (India)
- 42.101** Plasma cytokine and chemokine levels and their impact on HIV disease non-progression among HIV-1 subtype-C long-term non-progressors from South India
S. Chinnambedu Ravichandran¹, V. Ramachandran¹, B. Pachamuthu¹, S. I. Syed Hussain¹, S. Mohandas¹, G. Waldrop², S. S. Solomon¹, S. Solomon¹, M. Kailapuri Gangadharan¹
¹Chennai (India), ²Baltimore, MD (USA)
- 42.102** Micro-level social and structural syndemic of HIV risk among Nepalese female sex workers
K. Deuba
Kathmandu (Nepal)
- 42.103** Poor condom-negotiation skills, inadequate social support, depression and incarceration associated with HIV risks among young key populations in Nepal
K. Deuba
Kathmandu (Nepal)
- 42.104** Ecological study of HIV cases with socio-crime factors associated in Indonesia
A. P. M. Dewi
Depok (Indonesia)
- 42.105** Archived drug resistance profile among suppressed HIV patients using conventional and sensitive allele specific PCR in Tenofovir experienced patients in South India
T. R. Dinesha¹, S. Sivamalar¹, S. Gomathi¹, J. Boobalan¹, S. Poongulali¹, N. Kumarasamy¹, P. Balakrishnan¹, S. S. Solomon¹, S. Solomon¹, D. Katzenstein², R. Kantor³, S. Saravanan¹
¹Chennai (India), ²Stanford, CA (USA), ³Providence, RI (USA)
- 42.106** Low virulence of HIV-1 subtype C underlies treatment success despite high baseline viral loads
A. Shet, P. Nagaraja, **N. Dixit**
Bangalore (India)
- 42.107** HLA-C*07 allele group confers protection against cytomegalovirus retinitis development among Brazilian AIDS patients
T. Birbeg-Salum, M. D. L. Rodrigues, N. Deghaide, C. Mendes-Júnior, A. P. Fernandes, **E. Donadi**
Ribeirão Preto (Brazil)
- 42.108** Secondary data analysis of HIV/AIDS control programme data, Enugu State (2010–2013)
C. C. Ezeudu
Abuja (Nigeria)
- 42.109** HIV missed ...CMV shows the way
K. A. C. G. Gandhi, S. Mankar, B. Purandare, S. Ialwani, J. Oswal, V. Kalrao
Pune (India)
- 42.110** HIV-1 pol gene polymorphism and transmitted drug resistance (TDR) in chronically infected HIV-1 antiretroviral treatment naïve patients in South India
S. Gomathi, S. Sivamalar, T. R. Dinesha, J. Boobalan, P. Balakrishnan, A. Pradeep, S. Poongulali, S. S. Solomon, S. Solomon, S. Saravanan
Chennai (India)
- 42.111** Low plasma nevirapine levels during antiretroviral treatment initiation and dose escalation in HIV-infected children: Therapeutic implications
B. P. Gopalan¹, R. D'souza², N. Rajnala², H. Kumar A. K.², A. Shet²
¹Bangalore (India), ²Chennai (India)
- 42.112** Knowledge and practice of the prevention of mother-to-child transmission of HIV guidelines among doctors and nurses at Tswane District, South Africa
I. Govender, K. Ogbonna
Pretoria (South Africa)
- 42.113** The characteristics of HIV/AIDS patients with deep vein thrombosis at Dr. George Mukhari Academic Hospital
I. Govender
Pretoria (South Africa)
- 42.114** The profiles of HIV-infected patients treated at A. Wahab Sjahranie General Hospital Samarinda, Indonesia
C. Gunawan
Samarinda (Indonesia)



- 42.115** Metabolic syndrome among people living with HIV (PLHIV)
G. R. Jammy¹, M. Dinaker², P. S. Reddy², C. H. Bunker¹
¹Pittsburgh (USA), ²Hyderabad (India)
- 42.116** Retrospective analyses of CD4 count monitoring to detect ART response
M. Katiyar, R. Singh, S. C. Parija
Puducherry (India)
- 42.117** Association of nadir CD4 counts with carotid-intima media thickness and inflammation markers in HIV infected patients
B. Kausalya¹, S. Gomathi¹, S. Iqbal¹, K. Murugavel¹, N. Kumarasamy¹, S. Poongulali¹, S. S. Solomon¹, S. Solomon¹, S. Pallikkuth², S. Pahwa², S. Saravanan¹
¹Chennai (India) ²Miami, FL (USA)
- 42.118** Anxiety levels of HIV-infected patients after learning their diagnosis: A preliminary study for the first time in Turkey
B. Kocazeybek, I. Balcioglu, O. F. Demirel, N. Yildiz, P. Yuksel, H. Saglam, Z. Habip, E. Kocazeybek, Y. H. Balcioglu, M. M. Kirpinar
Istanbul (Turkey)
- 42.119** Frequency, social and demographic characteristics of HIV-serodiscordant heterosexual couples in Ukraine
I. Kuzin, V. Martsynovska
Kiev (Ukraine)
- 42.120** Caregiver burden among adults caring for people living with HIV/AIDS (PLWHA) in South India
D. Madi, V. Chandran, N. Chowta, J. Ramapuram
Mangalore (India)
- 42.121** Evaluation of immune response to hepatitis B vaccine among isolated HBC Ab positive patients who coinfectd with HIV/HCV
M. M. Majzoobi, M. Mamani, S. H. Hashemi, G. Hadis, J. Poorolajal
Hamadan (Iran)
- 42.122** HIV-mediated CD8 encephalitis: An under recognised entity
A. Manesh, R. Barnabas, R. Karthick, G. Chacko, R. Kannangai, G. M. Varghese
Vellore (India)
- 42.123** The level of education affects CD4 cell count and wellness among HIV infected adult between age group 18 to 60 years
S. P. Maurya, R. Singh, N. Negi, A. Kapil, R. Chaudhry, B. K. Das
New Delhi (India)
- 42.124** Feeling the pressure: Prevalence and risk factors associated with systemic hypertension among HIV infected children and adolescents
K. Mehta¹, S. Suneetha¹, S. Prasad Tenali¹, L. Suneetha¹, A. Shet², N. Rao S¹
¹Hyderabad (India), ²Bangalore (India)
- 42.125** Disclosure of HIV status: Perspectives from infected children in India
K. Mehta¹, M. Ekstrand², E. Heylen², G. Sanjeeva¹, A. Shet¹
¹Bangalore (India), ²San Francisco, CA (USA)
- 42.126** Association of anti retroviral therapy with changes in peripheral arterial disease status and severity—A vision
A. Mukherjee¹, D. Khanra², P. Ghosh¹, A. Talukdar¹
¹Kolkata (India), ²Kanpur (India),
- 42.127** Effectiveness of AIDS education program on nursing students' knowledge and attitudes in Sri Lanka
G. N. Nanayakkara¹, E.-O. Choi²
¹Sri Jayawardenapura (Sri Lanka), ²Busan (Republic of Korea)
- 42.128** Mothers' knowledge and practice on modified infant feeding for prevention of postnatal HIV transmission in post conflict northern Uganda district
R. Naturinda¹, G. Akello², C. Muwonge³, V. Nyakato², A. Bameka⁴, J. Esiru², D. Amone², A. Wokorach², L. Oonyu⁵, L. Ssekiswa⁶
¹Kampala, central Uganda (Uganda), ²Gulu (Uganda), ³Fort Portal (Uganda), ⁴Jinja (Uganda), ⁵Mbale (Uganda), ⁶Hoima (Uganda)
- 42.129** CD4 pattern in HIV positive patients on HAART exposed to moringa oleifera leaf powder in South East Nigeria
E. N. Ogbuagu, S. Ufearo, C. N. Ogbuagu, R. Okonkwo
Nnewi (Nigeria)
- 42.130** Malaria preventive practices and clinical burden among HIV patients attending clinic at a tertiary hospital in Nigeria
A. A. Olorukooba¹, S. S. Yahaya², C. Okeke¹, M. J. Ibrahim¹, L. Amadu¹, H. Abdulrahman¹
¹Zaria (Nigeria), ²Katsina (Nigeria)
- 42.131** Elite neutralizers among HIV-1 Subtype-C infected individuals from southern India
N. Paneerselvam¹, S. Iqbal¹, S. Solomon¹, S. S. Solomon¹, D. C. Montefiori², P. Balakrishnan¹
¹Chennai (India), ²Durham, NC (USA)



- 42.132** DC-SIGN and L-SIGN repeat-region polymorphisms influence HIV-1 disease progression in slow and rapid progressors among perinatally-infected children in India
N. Rajnala, B. P. Gopalan, R. D'Souza, A. Shet
Bangalore (India)
- 42.133** CD4 Levels >350 cell/μl at initiation of option B+ Predict retention in care amongst mothers in urban health facilities in Uganda
D. Senjovu, P. Mugabe, U. Ssekabira
Kampala (Uganda)
- 42.134** An analysis of global HIV prevalence among refugees, asylum seekers, and migrants, using the US Bureau of the Census databank
W. Shandera
Houston, TX (USA)
- 42.135** Mitochondrial dysfunction among HIV-1 infected patients of South India and evaluation of mitochondrial DNA as a biomarker of mitochondrial toxicity
D. Subashini¹, T. R. Dinesha¹, S. Gomathi¹, J. Boobalan¹, C. Swathirajan¹, L. Samuel¹, S. Poongulali¹, D. Chitra¹, R. Srirama², S. Mothi², S. S. Solomon¹, S. Solomon¹, S. Saravanan¹, P. Balakrishnan¹
¹Chennai (India), ²Mysore (India)
- 42.136** Pre-exposure Prophylaxis (PrEP): Attitudes, preferences and risk compensation behavior among men who have sex with other men (MSM) in India
C. K. Uthappa¹, S. Pal², R. Panth², R. Allam¹, V. Yeldandi³
¹Hyderabad (India), ²New Delhi (India), ³Chicago, IL (USA)
- 42.137** Health related quality of life of HIV/AIDS patients on highly active antiretroviral therapy in Ahmadu Bello University Teaching Hospital
S. S. Yahaya¹, A. A. Olorukooba², R. Yusuf², H. Abdulrahman², L. Amadu²
¹Katsina (Nigeria), ²Zaria (Nigeria)
- 42.138** Current problems in serologically based diagnostic algorithm of HIV 1/2: The re-evaluation of immunodot blot assays in HIV 1/2 verification in Turkey
P. Yuksel, R. Caliskan, M. Kuskucu, S. Islak Mutcali, E. Kosan, H. Kirkoyun Uysal, Z. Habip, A. Abdelkerem, B. Mete, S. Saribas, E. Bonabi, I. Birinci, O. Dinc, K. Midilli, B. Kocazeybek
Istanbul (Turkey)

Infection Control

- 42.139** Uptake of intermittent preventive therapy among pregnant women attending antenatal clinics in public and registered private health facilities in Oyo State, Nigeria
A. O. Akpasa¹, A. Adebayo¹, J. Onyilo¹, B. Ahmed¹, T. O. Ladipo¹, Y. Oke², A. Karim-Mohammed¹, O. Adeusi², B. Aiyenigba²
¹Ibadan (Nigeria), ²Abuja (Nigeria)
- 42.140** Prospective cohort study on rectal colonization with Carbapenem Resistant Enterobacteriaceae in patients admitted in a tertiary care hospital
R. Arjun, P. Patil, P. Gupta, P. Wagle
Trivandrum (India)
- 42.141** Evaluation of antimicrobial and disinfectant resistant bacteria isolated from the environment of a University Health Centre
O. O. Ayepola, L. O. Egwari, G. I. Olasehinde
Ota (Nigeria)
- 42.142** Tetanus and use of magnesium in resource limited country
A. Basher
Mymensingh (Bangladesh)
- 42.143** The role of toxin-antitoxin systems in the survival of multidrug tolerant pathogens and designing of new approaches to treat them
R. K. Chaudhary¹, R. Narain², G. Singh³, A. Kumar¹, S. Ram¹
¹Greater Noida (India), ²Jaunpur (India), ³New Delhi (India)
- 42.144** Impact of antimicrobial stewardship in collaboration with infection control on hospital-acquired infection rates in a subspecialty cancer treatment facility
M. Chowdhury, D. Miller, M. Lewis, M. Niesley, T. Patel
Philadelphia, PA (USA)
- 42.145** Inhibition of Japanese encephalitis virus infection by biogenic catechin silver nanoparticles: An in-vitro study
P. Chowdhury¹, T. Bora², S. A. Khan², B. Chakraborty³, K. Senapati⁴, M. Sengupta³, S. Borchetia¹, T. Bandyopadhyay¹
¹Jorhat (India), ²Dibrugarh (India), ³Silchar (India), ⁴Guwahati (India)



- 42.146** Point surveillance of *Staphylococcus aureus* nasal carriage among health care workers in rural tertiary care center of Central India
G. Dangre¹, A. Mudey¹, N. Tankhiwale¹, S. Nayak²
¹Wardha (India), ²Sawangi (India)
- 42.147** Evaluating the effect of hand washing and sanitization on the microbial burden of the hand
L. O. Egwari, O. O. Ayepola, B. Adekeye, T. Adegbayi, S. Olurunshola, A. Kuye, Ota (Nigeria)
- 42.148** Study of *Listeria monocytogenes* contamination in raw milk and some Moroccan traditional dairy derivatives (Lben and Jben)
B. El Marnissi, R. Belkhou, L. Bennani Fès (Morocco)
- 42.149** Clinical symptomatology and treatment with ambisome in cases with visceral leishmaniasis hospitalised in pediatric infective care unit, Tirana, Albania
E. Foto, F. Zavalani, G. Kuli, R. Petrela, H. Bregu, B. Neza, S. Zavalani Tirana (Albania)
- 42.150** Non-microbiological system to improve hospital hygiene in a critical care unit (CCU)
C. Freuler, D. Torres, M. Urquiza, R. Prieto, P. Montero, A. V. Sanchez, M. Mayer Wolf, M. Garcia Posadas, M. Radosta, N. Garcia Allende, C. Ezcurra, V. Rodríguez Buenos Aires (Argentina)
- 42.151** Attitude is a little thing which makes a big difference—KAP on isolation practices amongst visitors
S. Y. Gohel, A. Ghafur, V. Devrajan, K. J., K. Chandra, J. S. Alex Chennai (India)
- 42.152** Surveillance of nosocomial *Clostridium difficile* infection (nCDI) in a large tertiary community hospital
F. Smok, M. Macholz, G. Görsch, **T. Grünwald** Leipzig (Germany)
- 42.153** Brucella exposure in a microbiology laboratory in South India—Never sniff a gift fish
J. Hemalatha¹, D. Sureshkumar¹, S. Saravanakumar²
¹Chennai (India), ²Mangalore (India)
- 42.154** Reflection on observation: A qualitative study using practice development methods to explore the experience of being a hand hygiene auditor in Australia
S. Jain¹, D. Edgar², J. Bothe³, J. Harris², H. Newman², A. Wilson², B. Bint², M. Brown², S. Alexander²
¹Sydney (Australia), ²Wollongong (Australia), ³Kogarah (Australia)
- 42.155** *Enterococcus* spp synergises the antimicrobial activities of conventional antibiotics against ciprofloxacin-resistant *Salmonella enterica* serovar Typhi
S. Kaur, P. Sharma Amritsar (India)
- 42.156** Antiviral effect of Glycine coated Iron oxide nanoparticles iron against H1N1 influenza A virus
R. Kumar¹, G. C. Sahoo¹, M. Chawla-Sarkar², M. K. Nayak², K. Trivedi¹, S. Rana¹, K. Pandey¹, V. Das¹, R. Topno¹, P. Das¹
¹Patna (India), ²Kolkata (India)
- 42.157** Design of a study to examine contact mixing and acute respiratory infection in Ballabgarh, Haryana
S. Kumar¹, R. Amarchand², M. Gosain², H. Sharma², F. Dawood³, S. Jain³, K. Lafond³, M.-A. Widdowson³, J. Read⁴, A. Krishnan²
¹Pittsburgh (USA), ²New Delhi (India), ³Atlanta (USA), ⁴Lancaster (United Kingdom)
- 42.158** Social media for infection control and prevention
V. V. Kumar¹, P. Thirumalaikolundusubramanian¹, A. Uma¹, N. Balamurugan²
¹Trichy (India), ²Salem (India)
- 42.159** Institutional Chickenpox Prevention Programme (ICPP) in a tertiary care hospital in Singapore: Lessons from epidemiology and contact tracing
C. Mittal, R. Sridhar, H. C. Chan, Y. Hou, J. G. K. Sng, R. Lin, P. A. Tambyah, D. Fisher, I. Venkatachalam Singapore (Singapore)



- 42.160** Cultural rationale and architectural designs of Isolation Centres (ICs): A case of dangerous pathogens such as Ebola
G. Nakibaala
Kampala (Uganda)
- 42.161** Modifying the existing water tap system to create a no touch, cost effective solution
G. Nakibaala
Kampala (Uganda)
- 42.162** Investigation of an outbreak due to *Serratia marcescens* in a neonatal intensive care unit in a tertiary care hospital
S. Poddar, S. Sengupta
Kolkata (India)
- 42.163** Disinfection against healthcare-associated infections: Current status and recent progress in products and procedures
S. A. Sattar
Ottawa (Canada)
- 42.164** Decontamination of high-touch environmental surfaces in healthcare: Quantitative assessment of disinfectant pre-soaked wipes
S. A. Sattar
Ottawa (Canada)
- 42.165** Dynamical behavior of SIRS epidemic model with media awareness as control strategy
H. Singh¹, J. Dhar², H. S. Bhatti³, G. P. Sahu⁴
¹Amritsar (India), ²Gwalior (India), ³Fatehgarh Sahib (India), ⁴Raipur (India)
- 42.166** Need for more communication between hospitals in different countries: Two cases of carbapenem-resistant Enterobacteriaceae
J. H. Ochieng, D. Taherzadeh, K. Voy-Hatter, **P. Sreeramoju**
Dallas, TX (USA)
- 42.167** Relation of risk factors and mortality in the Carbapenem-resistant *Klebsiella pneumoniae* infection: Case control study
F. Akgul, I. Bozkurt, **M. Sunbul**, S. Esen, H. Leblebicioglu
Samsun (Turkey)
- 42.168** Contact isolations in South India: Guidelines vs practice
D. Sureshkumar¹, J. Hemalatha¹, S. Saravanakumar²
¹Chennai (India), ²Mangalore (India)
- 42.169** Consistent use of LLINs among household members of Kersa, Eastern Ethiopia
T. G. Tesema, T. Gobena
Harar (Ethiopia)
- 42.170** Multi resistant VIM-positive *Pseudomonas aeruginosa* in the health care setting—Lessons learned to combat transmission
M. C. Vos, A. Voorintholt, D. Gommers, J. Severin
Rotterdam (Netherlands)
- 42.171** Antibiofilm and antimicrobial activity of bacteria from hard corals and sponges in Indonesia
D. Waturangi¹, A. E. Putra¹, A. Lukito¹, A. Camesi¹, J. K. Hwang²
¹Jakarta (Indonesia), ²Seoul (Republic of Korea)
- 42.172** Infection prevention and control—Bridging the knowledge gap among Kenyan health care workers
E. Wesangula, R. Kamau, V. Kamau, F. Kiberenge, J. Gituku
Nairobi (Kenya)
- 42.173** Active fractions from *Zanthoxylum acanthopodium* fruit modulate inflammatory biomarkers in lipopolysaccharide-induced macrophages in vitro
Y. Yanti
Jakarta (Indonesia)

Infectious Disease Surveillance and Notification

- 42.174** Evaluation of Ondo State acute flaccid paralysis surveillance system (2009–2013)
A. Adewole
Ibadan (Nigeria)
- 42.175** Molecular characterization of group A rota viral diarrhea complicated by enteropathogenic *E.coli*—Study of dual infections in children from Kashmir-Himalaya
I. Ahmad¹, S. Zafurullah², A. Afshan²
¹Srinagar, Jammu, Kashmir (India), ²Dammam (Saudi Arabia)
- 42.176** Severe acute respiratory infections associated with influenza and non-influenza viruses—Yemen, 2011–2014
M. Al Amad, A. Al Mahqri, A. Al Serouri
Sana'a (Yemen)
- 42.177** M health technology for surveillance of infectious diseases: Challenges and learning for scale up and replication
F. Ali
Jhunjhunu (India)



- 42.178** Animal-cell phone based surveillance and notification of infectious diseases in remote settings: A case study of plague in Uganda
S. T. Asaku, K. Odhiambo Ojwang, L. Adiru Atiku, T. Apangu, J. Tendo Mpanga
Kampala (Uganda)
- 42.179** Molecular characterization of human enteric adenovirus circulating among children below five years of age in Kolkata, India
A. Banerjee, M. Chawla-Sarkar
Kolkata (India)
- 42.180** Is the South African notifiable diseases surveillance system effective in preventing outbreaks? Perceptions of key stakeholders
F. Benson¹, A. Musekiwa², L. Blumberg¹, L. C. Rispel¹
¹Johannesburg (South Africa), ²Pretoria (South Africa)
- 42.181** Increasing tuberculosis yield from investigation of contacts of smear positive TB cases through engagement of civil society organizations: Active TB case finding in Mombasa, Kenya
U. O. Benson¹, D. Mobegi¹, T. Kiptai¹, J. Mueni¹, M. Mungai¹, F. Ngari¹, C. Mwamburi², Z. Samoei¹, C. Kamau¹
¹Nairobi (Kenya), ²Mombasa (Kenya)
- 42.182** Bacterial and fungal infections among hospitalized patients with respiratory infections
M. R. Bojary Nasrabadi
Tehran (Iran)
- 42.183** Mapping the awareness levels of mothers about the danger signs of acute respiratory infections in children of the Southern States of India, its relation with treatment seeking behaviour
S. Challa, R. R. Chowdavarapu, S. Pattnaik, D. Mathai
Hyderabad (India)
- 42.184** Etiology of diarrheal disease in children from 0 to 14 years old admitted in Hospital Geral Mavalane, Mozambique
J. J. Chilaule, I. Moiane-Cossa, M. Cassocera, E. Guimarães, J. Langa, J. P. Langa, L. Manhique, J. Sambo, D. Bero, N. De Deus
Maputo (Mozambique)
- 42.185** Measles outbreak investigation in Cacuo municipality between the period from 01 to 15 November 2013
C. G. Claudete, I. Neves, R. Antonio, R. Morreira, J. Leite
Luanda (Angola)
- 42.186** Clinical presentation, management and outcomes of influenza in Africa: systematic review, 2009–2014
M. H. Ekat
Brazzaville (Democratic Republic of Congo)
- 42.187** Reducing contamination rate of Löwenstein Jensen sputum culture media by use of Panta antimicrobial panel
G. Ekuka
Kampala (Uganda)
- 42.188** Prevalence of congenital malaria in Blue Nile state, Sudan
S. A. O. Elhaj¹, M. Abdrahim², M. O. Elhassan¹
¹Khartoum (Sudan), ²Damazin (Sudan)
- 42.189** Identification of etiologic agents in meningitis cases by multiplex real-time polymerase chain reaction and culture
D. Findik, H. Turk Dagi, U. Arslan, M. Demirayak
Konya (Turkey)
- 42.190** A Laboratory Information Management System (LIMS) for animal health: Experiences of the Istituto Zooprofilattico Sperimentale of Sicily (Italy)
S. Vullo¹, G. Purpari¹, G. Chiarenza¹, M. T. Mercante², **A. Guercio**¹, G. Tumino³, P. Colangeli²
¹Palermo (Italy), ²Teramo (Italy), ³Ragusa (Italy)
- 42.191** Trends of acute watery diarrhea in Lao People's Democratic Republic, 2009–2013
S. Houadthongkham¹, G. Jennings¹, N. Sithivong¹, M. Phengxay¹, P. Teepruksa¹, B. Khamphaphongphane¹, P. Vongphachanh¹, K. Southalack¹, D. Luo¹, M. O'Reilly², C. H. Chiu¹
¹Vientiane (People's Republic of Lao), ²Manila (Philippines)
- 42.192** Mantle: A free and multilingual software for one health biosurveillance & research
A. G. Huff, T. Allen
New York City, NY (USA)
- 42.193** Evaluation of Ebola virus disease surveillance system in Tonkolili District, Sierra Leone, 2015
O. S. Ilesanmi¹, O. Fawole², P. Nguku¹, A. Oladimeji¹
¹Abuja (Nigeria), ²Ibadan (Nigeria)
- 42.194** Integration from patient registration to WHO reporting in Azerbaijan and Georgia
V. Qasimov¹, V. Allahverdiyeva¹, **P. Imnadze**², K. Zakhashvili², A. Burdakov³, A. Ukharov³
¹Baku (Azerbaijan), ²Tbilisi (Georgia), ³Moscow (Russian Federation)



- 42.195** Information and Communications Technology (ICT) solutions for enhanced disease surveillance in India
P. Jacob¹, A. Babu², R. Samuel², V. Varma²
¹Bengaluru (India), ²New Delhi (India)
- 42.196** Hospital based sentinel surveillance of bacterial meningitis in India
S. Mehendale¹, **Y. Jayaraman**¹, B. Veeraraghavan²
¹Chennai (India), ²Vellore (India)
- 42.197** Evaluation of passive pharmacovigilance surveillance system in Tanzania—A review of secondary data
J. V. Kapiga
Tanga (Tanzania)
- 42.198** Device-associated infection rates with microbiological profile and antibiogram pattern from an adult medical-surgical ICU of a tertiary care hospital
B. Kashyap, S. Gupta, Y. Sarin
New Delhi (India)
- 42.199** Bacterial and fungal infections in liver transplant recipients
V. Khillan, N. Rathor, S. K. Sarin
New Delhi (India)
- 42.200** Molecular identification of beta lactamase producing gram negative bacteria in water samples collected from River Yamuna in Agra Region
A. Kumar¹, M. Asthana¹, R. Sharma¹, S. Amdekar², P. Raghav¹, M. Katoch³, V. M. Katoch⁴
¹Agra (India), ²Bhopal (India), ³Jammu Tawi (India), ⁴New Delhi (India)
- 42.201** Detection of the emerging rotavirus G12P[8] genotype at high frequency in Brazil in 2014: Successive replacement of predominant strains
A. Luchs, A. Cilli, S. Morillo, D. de Souza Gregorio, K. A. Farias de Souza, H. Rosa Vieira, A. de Mira Fernandes, R. D. C. Carmona, M. D. C. S. T. Timenetsky
Sao Paulo (Brazil)
- 42.202** Hospital-based surveillance of enterovirus 71 in HCM City, Vietnam, 2011–2014
S.-T. Luo¹, W.-Y. Chung², L. N. T. Nhan³, L. B. Lien³, T. H. Khanh³, T. N. H. Dan³, L. P. K. Thoa³, N. T. Hung³, P.-S. Chiang², I.-J. Su⁴, M.-S. Lee¹
¹Zhunan (Taiwan), ²Miaoli County (Taiwan), ³Ho Chih Minh (Viet Nam), ⁴Miaoli (Taiwan)
- 42.203** Investigation of a suspected diarrhoeal illness outbreak in Upington–ZF Mgcawu District, Northern Cape, South Africa, March–July 2015
P. Manana¹, N. Page¹, G. Maupye¹, A. Rakgantso¹, T. Mkhencele¹, G. Hottie², K. Dokubo³, K. Mc Carthy¹
¹Johannesburg (South Africa), ²Upington (South Africa), ³Atlanta, GA (USA)
- 42.204** Active veterinary and entomological surveillance to assess emerging vector-borne disease risk in the Autonomous Province of Bolzano (Italy)
G. Morosetti¹, F. Severini², G. Bongiorno², C. Fortuna², C. Piffer¹, R. Binazzi¹, J. Simeoni¹, L. Gradoni²
¹Bozen (Italy), ²Rome (Italy)
- 42.205** Unexplained neurological illness in children, Malkangiri District, Odisha, India 2014
P. Nayak¹, M. Papanna¹, A. Shrivastava¹, P. Khasnobis¹, G. Lokhande¹, A. Kumar¹, S. Venkatesh¹, B. Patnaik², M. Pradhan²
¹New Delhi (India), ²Bhubaneswar (India)
- 42.206** Prevalence of Methicillin-Resistant *Staphylococcus aureus* (MRSA) nasal colonization among healthy AAU undergraduates
F. A. Olajubu, A. Owolabi
Akungba-Akoko (Nigeria)
- 42.207** Seroprevalence of brucellosis in different animal species of Kailali district, Nepal
Y. R. Pandeya¹, D. Joshi², S. K. Shah²
¹Nepalganj (Nepal), ²Kathmandu (Nepal)
- 42.208** Acute encephalitis syndrome and Japanese Encephalitis, status and trends in Bihar State, India
P. Kumar¹, **P. M. Pisudde**², P. P. Sarthi¹, M. P. Sharma¹, V. R. Keshri¹
¹Patna (India), ²Kolkata (India)
- 42.209** The prevalence of *Entamoeba histolytica* antibody and antigen in relation to interleukin 10 (IL10) levels in serum samples From HIV patients from Limpopo Province, South Africa
A. Samie¹, R. Ngobeni¹, A. Traore¹, J. Ramalivhana², P. Mbatia¹
¹Thohoyandou (South Africa), ²Polokwane (South Africa)
- 42.210** Surveillance of tropical infections in medical intensive care unit
R. Singhal, P. Tiwari, A. Mandal, A. Sharma
Mohali (India)



- 42.211** Influenza-associated hospitalizations In Maputo City, Mozambique
M. A. Pale, N. M. C. Nguenha, A. Tivane,
J. J. Salencia
Maputo (Mozambique)
- 42.212** Dengue virus infection in the Democratic Republic of Sao Tome and Principe
T.-Y. Yen¹, L.-F. Tseng², C.-F. Cheng², M. D. J. Trovoados Santos², A. V. D. A. Carvalho², P.-Y. Shu¹, J.-C. Lien¹, **K.-H. Tsai¹**
¹Taipei (Taiwan), ²Sao Tome (Sao Tome and Principe)
- 42.213** Identification of potential source of vibrio cholera—A subgroup analysis from cholera outbreak of an urban resettlement colony, North India
S. Kathirvel, J. Thakur, **D. Valecha**, K. Rana
Chandigarh (India)
- 42.214** Analysis of surveillance data for hepatitis C in China: From 2005 to 2014
X. Zhang, **T. Zhang**, L. Zhou, Y. Liu, X. Li
Chengdu (China)
- 42.215** The analysis of infectious disease surveillance data based on fuzzy time series method
T. Zhang¹, X. Zhang², Y. Liu¹, Y. Luo¹, T. Zhou¹, X. Li¹
¹Chengdu (China), ²Auckland (New Zealand)
- 42.216** Epidemiological study of scarlet fever in Sichuan province, China
L. Zhou¹, X. Zhang², T. Zhang¹, T. Huang¹, Q. Lu¹, L. Liu¹, X. Cheng¹
¹Chengdu (China), ²Auckland (New Zealand)
- 42.217** Molecular diagnosis and antifungal susceptibility profiles of rare isolates of filamentous fungi among patients with cancer from South India
R. Baskar¹, K. Umamaheswari¹, D. Jeyakumar², M. Alli²
¹Chennai (India), ²Kancheepuram (India)
- 42.218** Thirty five years scenario of cryptococcal meningitis: An analysis in pre- and post-HIV era
N. Chandrashekar, S. L. Mukhopadhyay, V. K. HB, K. Fathima, N. Manjunath, S. Maji, P. Marimuthu, P. Satishchandra
Bangalore (India)
- 42.219** *Cryptococcus meningitis* and the genotypes of *cryptococcus neoformans* prevalent in Western Maharashtra, India
S. N. Dharmshale, R. S. Bharadwaj, A. Kagal
Pune (India)
- 42.220** Antifungal prophylaxis with posaconazole suspension versus tablet in pediatric patients after hematopoietic stem cell transplantation
M. Döring¹, K. M. Cabanillas Stanchi², M. Queudeville², J. Feucht², P. Schlegel², T. Feuchtinger¹, P. Lang², I. Müller³, R. Handgretinger², W. J. Heinz⁴
¹Munich (Germany), ²Tübingen (Germany), ³Hamburg-Eppendorf (Germany), ⁴Wuerzburg (Germany)
- 42.221** Randomized clinical trial on evaluation of the effect of Bergamot oil on treatment of ring worm infection in calves and cats
W. R. El-Ashmawy, M. Elsaed, M. Gebely
Giza (Egypt)
- 42.222** Virulence determinants and antifungal susceptibility pattern of yeast flora from droppings of *Gallus gallus domesticus*
S. Hosuru Subramanya¹, N. Kishor Sharan¹, B. Prasad Baral¹, D. Hamal¹, N. Nayak¹, P. Peralam Yegneswaran², B. Sathian¹, I. Bairy², S. Gokhale¹
¹Pokhara (Nepal), ²Manipal (India)
- 42.223** Disseminated phaeohyphomycosis presenting as chromoblastomycosis in an immunocompetent host: A rare manifestation
L. G. Jessani¹, M. Thirunarayan¹, A. Chakrabarti², D. Sureshkumar¹, A. Parameswaran¹, R. Gopalakrishnan¹
¹Chennai (India), ²Chandigarh (India)
- 42.224** Clinical diversity in central nervous system cryptococcosis
J. M. Koshy, S. Mohan, D. Deodhar, M. John, A. Oberoi
Ludhiana (India)
- 42.225** Oral candidal carriage and their antifungal susceptibility pattern in potentially malignant disorders
K. Mahalakshmi, S. LeenaSankari, K. Gayathri
Chennai (India)

Mycology, Fungal Infections and Antifungal Drugs



- 42.226** Detection of invasive fungal infections with broad range panfungal primers and molecular beacons in a real time quantitative polymerase chain reaction
M. Mugunthan, M. Kumar
Pune (India)
- 42.227** Epidemiology and in vitro susceptibilities of candida albicans isolated from HIV patients in South India
S. Periasamy¹, T. Menon²
¹Villupuram (India), ²Chennai (India)
- 42.228** Microbiological profile of mycotic eye infections at a tertiary care institution in the Caribbean: A retrospective analysis
G. Reynolds, L. Campbell,
T.-D. Monroe-Williams, O. Heslop
Kingston (Jamaica)
- 42.229** Oral candidiasis in patients with type II Diabetes: Comparison of a novel multiplex PCR and chromagar in species identification
A. Sampath, M. Weerasekera,
C. Gunasekara, A. Dilhari,
U. Bulugahapitiya, N. Fernando
Colombo (Sri Lanka)
- 42.230** Epidemiological and etiological diagnosis of suppurative keratitis in Vadodara, Gujarat, India
P. Sharma
Greater Noida (India)
- 42.231** Rising prevalence of dermatophytosis in India: A matter of concern
S. Tripathy
Bhubaneswar (India)
- 42.232** Burden of *Pneumocystis pneumonia* in HIV-infected adults in sub-Saharan Africa: A systematic review and meta-analysis
S. A. Wasserman, M. Engel, R. Griesel,
M. Mendelson
Cape Town (South Africa)
- 42.233** Epidemiology and treatment outcome of mucormycosis in Khuzestan, Southwest Iran
F. Yousefi, R. Nashibi, S. Afzalzadeh
Ahvaz (Iran)
- 42.235** Carbapenem-resistant *Acinetobacter* species: An emerging nosocomial superbug
S. Chatterjee, S. Datta, S. Basu
Kolkata (India)
- 42.236** Prevalence of hospital acquired blood stream infections and its microbial pathogens in a tertiary hospital in Oman
A. Balkhair, Y. Al-Farsi, A.A. El Tahir,
M. El Beeli
Muscat (Oman)
- 42.237** Antibiotic prophylaxis for early ventilator associated pneumonia in patients with stroke
A. Farazi, M. Ebrahimi Monfared, A. Jokar,
N. Mirtalaei
Arak (Iran)
- 42.238** Etiology, clinical course, and antimicrobial resistance of bacterial agents of ventilator-associated tracheobronchitis in surgical and medical intensive care units in Hamedan, Iran
S. H. Hashemi, N. Hashemi, A. Taher,
F. Esna-ashari, A. Dehghan
Hamedan (Iran)
- 42.239** Nosocomial infection in an intensive care unit of a tertiary hospital in Nigeria: A four year review
G. Ilyasu, F. M Dayyab, S. Abubakar,
Z. G Habib, A. G Habib, A. M Sarki
Kano (Nigeria)
- 42.240** Risk Factors, outcomes and profile of central line associated bloodstream infections in a tertiary care referral PICU in South India
V. Krishna, R. Padur Sivaraman, P. Venkat Ramanan, S. Sankaranarayan
Chennai (India)
- 42.241** Prevalence of meticillin resistant *Staphylococcus aureus* and coagulase negative staphylococci bacteremia and nasal carriage in a tertiary care hospital, South India
V. H. B. Kumari, H.B. Veenakumari,
S. Sasidharan, J. Priya, S. Nagarathna
Bengaluru (India)
- 42.242** Sepsis registry in a tertiary care hospital—A nine-month observational study
V. Menon, S. M. Alex, S. Nair, V. Menon, T. S. Dipu, V. R. Ragoori
Kochi (India)
- Nosocomial Infections and Critical Care**
- 42.234** Incidence of healthcare associated infection in neurosurgical patients
R. Agrawal, S. Mohapatra, G. Rath,
D. Gupta, A. Kapil
New Delhi (India)



- 42.243** Evaluation of nosocomial infection rate during 2013–2014 in Razi Hospital, Ahvaz, Iran
M. J. Mohammadi, S. Geravandi, R. Malihi, S. M. Alavi, S. Moogahi, S. Salmanzadeh, F. Soltani, A. Ghomeishi, F. Yousefi, R. Nashibi, Z. Aslani Ahvaz (Iran)
- 42.244** Genetic diversity of common environmental enterobacteriaceae bacilli in intensive care units of hospitals from central Iran
M. Nateghi Rostami, F. Mehraban Tehran (Iran)
- 42.245** Antibiotic sensitivity assay of pathogenic microorganisms isolated from selected areas in some primary health centres in Akure Metropolis
F. O. Omoya Akure (Nigeria)
- 42.246** Evaluation of needle stick injuries among health care workers in a teaching hospital
S. Salmanzadeh, S. Geravandi, M. J. Mohammadi, R. Malihi, S. Kamaei, S. M. Alavi, S. Moogahi, F. Yousefi, F. Soltani, A. Ghomeishi, R. Nashibi, Z. Aslani Ahvaz (Iran)
- 42.247** An integrated and active system based on a multiple PCR method for the surveillance of Carbapenemase producing enterobacteria in an Italian “hub and spoke” large laboratory model
V. Sambri¹, M. F. Pedna¹, M. Samuelli¹, G. A. Tura², A. Argento², D. Protti²
¹Pievesestina (Italy), ²Rimini (Italy)
- 42.248** Evaluation of multiple antibiotic resistance (MAR) index and Doxycycline susceptibility of *Acinetobacter* species among inpatients
R. Sandhu Sonapat (India)
- 42.249** HSV positivity in broncho-alveolar lavage fluid and clinical outcome in hospitalized patients
A. Volpi, F. Pica, M. Maurici, M. Ciotti, P. Nardi, S. Bondanini, P. Rogliani, C. Buè Rome (Italy)
- 42.250** An outbreak of 19 cases of *Serratia marcescens* meningitis after spinal anesthesia
M. Yousfi, A. Abdellah, L. Hadj Ali, K. Saighi, A. Meftah, N. Ait Kaci, F. Z. Mechtoub, A. Baba Ami, F. Madi, K. Lassas Algiers (Algeria)

Other

- 42.251** Risk factors associated with outbreak of methanol poisoning in southern districts of Ondo State Nigeria, May 2015
A. Adewole Abuja (Nigeria)
- 42.252** wgMLST as a standardized tool for assessing the quality of genome assembly data
D. Babenko¹, I. Azizov¹, M. Toleman²
¹Karaganda (Kazakhstan), ²Cardiff (United Kingdom)
- 42.253** Dependence of the genetic relatedness between isolates on the size of sequencing genes in MLST analysis
D. Babenko¹, M. Toleman²
¹Karaganda (Kazakhstan), ²Cardiff (United Kingdom)
- 42.254** In silico comparison of different PFGE and wgMLST
D. Babenko¹, M. Toleman²
¹Karaganda (Kazakhstan), ²Cardiff (United Kingdom)
- 42.255** Hemophagocytic lymphohistiocytosis (HLH) secondary to infections—Experience at a tertiary care centre
S. Deme Hyderabad (India)
- 42.256** Hemophagocytic lymphohistiocytosis (HLH) secondary to tropical infections—experience at a tertiary care center
S. Deme, K. P. Adiraju, S. Malladi, N. Chandra, S. Mallikarjuna, A.M.V.R. Narendra, N. R. Modugu, S. Raju Hyderabad (India)
- 42.257** The hidden epidemic: MERS-CoV-related stigma observations from the field, Qatar 2012–2015
E. Farag¹, M. Nour¹, O. Marufu¹, R. Sikkema², H. Al-Romaihi¹, M. Al Thani¹, S. Al-Marri¹, A. El-Sayed¹, C. B. E. M. Reusken², M. Al-Hajri¹, M. P. G. Koopmans²
¹Doha (Qatar), ²Bilthoven (Netherlands)
- 42.258** Comparison of severity of sepsis with various biochemical parameters
A. Ghosh, M. Prabhu, V. Shenoy, K. Prabhu Manipal (India)
- 42.259** Dengue: Mathematical modelling of cytokine levels in the evolution of severity
P. Jayasundara, N. Malavige, S. Perera, S. Jayasinghe Colombo (Sri Lanka)



- 42.260** Engineering of measles virus to target cancer cells, an attempt
G. Lal, M. Rajala
New Delhi (India)
- 42.261** Prevalence of otitis media and its hearing loss in children of South Indian population
S. K. Manche, M. Jangala, R. M. Koralla, J. Akka
Hyderabad (India)
- 42.262** Association of Histone acetylation and DNA repair genes of *Leishmania donovani* effect the cytotoxicity of Ultraviolet radiation
A. Mishra¹, I. Khan¹, P. Jha¹, P. Das², K. K. Sinha¹
¹Hajipur (India), ²Patna (India)
- 42.263** A sudden paediatric death due to hand, foot and mouth disease: The importance of vigilance
R. Rahimi¹, E. Omar¹, T. S. Tuan Soh¹, **S. F. A. Mohd Nawi**², S. MD Noor¹
¹Selangor (Malaysia), ²Shah Alam (Malaysia)
- 42.264** The outcome of cancer treatment is independent of baseline HIV viral load and CD4 + cell count status: a pilot study from South Africa
A. Musyoki¹, O. Mogorosi¹, T. Msibi², S. Monokuane¹, M. J. Mphahlele¹
¹Pretoria (South Africa), ²Medunsa (South Africa)
- 42.265** Effects of dietary supplementation of *Lactobacillus plantarum* probiotics from corn slurry on growth performance, gut morphometry and profile of the intestinal microbial flora of *Clarias gariepinus* fingerlings
A. Falaye, B. O. Emikpe, **E. T. Ogundipe**
¹Ibadan (Nigeria)
- 42.266** Improvement of DNA extraction from human biopsies for a microbiome metagenomic approach
P. Orduña, R. Arerondo-Henardez, R. Santiago, P. Rojas, M. Schmulson, E. Graue-Hernandez, F. Bernal-Sahagún, E. Graue-Wiechers, S. Ponce de Leon, Y. López-Vidal
Mexico City (Mexico)
- 42.267** Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) might be an independent marker for anticipating scar formation in children with acute pyelonephritis
A. Rafiei, H. Mohammadjafari
Sari (Iran)
- 42.268** Elucidation of the role of non-structural viral protein (W) of Newcastle disease virus
S. P. Vaidyanathan, S. Gawai, **M. Subbiah**
Hyderabad (India)

Pediatric and Perinatal Infections

- 42.269** Community acquired *Staphylococcus aureus* infection in previously healthy neonates in Argentina
G. Berberian, G. Castro, A. Monaco, H. Lopardo, C. Hernandez, M. T. Rosanova
Buenos Aires (Argentina)
- 42.270** Utility of the QuantiFERON-TB Gold In-tube test (QFT) compared with the Tuberculin Skin Test (TST) in diagnosing tuberculosis in Indian children with malnutrition: A prospective study
D. Boddu, V. P. Verghese, J. S. Michael, A. Chacko, V. Jeyaseelan
Vellore (India)
- 42.271** Etiology of acute respiratory infections in infants: A prospective birth cohort study
P. Kumar
New Delhi (India)
- 42.272** Congenital syphilis: Complicating an already complex adoption process
K. Mehta, S. Narreddy, N. Rao S
Hyderabad (India)



- 42.273** Bacteraemia in paediatric: Epidemiology and aetiology at tertiary care centre, Malaysia
N. Abu¹, **F. Mohd Nor**¹, M. B. Mohamad¹,
A. S. Zainal Abidin¹, A. K. Ahluwalia²
¹Sg. Buloh (Malaysia), ²Selayang (Malaysia)
- 42.274** Five-year review of non-typhoidal salmonella meningitis in Cape Town, 2010–2015
P. Naicker¹, M. Khonga¹, J. Wojno¹,
C. Bamford², S. Ntuli¹, R. Oladokun¹,
B. Eley², A. Ryan¹, S. Gardiner¹, A. Sooka³,
A. M. Smith⁴, K. H. Keddy⁴
¹Cape Town (South Africa), ²Observatory
(South Africa), ³Sandringham (South Africa),
⁴Johannesburg (South Africa)
- 42.275** Increased isolation of *Enterococcus faecium* from neonates with sepsis: An attempt to investigate the suspected outbreak
V. V. Shailaja, A. K. Reddy,
A. Rangaiahgari, M. Alimelu,
L. N. R. Sadanand
Hyderabad (India)
- 42.276** Vaginal colonization by microbes during early pregnancy and their association with adverse pregnancy outcomes
C. Tellapragada¹, V. Kalwaje Eshwara²,
P. Bhat¹, A. Kamath¹, C. Mukhopadhyay¹
¹Manipal (India), ²Udupi (India)
- 42.277** Is the QuantiFERON-TB Gold test (QFT) better than the Tuberculin skin test (TST) in diagnosing active and latent tuberculosis in BCG-vaccinated children?
L. Thomas, J. S. Michael, V. P. Verghese,
A. Chacko, V. Jeyaseelan
Vellore (India)
- 42.278** Accuracy of the Xpert MTB/RIF assay compared to the “gold standard” AFB culture in the diagnosis of tuberculosis in children in India
V. P. Verghese, L. Thomas, J. S. Michael,
W. Rose, V. Jeyaseelan
Vellore (India)



Poster Presentations ~ Saturday, March 5, 2016

Session 43

Poster Presentations

Poster Session III

Room: Hall 3

12:45–14:15

(Posters & Exhibition)

Saturday, March 5, 2016

Poster Prize Finalists (Saturday)

43.001 Population structure and molecular epidemiology of human clinical multi-drug resistant (MDR) *Escherichia coli* strains from Pune, India

N. Nandanwar¹, A. Hussain¹, A. Ranjan¹, S. Jadhav², N. Ahmed¹

¹Hyderabad (India), ²Pune (India)

43.002 Antibiotic resistance among gastrointestinal and respiratory tract bacterial pathogens in Mauritius

M. Issack

Quatre-Bornes (Mauritius)

43.003 Re-emergence of susceptibility to conventional first line drugs in *Salmonella* isolates: an old weapon to fight NARS

B. K. Awal¹, S. Basnet², A. K. Koirala²

¹Bhaktapur (Nepal), ²Kathmandu (Nepal)

43.004 Non-typhoidal *Salmonella* urinary tract infection: Molecular resistance and clinical correlation—A four year study from a tertiary care centre

R. D. Sahni, **B. Subashini**,

B. Veeraraghavan, D. Prabha, Y. D. Devi,

A. Devasia, T. D. Sudarsanam

Vellore (India)

43.005 Burden of rotavirus gastroenteritis and distribution of rotavirus strains in India: A systematic review and meta-analysis

R. Ahlawat, P. Tiwari, R. Singhal

S.A.S Nagar (India)

43.006 Development of predictive dengue risk map using random Forest

X. Liu, J. Rajarethinam, Y. Shi, S. Liang,

G. Yap, L. C. Ng

Singapore (Singapore)

43.007 Hand hygiene program: “Go for 100*”. Whole impact (hospital cost, MRSA attack, nosocomial infections and device related infections)

D. de la Rosa, J. Xicoténcatl-Cortés,

A. Cervantes-Castillo, S.-A. Ochoa-Pérez,

A. Cruz-Cordoba, B. López-Martínez,

A. Reyes-López, R. Mora-Juárez,

M. Torres-García, A. Vázquez-Flores,

M. Medina-Pelcastre, Y. Flores¹,

I. Parra-Ortega, M. Castellanos-Cruz

Mexico City (Mexico)

43.008 Morbidity, mortality, and seasonality of influenza hospitalizations in Egypt, November 2007–November 2014

A. Kandeel, **P. Dawson**, M. Labib, M. Said,

S. El-Refai, A. El-Gohari, M. Talaat

Cairo (Egypt)

43.009 Fecal microbiome therapy in relapsing *Clostridium difficile* infection—Long-term results

T. Wiecezorek, M. Macholz, A. Bethge,

F. Neumann, K. Schreiter, M. Lindner,

T. Grünewald

Leipzig (Germany)

43.010 *Plasmodium falciparum* malaria: Association of sickle cell trait in the reduction of parasite density in symptomatic Fulani tribe living in sympatry in Mali, West Africa

B. Maiga

Bamako (Mali)

43.011 Diagnosis of *Mycoplasma pneumoniae* infection in children by using serology and polymerase chain reaction in community-acquired lower respiratory tract infections

S. Kumar, I. B. Garg, G. R. Sethi, S. R. Saigal, S. Kumar

New Delhi (India)

43.012 Quantifying tuberculosis burden and underrepresentation in Malaysia, 1990–2014

N. Ismail¹, A. M. Bulgiba², S. Rampal²,

F. D. Jiloris³, N. Nagelkerke⁴, M. O. Awang²

¹Sungai Buluh (Malaysia), ²Kuala Lumpur

(Malaysia), ³Putrajaya (Malaysia),

⁴Al Ain (United Arab Emirates)

43.013 TB outbreak investigation in a faith based boarding school: Challenges and control measures

L. Inamdhar, M. Gent, R. Ingham, K. Metcalfe

Leeds (United Kingdom)

43.014 Age-dependent carriage of alleles and haplotypes of *Plasmodium falciparum* sera5, eba-175, and csp in a region of intense malaria transmission in Uganda

P. Kyambadde

Kampala (Uganda)

43.015 Occurrence of novel and emergent tick-borne pathogens in a Kenyan biodiversity hotspot

M. M. Mwamuye, E. Kariuki, D. Omondi,

J. Kabii, D. Odongo, D. Masiga, J. Villinger

Nairobi (Kenya)



Parasitology and Parasitic Infections

- 43.016** Rising trend of seroprevalence of human amoebiasis in tertiary care hospital of North India
S. K. Agrawal
Chandigarh (India)
- 43.017** Polyparasitic infections in Coeliac disease—A newer paradigm
N. Arif, K. Kant, B. R. Mirdha, N. Verma
New Delhi (India)
- 43.018** Performance evaluation of malaria microscopists working at malaria slides rechecking laboratories for external quality assessment in Ethiopia
A. A. Assefa
Addis Ababa (Ethiopia)
- 43.019** Assessing geohelminth parasites among geophagous school children, in Owerri Metropolis Area, Imo State, South-Eastern Nigeria
N. I. Austin
Owerri (Nigeria)
- 43.020** Pediculosis among school children, in Owerri north local government area of Imo State, South Eastern Nigeria
N. I. Austin
Owerri (Nigeria)
- 43.021** Changing profile of malaria: An observational study in a central Mumbai hospital, India
A. Barua, M. E. Yeolekar
Mumbai (India)
- 43.022** Kala-azar patients management in a renovated SK Hospital, Mymensingh—A real experience
A. Basher, P. N. Nath, F. Rahman
Mymensingh (Bangladesh)
- 43.023** Sporotrichoid papulo-nodules with Retiform rash: Unusual presentation of Leishmaniasis
K. Bhardwaj, S. Ghatge, A. Dandale, R. Dhurat
Mumbai (India)
- 43.024** Utility of polymerase chain reaction in diagnosis of acanthamoeba and microsporidial keratitis
N. K. Bhosale¹, J. Mandal², S. parija³, S. Ahuja¹
¹Pondicherry (India), ²Puducherry (India)
- 43.025** Molecular cloning and production of type III Hsp40 protein co-chaperone PfZRF1 of human malaria parasite *Plasmodium falciparum*
P. Chahar, S. S. Gill, R. Gill
Rohtak (India)
- 43.026** Molecular evidence of *Bothriocephalus acheilognathi* (Cestoda: Bothriocephalidea) from India
A. Chaudhary, H. S. Singh
Meerut (India)
- 43.027** Parasitic infections in children presenting with acute diarrhea in Mozambique: National surveillance data (2013–2015)
I. L. C. Cossa-Moiane, J. J. Chilaule, H. Cossa, M. Cassocera, E. Guimarrães, N. De Deus
Maputo (Mozambique)
- 43.028** *Trypanosoma cruzi* infection in the heart of Colombian wild bats
E. Delgado-Sarmiento¹, M.-T. Herrera-Sepúlveda¹, P. Pavía¹, J. Pérez-Torres¹, **C. L. Cuervo**²
Bogota (Colombia)
- 43.029** A novel spiroindoline kills human malaria parasites via modulation of Na ion influx mediated autophagy and apoptosis
P. Dangi
Gautam Budh Nagar (India)
- 43.030** Subtype distribution of *Blastocystis* sp. isolated from children in Eskisehir, Turkey
N. Dogan¹, F. Dogruman Al², N. U. Kocman¹, E. C. Dinleyici¹, I. Oguz², M. Aydın³
¹Eskisehir (Turkey), ²Ankara (Turkey), ³Erzincan (Turkey)
- 43.031** Detection of *Blastocystis* sp. Infection using different investigation techniques in children with or without acute diarrhea
N. Dogan, N. U. Kocman, E. C. Dinleyici
Eskisehir (Turkey)
- 43.032** In vitro activity of different 5-nitroimidazole derivatives and essential oils against *Trichomonas vaginalis*
N. Dogan, I. Qoran, M. Kurkcuoglu
Eskisehir (Turkey)
- 43.033** Increased transcriptional level of the H2-T23 (Qa1) and H2-Q7/Q9 (Qa2) genes during acute infection induced by two strains of *Trypanosoma cruzi*
F. C. Dias, F. S. M. Tristao, M. C. Silva, J. S. Silva, **E. Donadi**
Ribeirão Preto (Brazil)
- 43.034** Liver parasites of cattle slaughtered in Onitsha urban and environ, Southeast Nigeria
C. Ekwunife¹, O. C. Nwaorgu¹, M. Ezeunala², C. N. Ukaga³
¹Awka (Nigeria), ²Abuja (Nigeria), ³Owerri (Nigeria)



- 43.035** Malaria and soil transmitted helminthes co-infection among Abia State polytechnic students, Aba, Southeastern Nigeria
O. R. Ezeigbo, N. G. Agomoh
Aba (Nigeria)
- 43.036** Genome wide collation of zinc finger family in *P. falciparum*
M. Kaushik, S. S. Gill, **R. Gill**
Rohtak (India)
- 43.037** The level of profilin and interleukin-12 in obese patients infected by *Toxoplasma gondii*: A correlation study between *Toxoplasma gondii* infection and obesity
A. Iskandar, M. R. Indra, I. A. Wulanda, H. Hartojo
Malang (Indonesia)
- 43.038** Comparative study between *vivax* and *falciparum* malaria in Eastern India: Breaking a myth
A. Karak¹, A. Mukherjee¹, A. Chakraborty¹, B. Samanta¹, S. Verma¹, A. Talukdar¹, S. Srivastava²
¹Kolkata (India), ²Mumbai (India)
- 43.039** Assessment of malaria transmission intensity using anti-MSP1₁₉ (*Plasmodium vivax*) antibody as a serological marker in a previously malaria endemic district in Sri Lanka
R. L. Dewasurendra¹, N. Sepulveda², S. Gunewardena¹, N. Chandrasekharan¹, C. Drakeley², **N. Karunaweera**¹
¹Colombo (Sri Lanka), ²London (United Kingdom)
- 43.040** In-silico analysis of chromatin assembly factor 1 (CAF-1) family and production of PF3D7_0110700 protein in human malaria parasite *Plasmodium falciparum*
M. Kaushik, S. S. Gill, R. Gill
Rohtak (India)
- 43.041** Effect of *Valeriana officinalis* hydroalcoholic extract on *Giardia lamblia* cysts
B. Khalilidehkordi¹, M. Mohamadi¹, H. Yousefi²
¹Shahrekord (Iran), ²Isfahan (Iran)
- 43.042** *Isospora belli* associated recurrent diarrhea in a patient with AIDS
H. Kirkoyun Uysal, Y. A. Oner, Ö. Akgül, K. Kart Yasar, S. Gursoy, S. Çaglar
Istanbul (Turkey)
- 43.043** Association of interleukin-18 gene polymorphism with susceptibility to visceral leishmaniasis in endemic area of Bihar, an Indian population
D. Kumar, P. Tiwary, J. Chakravarty, S. Sundar
Varanasi (India)
- 43.044** Detection of *Entamoeba dispar* and *Entamoeba moshkovskii* DNA in liver abscess pus: Newer perspectives to be considered in diagnosis of amoebiasis
M. Kumar¹, G. Nath², S. C. Parija¹
¹Puducherry (India), ²Varanasi (India)
- 43.045** Development of glycine coated magnetic nanoparticles (GMNPs) advance drug delivery system against visceral leishmaniasis
R. Kumar, G. C. Sahoo, K. Pandey, V. Das, P. Das
Patna (India)
- 43.046** ITS Typing, a potent genetic tool for discrimination of *Trichomonas vaginalis* isolates
H. Ertabaklar, S. Ertug, S. O. Caliskan, **E. Malatyali**, B. Bozdogan
Aydin (Turkey)
- 43.047** Biological pollution of drinking water ponds (hafirs) with *Toxoplasma gondii*, *giardia* and *Cryptosporidium spp* in Eastern Sudan
M. Y. I. Medani, H. Khogali, S. Abdel Rahman, S. Khogali
Khartoum (Sudan)
- 43.048** Genotyping of *Acanthamoeba spp* causing granulomatous amoebic encephalitis
K. Megha, S. Khurana, R. Sehgal
Chandigarh (India)
- 43.049** Zoonotic parasitic diseases at human-animal interface: a comprehensive study at a Zoological Garden in Punjab, India
A. D. Moudgil¹, L. D. Singla¹, M. P. Singh²
¹Ludhiana (India), ²Chhatbir (India)
- 43.050** An oral formulation of Amphotericin B for the treatment of visceral Leishmaniasis: f-Gr-AmB
S. L. Mudavath¹, M. Talat², M. Rai², O. N. Srivastava², S. Sundar²
¹Mohali (India), ²Varanasi (India)
- 43.051** Study of profile of *Plasmodium vivax* malaria in a medical college hospital
N. Nanjundaiah, A. Fatima, D. Y. V. Reddy
Kuppam (India)
- 43.052** Prevalence and drivers of human scabies in Cameroonian prisons
E. A. Kouotou¹, **J. R. N. Nansseu**¹, I. Sieleunou², L.-L. Moguieu Bogne³, A. Sangare⁴, H. Adegbidi⁵, J. Tameyi Tatsa³, R. Moyou Somo¹
¹Yaoundé (Cameroon), ²Montréal (Canada), ³Bangangté (Cameroon), ⁴Treichville (Cote d'Ivoire), ⁵Cotonou (Benin)



- 43.053** The highly neglected burden of human scabies in a Cameroonian penitentiary
E. A. Kouotou¹, **J. R. N. Nansseu**¹, I. Sieleunou², H. Atenkeng Apasew¹, F. Kechia Agem¹, D. Defo¹, R. Moyou Somo¹
¹Yaoundé (Cameroon), ²Montréal (Canada)
- 43.054** *Trichomonas vaginalis* infection and reproductive complications in women from central Iran
M. Nateghi Rostami¹, A. Habibi²
¹Tehran (Iran), ²Arak (Iran)
- 43.055** Molecular approach to detect Albendazole resistance in *Trichuris trichiura* among Orang Asli in Malaysia
M. Nisha
Kuala Lumpur (Malaysia)
- 43.056** Influence of nutritional status on pro and anti inflammatory cytokine balance in *Plasmodium falciparum* malaria children in Imo State, Nigeria
C. I. G. Nwalor, U. Chinyere, B.E.B Nwoke, E. Cletus, O. Oluchi
Owerri (Nigeria)
- 43.057** Studies on the current status of malaria and its management practices in rural communities of southeast Nigeria
O. O. Odikamnor, I. Ikeh
Abakaliki (Nigeria)
- 43.058** Moringa oleifera leaf powder role in reinfection pattern of soil-transmitted helminth infection amongst children in Nigeria
C. N. Ogbuagu¹, O. Nwaorgu², E. N. Ogbuagu¹, U. Amazigo²
¹Nnewi (Nigeria), ²Awka (Nigeria)
- 43.059** Common parasites prevalent among school children in Nnobi, Idemili South Local Government Area, Anambra State, Nigeria.
F. N. Okoh¹, O. Odikamnor², I. C. Okoye³, F. C. Okafor³
¹Enugu (Nigeria), ²Abakaliki (Nigeria), ³Nsukka (Nigeria)
- 43.060** Diagnosis and treatment of uncomplicated malaria in children at a tertiary hospital in Abuja
C. H. Okonkwo¹, A. A. Ajemigbitse¹, O. A. Akinmola¹, O. Ogunfowokan¹, I. N. Dozie²
¹Abuja (Nigeria), ²Owerri (Nigeria)
- 43.061** *Giardia lamblia* infection in institutionalized Romanian children
T. R. Olariu¹, V. Dumitrascu¹, T. Ududec², C. Petrescu¹
¹Timisoara (Romania), ²Arad (Romania)
- 43.062** The in vivo assessment of antiplasmodial activities of leaves and stem bark extracts of *Mangifera indica* (linn) and *Cola nitida* (linn)
F. O. Omoya
Akure (Nigeria)
- 43.063** Comparison of the incidence of *Dientamoeba fragilis* in a cohort of paediatric children with allergic asthma and aontrols: Is it a pathogen or protector?
Y. A. Oner, S. Saribas, S. Ö. Okullu, S. Nepesov, M. Demirci, A. Karakullukcu, H. Kirkoyun Uysal, E. Bonabi, H. Çokugras, Ö. Kurt, G. Ayaz, H. Bahar Tokman, B. Kocazeybek
Istanbul (Turkey)
- 43.064** Detection and subtype identification of Blastocystis in a hospital setting from Southeastern India
S. Padukone¹, J. Mandal¹, N. Rajkumari¹, P. K. Pandey², A. Sharma³, S. C. Parija¹
¹Puducherry (India), ²Lima (Peru), ³Pune (India)
- 43.065** MicroRNA mediated immune regulation of T helper cell differentiation and plasticity during visceral leishmaniasis infection: A computational approach
R. Pandey¹, V. K. Prajapati¹, S. Sundar²
¹Ajmer (India), ²Varanasi (India)
- 43.066** The epidemiologic considerations about visceral leishmaniasis in Albania 2010–2014
R. Petrela, E. Foto, G. Kuli, H. Hoxha, F. Zavalani, B. Neza
Tirana (Albania)
- 43.067** Cervical cytology as a diagnostic tool for genital schistosomiasis and cervical squamous cell atypia among young women from schistosoma and HIV endemic populations in South Africa
P. Pillay¹, M. Taylor¹, H. N. Galappathi-Arachchige², S. G. Zulu¹, B. Roald², E. F. Kjetland²
¹Durban (South Africa), ²Oslo (Norway)
- 43.068** Efficacy of percutaneous interventions in patients with hepatic echinococcosis
Y. Kirtanasov¹, L. Ermakova¹, **N. Pshenichnaya**¹, A. Zhuravlev²
¹Rostov-on-Don (Russian Federation), ²Moscow (Russian Federation)



- 43.069** Features of dirofilariasis in the Northwest of the Russian Federation
S. Nagorny, E. Krivorotova, L. Ermakova,
N. Pshenichnaya
Rostov-on-Don (Russian Federation)
- 43.070** Antibodies to *Plasmodium falciparum* glutamic acid rich protein (PfGARP) inhibit parasite growth by arresting trophozoite development
D. K. Raj, C. Nixon, S. Pond-Tor1, J. Kurtis
Providence, RI (USA)
- 43.071** HLA determinants of susceptibility and protection to *L. donovani*: In silico analysis
N. Samaranayake, D. Fernando,
N. Karunaweera, V. Dissanayake
Colombo (Sri Lanka)
- 43.072** Evaluation of loop mediated isothermal amplification for the diagnosis of amoebic liver abscess
R. Sehgal, S. Khunger, A. Duseja, D. Handa,
R. Singh
Chandigarh (India)
- 43.073** Hemoglobinuria (Black Water Fever) in severe falciparum malaria—A case report
A. Sher
Kuwait (Kuwait)
- 43.074** Role of B-cells and antibodies in visceral leishmaniasis infection
B. Singh, S. Sundar
Varanasi (India)
- 43.075** Deciphering the interplay between cysteine synthase and thiol cascade proteins in the survival of *L. donovani* under oxidative stress
K. Singh¹, V. Ali²
¹Hajipur (India), ²Patna (India)
- 43.076** Investigating changes in monocyte phenotypes and functions in active visceral leishmaniasis patients
N. Singh¹, R. Kumar², S. B. Chauhan¹,
S. Nylén³, D. Sacks⁴, C. Engwerda⁵,
S. Sundar¹
¹Varanasi (India), ²New Delhi (India),
³Stockholm (Sweden), ⁴Bethesda, MD (USA),
⁵Herston (Australia)
- 43.077** Microplate whole blood interferon- γ release assay for marker of *Leishmania donovani* infection
O. P. Singh, S. Sundar
Varanasi (India)
- 43.078** Decreased miltefosine susceptibility in clinical isolates of *Leishmania donovani* derived from visceral leishmaniasis and post kala-azar dermal leishmaniasis: Apparent mechanisms and clinical implications
R. Singh, D. K. Deep, V. Bhandari, V. Sharma,
N. S. Negi, V. Ramesh, P. Salotra
New Delhi (India)
- 43.079** Immunomodulatory and toxicological safety studies of two novel anti-leishmanial compounds
S. Singh¹, M. Sankar¹, A. Karim¹, A. Cordeiro Da-Silva², K. Project Team³
¹New Delhi (India), ²Porto (Portugal),
³Noisy le Grand (France)
- 43.080** Malaria in Hong Kong: Impact, eradication and legacy
R. Sinha
Hong Kong (China)
- 43.081** Correlation between albendazolesulphoxide in plasma and hydatid cyst and clinical outcome in patients with liver echinococcosis
T. Skuhala, B. Desnica
Zagreb (Croatia)
- 43.082** Comparative analysis and identification of immunoreactive and dominant proteins of *Cysticercus cellulosae* antigens by 2D-Electrophoresis and MALDI-TOF
P. T. Tamilselvan, K. R. Muthuraman,
S. C. Parija
Puducherry (India)
- 43.083** The possible roles of IPT and ITNS in gestational, placental and cord blood malaria parasitemia, pregnancy outcome and fetal weight in Isu, Imo State Nigeria
C. N. Ukaga¹, C. Ekwunife², D. Ogacheko¹,
B. Nwoke¹
¹Owerri (Nigeria), ²Awka (Nigeria)
- 43.084** The possible role of nutritional status on the pro and anti-inflammatory cytokine balance of children with malaria from Imo State, Nigeria
C. N. Ukaga¹, C. Okoro¹, B. Nwoke¹, M. Ezeunala²
¹Owerri (Nigeria), ²Abuja (Nigeria)
- 43.085** Macrophage cell responses in cutaneous leishmaniasis caused by *Leishmania donovani*
H. D. Wijesooriya, T. N. Samaranayake,
K. K. V. N. Somaratne, N. D. Karunaweera
Colombo (Sri Lanka)



- 43.086** Novel cysteine desulphurase interacting protein Isd11 from *Leishmania donovani*: Identification and the role in Fe-S cluster biogenesis
A. Zaidi, V. Ali
Patna (India)

Tuberculosis and Other Mycobacterial Infections

- 43.087** Association between BCG scars and risk of tuberculosis transmission among household contacts of active tuberculosis patients
M. Ali¹, G. Velásquez², M. Murray²
¹New York, NY (USA), ²Boston, MA (USA)
- 43.088** Trends of tuberculosis cases in Ondo state, southern Nigeria; 2011–2014
M. O. Anyanwu¹, S. Akingbesote², O. Ajumobi³, A. Olayinka³, B. Adedokun¹, V. Adelus²
¹Ibadan (Nigeria), ²Akure (Nigeria), ³Abuja (Nigeria)
- 43.089** Predictors of adherence to isoniazid preventive therapy in HIV patients in Ethiopia: A prospective cohort study
H. T. Ayele, M. S. V. Mourik, M. Bonten
Utrecht (Netherlands),
- 43.090** Seventeen years of drug-resistant tuberculosis in Argentinian children
G. Berberian, S. Gonzalez, V. Reijtmann, N. Miño, L. Casimir, C. Sarkis, D. Mecicovsky, M. T. Rosanova
Buenos Aires (Argentina)
- 43.091** Early cardiac safety of the 9-11 month Short course regimen for MDR-TB treatment
C. E. Berry¹, J. McMahon², B.-T. Nyang'wa¹, J. Archer¹, A. Ronnachit³, A. Khamraev³, Z. Tigay³, P. du Cros¹
¹London (United Kingdom), ²Melbourne (Australia), ³Nukus (Uzbekistan)
- 43.092** Detection of *Mycobacterium leprae* in tissue sections using auramine O fluorescent stain versus modified fite-faraco: A comparative study
K. Bhardwaj, S. Ghate, R. Dhurat
Mumbai (India)
- 43.093** Curvilinear scars indicator of Lucio's phenomenon in leprosy
K. Bhardwaj, R. Dhurat, S. Ghate, A. Dandale
Mumbai (India)
- 43.094** New antibacterial agents targeting mycobacterial the ATP synthase
S. K. Bhola, I. A. Khan
Jammu (India)
- 43.095** Clinical profile and evaluation of diagnostic tests in culture positive childhood tuberculosis
D. Boddu, V. P. Vergese, J. Sarojini
Vellore (India)
- 43.096** Pharmacists contributing to the WHO Stop TB theme: "Find, Treat, Cure Everyone"
A. Bompelli¹, M. Gharat², S. Prasad³
¹Hanamkonda (India), ²Mumbai (India), ³Gurgaon (India)
- 43.097** Prevalence, risk factors and clinical outcomes of Xpert MTB/RIF identified rifampicin-resistant tuberculosis in Bukavu, Democratic Republic of the Congo
A. Bulabula¹, A. B. Shindano², J. B. Nachega³
¹Cape Town (South Africa), ²Bukavu (Democratic Republic of Congo), ³Pittsburgh, PA (USA)
- 43.098** Hospital based prospective observational case study to evaluate the prevalence of diabetes mellitus among tuberculosis patients in a tertiary care hospital, in India
T. K. Charkha, S. Narreddy
Hyderabad (India)
- 43.099** Role of PCR for diagnosing male genital tuberculosis
K. Chawla, A. Chawla, P. Hegde
Manipal (India)
- 43.100** Intranasal delivery of antituberculosis agents in a murine tuberculosis model
C. Shoen, **M. Cynamon**
Syracuse, NY (USA)
- 43.101** Real-time PCR of whole blood specimens transported in PrimeStore MTM® to detect and monitor MTB bacteremia
L. T. Daum¹, R. Schuman², C. Sei², N. Rikhi², A. Mesadieu², F. Gerald²
¹San Antonio, TX (USA), ²Gaithersburg, MD (USA)
- 43.102** GeneXpert detection of *Mycobacterium tuberculosis* from sputum collected and transported in a molecular transport medium
L. T. Daum¹, P. Fourie², R. Peters², J. Rodriguez¹, S. Worthy¹, M. Khubbar³, S. Bhattacharyya³, M. Gradus³, C. Helm¹, G. Fischer¹
¹San Antonio, TX (USA), ²Pretoria (South Africa), ³Milwaukee, WI (USA)



- 43.103** Identification of *Mycobacterium tuberculosis* complex in clinical specimens of HIV-infected patients at Instituto de Infectologia Emilio Ribas, São Paulo-Brazil
M. D. Eira, E. Boccardo, R. J. Costa Silva, U. Barbosa, I. Moreira, S. A. Souza, F. I. Oliveira Junior
São Paulo (Brazil)
- 43.104** Cholecalciferol adjunctive therapy in active tuberculosis
A. Farazi, F. Didgar, M. Jabbariasl, A. Sarafraz
Arak (Iran)
- 43.105** *Mycobacterium tuberculosis* acetyltransferase reduces the oxidative stress response through expression of peroxisomal membrane transporter protein
G. Ganguli, A. Sonawane
Bhubaneswar (India)
- 43.106** Analysis on direct medical costs and compensation for whole course of treatment of pulmonary tuberculosis patients in Shanghai
M.-L. Guo, W. Wang, X. Shen, J. Chen, Z. Yuan, F. Yan
Shanghai (China)
- 43.107** Confirmation of silent mutations in the *rpoB* gene locus of *M. tuberculosis* isolates using pyrosequencing and phenotypic DST
N. N. Hirani
Mumbai (India)
- 43.108** Phytochemical and antimycobacterial analysis of aqueous and ethanolic extracts of *Annona muricata* Linn (Soursop)
W. O. Iyanda-Joel¹, S. Chinedu¹, E. Iweala¹, N. Onyejebu², M. Nshiogu²
¹Ota (Nigeria), ²Lagos (Nigeria)
- 43.109** Prevalence of culture-positive mycobacteria among suspected cases of pulmonary tuberculosis in Ahmadu Bello University Teaching Hospital, Zaria, Northern, Nigeria
O. Jimoh, A. Olayinka, B. O. Musa, N. Ezati, P. F. Ajiboye
Zaria (Nigeria)
- 43.110** Vitamin D deficiency, CNS inflammation, and clinical outcome in tubercular meningitis
T. Kadhavan, G. Dangeti, S. Mailankody, C. Neeradi, R. Soundravally, J. Mandal, R. Swaminathan
Puducherry (India)
- 43.111** The acceptability and feasibility of chemical prophylaxis for schoolchildren and adolescents with latent tuberculosis infection in Shanghai, China: A qualitative study
Y. Li, C. Zhou, Y. Zheng, J. Hong, M. Yang, Z. Yuan, Y. Hu, **B. Xu**
Shanghai (China)
- 43.112** Effects of motivational interviewing on the treatment adherence of tuberculosis patients
R. F. Loa
Manila City (Philippines)
- 43.113** The referral pathway of presumptive drug resistant tuberculosis in the urban poor areas of Metro Manila, Philippines
E. G. Lopez
Manila City (Philippines)
- 43.114** Predictors, outcome, profile of anti-tubercular drug induced hepatitis—A prospective nested case-control study in a South Indian tertiary hospital
S. S. R. Mani, M. Krishna, R. Iyyadurai, J. H. Prasad, S. Jasmine, S. G. Hansdak, S. Danda, A. Zachariah
Vellore (India)
- 43.115** Thyroid tuberculosis: report of a case and review of literature
E. Maryem
Casablanca (Morocco)
- 43.116** Trend of multidrug resistance extra pulmonary tuberculosis cases presenting to a tertiary care hospitals in Northern part of India
A. K. Maurya¹, V. L. Nag¹, S. Kant², R. A. S. Kushwaha², M. Kumar², A. K. Singh², T. N. Dhole²
¹Jodhpur (India), ²Lucknow (India)
- 43.117** Evaluation of the diagnostic performance of MTBDRplus VER 2.0 line probe assay for the detection of MDR-TB in sputum samples referred to National TB Reference Laboratory, Ethiopian Public Health Institute
A. Meaza, K. Desta, A. Kebede, Z. Yaregal, Z. Dagne, S. Moga, M. Getahun, B. Yenew, G. Diriba, H. Molalign, M. Tadesse, D. Addise, A. M. Dasho
Addis Ababa (Ethiopia)
- 43.118** Insertion Sequence IS6110 mapping, a tool to characterize TB strains into genetic lineages
K. Moganeradj, P. Sonnenberg, I. Abubakar, T. McHugh, C. Arnold
London (United Kingdom)



- 43.119** Tuberculous osteomyelitis of mid-clavicle in a healthy normal girl
A. Mudunuri
Secunderabad (India)
- 43.120** A study on factors influencing management and outcomes of tuberculosis
J. R. Mutukuloju
Hyderabad (India)
- 43.121** Under-recognised and misdiagnosed; post surgical rapidly growing mycobacterial infections in South India
L. E. B. Nabarro, P. Rupali, J. Sarojini Michael
Vellore (India)
- 43.122** Interferon gamma release assay (IGRA) friend or foe—Clinical application of IGRA in a tuberculosis endemic country
J. S. Michael¹, B. F. B. Ascencio², B. Shalini¹, P. Rupali¹, **M. M. Ninan**¹
¹Vellore (India), ²Setubal (Portugal)
- 43.123** Outcomes of multidrug resistant tuberculosis treatment among human immunodeficiency virus co-infected patients taking anti-retroviral treatment at Sizwe Tropical Disease Hospital Johannesburg, South Africa
T. Umanah, J. Ncayiyana, X. Padanilam, **P. S. Nyasulu**
Johannesburg (South Africa)
- 43.124** Cellular iron status affects drug susceptibilities and biofilm formation of mycobacterium
R. Pal, S. Hameed, Z. Fatima
Gurgaon (India)
- 43.125** TRUNCATE-TB: an innovative trial design for drug-sensitive tuberculosis
P. Papineni¹, P. Phillips², Q. Lu¹, Y. B. Cheung¹, A. Nunn², N. Paton¹
¹Singapore (Singapore), ²London (United Kingdom)
- 43.126** Identification of new efflux pump proteins from multidrug resistant *Mycobacterium tuberculosis* and screening for peptide based efflux pump inhibitors
K. Parthasarathy, A. Sivaraj, R. Sundar
Chennai (India)
- 43.127** Determinants of MDR-TB in a district tuberculosis centre of a metropolitan city: A case-control study
A. E. Patel, L. Krishnappa, D. Rajaram, R. Kunnavil, N. S. Murthy
Bengaluru (India)
- 43.128** Mycobacterial dormancy associated proteins: Role in the survival of bacteria under stress conditions
V. Peddireddy, S. N. Doddam, N. Ahmed
Hyderabad (India)
- 43.129** Validation of non-uniform illumination correction techniques in microscopic digital TB images using image sharpness measures
E. Priya, S. Srinivasan
Chennai (India)
- 43.130** Paradoxical reaction (PR) in HIV negative patients with tuberculosis: Case series
A. Rajendra, K. Sabnis, J. S. Michael, P. Rupali
Vellore (India)
- 43.131** Comparative analysis of the host mediated antigen-specific responses In Indian cohorts with different TB infected states
S. Rakshit¹, B. K. Sundararaj¹, P. N. Sahoo¹, T. H. M. Ottenhoff², K. E. van Meijgaarden², A. Jesuraj¹, G. D'Souza¹, A. Vyakarnam¹
¹Bangalore (India), ²Leiden (Netherlands)
- 43.132** Repurposing of old drugs: Identification of novel sila analogues of rimonabant as potent antitubercular agents
R. Ramesh¹, R. Shingare¹, A. Anand², S. Veeraraghavan³, S. Viswanadha³, R. Ummanni³, R. Gokhale², D. S. Reddy¹
¹Pune (India), ²New Delhi (India), ³Hyderabad (India)
- 43.133** Orbital tuberculosis: Clinical and microbiology profile
A. K. Reddy, S. Chaugule, A. Rangaiahgari, K. Mulay, S. Honavar
Hyderabad (India)
- 43.134** The urgency of effective antitubercular drug development—New promising structures derived from natural terpenoids
V. V. Ruseva, G. Dobrikov
Sofia (Bulgaria)
- 43.135** Genotypes of mycobacterium tuberculosis isolated from blood of active tuberculosis patients
M. Sankar, J. Singh, A. Munawwar, S. K. Kabra, R. Sood, M. Praneeth, S. Singh
New Delhi (India)



- 43.136** Diagnostic performance of RT-qPCR method by targeting 85B mRNA in the laboratory diagnosis of *Mycobacterium tuberculosis* infection: A preliminary study in Turkish patients
S. Saribas, M. Demirci, S. Toprak, N. Ozer, E. Caglar, G. Ortakoylu, P. Yuksel, G. Ayaz, E. Bonabi, H. Bahar Tokman, N. Kiraz, B. Kocazeybek
Istanbul (Turkey)
- 43.137** Head-to-head comparison of two multi-locus sequence typing (MLST) schemes for characterization of *Acinetobacter baumannii* outbreak and sporadic isolates
H. Seifert, P. Higgins, H. Wisplinghoff, F. Tomaschek
Cologne (Germany)
- 43.138** Non-tuberculous mycobacterial empyema in an immunocompetent child
I. Shah, F. Shah
Mumbai (India)
- 43.139** Ocular tuberculosis masquerading as retinoblastoma in a young boy
I. Shah, P. Chandane
Mumbai (India)
- 43.140** Fluorescent In Situ Hybridization (FISH) for the detection and differentiation of *Mycobacterium tuberculosis* and NTM in sputum and culture
L. Sharon¹, S. Baliga¹, J. Shah², C. Murphy², H. Weltman²
¹Mangalore (India), ²Palo Alto, CA (USA)
- 43.141** Prevalence and predictors of tuberculosis among adults with newly diagnosed HIV/AIDS
Y. Shen, H. Lu
Shanghai (China)
- 43.142** Molecular characterization of *Mycobacterium tuberculosis* strains isolated in India
J. Singh¹, P. Kumar¹, M. Sankar¹, S. Singh¹, D. Couvin², D. N. Rastogi³, V. M. Katoch¹, D. Chauhan⁴, M. D. K. Katoch⁴, C. Rodrigues⁶, D. Lakshmi⁷, D. G. Taori⁷, D. B. Bhattacharya⁸, D. Singh¹, S. Swaminathan⁹
¹New Delhi (India) ²Montpellier (France), ³Abymes (France), ⁴Agra (India), ⁵Mumbai (India), ⁶Hyderabad (India), ⁷Nagpur (India), ⁸Kolkata (India), ⁹Chennai (India)
- 43.143** Interleukin-6: a potential biomarker of the success of tuberculosis treatment
P. P. Singh
Mohali (India)
- 43.144** Diagnosis of human tuberculosis: identification of new biomarker(s) and biosignature(s)
P. P. Singh¹, S. Sinha², M. Goyal²
¹Mohali (India), ²New Delhi (India)
- 43.145** Biological evaluation of a novel nitroimidazooxazole derivative, IIM-MCD-019 against *Mycobacterium tuberculosis* and its in vivo efficacy
S. Singh, G. Munagala, K. Y. Reddy, S. K. Bhola, R. Chib, R. Sharma, C. Rani, P. P. Singh, R. A. Vishwakarma, I. A. Khan
Jammu (India)
- 43.146** Evaluation of *Mycobacterium tuberculosis* (Mtb) cell wall protein as a novel genetic marker for diagnosing pulmonary and extra pulmonary TB
A. Srikantam, U. Mannela, A. Babu, S. Jonnalagadda
Hyderabad (India)
- 43.147** Isolation and identification of a novel Non-tuberculous *Mycobacterium* species of canine origin by multiple gene sequencing approach
E. Vise¹, S. Das¹, A. Garg², A. Karam¹, S. Ghatak¹, A. Sen¹, I. Shakuntala¹, K. Puro¹, R. Sanjukta¹, A. Ahuja¹, U. Bhattacharjee¹, K. Kakoty¹, N. R. Sharma²
¹Shillong (India), ²Jalandhar (India)
- 43.148** Patients satisfaction with TB DOTS services in PHC facilities in Katsina State, Nigeria
A. A. Olorukooba¹, **S. S. Yahaya**², M. Ibrahim¹, N. Sambo¹, L. Amadu¹, H. Abdulrahman¹
¹Zaria (Nigeria), ²Katsina (Nigeria)
- 43.149** Knowledge of health care workers on TB and DOTS strategy in PHC facilities in Katsina State, Nigeria
S. S. Yahaya¹, A. A. Olorukooba², M. S. Ibrahim², H. Abdulrahman², L. Amadu²
¹Katsina (Nigeria), ²Zaria (Nigeria)
- 43.150** Latent tuberculosis infection among close contacts of non-residential pulmonary tuberculosis patients in Shanghai, China
Z. Yang, Y. Hu, J. Xu, W. Jiang, **B. Xu**
Shanghai (China)
- 43.151** The serum Th1 and Th2 cytokines levels in active tuberculosis patients before and after 2 month anti-TB treatment
Y. Sheng, L. Yuan, W. Jiang, **Q. Zhao**, B. Xu
Shanghai (China)



Vaccines and Vaccine Development

- 43.152** A quick method to determine the best threshold level for universal vaccination when there is an outbreak of Japanese encephalitis
P. H. Chung
Hong Kong, (China)
- 43.153** Clinical Review of Shanchol™ (a WHO pre-qualified oral cholera vaccine)
N. A. D'Cor, B. N. Patnaik
Hyderabad (India)
- 43.154** Vero cell derived novel inactivated Japanese encephalitis vaccine JENVAC^R
V. Ramasamy, **P. K. Duvvuri**, Y. Kaushik
Hyderabad (India)
- 43.155** Routine immunization data management need assessment survey of selected health facilities and local government areas in Enugu State, June, 2015
C. C. Ezeudu, E. Hashim, J. Adegoke, C. Abah, K. Akerele
Abuja (Nigeria)
- 43.156** Development of new generation blood-stage malaria vaccines against *Plasmodium falciparum* targeting the PfRH5-CyRPA multiprotein adhesion complex
D. Gaur
New Delhi (India)
- 43.157** Development of safe, effective and immunogenic vaccine candidate for diarrheagenic *Escherichia coli* main pathotypes in mouse model
A. M. I. H. Gohar, N. F. Abdeltawab, A. Fahmy, M. Amin
Cairo (Egypt)
- 43.158** Vaccines for emerging infections: Chikungunya vaccine
S. Kandaswamy, S. Srinet, U. Praturi, J. Pydigummala, K. Ella
Hyderabad (India)
- 43.159** An Ebola vaccine candidate based on controlled expression of antigen through the recombinant adenovirus system
D. Kumar, S. Gauthami, U. Madala, P. Panduranga Rao, K. Ella, N. R. Hegde
Hyderabad (India)
- 43.160** Cost-effectiveness analysis of dengue vaccination in the Philippines
H. Lam¹, G. M. Ku¹, D. Wu², K. J. G. Cheng³, A. Rivera¹, B. Tumanan-Mendoza¹, M. Alejandria¹
¹Manila (Philippines), ²Selangor (Malaysia), ³Ermita, (Philippines)
- 43.161** Pneumococcal carriage in South Africa, a community based cross sectional study
N. Mbelle¹, L. Godwana², T. Adams¹, H. Skhosana¹, S. Vally¹, J. Wadula¹
¹Johannesburg (South Africa), ²Pretoria (South Africa)
- 43.162** Integrated analysis of immunogenicity data from 11 dengue vaccine trials across 14 countries at risk for dengue
J. Menezes¹, C. Frago¹, T. Laot², D. Chansinghakul³, T. Wartel¹, B. Zambrano⁴, A. Bouckennooghe¹, F. Noriega⁵
¹Singapore (Singapore), ²Manila (Philippines), ³Bangkok (Thailand), ⁴Montevideo (Uruguay), ⁵Swiftwater, PA (USA)
- 43.163** Prediction MHC class I and II T-Cell epitopes from *Echinococcus granulosus* 14-3-3 antigen using IEDB and TmhCPred algorithms
G. Moghaddam, M. M. Pourseif, Y. Omid Tabriz (Iran)
- 43.164** Preliminary immunoinformatics research for prediction the most immunogenic linear and conformational B-cell epitopes of 14-3-3 antigen in echinococcus granulosus
G. Moghaddam, M. M. Pourseif, Y. Omid, H. Daghighkia, A. Nematollahi, R. Jafari-Jozani, A. Barzegari, J. Dehghani Tabriz (Iran)
- 43.165** Nasopharyngeal carriage of *Streptococcus pneumoniae* in children under 5 years of age before introduction of pneumococcal vaccine (PCV 10) in urban and rural Sindh
M. I. Nisar¹, F. Jehan¹, T. Akhund², F. Kabir¹, S. Shakoor¹, S. Qureshi¹, A. Zaidi¹
¹Karachi (Pakistan), ²Hyderabad (Pakistan)
- 43.166** Ex vivo evaluation of the mucoadhesive properties of *Cedrela odorata* and *Khaya senegalensis* gums with possible applications for veterinary vaccine delivery
B. Emikpe, **V. O. Oyeibanji**, T. Jarikre, D. Odeniyi, A. Salami, O. Oladele, O. Akinboade
Ibadan (Nigeria)
- 43.167** Identification and characterization of a novel protein PfCDPK-5 for the development of pediatric malaria vaccine
D. K. Raj, S. Pond-Tor1, B. Sherman, J. Kurtis
Providence, RI (USA)
- 43.168** Lesson learned from investigating cluster adverse event following immunization in mass campaign of Japanese encephalitis vaccine in India
A. K. Singh, J. Joshi, A. Shewale, N. Gupta
New Delhi (India)



- 43.169** The seroprevalence of neutralizing antibody against Japanese encephalitis virus in health care workers
W. P. Vandepitte¹, S. Yoksan², M. Wannachart¹
¹Bangkok (Thailand), ²Nakhonpathom (Thailand)
- 43.170** Immunogenicity of a chimeric protein of Bacillus anthracis protective antigen and lethal factor in murine model
A. Varshney, N. Puranik, M. Kumar, A. K. Goel
Gwalior (India)
- 43.171** Antibody response to various domain of protective antigen in cutaneous anthrax cases in India
A. Varshney, N. Puranik, M. Kumar, A. K. Goel
Gwalior (India)
- 43.172** Time trends in vaccine delivery over two decades in a full-time immunization clinic of a tertiary care centre
V. P. Verghese, R. Z. Kompithra, L. Mathew, A. Simon, S. Mathai, T. J. John, P. Raghupathy
Vellore (India)
- Virology and Viral Infections (Non-HIV)**
- 43.173** Correlation of Interferon-gamma and Interleukin-28B levels in patients with chronic hepatitis C viral infection with or without Schistosoma mansoni coinfection
S. Z. A. Eid, **N. F. Abdeltawab**, S. Melek, M. Amin
Cairo (Egypt)
- 43.174** Outbreak investigation of suspected hepatitis E among South Sudan refugees, Gambella regional state, Ethiopia, July 2014
W. K. Abera
Addis Ababa (Ethiopia)
- 43.175** Laboratory diagnosed dengue among clinically suspected febrile patient-samples at National Dengue Laboratory, Sri Lanka
J. I. Abeynayake, S. Gunasena, A. Mahanama, K. Nawarathna
Colombo (Sri Lanka)
- 43.176** Measles among pregnant women in South Kazakhstan in recent times
G. Abuova, I. Abenova, G. Asubayeva
Shymkent (Kazakhstan)
- 43.177** An outbreak of measles in Ondo West LGA, Ondo State, Nigeria, February–May, 2013
A. Adewole
Ibadan (Nigeria)
- 43.178** Assessment of Human Papillomavirus (HPV) type 16 and 18 status by nested multiplex PCR in cervical cancer patients and in healthy women from a tertiary care hospital
P. Arumugam, S. C. Parija, S. Habeebullah
Puducherry (India)
- 43.179** Is HLA-DRB1*13 allele a risk factor for prognosis of hepatitis C virus infection?
N. Aydin¹, R. Bulbul¹, A. Coskun¹, S. Kirdar¹, S. Oncu¹, Y. Kilinc²
¹Aydin (Turkey), ²Antalya (Turkey)
- 43.180** Microbead array based technology for detection and quantitation of viral respiratory pathogens associated with pneumonia among children
F. Aziz¹, S. Kerai¹, S. Qureshi¹, I. Nisar¹, N. Brown², F. Jehan¹
Karachi (Pakistan), ²Salisbury (United Kingdom)
- 43.181** Seasonal drivers of WHO defined fast breathing pneumonia—Impact of viral activity in the nasopharyngeal niche
S. Kerai¹, **B. Baloch¹**, I. Nisar¹, N. Brown², F. Aziz¹, F. Jehan¹
¹Karachi (Pakistan), ²Salisbury (United Kingdom)
- 43.182** The curious cases of pandemic H1N1 pathology
A. Basu, M. Chadha
Pune (India)
- 43.183** Identification of occult hepatitis B virus (HBV) infection and viral antigens in healthcare workers who presented low to moderate levels of anti-HBs after HBV vaccination
Z. Borzooy
Bucharest (Romania)
- 43.184** Sero-epidemiological investigation on enterovirus 71 among population in Chengdu, China
Z. Chen, L. Long, K. Zheng, X. Zhang, H. Chen, W. Huang, W. Huang, D. Han, Y. Bai, J. Meng
Chengdu (China)
- 43.185** Circulation of dengue virus-1 Genotype III during 2015 dengue outbreak in Arunachal Pradesh: A maiden report from Northeast India
S. Chetry¹, S. A. Khan¹, B. Apum², P. Dutta¹
¹Dibrugarh (India), ²Pasighat (India)



- 43.186** Cross-protective immunity against circulating Japanese encephalitis virus and West Nile Virus by live attenuated Japanese encephalitis vaccine SA 14-14-2
P. Chowdhury, S. A. Khan, P. Chowdhury, J. Borah, P. Dutta Dibrugarh (India)
- 43.187** Minimisation study of dengue prognostic biomarker panel test
J. S. A. Chua¹, G. N. Malavige², T. Chang³, M. L. Ng¹
¹Singapore (Singapore), ²Nugegoda (Sri Lanka), ³Colombo (Sri Lanka)
- 43.188** The efficacy and particular side effects of therapy peginterferon alpha-2a acute hepatitis C hemodialysed patients
N. Como, E. Meta, M. Qato, V. Ostreni, P. Preka, E. Zogu, A. Harxhi, P. Piperio
¹Tirane (Albania)
- 43.189** The role of adenovirus 36 induced obesity in obese adults with cardiovascular disorders: The first clinical study investigating ad-36 antibody in sera and DNA in mediastinal adipose tissues of cases with cardiovascular disorders from Turkey (A preliminary study)
S. Ergin, B. S. Kocazeybek, S. Gode, O. Dinc, U. Cizmecigil, N. Turan, I. Bakir, M. Keskin, S. Sirekbasan, S. Saribas, K. Atalik, E. Bonabi, G. Ayaz, M. Yeniterzi, H. Yilmaz
Istanbul (Turkey)
- 43.190** Factors leading to liver injury in acute dengue infection
S. M. Fernando¹, A. Wijewickrama¹, L. Gomes¹, C. Punchihewa¹, P. Madusanka¹, H. Dissanayake¹, C. K. Jeewandara¹, H. Peiris¹, G. Ogg², N. Malavige¹
¹Colombo (Sri Lanka), ²Oxford (United Kingdom)
- 43.191** Molecular diversity of rotavirus strains from hospitalized children in Central Kerala
S. George, O.A. Jagan, S. Jes, S. Bai, S. Oommen, S. Chandy
Tiruvalla (India)
- 43.192** High prevalence of hepatitis C and hepatitis B infection among pregnant women and their blood donors attending a surgical referral clinic in District Naushahro Feroze, Sindh, Pakistan 2014
A. A. Ghanghro, P. Jokhio
Islamabad (Pakistan)
- 43.193** Significance of diagnostic kits evaluation for emerging dengue infection
J. Mahalingam, S. Subramanian, S. K. Va, M. Paulraj, S. Murugesan, K. Arunagiri, S. Kumar, K. Krishnaswamy, **P. Gunasekaran**
Chennai (India)
- 43.194** Rabies virus infection: Role of the rabies virus phosphoprotein in producing neuronal injury mediated by mitochondrial dysfunction and oxidative stress
A. Jackson, W. Kammouni, H. Wood, M. Carpenter
Winnipeg (Canada)
- 43.195** Dengue 2 virus infection associated vascular endothelial cellular stress response imaged by high resolution electron and correlative microscopy shows distinct evidence of altered cytoskeleton and vesicular traffic
A. Basu, **D. P. Jain**
Pune (India)
- 43.196** Expansion of regulatory T cells in acute dengue infection does not associate with disease severity
H. E. Jayaratne¹, N. Wickramasinghe², T. N. Adikari¹, L. Gomes¹, A. Kamaladasa¹, G. S. Ogg³, G. N. Malavige¹
¹Nugegoda (Sri Lanka), ²Colombo (Sri Lanka), ³Oxford (United Kingdom)
- 43.197** Obesity and the presence of asthma are associated with hospitalization due to dengue infection
K. C. Jeewandara¹, L. Gomez¹, S. A. Paronavitane¹, M. C. K. Jayarathne¹, M. Tantirimudalige¹, **S. Fernando**¹, R. Fernando¹, S. Prathapan¹, G. S. Ogg², G. N. Malavige¹
¹Nugegoda (Sri Lanka), ²Oxford (United Kingdom)
- 43.198** Identification of viral and immunological correlates of disease severity and recovery in pediatric dengue patients
M. Kar¹, M. Singla², T. Sethi², S. Kabra², R. Lodha³, A. Chandele², G. Medigeshi³
¹Faridabad (India), ²New Delhi (India), ³Haryana (India)
- 43.199** In-vitro problems of screening (Anti-HCV) and confirmatory tests (RIBA) for the diagnosis of HCV infections : The relation of neopterin and sCD14 with low Anti-HCV reactivity and different RIBA patterns
B. Kocazeybek, Z. Habip, P. Sohrabi, S. Saribas, R. Caliskan, M. Demirci, A. Karakullukcu, K. Atalik, E. Bonabi, P. Yuksel, S. Vehid, E. Kosan, H. Bahar Tokman
Istanbul (Turkey)



- 43.200** Influenza illness in pregnant Indian women: A cross sectional study
P. A. Koul, N. K. Bali, H. Mir, F. Jabeen, A. Ahmad
Srinagar (India)
- 43.201** Viral etiology of anterior uveitis in immunocompetent patients in North India
A. Kumar, M. P. Singh, A. Gupta, R. Bansal, U. N. Sakia, R. K. Ratho
Chandigarh (India)
- 43.202** Real time PCR for the diagnosis of Rubella virus, *Herpes simplex virus-1* and *Toxoplasma gondii* in patients with congenital cataract
M. Singh, J. Ram, **A. Kumar**, J. Khurana, M. Marbaniang, R. K. Ratho
Chandigarh (India)
- 43.203** Hepatitis A outbreak associated with unsafe drinking water in a medical college student's hostel, New Delhi, India, 2014
T. Kumar, A. Shrivastava, A. Kumar, P. Khasnobis, J. P. Narain, K. F. Laserson, S. Venkatesh
New Delhi (India)
- 43.204** Immature platelet fraction in dengue cases
V. V. Kumar¹, S. Senthilkumaran², P. Thirumalaikolundusubramanian¹
¹Trichy (India), ²Erode (India)
- 43.205** Molecular detection and characterization of sapovirus from hospitalized cases of acute gastroenteritis from western India
N. Lasure, V. Gopalkrishna
Pune (India)
- 43.206** Identification of human papillomavirus types causing lesions in penile cancerous, pre-cancerous and benign lesions using laser microdissection
R. L. Lebelo¹, S. Thys², I. Benoy², C. Depuydt², J.-P. Bogers², J. Mphahlele³
¹Pretoria (South Africa), ²Antwerp (Belgium), ³Medunsa (South Africa)
- 43.207** Viral aetiologies of acute encephalitis in a hospital-based population in Sri Lanka
J. Lohitharajah¹, G. N. Malavige², C. Arembepola¹, J. Wanigasinghe¹, R. Gamage¹, P. Gunaratne¹, P. Ratnayake¹, T. Chang¹
¹Colombo (Sri Lanka), ²Nugegoda (Sri Lanka)
- 43.208** Clinical, laboratory profile and outcome of patients with dengue viral infection at a South Indian tertiary care hospital
S. V. S. Malladi, V. Gone, K. P. Adiraju, N. Chandra, S. R. Yadati
Hyderabad (India)
- 43.209** Multiple siRNAs against HCV and host genes are more effective in inhibition of HCV replication
A. Mandal, K. K. Ganta, B. Chaubey
Kolkata (India)
- 43.210** Detection and molecular characterization of unusual rotavirus group A genotypes G12P[11] and G10P[14] in hospitalized children with acute gastroenteritis in Kolkata, India
P. Mandal, S. Mullick, M. Chawla-Sarkar
Kolkata (India)
- 43.211** Co-circulation of all four dengue virus serotypes with concurrent infections in a single dengue season
B. Mishra, J. Turuk, S. J. Sahu, A. Khajuria, S. Kumar, A. Dey, A. K. Praharaj
Bhubaneswar (India)
- 43.212** Elucidating the role of essential RNA secondary structural elements in dengue biology and their implication in dengue virulence
B. Mishra¹, H. Beesetti², A. Advait¹, S. Swaminathan², R. Aduri¹
¹Goa (India), ²Hyderabad (India)
- 43.213** Hepatitis A virus outbreak in a compound in Tshwane district, Gauteng, South Africa: October 2014-March 2015
M. R. Mphaka¹, T. Ntshiga¹, L. Majake², C. Mugero², A. Maphela², M. Van Der Westhuizen², M. Moshime², R. Ncha¹, G. M. Ntshoe¹, T. Mkhencele¹
¹Johannesburg (South Africa), ²Pretoria (South Africa)
- 43.214** Exploring the instability of reporters expressed under the subgenomic promoter in Chikungunya virus infectious cDNA clones
P. P. Mudaliar, E. Sreekumar
Trivandrum (India)
- 43.215** Inhibition of CCL2 dependent human cytomegalovirus replication by triclin
T. Murayama, R. Yamada, K. Matsubara, H. Sadanari
Kanazawa (Japan)



- 43.216** Epidemiology of dengue / dengue hemorrhagic fever in the northern Sri Lanka from 2009 to 2012
K. Murugananthan¹, A. Murugananthan², F. A. Careem³, F. Noordeen¹
¹Kandy (Sri Lanka), ²Jaffna (Sri Lanka), ³Calgary (Canada)
- 43.217** Interferon-gamma and IL-1beta activation precede death in neonatal mice models of central nervous system (CNS) infection by Chikungunya virus
S. R. Nair, R. Abraham, E. Sreekumar
Thiruvananthapuram (India)
- 43.218** Surveillance and molecular characterization of Rotavirus strains in hospitalized children with gastroenteritis in West Bengal
M. K. Nayak¹, P. Mandal¹, N. Ganguly¹, P. Niyogi¹, C. Ghosh², S. Panda¹, M. Chawla-Sarkar¹
¹Kolkata (India), ²Medinipur (India)
- 43.219** Prevalence of asymptomatic hepatitis B virus among sexually active youths in a rural community of Ebonyi state, Southeast Nigeria
O. O. Njoku
Abakaliki (Nigeria)
- 43.220** Molecular diversity of Hepatitis B virus (HBV) x gene: A preliminary report from Kerala
O. A. Jagan¹, M. Gopi², J. N S³, G. Thomas¹, S. Chandy¹
¹Tiruvalla (India), ²Trivandrum (India), ³Vellore (India)
- 43.221** Hepatitis B virus genotypes and unique recombinants circulating among outpatients in selected hospitals in Kenya
M. Ochwoto¹, J. Kimotho¹, J. Oyugi¹, A. Andonov², E. Songok¹, C. Osiowy²
¹Nairobi (Kenya), ²Manitoba (Canada)
- 43.222** Molecular detection of enteroviruses in pigs in Lagos, southwestern Nigeria
L. O. Olayemi
Lagos (Nigeria)
- 43.223** Diarrhea in adult patients with influenza B
N. Pshenichnaya¹, A. Usatkin¹, O. Shmaylenko¹, A. Zhuravlev²
¹Rostov-on-Don (Russian Federation), ²Moscow (Russian Federation)
- 43.224** Thrombocytopenia and anti-platelet antibodies in patients with chronic hepatitis C
N. Pshenichnaya¹, G. Gopatz¹, A. Zhuravlev²
¹Rostov-on-Don (Russian Federation), ²Moscow (Russian Federation)
- 43.225** Indian experience with use of sofosbuvir for treatment of hepatitis C virus infection: Preliminary data from southern India
K. Radhakrishnan, A. Karunakaran, S. Jindal, A. Raghavendran, A. Goel, S. Kattiparambil Gangadharan, U. G. Zachariah, C. E. Eapen, P. Abraham
Vellore (India)
- 43.226** Serum levels of soluble CD26, a novel prognostic marker for acute hepatitis E infection
A. Rafiei, M. J. Safaar
Sari (Iran)
- 43.227** Splenic infarction, a rare complication of infectious mononucleosis in a patient with no significant comorbidity: Case report and review of the literature
A. N. Koul, **A. B. Rather**, G. N. Dhobi, F. A. Bhat
Srinagar (India)
- 43.228** Cytokine profile in response to Chikungunya virus (CHIKV) associated with CHIKV polyarthritides in acute febrile patients from South India
G. Sarangan¹, S. Nayar², G. Palani¹, J. Damodharan¹, K. Muthumani³, P. Srikanth¹
¹Chennai (India), ²Trivendrum (India), ³Philadelphia, PA (USA)
- 43.229** Elucidation of viral load and host immune responses as severity predictors of acute lower respiratory tract infections (ALRTI) mediated by respiratory syncytial virus (RSV) and human metapneumovirus (hMPV)
S. Sarkar, R. K. Ratho, M. Singh, M. P. Singh, P. A. Singh
Chandigarh (India)
- 43.230** Genetic variability and molecular evolution of hepatitis B virus in HIV co-infected patients on lamivudine based anti-retroviral therapy: A 5 year longitudinal study
E. Amponsah-Dacosta¹, **G. Selabe**¹, M. P. Gedezha¹, J. N. Rakgole¹, J. Blackard², J. Mphahlele¹
¹Pretoria (South Africa), ²Cincinnati, OH (USA)



- 43.231** Elevation in liver enzymes are associated with increased IL-2 and may predict severe outcomes of dengue virus infection in a Sri Lankan cohort
T. Senaratne¹, J. Carr², F. Noordeen³
¹Peradeniya (Sri Lanka), ²Adelaide (Australia), ³Kandy (Sri Lanka)
- 43.232** Co-infections with multiple dengue virus serotypes in patients from 3 different Provinces of Sri Lanka, a dengue hyper endemic country
T. Senaratne¹, P. N. Sirisena², K. Muruganathan³, F. Noordeen², J. Carr⁴
¹Peradeniya (Sri Lanka), ²Kandy (Sri Lanka), ³Jaffna (Sri Lanka), ⁴Adelaide (Australia)
- 43.233** Upsurge in vaccine preventable hepatitis A virus infection in adult patients from a tertiary care hospital of North India
A. K. Sharma, U. Dutta, S. K. Sinha, R. Kochhar
Chandigarh (India)
- 43.234** Prevalence of hepatitis C virus infection among asymptomatic Pakistani children
G. A. Sheikh, **G. A. Sheikh**
Lahore (Pakistan)
- 43.235** Delayed appearance of virus induced morphological changes in cultures derived from dengue and dengue haemorrhagic fever patients
P. N. Sirisena¹, F. Noordeen¹, L. K. Fernando²
¹Kandy (Sri Lanka), ²Negombo (Sri Lanka)
- 43.236** Phylogenetic analysis of the complete genome of the APMV-13 isolate from Ukraine
I. Goraichuk¹, S. Poonam², K. Dimitrov², B. Stegny¹, D. Muzyka¹, M. Pantin-Jackwood², A. Gerilovych¹, **O. Solodiankin**¹, V. Bolotin¹, O. Rula¹, C. Afonso²
¹Kharkiv (Ukraine), ²Athens, GA (USA)
- 43.237** Characterisation of chronic hepatitis B virus carriers with viral load and correlation with other viral markers
S. Subramanian, M. Mani, G. Sarangan, R. Barani, P. Srikanth
Chennai (India)
- 43.238** Changing trend of rotavirus strains circulating in children <5 years in Delhi
V. R. Tikku, P. Ray, A. Bagga
New Delhi (India)
- 43.239** Molecular detection of Chikungunya virus infection during 2013–2014 in Delhi
A. K. Verma, R. Lodha, P. Ray
New Delhi (India)
- 43.240** Detection of rotavirus in diarrhoeic children from 0–5 years of age in Kano North-Western Nigeria
A. Wada Kura¹, M. Aminu²
¹Dutse Jigawa (Nigeria), ²Zaria (Nigeria)
- 43.241** Survey of Hepatitis B surface Antigen (HBsAg) prevalence and its risk factors among pregnant women at Bishoftu Hospital, Oromia Regional State, Ethiopia
Z. D. Woldesonbet
Addis Ababa (Ethiopia)
- 43.242** Memory B cell response to Japanese encephalitis (JE) vaccination in JE endemic area of Uttar Pradesh
A. Zia, D. V. Singh, S. Saxena, T. N. Dhole
Lucknow (India)
- 43.243** Practice of people in dealing with animals related to Crimean-Congo Hemorrhagic Fever in Nur County, Mazandaran Province, Northern Iran
S. P. Ziapour¹, A. Enayati¹, S. Kheiri², S. Chinikar³, S. Khakifirouz³, S. H. Nikookar¹, F. Babamahmoodi¹, M. R. Haghshenas¹, M. Moosazadeh¹
¹Sari (Iran), ²Amol (Iran), ³Tehran (Iran)
- 43.244** Viral burden in acute respiratory tract infections in hospitalized children in the wet and dry zones of Sri Lanka
J. A. A. S. Jayaweera¹, **F. Noordeen**², A. Morel², N. Pitchai², S. Kothalawala³, A. M. S. B. Abeykoon³, J. S. M. Peiris⁴
¹Anuradhapura (Sri Lanka), ²Kandy (Sri Lanka), ³Peradeniya (Sri Lanka), ⁴Hong Kong (Sri Lanka)

Zoonoses and Infections in Animals

- 43.245** Cross-species transmission of *Mycobacterium tuberculosis* in mahouts and captive elephants: Implications to health policy
D. Abraham¹, V. Kummannoor Parameswaran Pillai²
¹Thrissur (India), ²Kottayam (India)
- 43.246** Serological survey of porcine cysticercosis and associated risk factors in pigs slaughtered at Ndumbuini abattoir in Nairobi, Kenya
J. M. Akoko¹, E. MacLeod², E. Kang'ethe¹, P. Muinde¹, P. Alarcon³, D. Muloi¹, J. Gachoya¹, E. Fevre⁴
¹Nairobi (Kenya), ²Edinburgh (United Kingdom), ³London (United Kingdom), ⁴Liverpool (United Kingdom)



- 43.247** Coagulase positive staphylococci and food poisoning toxins—A case study of an outbreak investigation occurred in a shepherd hut
M. Armani¹, G. Macori², S. Gallina², A. Tavella¹, M. Giusti¹, G. Paolazzi¹, L. Trentini¹, M. Rabini¹, L. Decastelli², D. Lombardo¹
¹Bozen (Italy), ²Turin (Italy),
- 43.248** Rodent leptospirosis in North Khorasan Province, Northeast of Iran
J. Darvish¹, **K. Arzamani**², G. Abdolapoor³, M. R. Shirzadi³, Z. Mohammadi¹, M. Alavinia⁴
¹Mashhad (Iran), ²Bojnurd (Iran), ³Tehran (Iran), ⁴Toronto (Canada)
- 43.249** Biosecurity risk of wild bird markets and wild bird trade to avian influenza in Kaduna State, Nigeria
A. Assam, P. A. Abdu, A. Ezealor
Zaria (Nigeria)
- 43.250** Ecoepidemiology of *Rickettsia parkeri* in the Paraná Delta, Argentina
P. M. Beldomenico¹, V. Colombo¹, L. Monje¹, L. Antoniazzi¹, S. Nava²
¹Esperanza (Argentina), ²Rafaela (Argentina)
- 43.251** A survey of human and animal casualties resulting from bites of stray dogs in the municipal area in Palakkad district, Kerala
J. Davis, N. Menon
Palakkad (India)
- 43.252** Predominance of “atypical” enteroaggregative *Escherichia coli* among human, animal, foods and associated environmental sources
P. Dhaka¹, D. Vijay², J. Vergis³, V. Mohan¹, M. Kumar¹, A. Kumar¹, S. Malik¹, S. Barbuddhe⁴, D. B. Rawool¹
¹Izatnagar (India), ²Mannuthy (India), ³Wayanad (India), ⁴Raipur (India)
- 43.253** Development of safe, effective and immunogenic vaccine candidate for diarrheagenic *Escherichia coli* main pathotypes in mouse model
O. Khurtsbaatar, B. Bayarsaikhan, V. Batbaatar, B. Bayartsetseg, **J. Erdenebaatar**
Ulaanbaatar (Mongolia)
- 43.254** Mozambique experience in implementing One Health Surveillance as an innovative tool to understand the risk of spillover of emerging and zoonotic infections between wildlife and humans
E. S. Gudo, J. Fafetine, P. Alho, A. Muianga, S. Ali, G. Pinto, A. Tivane, V. Monteiro, L. Neves
Maputo (Mozambique)
- 43.255** Study of antibody dynamics in horses vaccinated against West Nile Virus (WNV)
G. Purpari¹, G. Savini², A. Conte², F. Mira¹, P. Di Marco¹, V. Cannella¹, G. Zammuto¹, A. Console¹, C. Di Bella¹, S. Vullo¹, S. Di Bella¹, **A. Guercio**¹
¹Palermo (Italy), ²Teramo (Italy),
- 43.256** Endemic toxoplasmosis and listeriosis in the perspective of ‘The problem of shelter dogs’ in Istanbul
H. Kirkoyun Uysal, Y. A. Oner, Ö. Akgül, S. Bayırlıoğlu, Ü. Tunga Babaoglu, S. Purisa
Istanbul (Turkey)
- 43.257** Brucellosis presenting as mediastinal lymphadenopathy with raised B2 microglobulin
A. N. Koul, J. A. Sheikh, F. A. Shaheen
Srinagar (India)
- 43.258** Clinical spectrum of melioidosis at a tertiary care hospital in South India
S. V. S. Malladi, L. Vemu, N. C. Chandra, M. Shetty, K. P. Adiraju, N. R. Modugu, S. R. Yadati
Hyderabad (India)
- 43.259** Study of clinical, laboratory abnormalities and outcome in patients with scrub typhus at a south Indian tertiary care hospital
S. V. S. Malladi, R. R. Keesari, K. P. Adiraju, N. R. Modugu, S. Reddy, L. Vemu, S. R. Yadati
Hyderabad (India)
- 43.260** Camel’s milk as a source of human toxoplasmosis in Butana area—Sudan
M. Y. I. Medani, H. Mohamed
Khartoum (Sudan)
- 43.261** Survey for avian influenza and Newcastle disease antibodies and viruses in domestic and wild birds in Bauchi and Gombe States, Nigeria
W. I. Musa, P. A. Abdu, L. Sa’idu, M. Bello
Zaria (Nigeria)
- 43.262** Cutaneous anthrax in the Rostov region of Russia: Difficulties in the clinical diagnostics
N. Pshenichnaya¹, N. Mamedova¹, Y. Ambalov¹, A. Usatkin¹, O. Shmaylenko¹, A. Zhuravlev²
¹Rostov-on-Don (Russian Federation), ²Moscow (Russian Federation)



- 43.263** Reducing vulnerability to the threat of Japanese encephalitis transmission in high risk districts in Nepal
D. Ratala, M. Sharma Joshi, B. Gupta
Kathmandu (Nepal)
- 43.264** Is ocular dirofilariasis an emerging zoonoses in India? Report of five cases and review of literature
A. K. Reddy, A. Rangaiahgari, R. Swarup, E. Aggarwal, S. Chaugule, S. Honavar
Hyderabad (India)
- 43.265** Infection with *Coxiella burnetti*: A rare cause of acute glomerulonephritis
M. Sargianou, I. Galinos, E. Mazonakis, G. Aloizos
Athens (Greece)
- 43.266** Incidence of brucellosis in Livestock in North-Eastern India
I. Shakuntala, S. Ghatak, R. Sanjukta, A. Sen, S. Das, A. K. Puro, A. Dutta, K. Kakoty
Ribhoi (India)
- 43.267** Mixed infection of bovine tuberculosis and paratuberculosis in domestic livestock species of North India
A. V. Singh, D. Chauhan, A. Singh
Agra (India)
- 43.268** Active surveillance for human plague in Northwestern Uganda, 2008–2014
A. Titus
Kampala (Uganda)
- 43.269** Comparison of serology, culture and polymerase chain reaction (PCR) for diagnosis of human brucellosis
S. Hamid Hashemi, **F. Torkaman Asadi**, M. Yousef Alikhani, A. Moghimbeigi, Z. Naseri
Hamedan (Iran)
- 43.270** Serological Survey and Identification of *Brucella spp* of male breeding animals in Some Soums of Arkhangai Province, Mongolia
B. Vanaabaatar, G. Ulziisaikhan, B. Enkhtur, J. Erdenebaatar
Ulaanbaatar (Mongolia)
- 43.271** Quantitative analysis of *Brucella spp* in aborted bovine fetuses by real-time PCR
S. Aslan¹, A. Yoldas, A. Yigin¹, M. Demirci², **F. Yarimcam Saglam**²
¹Adana (Turkey), ²Istanbul (Turkey)



Authors Index

- Abadom N. 42.048
 Abah C. 43.155
 Abazari M. 41.077
 Abbas K. **41.190**
 Abbas S. 41.216
 Abdallah T. M. 42.019
 Abdel Rahman S. 43.047
 Abdelkerem A. 42.138
 Abdellah A. 42.250
 Abdeltawab N. F. 43.157, **43.173**
 Abdolahpoor G. 43.248
 Abdrahim M. 42.188
 Abdu A. 41.268
 Abdu P. A. 42.057, 43.261, 43.249
 Abdulaziz M. M. **41.024**
 Abdulkadir I. 42.086
 Abdullahi U. I. **41.025**
 Abdulrahman H. 43.149, 42.130, 42.137, 43.148
 Abenova I. 43.176
 Abera W. K. **43.174**
 Abeykoon A. M. S. B. 43.244
 Abeynayake J. I. **43.175**
 Abeyrathna G. 14.003
 Abeywardena H. M. W. **41.026**
 Abouelfetouh A. A. Y. **41.005**
 Abraham D. **43.245**
 Abraham N. 21.008
 Abraham O. **04.004**
 Abraham P. 43.225, **27.004**
 Abraham R. 43.217
 Abraham T. **41.131**
 Abu N. 42.273
 Abubakar A. T. **41.132**
 Abubakar I. 43.118
 Abubakar S. 42.239
 Abuova G. **43.176**
 Abutarbush S. M. **41.200**
 Achappa B. **42.092**
 Acosta A. P. **41.133**
 Adams T. 43.161
 Adamu B. 41.268
 Addise D. 43.117
 Adebayo A. 42.139
 Adedokun B. 43.088
 Adegbayi T. 42.147
 Adegbi H. 43.052, 42.058
 Adegoke J. 43.155
 Adekeye B. 42.147
 Adeleye A. 42.017
 Adelusi V. 43.088
 Adeniji J. A. 42.056
 Adetokunboh O. **42.093**
 Adeusi O. 42.034, 42.139
 Adewole A. **42.174**, 42.022, **43.177**, **42.251**
 Adhikari R. P. 41.098
 Adhikari R. **41.027**
 Adhikari S. 41.072
 Adikari T. N. 43.196
 Adiraju K. P. 43.259, 42.256, 43.208, 43.258
 Adiru Atiku L. 42.178
 Aduri R. 43.212
 Advait A. 43.212
 Afonso C. 43.236
 Afshan A. 42.175
 Afzalzadeh S. 42.233
 Agampodi S. 41.174
 Agarwal G. 42.098
 Agarwal M. 42.024
 Agarwal V. 41.047
 Agbaje-Daniels F. **42.017**
 Aggarwal E. 43.264
 Aggarwal P. 41.208
 Agomoh N. G. 43.035
 Agrawal R. **42.234**
 Agrawal S. K. **43.016**
 Agwu E. J. **41.010**
 Ah Tow L. E. 41.156
 Ahamed S. F. **41.201**
 Ahammad R. U. 28.005
 Ahlawat R. **43.005**
 Ahluwalia A. K. 42.273
 Ahmad A. 43.200
 Ahmad I. **42.175**
 Ahmad R. 41.112
 Ahmed A. **21.010**
 Ahmed B. 42.139
 Ahmed B.-N. 35.008
 Ahmed N. 43.128
 Ahmed N. 43.001
 Ahmed N. **14.007**
 Ahmed N. 42.073
 Ahmed N. **42.007**
 Ahmed Z. 41.089
 Ahuja A. 43.147
 Ahuja S. 43.024
 Ainoda Y. 41.148
 Aisiri A. A. 42.034
 Ait kaci N. 42.250
 Aiyenigba B. 42.034
 Aiyenigba B. 42.139
 Ajayi A. A. 42.062
 Ajemigbitse A. A. 43.060
 Ajiboye P. F. 43.109
 Ajumobi O. 41.158, 43.088
 Akanbi F. R. **42.018**
 Akello G. 42.128
 Akerele K. 43.155
 Akgul F. 42.167
 Akgül Ö. 43.042, 43.256
 Akhmedjanov D. 42.094
 Akhmedjanova Z. **42.094**
 Akhmedova Z. 42.094
 Akhund T. 43.165
 Akinboade O. 43.166
 Akingbesote S. 43.088
 Akinmade O. V. **41.191**
 Akinmola O. A. 43.060
 Akintayo I. 42.017
 Akinyode F. 42.022
 Akka J. 42.261
 Akoko J. M. **43.246**
 Akpan I. 42.034
 Akpasa A. O. **42.139**
 Al Amad M. **42.176**
 Al Mahqri A. 42.176
 Al Naiemi N. 41.101
 Al Serouri A. 42.176
 Al Thani M. 41.219, 42.257
 Al-azawi N. 41.028
 Al-bayati A. 41.028
 Al-Farsi Y. 42.236
 Al-Hajri M. 42.257
 Al-Hajri M. 41.219
 Al-Marri S. 42.257, 41.219
 Al-rifai S. B. I. **41.028**
 Al-Romaihi H. 42.257, 41.219
 Alaerts M. 21.002
 Alao K. 42.005
 Alarcon P. 43.246
 Alavi S. M. 42.246
 Alavi S. M. 42.243
 alavinia M. 43.248
 Alejandria M. 43.160
 Alex J. S. 42.151
 Alex S. M. 42.242
 ALEX ANAND D. 42.096
 Alexander S. 42.154
 Alho P. 43.254
 Ali A. A. **42.019**
 Ali F. **41.192**, **42.177**
 Ali M. 42.065
 Ali M. **43.087**
 Ali S. 41.242, 43.254, 41.222
 Ali V. 43.086, 43.075
 Ali Mahdi A. 42.035
 Alikhani M.-Y. 41.049, **41.134**, 41.077
 Alimelu M. 42.275
 Aljumaah D. S. A. 42.009
 Alkhenizan D. A. H. 42.009
 Allahverdiyeva V. 42.194
 Allam R. 42.136
 Allam R. R. **42.095**, **42.020**
 Allen T. 42.192
 Alli M. 42.217
 Almeida P. 35.008
 Aloizos G. 43.265
 Alvandi A. 41.178
 Alvar J. 35.007
 Alves F. 35.007
 Alwan A. 41.028
 Aly I. R. **41.169**, **41.170**
 Alzeini A. 42.019
 Amadu L. 43.148, 42.137, 43.149, 42.130
 Amarchand R. 42.157
 Amartya R. 41.098
 Amazigo U. 43.058
 Ambalov Y. 43.262
 Amberpet R. **41.029**
 Amdekar S. 42.200
 Amin M. 43.173
 Amin M. 43.157
 Aminimoqaddam S. 42.047
 Aminu M. 43.240
 Amone D. 42.128
 Amponsah-Dacosta E. 43.230
 Anand A. 43.132
 Anand T. **42.084**
 Anandan S. 42.002
 Anandan S. 42.001
 Anandan S. 41.080, 41.099, 41.097
 Anandaram H. **42.096**
 Ananthabalrajurs T. **41.030**
 Anantharaj U. J. 41.283
 Anbalagan K. **41.135**
 Anbessie T. B. 42.078
 Andonov A. 43.221
 Anebonam U. P. **42.021**
 Ang B. 41.211
 Angelakis E. **13.004**, **17.002**
 Aniceto R. N. **41.202**
 Anjana M.V. **41.110**
 Annamalai R. 41.258
 Annapurneshwari D. 41.228
 Antoniazzi L. 43.250
 Antonio M. 41.008
 Antonio R. 42.185
 Anwar Q. 41.260
 Anyanwu M. O. **42.022**, **43.088**
 Aoun J. 28.010, 28.003
 Apangu T. 42.178
 Apum B. 43.185
 Aravind L. 42.084
 Archer J. 43.091
 Årdal C. **31.003**
 Arembepola C. 43.207
 Arerondo- Henardez R. 42.266
 Argento A. 42.247
 Aribodor D. N. **42.023**
 Arif N. **43.017**
 Arjun R. **42.140**, **41.031**
 Arjyal A. **38.003**
 Armani M. **43.247**
 Arnold C. 43.118
 Arora R. 41.220
 Arslan U. 42.189
 Arumugam P. **43.178**
 Arunagiri K. 43.193
 Arzamani K. **43.248**
 Asaku S. T. **42.178**
 Ascencao B. F. B. 43.122
 Asha F. 42.083
 Ashley E. **12.001**
 Aslan S. 43.271
 Aslani Z. 42.243, 42.246
 Aslanov B. 41.239
 Asogun D. 42.044
 Assam A. **43.249**
 Assefa A. A. **43.018**
 Asthana M. 42.200
 Aston S. 21.002
 Asubayeva G. 43.176
 Atalik K. 43.199
 Atalik K. 43.189
 Atenkeng Apasew H. 43.053
 Athalye Shetye S. **28.011**
 Athan E. 41.235
 Atunga N. 41.083
 Austin N. I. **43.019**, **43.020**
 Avaliani L. 41.193
 Awal B. K. **43.003**
 Awang M. O. 43.012
 Awashti S. **02.002**
 Awasthi S. **42.024**
 Ayaz G. 41.138, 43.189, 43.136, 43.063
 Aydemir S. 41.048
 Aydın M. 43.030
 Aydın N. **43.179**
 Ayele H. T. **43.089**



Authors Index

- Ayepola O. O. **42.141**, 42.147, 42.062
 Azim T. **27.001**
 Aziz F. 43.181, 41.117, **43.180**
 Azizov I. **41.119**, 42.252, B Tamiyu A. 41.268
 Baba K. 41.050
 Baba ami A. 42.250
 Babalola A. 42.017
 Babamahmoodi F. 43.243
 Babenko D. **42.254**, **42.253**
 Babenko D. 41.119
 Babenko D. **42.252**
 Babu A. 42.195
 babu A. 43.146
 Babu P. 41.097
 Babu S. 21.010
 Badawi A. **41.203**
 Badiger S. **42.097**, **42.025**
 Baffoe-Bonnie A. 41.091
 Bagga A. 43.238
 Bahar Tokman H. 43.136, 41.138, **41.032**, 43.063, **41.136**, 43.199
 Bai S. 43.191
 Bai Y. 43.184
 Bairy I. 41.235
 Bairy I. 42.222
 Baker S. 42.065
 Bakir I. 43.189
 Bakker J. M. 41.160
 Bala U. 41.158
 Balaji V. 41.099
 Balakrishnan P. 42.110, 42.135, 42.131, 42.099, 21.001, 42.105
 Balakrishnan R. 41.176, 21.007
 Balamurugan N. 42.158
 Balamurugan V. 14.001
 Balasegaram M. 35.007
 Balasooriya P. 35.005
 Balasubramaniam M. 41.269, 41.270
 Balasubramanian U. 41.033
 Balcioglu I. 42.118
 Balcioglu Y. H. 42.118
 Bali N. K. **42.026**, 43.200
 Baliga S. 43.140
 Balkhair A. 42.236
 Baloch B. **43.181**
 Balouch B. 41.117
 Baloyi R. E. **42.027**
 Balsara K. 41.111
 Bameka A. 42.128
 Bamford C. 42.274
 Bandara N. B. 42.067, 35.005
 Bandyopadhyay T. 42.145
 Banerjee A. **42.179**
 Banerjee A. **41.095**
 Bansal R. 43.201
 Bansal S. 41.058
 Banu S. S. **35.009**
 Banwat E. 41.275
 Baraitareanu D. 41.261
 Barani R. 21.007
 Barani R. 41.258, 43.237
 Barani R. 41.176
 Barbosa U. 43.103
 Barbuddhe S. 43.252
 Barigala R. K. 41.269, 41.270
 Barman T. K. 41.126
 Barmana T. K. 41.127
 Barnabas R. 42.122
 Barr J. 41.252
 Barua A. **41.204**, **43.021**
 Baruah K. 41.208
 Barzegari A. 43.164
 Basher A. **43.022**, **42.142**
 Baskar R. **42.217**
 Basnet S. 43.003
 Bassetti M. **19.002**
 Basu A. 43.195, **43.182**
 Basu S. 41.006, 41.095, 41.002, 42.235
 Batbaatar V. 43.253
 Batra N. 41.058
 Baurin N. 41.195
 Bayarsaikhan B. 43.253
 Bayartsetseg B. 43.253
 Bayirlioglu S. 43.256
 Bayramoglu G. 41.048
 Bearman G. **39.002**
 Beesetti H. 43.212
 Behera B. **41.205**
 Belciad M. 14.010
 Beldominico P. M. **43.250**
 Belkhou R. 42.148
 Bello M. 42.057, 43.261
 Bennani L. 42.148
 Benoy I. 43.206
 Benson F. **42.180**
 Benson U. O. **42.181**
 Berberian G. **43.090**, **42.269**
 Bernal-Sahagún F. 42.266
 Bero D. 42.184
 Berry C. E. **43.091**
 Beshiru A. 41.052
 Betancourt-Cravioto M. **03.004**
 Bethge A. 43.009
 Bettampadi D. 42.006
 Bhagabati B. 42.046
 Bhake A. 41.173
 Bhakuni D. S. 41.277
 Bhalla A. 41.206
 Bhandari V. 43.078
 Bharadwaj R. S. 42.219, **41.033**, 41.078, 42.071, **41.137**, 41.253
 Bhardwaj K. **43.023**, **43.092**, **43.093**, **41.276**
 Bhargava A. 41.220
 Bhargava S. **42.098**
 Bharti S. K. 41.120
 Bharucha T. **41.171**
 Bhat F. A. 43.227
 Bhat P. 42.276
 Bhat V. 41.254
 Bhat K G. 41.068
 Bhateja P. 41.123
 Bhatnagar N. 41.221
 Bhatta D. R. 42.064
 Bhattacharjee A. 41.039, 41.037, 41.071, 41.054, 41.086, 41.035, 41.044
 Bhattacharjee U. 43.147
 Battacharya D. B. 43.142
 Bhattacharyya P. 28.007
 Bhattacharyya S. 43.102
 Bhatti H. S. 42.165
 Bhavsar A. 41.227
 Bhola S. K. 43.145
 Bhola S. K. **43.094**
 Bhosale N. K. **43.024**
 Bhosle D. 41.282
 Bicheru S. 41.261
 Binazzi R. 42.204
 Bino S. 41.213
 Bint B. 42.154
 Birbeg-Salum T. 42.107
 Birinci I. 42.138
 Bisenova N. 41.119
 Bisi Johnson M. 41.168
 Biswal M. **41.206**
 Blackard J. 43.230
 Blackwell J. 41.255
 Blaney D. 41.234
 Block P. 41.244
 Blumberg L. **07.003**, 42.180
 Boccardo E. 43.103
 Boddu D. **42.270**, **43.095**
 Boelaert M. 41.186
 Boer M. D. 35.008
 Bogers J.-P. 43.206
 Bojang K. 41.008
 Bojary Nasrabadi M. R. **42.182**
 Bolotin V. 41.046, 43.236
 Bomoi I. M. **14.008**
 Bompangue D. 41.145
 Bompelli A. **43.096**, **42.028**
 Bonabi E. 43.063, 43.199, 42.138, 43.136, 43.189, 41.138
 Bonam W. 21.011
 Bonaparte M. 42.011
 Bondanini S. 42.249
 Bongiorno G. 42.204
 Bonten M. 43.089
 Boobalan J. 42.105, 42.135, **42.099**, 42.110, 21.001
 Bora T. 42.145, 41.233, **41.207**
 Borah J. 43.186
 Borchetia S. 42.145
 Boroumand M. A. 41.042
 Borzooy Z. **43.183**
 Bothe J. 42.154
 Bouckenooghe A. 42.075, 43.162
 Boulton M. 42.006, **42.029**
 Bozdogan B. 43.046
 Bozkurt I. 42.167
 Brady O. **03.001**
 Bregu H. 42.149
 Brima J. K. 41.091
 Broeks A. 41.160
 Brown M. 42.154
 Brown N. 43.180, 43.181
 Brown P. **41.016**
 Brownstein J. 14.002
 Bswas A. **41.208**
 Buba M. 41.158
 Buchy P. 42.004
 Buckee C. O. 35.003
 Buddamakuntala L. **42.100**
 Buè C. 42.249
 Bukenya H. 41.234
 Bulabula A. **43.097**
 Bulbul R. 43.179
 Bulgiba A. M. 43.012
 Bulugahapitiya U. 42.229
 Bulwadda D. 41.236
 Bunker C. H. 42.115
 Burdakov A. 42.194
 Burman R. P. **42.015**
 Burman T. K. **41.123**
 Burza S. **35.008**, **33.004**, 35.007, 35.001
 Bwogi J. 41.234
 Byotra S. 41.266
 Cabanillas Stanchi K. M. 42.220
 Caglar E. 43.136
 Çağlar S. 43.042
 Caliskan R. **41.138**, 43.199, 42.138
 Caliskan S. O. 43.046
 Camesi A. 42.171
 Campara M. 41.274
 Campbell C. **41.193**
 Campbell L. 42.228
 Cannella V. 43.255
 Careem F. A. 43.216
 Carlson B. 42.029
 Carmona R. D. C. 42.201
 Carpenter M. 43.194
 Carr J. 43.232, 43.231
 Carvalho A. V. D. A. 42.212
 Carvalho L. 41.139
 Cashwell A. **41.194**
 Casimir L. 43.090
 Cassocera M. 42.184, 43.027
 Castellanos-Cruz M. 43.007
 Castro G. 42.269
 Castro-Sánchez E. 41.112
 Çelik V. 41.136
 Cervantes-Castillo A. 43.007
 Ceyhan M. 41.048
 Chaaithanya I. K. 41.244
 Chacko A. 42.270, 42.277
 Chacko G. 42.122
 Chadha M. **10.002**
 Chadha M. 43.182
 Chahar P. **43.025**
 Chain P. 41.262
 Chaitra Y. 42.066
 Chakma S. **41.209**
 Chakrabarti A. 41.189, **17.001**, 42.223
 Chakraborty A. 43.038
 Chakraborty B. 42.145
 Chakrapani H. 41.067
 Chakravarti A. 42.011
 Chakravarty A. 41.054, 41.035
 Chakravarty A. 41.037
 Chakravarty A. 41.039, 41.044, 41.071
 Chakravarty J. 43.043
 Challa S. **42.183**
 Chan H. C. 42.159



Authors Index

- Chandane P. 43.139
 Chandanwale A. 42.071
 Chandele A. 43.198, 41.201
 Chandra J. 41.256
 Chandra K. 42.151
 Chandra N. 43.208, 42.256
 Chandra N. C. 43.258
 Chandra Sistla S. 41.131
 Chandrabose J. 21.006
 Chandran S. 41.081, **41.034**
 Chandran V. 42.120
 Chandrasekharan N. 43.039
 Chandrasena T. 35.005
 Chandrashekar N. **42.218**
 Chandy S. 43.191, 43.220
 Chang B. **28.002**
 Chang T. 43.207, 43.187
 Chansinghakul D. 43.162
 Chanthongthip A. 41.171
 Charani E. 41.112
 Charkameh A. 41.264
 Charkha T. K. **43.098**
 Charlett A. 42.010
 Chatterjee S. 41.006, **42.235**
 Chattopadhyay S. 41.233
 Chaturvedi S. 41.216
 Chaubey B. 43.209
 Chaudhary A. **43.026**
 Chaudhary M. **41.210**
 Chaudhary R. **09.004**
 Chaudhary R. K. **42.143**
 Chaudhary U. 41.040
 Chaudhry R. 41.113, 41.057, 42.123
 Chaugule S. 43.264, 43.133
 Chauhan D. 43.142, 43.267
 Chauhan H. 41.221
 Chauhan R. 42.069
 Chauhan S. B. 43.076
 Chavali P. 41.151
 Chawla A. 43.099
 Chawla K. **43.099**
 Chawla-Sarkar M. 43.218, 42.156, 43.210, 42.179
 Chen H. 43.184
 Chen J. 43.106
 Chen M.-C. 14.005
 Chen W. **42.030**
 Chen Z. 42.052, **43.184**
 Cheng C.-F. 42.212
 Cheng K. J. G. 43.160
 Cheng X. 42.216
 Chepkorir E. 41.251
 Cherabuddi K. **28.004**
 Cheska A. 41.119
 Chetri S. **41.035**
 Chetry S. **43.185**
 Cheung Y. B. 43.125
 Chheang R. **41.036**
 Chhoeung R. 42.004
 Chia P. Y. **41.211**
 Chiang P.-S. 42.202
 Chiarenza G. 42.190
 Chib R. 43.145
 Chigor V. 41.053
 Chilaule J. J. **42.184**, 43.027
 Chillarge C. 41.150
 Chimoyi L. 42.061
 Chin'ombe N. **41.212**
 Chinedu S. 43.108
 Chinikar S. 43.243
 Chinnambedu Ravichandran S. **42.101**
 Chinni V. S. 41.135
 Chinyere U. 43.056
 Chisti M. J. 41.225
 Chitra D. 42.135
 Chiu C.-H. 41.175
 Chiu C. H. 42.191
 Choi E.-O. 42.127
 Chopra S. 41.067
 Choudhury N. A. **41.037**
 Chouhan M. I. 41.272
 Chow A. 42.042
 Chowdavarapu R. R. 42.183
 Chowdhury M. **42.144**
 Chowdhury P. **42.145**, 43.186
 Chowdhury P. **43.186**, 41.232
 Chowta N. 42.120
 Chu C. **12.004**
 Chu D. K. 14.006
 Chu V. T. 41.217, 42.012
 Chua J. S. A. **43.187**
 Chung P. H. **43.152**
 Chung W.-Y. 42.202
 Cilli A. 42.201
 Ciotti M. 42.249
 Ciulacu-Purcareu V. 41.261
 Cizmecigil U. 43.189
 Claassens M. M. 21.008
 Claudete C. G. **42.031**, **42.185**
 Clemens J. D. 42.065
 Clerigo V. **41.139**
 Cletus E. 43.056
 Cohen J. **37.003**
 Cohn E. 14.002
 Cokugras H. 41.138, 43.063
 Colangeli P. 42.190
 Coldren R. 41.251
 Collard J.-M. 41.144
 Colombo V. 43.250
 Como N. **43.188**, **41.213**
 Companys R. W. 41.241
 Compes E. 42.008
 Console A. 43.255
 Consortium Investigators P. 42.087
 Conte A. 43.255
 Cooper P. **26.003**
 Cordeiro Da-Silva A. 43.079
 Corea E. M. **41.214**, **41.174**
 Coskun A. 43.179
 Cossa H. 43.027
 Cossa-Moiane I. L. C. **43.027**
 Costa Silva R. J. 43.103
 Cotarelo M. J. F. 41.091
 Cotter P. **23.004**
 Coudeville L. **41.195**
 Couvin D. 43.142
 Cowen P. **07.004**
 Crameri G. 41.252
 Crawley A. 14.002
 Cruz-Cordoba A. 43.007
 Cuervo C. L. **41.215**, **43.028**
 Cynamon M. **43.100**
 D'Alessandro U. 41.181
 D'Cor N. A. **43.153**
 D'Souza G. 21.011, 43.131
 D'Souza R. 42.132
 Dagan R. **02.003**
 Daghighkia H. 43.164
 Dagne Z. 43.117
 Dahiya S. 41.122
 Dal F. 41.136
 Dalhat M. 41.132
 Damodharan J. 43.228, 41.258
 Dan T. N. H. 42.202
 Danansuriya D. 42.067
 Dance D. A. B. **20.004**
 Danda S. 43.114
 Dandale A. 41.276, 43.023, 43.093
 Dandamudi R. R. **41.038**
 Danes D. 41.261
 Dang O. 42.012
 Dangeti G. 43.110
 Dangi P. **43.029**
 Dangor Y. **42.032**
 Dangre G. **42.146**
 Danilova E. 42.094
 Dar L. 41.208
 Darvish J. 43.248
 Das A. 41.070
 Das A. 41.189
 Das A. K. 35.008
 Das B. 28.009, 41.280
 Das B. 42.046
 Das B. K. 41.057, 42.123
 Das B. K. 41.122, 21.003
 Das B. C. 41.096
 Das P. 41.220
 Das P. 42.262
 Das P. 35.007
 Das P. 43.045
 Das P. 42.156
 Das P. **33.001**
 Das S. 41.096, 43.266, 43.147
 Das S. 41.001
 Das V. 43.045, 42.156
 Dasgupta N. **41.039**
 Dashed A. M. 43.117
 Dass B. S. **41.017**
 Datta S. 42.235, **41.006**
 Daum L. T. **43.101**, **43.102**
 Dave P. 41.282
 David P. 41.273
 David T. 41.149
 Davies S. **29.001**
 Davis J. **43.251**
 Dawood F. 42.157
 Dawson P. **43.008**
 De Clerck H. **39.004**, **10.003**
 De Deus N. 43.027, 42.184
 de la Rosa D. **43.007**
 de Mira Fernandes A. 42.201
 De Silva A. 41.012
 De Silva D. 41.214
 de Souza Gregorio D. 42.201
 Debi U. 41.014
 Decastelli L. 43.247
 Deep A. **41.040**
 Deep D. K. 43.078
 Defo D. 43.053
 Deghaide N. 42.107
 Dehghan A. 42.238
 Dehghani J. 43.164
 Delarocque C. 42.004
 Delarocque-Astagneau E. 41.144
 Delgado-Sarmiento E. 43.028
 Deme S. **42.255**, **42.256**
 Dementieva E. 41.015
 Demir C. 41.032
 Demirayak M. 42.189
 Demirci M. 43.136, 43.063, 41.138, 41.136, 41.032, 43.271, 43.199
 Demirel O. F. 42.118
 Dengo Baloi L. C. **41.041**
 Deodhar D. 42.224
 Depuydt C. 43.206
 Desai A. **16.003**
 Desnica B. 43.081
 Desta K. 43.117
 Deuba K. **42.103**, **42.102**
 Devasia A. 43.004
 Devi R. 41.285
 Devi S. 41.285
 Devi Y. D. 43.004
 Devrajan V. 42.151
 Dewasurendra R. L. 43.039
 Dewi A. P. M. **42.104**
 Dey A. 43.211
 Dey T. K. 41.096
 Dhaka P. **43.252**
 Dhanasekar T. 41.176
 Dhar D. 41.044, 41.086
 Dhar J. 42.165
 Dhar (Chanda) D. 41.071, 41.054, 41.037
 Dhar Chanda D. 41.035
 Dhar(Chanda) D. 41.039
 Dharmaprakash A. **28.006**
 Dharmaraja A. 41.067
 Dharmshale S. N. **42.219**
 Dhawan B. 41.113
 Dhobi G. N. 43.227
 Dhole T. 21.004
 Dhole T. N. 43.116
 Dhole T. N. 43.242, **41.216**
 Dhurat R. 43.093, 43.092, 41.276, 43.023
 Di Bella C. 43.255
 Di Bella S. 43.255
 Di Marco P. 43.255
 Diamant D. **26.001**
 Dias F. C. 43.033
 Didgar F. 43.104
 Didwal G. 41.058
 Diep D. T. N. 41.259
 Dillhari A. 42.229
 Dimitrov K. 43.236
 Dinaker M. 42.115
 Dinc O. 42.138, 41.138
 Dinc O. 43.189
 Dinesha T. R. 42.099, **42.105**, **21.001**, 42.110, 42.135



- Dinleyici E. C. 43.030, 43.031
Dipu T. S. 42.242, 41.240
Diriba G. 43.117
Dissanayake H. 43.190
Dissanayake V. 43.071
Dixit N. **42.106**
Do V. 41.248, 14.004
Do T H H. 41.217, 42.012
Doanh P. V. **42.012, 41.217**
Dobrikov G. 43.134
Doddam S. N. 43.128
Doddamallappa R. 42.083
Dogan N. **43.032, 43.031, 43.030**
Dogruman Al F. 43.030
Dohe V. 41.078
Doke P. **41.282**
Dokubo K. 42.203
Donadi E. **43.033, 42.107**
Donaldson H. 42.010
Döring M. **42.220**
Dorrotoltaj N. 41.190
Douraghi M. **41.042**
Dozie I. N. 43.060
Drakeley C. 41.234, 43.039
Drego L. 41.183
du Cros P. 43.091
Duarte R. **05.004**
Dube S. 41.126, 28.012, 41.128, **41.124**, 41.127, 41.123
Dubot-Peres A. 41.171
Dudeja M. 41.280
Dumitrascu V. 43.061
Dumitrescu G. 41.249, 41.261
Duong V. 42.004
Durairajan S. 41.031, 41.228
Duseja A. 43.072
Dutta A. 41.096, 43.266
Dutta J. B. 41.096
Dutta P. 41.232, 43.186, 41.233, 43.185
Dutta U. 43.233
Duvvuri P. K. **43.154**
Dzikwi A. A. 41.252
D'souza R. 42.111
Eapen C. E. 43.225
Earl A. 21.006
Ebara T. 41.062
Ebrahimi Monfared M. 42.237
Ebrahimzadeh Namvar A. 41.140
Edgar D. 42.154
Edwards M. S. 41.210
Effiong A. 41.191
Egah D. Z. 41.275
Egwari L. O. **41.043**, 42.062, **42.147**
Egwari L. O. 42.141
Eid S. Z. A. 43.173
Eilami O. **42.033**, 41.185
Eira M. D. **43.103**
Ekat M. H. **41.218, 42.186**
Ekstrand M. 42.125
Ekuka G. **42.187**
Ekwunife C. **43.034**, 43.083
El Beeli M. **42.236**
El Marnissi B. **42.148**
El-Ashmawy W. R. **42.221**
El-Gohari A. 43.008
El-Nakeeb M. 41.005
El-Nimair A. 41.102
El-Refai S. 43.008
El-Sayed A. 41.219, 42.257
Elechi I. **42.034**
Eley B. 42.274
Elhaj S. A. O. **42.188**
Elhassan M. O. 42.188
Elizabeth R. **41.044**
Ella K. 41.125, 43.159, 43.158
Ellis S. 35.007
Elrod M. 41.234
Elsaeed M. 42.221
Emikpe B. 43.166
emikpe B. O. 42.265
Enayati A.-A. 41.250
Enayati A. 41.264, 43.243
Endtz H. P. 41.226
Endtz H. P. 28.005
Enegela J. 41.191
Engel M. 42.232
Engwerda C. 43.076
Enkhtur B. 43.270
Enria L. 41.257
Erdenebaatar J. **43.253**
Erdenebaatar J. 43.270
Ergin S. **43.189**
Ermakova L. 43.068, 43.069
Ertabaklar H. 43.046
Ertug S. 43.046
Esen S. 42.167
Eshwara V. 41.089
Esiru J. 42.128
Esna-ashari F. 42.238
Eubank S. 41.190
Everett D. 21.002
Ezati N. 43.109
Ezcurra C. 41.267, 42.150
Ezealor A. 43.249
Ezeigbo O. R. **43.035, 41.116**
Ezeudu C. C. **43.155, 42.108**
Ezeunala M. 43.034, 43.084
Faccini-Martínez A. A. 41.215
Fadina I. 42.062
Fafetine J. 43.254
Fagbo S. **14.006, 42.005**
Fahmy A. 43.157
Fakiola M. 41.255
Falaye A. 42.265
Falk K. 41.242
Falk K. I. 41.222
Falzarano D. 14.009
Faneye A. 42.056
Farak E. **41.219, 42.257**
Farazi A. **42.237, 43.104**
Farias de Souza K. A. 42.201
Farshadzadeh Z. 41.075
Farzana R. **41.045**
Fathima K. 42.218
Fatima A. 43.051
Fatima G. **42.035**
Fatima Z. 43.124
Fawole O. 42.193
Fazeli-Dinan M. 41.250
Feldmann H. 14.009
Feliciano A. 41.139
Feng Y. 42.064
Fernandes A. P. 42.107
Fernandes L. S. C. S. 41.139
Fernando D. 43.071
Fernando L. K. 43.235
Fernando N. 28.008, 42.229
Fernando R. 43.197
Fernando S. **43.197**
Fernando S. M. **43.190**
Fernando S. 41.161, 41.088
Fernandopulle R. 41.012
Feucht J. 42.220
Feuchtinger T. 42.220
Fevre E. 43.246
Findik D. **42.189**
Fischer G. 43.102
Fisher D. 42.159
Flingai S. 41.244
Flores Y. 43.007
Fointama N. 42.059
Folkema A. 41.234
Forsberg B. 41.199
Fortuna C. 42.204
Foto E. **42.149**, 43.066
Fourie P. 43.102
Frago C. 43.162
Fraser T. 41.016
Freeman R. 42.010
French N. 21.002
Freuler C. **41.267, 42.150**
Fujita J. 41.143
Fukuoka E. 41.062
Fukuoka S. 41.062
Fung Deerin J. 42.065
G Habib A. 42.239, 41.268
G Habib Z. 42.239, 41.268
Gachoya J. 43.246
Gade N. 41.220
Gadkare R. 41.276
Gaikwad U. N. **41.220**
Galano G. 41.242
Galappathi-Arachchige H. N. 43.067
Galehdari H. 41.178
Galen K. 41.274
Galinou I. 43.265
Gallagher R. **39.001**
Gallina S. 43.247
Galloway R. 41.234
Gamage R. 43.207
Gandhale P. N. 41.021, 41.019
Gandhi K. A. C. G. **42.109**
Gandra S. 41.085
Ganesan A. 41.230
Ganesh V. 41.224
Ganguli G. **43.105**
Ganguly E. 41.227
Ganguly N. **09.001**
Ganguly N. 43.218
Gans J. 41.262
Gant V. **17.003**
Ganta K. K. 43.209
Gao L. 42.052
Garbati M. 14.006
Garbati M. 42.005
Garcia Allende N. 42.150, 41.267
Garcia Posadas M. 42.150, 41.267
Garcia-Roca R. 41.274
Gardiner S. 42.274
Gardiner S. 41.108
Garg A. 43.147
Garg I. B. 43.011
Garg S. 42.011
Garg S. 41.227
Garin B. 41.144
Garrett D. **38.001**
Gasmelseed N. 42.065
Gassama Sow A. 42.065
Gaur D. **43.156**
Gautam N. 41.073
Gautam V. 41.118, 41.058
Gauthami S. 43.159
Gawai S. 42.268
Gayathri K. 42.225
Gebely M. 42.221
Gedezha M. P. 43.230
Geetharani R. **42.037, 42.036**
Gelband H. **09.006**
Gent M. 43.013
George S. **43.191**
Gerald F. 43.101
Geravandi S. 42.055, 42.243, 42.246
Gerilovych A. 43.236, **41.046**
Getahun M. 43.117
Ghafur A. 42.151
Ghanghro A. **42.038**
Ghanghro A. A. **43.192**
Gharat M. 43.096
Ghatak S. 43.266
Ghatak S. 43.147
Ghatak S. 41.096
Ghate S. 43.023, 43.092, 41.276, 43.093
Ghimire S. 42.076
Ghobashy H. 41.219
Gholami A. **41.140**
Gholipour A. 41.178
Ghomeishi A. 42.055, 42.243, 42.246
Ghomeishi N. **41.108**
Ghosh A. **42.258**
Ghosh C. 43.218
Ghosh M. 41.095
Ghosh N. 41.172
Ghosh P. 42.126
Ghoshal U. 41.163
Gill M. S. 42.015
Gill R. 43.040, 43.025, **43.036**
Gill S. S. 43.036, 43.025, 43.040
Gimkala A. **42.039**
Gituku J. 42.172
Giusti M. 43.247
Gjermani N. 41.213
Gnana Soundari P. 41.066
Gobena T. 42.169
Gode S. 43.189
Godwana L. 43.161



Authors Index

- Goel A. K. 43.171, 43.170, **41.172**
 Goel A. 43.225
 Goel N. 41.266, 41.109
 Gohar A. M. I. H. **43.157**
 Gohar A. **42.040**
 Gohel S. Y. **42.151**
 Gokhale R. 43.132
 Gokhale S. 42.222
 Göksoy E. 41.136
 Gomathi S. 42.117, 21.001, 42.105, 42.135, **42.110**
 Gomes L. 43.190, 43.196
 Gomez L. 43.197
 Gommers D. 42.170
 Gone V. 43.208
 Gonullu N. 41.063, 41.064
 Gonzalez S. 43.090
 Gopalakrishnan R. **26.004**, 42.223
 Gopalakrishnan R. 41.031, 41.228, 41.164
 Gopalan B. P. 42.132, **42.111**
 Gopalkrishna V. 43.205
 Gopatza G. 43.224
 Gopi M. 43.220
 Gopi R. 42.001
 Goraichuk I. 43.236
 Görisch G. 42.152
 Gosain M. 42.157
 Goudarzi G. 42.055
 Gour R. 42.015
 Gouthami P. 41.230
 Govender I. **42.112**, **42.113**
 Goyal M. 43.144
 Goyal V. **35.007**
 Gradoni L. 42.204
 Gradus M. 43.102
 Graham T. 41.108
 Graue-Hernandez E. 42.266
 Graue-Wiechers E. 42.266
 Greenwood B. 41.257
 Griesel R. 42.232
 Grover M. **41.221**
 Grünewald T. **42.152**, 43.009
 Gryadunov D. 41.015
 Guddattu V. 42.077
 Gudo E. S. **41.222**, **43.254**
 Guercio A. **43.255**, **42.190**
 Guillemot D. 41.144
 Guimarães E. 42.184
 Guimarrães E. 43.027
 Gülay Z. 41.048
 Gültekin M. 41.048
 Gunaratne P. 43.207
 Gunardi H. 42.075
 Gunasekara C. 42.229
 Gunasekaran P. **43.193**
 Gunasekera C. 28.008
 Gunasena S. 43.175, 14.003
 Gunathilake M. 41.088, 41.161
 Gunawan C. **42.114**
 Günaydin M. 41.063, 41.136
 Gunewardena S. 43.039
 Guo M.-L. **43.106**
 Gupta A. 41.056
 Gupta A. K. **41.141**
 Gupta A. 41.033
 Gupta A. 43.201
 Gupta B. 43.263
 Gupta D. 42.234
 Gupta M. 41.058
 Gupta M. **41.047**
 Gupta M. 41.282
 Gupta N. 43.168
 Gupta P. **41.223**
 Gupta P. 42.140
 Gupta P. 41.272
 Gupta P. 41.256
 Gupta R. **21.005**
 Gupta S. 42.198
 Gupta S. **35.002**
 Gupta U. **41.018**
 Gupta V. **41.173**
 Guraza A. **42.041**
 Gürlér N. 41.048
 Gursoy S. 43.042
 Ha M. T. 14.004
 Ha D.Q. 41.259
 Ha T. 41.248
 Ha T N. 41.217
 Habeebullah S. 43.178
 Haberling D. 41.234
 Habibi A. 43.054
 Habip Z. 42.118, 43.199, 42.138
 Habtemichael A. K. 42.078
 Haddad Z. **14.002**
 Hadibasha N. 42.001
 Hadis G. 42.121
 Hadj ali L. 42.250
 Haghhkhan M. **41.142**
 Haghsheenas M. R. 43.243
 Haile K. 42.078
 Hajjeh R. **25.004**, **18.002**
 Hakawi A. M. 42.005, 14.006
 Halasa Y. 41.195
 Hallur V. 41.073
 Hamal D. 42.222
 Hameed S. 43.124
 Hamid Hashemi S. 43.269
 Han D. 43.184
 Handa D. 43.072
 Handgretinger R. 42.220
 Hang V.T.T. 41.259
 Hannah L. E. 21.011
 Hansdak S. G. 43.114
 Haranaga S. 41.143
 Harish B. 42.003, 41.106
 Harish B. 41.082
 Harish B. 41.188
 Harley D. **07.002**
 Harris J. 42.154
 Hartojo H. 43.037
 Harxhi A. 43.188, 41.213
 Hasan B. 41.045
 Hasçelik G. **41.048**
 Hashemi N. 42.238
 Hashemi S. H. 42.121
 Hashemi S. H. **41.049**, **42.238**
 Hashim E. 43.155
 Hatch A. 41.262
 Hayden T. A. **42.009**
 HB V. K. 42.218
 Hegde N. R. 42.074, 43.159, 42.066
 Hegde P. 43.099
 Heinz W. J. 42.220
 Helm C. 43.102
 Hemalatha J. **42.153**, 42.168
 Heng S. 41.036
 Herbretreau V. 35.003
 Herindrainy P. 41.144
 Hernandez B. 41.112
 Hernandez C. 42.269
 Herrera-Guibert D. 14.002
 Herrera-Sepúlveda M.-T. 43.028
 Heslop O. 42.228
 Heyderman R. 21.002
 Heylen E. 42.125
 Hidalgo M. 41.215
 Higgins P. 43.137
 Hinjoy S. 42.081
 Hirai J. **41.143**
 Hirani N. N. **43.107**
 Hisham M. **41.224**
 Hladish T. **03.003**
 Ho A. **21.002**
 Ho H. J. A. **42.042**
 Ho V. 41.248, 14.004
 Hoang V. 41.248
 Hoang V. M. T. **14.004**
 Hoang N.T. 42.012
 Hofland I. 41.160
 Holden D. W. 41.160
 Holmes A. H. 41.112, **42.010**, **31.004**
 Honavar S. 43.264, 43.133
 Hong J. 43.111
 Hoosen A. A. **41.050**
 Hoseinzadeh M. 41.185
 Hossain M. S. 41.225
 Hosuru subramanya S. **42.222**
 Hottie G. 42.203
 Hou Y. 42.159
 Houadthongkham S. **42.191**
 Hoxha H. 43.066
 Hsu M.-H. 41.175
 Hu S. 42.052
 Hu Y. **41.051**
 Hu Y. 43.111
 Hu Y. 43.150
 Huang T. 42.216
 Huang W. 43.184
 Huang W. 43.184
 Huff A. G. **42.192**
 Huhtala H. 42.059
 Huidrom S. 41.096
 Hung N. T. 42.202
 Hussain A. 43.001
 Huynh B.-T. **41.144**
 Hwang J. K. 42.171
 Ibrahim M. J. 42.130
 Ibrahim M. 43.148
 Ibrahim M. S. 43.149
 Idampitiya D. 14.003
 Ifabiyi O. 42.034
 Igbinosa E. 41.053, **41.052**, **42.043**
 Igbinosa I. 41.052, **41.053**
 Ignatius A. P. **41.003**
 Ihantamalala F. A. **35.003**
 Ike C. G. **42.044**
 Ikeh I. 43.057
 Ilesanmi O. S. **42.193**
 Iliyasu G. **41.268**, **42.239**
 Illapperuma C. 41.174
 Im J. 42.065
 Imamura A. 41.148
 Imnadze P. **42.194**
 Inamdar L. **43.013**
 Indra M. R. 43.037
 Ingham R. 43.013
 Inglis T. 41.214
 Ingiti B. **41.054**
 Ionescu L. 41.261
 Iqbal S. 42.117, 42.131
 Irawan Satari H. 42.075
 Irura Z. 41.251
 Isaac C. 41.010
 Ishii Y. **04.002**
 Iskandar A. **43.037**
 Islak Mutcali S. 42.138
 Islam K. 41.209
 Islam M. B. 41.226
 Islam M. B. 28.005
 Islam S. **41.225**
 Islam Z. **41.226**, **28.005**
 Isloor S. I. 42.066, 14.001
 Ismail F. 42.032
 Ismail N. **43.012**
 Issack M. **41.055**, **43.002**
 Ita O. I. **41.275**
 Iwata K. 41.159
 Iweala E. 43.108
 Iyanda-Joel W. O. **43.108**
 Iyyadurai R. 43.114
 Jabbariasl M. 43.104
 Jabeen F. 43.200
 Jackson A. **16.004**, **43.194**
 Jacob P. **42.195**
 Jacobs B. C. 41.226
 Jacobs J. 41.181, 41.087
 Jadhav S. 43.001
 Jafari-Jozani R. 43.164
 Jafer C.P. 41.110
 Jagan O.A. 43.191, **43.220**
 Jagannati M. 41.149
 Jagtap S. 41.282
 Jahan I. 28.005, 41.226
 Jain D. P. **43.195**
 Jain S. 42.157, **41.056**, **41.057**, **42.154**
 Jalan N. 21.005
 Jamir T. **42.046**
 Jammy G. R. **42.115**, **41.227**
 Jamshidi Makiani M. **42.047**
 Janapatla R. P. **41.175**
 Jangala M. 42.261
 Janssen H. 41.160
 Jarikre T. 43.166
 Jarju S. 41.008
 Jary H. 21.002
 Jasemi S. 41.042
 Jasmine S. 41.149, 43.114
 Javadekar T. 42.054
 Jayakumar E. **21.007**, **41.176**



Authors Index

- Jayaprasad R. 41.240
 Jayaprakash N.S. 43.220
 Jayaraman Y. **42.196**
 Jayarathne M. C. K. 43.197
 Jayaratne H. E. **43.196**
 Jayasinghe S. 42.259
 Jayasundara P. **42.259**
 Jayasundara V. K. **41.009**
 Jayaweera J. A. A. S. 43.244
 Jeewandara C. K. 43.190
 Jeewandara K. C. 43.197
 Jehan F. 43.180, 43.165, 43.181, 41.117
 Jelitta J. 41.240
 Jenardhanan P. 42.003
 Jennings G. 42.191
 Jeong S. K. 41.278
 Jes S. 43.191
 Jessani L. G. **41.228, 42.223**
 Jesuraj A. 43.131, 21.011
 Jeyakumar D. 42.217
 Jeyaseelan V. 42.278, 42.270, 42.277
 Jha N. 41.115
 jha P. 42.262
 Jhamb S. S. 42.015
 Jiang J. 41.233
 Jiang W. 43.151, 43.150
 Jiang W. 42.091
 Jiloris F. D. 43.012
 Jimoh O. **43.109**
 Jindal H. **41.285**
 Jindal S. 43.225
 John M. 42.224
 John T. J. 43.172, **18.001**
 Johnson C. 21.011
 Jokar A. 42.237
 Jokhio P. 43.192
 Jonnalagadda S. 43.146
 Joshi D. 42.207
 Joshi J. 43.168
 Joshi N. 35.002
 Joshi S. 42.071
 Joshi S. R. 28.007
 Joy V. M. **41.058**
 Junaid K. 42.086
 Jyothy A. 41.069
 K Goyal R. 41.176
 K Sundararaj B. 43.131, **21.011**
 Kaba M. **41.059**, 41.156
 Kabii J. 35.006, 43.015
 Kabir F. 43.165
 Kabra S. 43.198
 Kabra S. K. 41.057, 42.070
 Kabra S. K. 43.135
 Kadam D. 42.071
 Kadhiravan T. **43.110**
 Kafkova J. **34.003**
 Kagal A. 42.071, 41.033, 42.219
 Kailapuri Gangadharan M. 42.101
 Kaiser L. 41.259
 Kaja M. K. 41.201
 Kakati S. 41.232
 Kakhki R. K. 41.077
 Kakkar M. 41.216
 Kakoty K. 43.266
 Kakoty K. 43.147
 Kakru D. 42.026
 Kalal B. S. **41.229**
 Kalandadze I. 41.193
 Kalayci F. 41.064
 Kalrao V. 42.109
 Kalwaje Eshwara V. 41.254, **41.060**, 42.276
 Kamaei S. 42.246
 Kamaladasa A. 43.196
 Kamaraj R. 42.082
 Kamarulzaman A. **06.003**
 Kamath A. 42.276
 Kamau C. 42.181
 Kamau R. 41.107, 42.172
 Kamau V. 42.172, 41.107
 Kammouni W. 43.194
 Kamwiziku G. **41.145**
 Kanade S. 41.033
 Kanagasabai S. **41.230**
 Kandaswamy S. **43.158, 41.125**
 Kandeel A. 43.008
 Kang G. **18.004, 24.003**, 42.050
 Kang'ethe E. 43.246
 Kannadka C. 14.005
 Kannangai R. 42.122
 Kanne P. **41.146**
 Kant K. 43.017
 Kant R. **41.231**
 Kant S. 43.116
 Kant V. 41.020
 Kantor R. 42.105
 Kanu A. M. **42.048**
 Kapadia K. 41.111
 Kapil A. 41.113, 41.057, 42.123, 42.234, 41.122
 Kapil G. 42.083
 Kapinga J. V. **42.197**
 Kappes M. 14.005
 Kar M. **43.198**
 Kar S. 41.152
 Kar Mahapatra D. **41.120**
 Karak A. **43.038**
 Karak K. 41.095
 Karakullukcu A. 43.199, 41.138, 43.063
 Karam A. 43.147
 Karam G. H. **19.004**
 Kareko D. 42.085
 Karim A. 43.079
 Karim-Mohammed A. 42.139
 Kariuki E. 35.006, 43.015
 Karki P. 41.115
 Kart Yasar K. 43.042
 Karthick R. 42.122
 Karunakaran A. 43.225
 Karunaweera N. D. 43.085
 Karunaweera N. **43.039**, 43.071, 41.012
 Kashyap B. **42.198**
 Kashyap S. 21.004
 Kassem M. 41.005
 Katari S. **41.269, 41.270**
 Kathirvel S. 42.213
 Katiyar M. **42.116**
 Katoch M. 42.200
 Katoch M. D. K. 43.142
 Katoch V. **42.049**
 Katoch V. M. 42.200, 43.142
 Kattel H. 41.092, 42.076
 Kattiparambil Gangadharan S. 43.225
 Katzenstein D. 42.105
 Kaur H. 41.073
 Kaur I. 41.090
 Kaur S. **42.155**
 Kausalya B. **42.117**
 Kaushik G. 41.066
 Kaushik M. **43.040**, 43.036
 Kaushik Y. 43.154
 Kayla L. 42.082
 Kazi M. H. 28.010, 28.003
 Kebbeh N. 41.008
 Kebede A. 43.117
 Kebede Z. Z. 42.078
 Kechia Agem F. 43.053
 Keddy K. H. 42.065, 42.274
 Keesari R. R. 43.259
 Kerai S. 43.181, **41.117**, 43.180
 Kerkering T. M. 41.091
 Kerléguer A. 41.036
 Kermorvant E. 41.144
 Keshri V. R. 42.208
 Keskin M. 43.189
 Khajuria A. 43.211
 Khakifirouz S. 43.243
 Khalid M. M. 28.005
 Khalili R. S. 42.033
 Khalilidehkordi B. **43.041**
 Kham C. 41.087
 Khamphaphongphane B. 42.191
 Khamraev A. 43.091
 Khan I. 42.262
 Khan I. D. **41.265**
 Khan I. A. 43.145, 43.094
 Khan M. 42.013
 Khan S. A. 41.207, **41.233**, 43.185, 43.186, 42.145, **41.232**
 Khanal B. **41.061**
 Khanh T. H. 42.202
 Khanna S. **41.109**
 Khanra D. 42.126
 Khare V. 41.056
 Kharod G. **41.234**
 Khasnobis P. 42.205, 43.203
 Khatoon J. 41.163
 Kheiri S. 43.243, 41.264
 Khillan V. **42.199**
 Khogali H. 43.047
 Khogali S. 43.047
 Khonga M. 42.274
 Khryiem A. B. 28.007
 Khubbar M. 43.102
 Khunger S. 43.072
 Khurana J. 43.202
 Khurana S. 43.048
 Khurtsbaatar O. 43.253
 Kiberenge F. 41.107, 42.172
 Kilinc Y. 43.179
 Kim J. J. 14.009
 Kim J. J. 41.244
 Kim P. 14.009
 Kimotho J. 43.221
 Kimura S. I. **41.062**
 Kinjo T. 41.143
 Kiptai T. 42.181
 Kiraz N. 41.064, 41.136
 Kiraz N. 41.063, 43.136
 Kirdar S. 43.179
 Kirkoyun Uysal H. 42.138, 41.138
 Kirkoyun Uysal H. 43.063, **43.042, 43.256**
 Kirpinar M. M. 42.118
 Kirtanov Y. 43.068
 Kiruthiga A. 41.084
 Kishor Sharan N. 42.222
 Kitazawa T. **41.147**
 Kjetland E. F. 43.067
 Klein E. 41.085
 Klein K. 42.012
 Klinker K. 28.004
 Kobayashi K.-I. **41.148**
 Kobela M. 42.059
 Kobinger G. 14.009
 Kocazeybek B. 41.136
 Kocazeybek B. 43.136, 41.138, 43.063, **42.118**, 42.138, **43.199**
 Kocazeybek B. S. 43.189
 Kocazeybek E. 42.118
 Kochhar R. 43.233
 Kocman N. U. 43.030, 43.031
 Kodyalamoole N. K. 42.097
 Koek A. 41.101
 Koga I. 41.147
 Kogilla J. 42.151
 Kohli N. 42.024
 Koirala A. K. 43.003
 Koirala J. **27.002**, 42.076
 Koki Ndombo P. 42.059
 Kokici M. 41.213
 Koksak Cakirlar F. **41.064, 41.065, 41.063**
 Kolesnichenko S. 41.119
 Kombade S. 41.220
 Kompithra R. Z. 43.172
 Konstantynovska O. 41.046
 Konuru V. 42.028
 Koopmans M. P. G. 41.219, 42.257
 Koralla R. M. 42.261
 Koralur M. **41.235**
 Kosan E. 42.138
 Kosan E. 43.199
 Koshy J. M. **42.224**
 Koshy M. **41.149**
 Kotabagi S. 41.201
 Kothalawala S. 43.244
 Kotwal A. 41.221
 Koul A. N. 43.227, **43.257**
 Koul P. A. **43.200**
 Koul P. 42.026
 Kouotou E. A. 43.053, 42.058, 43.052
 Koutlakis-Barron I. 42.009



Authors Index

- Koyuncu E. 41.065
Kraja D. 41.213
Kraynyak K. 14.009
Krcmery V. **34.004**
Krishna M. 43.114
Krishna V. **42.240**
Krishnamurthy K. 43.1283
Krishnan A. 42.157
Krishnan P. 41.017, 41.007, **41.066**
Krishnani N. 41.163
Krishnappa L. 43.127
Krishnaswamy B. 41.017
Krishnaswamy K. 43.193
Krivorotova E. 43.069
Ku G. M. 43.160
Kubanov A. 41.015
Kucherenko I. 41.162
Küçük Y. 41.136
Kuli G. 43.066, 42.149
Kulkarni A. **41.067**
Kulkarni D. D. 41.019, 41.021
Kulkarni S. R. **41.150**
Kulkarni V. 41.033
Kumar A. 41.206
Kumar A. 42.143
Kumar A. 41.223
Kumar A. 42.205, 42.046, 43.203
Kumar A. **43.202, 43.201**
Kumar A. 41.216, 43.252
Kumar A. 41.019
Kumar A. **42.200**
Kumar C. G. **42.050**
Kumar D. N. 41.080
Kumar D. N. **42.002**
Kumar D. 35.001
Kumar D. **43.159**
Kumar D. 42.053
Kumar D. 41.013, **43.043**
Kumar H. 41.019, 41.021
Kumar M. 42.226
Kumar M. 43.252
Kumar M. **43.044**
Kumar M. 43.171, 41.172, 43.170
Kumar M. 21.004
Kumar M. 43.116
Kumar M. **41.126, 41.124**
Kumar M. 41.160
Kumar M. 14.010
Kumar P. 43.142
Kumar P. 42.208
Kumar P. **41.277**
Kumar P. **42.271**
Kumar R. 41.128
Kumar R. 35.010, 43.076
Kumar R. **02.004**
Kumar R. **43.045, 42.156**
Kumar S. 43.011
Kumar S. 41.254
Kumar S. 43.211
Kumar S. 42.011
Kumar S. **42.157**
Kumar S. 43.193
Kumar S. **43.011**
Kumar T. **43.203**
Kumar V. 41.113
Kumar V. V. **42.158, 43.204**
Kumar A.K. H. 42.111
Kumar Das S. 42.035
Kumar Kabra S. 21.003
Kumarasamy N. 42.099, 42.105, **32.004, 42.117**
Kumari J. **41.068**
Kumari V. H. B. **42.241**
Kummannoor Parameswaran Pillai V. 43.245
Kunnavil R. 43.127
Kurai H. 41.148
Kurkcuoglu M. 43.032
Kurokawa M. 41.180
Kurt Ö. 43.063
Kurtis J. 43.167, 43.070
Kushwaha R. A. S. 43.116
Kushwaha S. 21.005
Kuskucu M. 42.138
Kuye A. 42.147
Kuzin I. **42.119, 42.051**
Kwagga J. 42.086
Kwatra G. 42.032
Kweza P. F. **21.008**
Kyambadde P. **43.014**
Kyobe Bosa H. **41.236**
Laal S. 41.184
Labib M. 43.008
Ladipo T. O. 42.139
Lafond K. 42.157
Lagerqvist N. 41.242
Lai C.-L. **08.001**
Lakhey M. 41.072
Lakshmi D. 43.142
Lakshmi V. **41.151**
Lal G. **42.260**
Lal S. B. 41.014
Lalwani S. 42.109
Lam H. **43.160**
Lama R. 42.076
Lamba B. S. 41.272
Lan Y. 42.052
Landstedt Nilsson K. 41.114
Lang P. 42.220
Langa J. 42.184
Langa J. P. 42.184
Laot T. 43.162
Larson H. J. 41.257
Laserson K. F. 43.203
Laskar B. 41.233
Lassas K. 42.250
Lasure N. **43.205**
Lavrinenko A. 41.119
Laxminarayan R. 41.085, **09.007**
Le N. 41.248, 14.004
Le N. 41.248
Le T. 14.004, 41.248
Lebelo R. L. **43.206**
Leblebicioglu H. 42.167, **34.002**
Lee J. **41.278**
Lee M.-S. 42.202
Lee S. 41.171
LeenaSankari S. 42.225
Lees S. 41.257
Leigh B. 41.257
Leinsoo A. **41.015**
Leisha N. 42.012
Leite J. 42.185
Lekha S. 41.176
Leng L. 41.087
Leo Y. S. **25.003**
Leonardi-Bee J. 42.087
Lewis B. 41.190
Lewis M. 42.144
Li D. 41.051
Li X. 42.215, 42.214
Li Y. 43.111
Liang S. 43.006
Liao W.-T. 41.175
Liashenko O. 41.046
Lien J.-C. 42.212
Lien L. B. 42.202
Lim K. 41.087
Lima M. A. 42.053, 35.001, 35.008
Lima N. 35.007
Limmathurotsakul D. **20.002**
Lin R. 42.159
Lin S.-C. 14.005
Linde G. B. 41.101
Lindner M. 43.009
Liu L. 42.216
Liu X. **43.006**
Liu Y. 42.214, 42.215
Liu Z. 42.030
Ljungman P. **30.004**
Loa R. F. **43.112**
Lodha R. 43.198
Lodha R. 43.239, 21.003
Lohitharajah J. **43.207**
Lokhande G. 42.205
Lombardo D. 43.247
Long L. 43.184, **42.052**
Lopardo H. 42.269
López C. A. 41.215
Lopez D. 14.011
Lopez E. G. **43.113**
López-Martínez B. 43.007
López-Vidal Y. 42.266
Lotfi Z. 41.142
Lu H. 43.141
Lu Q. 42.216
Lu Q. 43.125
Lu W. 42.091
Lubis C. P. 41.237
Lubis I. N. D. **41.237**
Lubis M. 41.237
Lucey D. **10.004**
Luchs A. **42.201**
Luckie T. 42.009
Luke N. 41.161, 41.088
Lukito A. 42.171
Luo D. 42.191
Luo K. 42.052
Luo S.-T. **42.202**
Luo Y. 42.215
Luz K. G. **25.004, 25.001**
Ly TTT. 41.217
M Dayyab F. 42.239, 41.268
M Sarki A. 42.239
Macaden R. 41.081
Macholz M. 43.009, 42.152
MacLeod E. 43.246
Macori G. 43.247
Madabhushi A. 41.099
Madala U. 43.159
Madarasingha N. 41.012
Madhavani K. 42.054
Madhavi J. **41.069**
Madhi S. 42.032
Madi D. **42.120**
Madi F. 42.250
Madoff L. 14.002
Madusanka P. 43.190
Magazi B. 21.009
Magdy S. 41.005
Mahabala C. 41.068
Mahabeer P. **42.013**
Mahajan J. K. 41.020
Mahajan R. 35.008, **35.001, 35.007, 42.053**
Mahalakshmi K. **42.225**
Mahalingam J. 43.193
Mahanama A. 43.175
Mahindroo J. **41.238**
Mahloojirad M. 41.182
Mahmood S. 41.209
Maiga B. **43.010**
Mailankody S. 43.110
Mailu C. **09.003**
Majake L. 43.213
Majeed S. 41.022
Maji S. 42.218
Majlesi A. 41.077
Majzoobi M. M. **42.121**
Makhado N. 21.009
Makvandi M. 41.178
Malaiyan J. 41.017
Malakyan K. 42.053, 35.001
Malathi M. **41.279**
Malatyali E. **43.046**
Malavige G. N. 43.197, 43.196, 43.207, 43.187, **25.002**
Malavige N. 42.259
Malavige N. 43.190
Malhotra R. 41.113
Malhotra S. 41.118
Malihi R. 42.243, 42.055, 42.246
Malik S. 43.252
Malinga L. A. **21.009**
Malladi S. V. S. **43.259**
Malladi S. 42.256
Malladi S. V. S. **43.258, 43.208**
Mallewa J. 21.002
Mallik S. 41.095
Mallikarjuna S. 42.256
Maloba F. 41.083
Maluleka C. 21.009
Mamani M. 42.121
Mamedova N. 43.262
Mamidi N. 41.146, 41.151
Manana P. **42.203**
Manche S. K. **42.261**
Mandal A. 42.210
Mandal A. **43.209**



Authors Index

- Mandal J. 43.024, 43.110, 41.152, 41.082, **41.070**, 43.064
- Mandal P. 43.218, **43.210**
- Manenzhe R. I. 41.059
- Manesh A. **42.122**
- Manhique L. 42.184
- Mani M. 41.258, 43.237, 41.176, 21.007
- Mani S. S. R. **43.114**
- Manisha R. 14.001
- Manjunath N. 42.218
- Manjunathan D. 41.082, **41.152**
- Mankar S. 42.109
- Mannela U. 43.146
- Manohar T. P. **41.153**
- Manoharan A. 42.080
- Manuja L. 42.083
- Maphele A. 43.213
- Marathe A. 41.190
- Marbaniang I. 42.071, 41.033
- Marbaniang M. 43.202
- Mard S. A. 41.178
- Marimuthu K. 41.211
- Marimuthu P. 42.218
- Marimuthu V. K. N. **41.154**
- Marks F. 42.065
- Maroof K. 41.001
- Marquez A. C. 41.215
- Martinez-Martinez L. **04.001**
- Martsynovska V. 42.119
- Marufu O. 42.257
- Maruthi P. 42.083
- Marwah S. 41.040
- Maryem E. **43.115**
- Masakorala J. 41.214
- Masiga D. 35.006, 43.015
- Maslow J. 14.009
- Mathai D. 42.183
- Mathai S. 43.172
- Mathew L. 43.172
- Mathew P. 35.001, 42.053
- Mathur P. 42.003
- Mathur T. 41.124
- Matsoso P. **09.002**
- Matsubara K. 43.215
- Matthews G. **27.003**
- Maupye G. 42.203
- Maurici M. 42.249
- Maurya A. K. **43.116**
- Maurya A. P. **41.071**
- Maurya S. P. **42.123**
- Mave V. 42.071, 41.033
- Mayer K. **32.001, 40.001**
- Mayer Wolf M. 41.267, 42.150
- Mazonakis E. 43.265
- Mbelle N. 42.032, **43.161**
- Mbulaitaye S. 41.234
- McCarthy K. 42.203
- McDermott L. 41.108
- McGuire A. 21.006
- McHugh T. 43.118
- McMahon J. 43.091
- MD Noor S. 42.263
- Meaza A. **43.117**
- Mechtoub F. Z. 42.250
- Mecicovsky D. 43.090
- Medani M. Y. I. **43.260, 43.047**
- Medigeshi G. 43.198
- Medina-Pelcastre M. 43.007
- Medino-Marino A. 21.008
- Medise B. 42.075
- Meftah A. 42.250
- Megha K. **43.048**
- Meghanadh K. R. 41.069
- Mehendale S. 42.036, 42.196, 42.050
- Meher D. 41.272
- Mehraban F. 42.244
- Mehta K. **42.125, 42.124, 42.272**
- Mehtar S. **39.003**
- Meintjes G. **32.003, 06.002**
- Melek S. 43.173
- Melnik V. **41.239**
- Meltzer M. I. 41.193
- Memish Z. **07.001**
- Memon A. A. 42.038
- Mendelson M. **09.002**, 42.232
- Mendes-Júnior C. 42.107
- Menezes J. **43.162**
- Meng J. 43.184
- Mengistie Z. **41.011**
- Menichetti F. **30.002**
- Menon N. 43.251
- Menon T. 42.227, 41.074
- Menon V. 41.240, 42.242
- Menon V. **42.242, 41.240**
- Menon V. C. **10.001**
- Menyere M. 21.002
- Mercante M. T. 42.190
- Mesadieu A. 43.101
- Meta E. 41.213, 43.188
- Metcalf C. J. E. 35.003
- Metcalf K. 43.013
- Mete B. 41.136, 42.138
- Mettananda C. D. 42.067
- Mewara A. 41.223
- Meyer C. G. 42.065
- Mgbajika N. 42.048
- Michael J. S. 43.130, 42.278, 43.122, 42.270, 42.277, 41.157
- Midde V. J. 28.001
- Midha G. 41.154
- Midilli K. 42.138
- Mihai F. 41.249
- Miishra A. **41.019**
- Miller D. 42.144
- Minaeian S. 42.047
- Minemura A. 41.062
- Mini Jacob S. 41.230
- Miño N. 43.090
- Mir H. 42.026, 43.200
- Mira F. 43.255
- Mirdha B. R. 43.017
- Mirtalaei N. 42.237
- Mishra A. 41.021
- Mishra A. **42.262**
- Mishra B. **43.211**
- Mishra B. 41.205
- Mishra B. **43.212**
- Mishra S. 41.092, 42.076
- Mishra S. K. **41.072**
- Misra R. **41.004**
- Mistry N. 41.194
- Mital A. 42.015
- Miththinda N. 41.088, 41.161
- Mitkos M. C. 41.091
- Mitra G. 35.001, 35.008, 42.053
- Mitra S. 41.006
- Mitreva M. **23.001**
- Mittal C. **42.159**
- Mkhencele T. 43.213, 42.203
- Mlisana K. 42.013
- Mobegi D. 42.181
- Modi M. **42.054**
- Modugu N. R. 43.258, 42.256, 43.259
- Moeeni Z. 42.047
- Moga S. 43.117
- Moganeradj K. **43.118**
- Moghaddam G. **43.164**
- Moghimbeigi A. 43.269
- Mogorosi O. 42.264
- Moguieu Bogne L.-L. 42.058, 43.052
- Mohamad M. B. 42.273
- Mohamadi M. 43.041
- Mohamed H. 43.260
- Mohammad Q. D. 41.226
- Mohammadi M. J. **42.243**, 42.246, **42.055**
- Mohammadi Z. 43.248
- Mohammadjafari H. 42.267
- Mohammed Ali K. 41.028
- Mohan B. 41.020
- Mohan B. 41.238
- Mohan B. **41.073**, 41.223
- Mohan S. 42.224
- Mohan T. **41.241**
- Mohan V. 43.252
- Mohan Kumar R. 42.037, 42.036, 42.083
- Mohanam L. **41.074**
- Mohandas S. 42.101
- Mohanraj P. 41.157
- Mohanty P. K. 42.068
- Mohanty S. 41.205
- Mohapatra S. 42.234
- Mohd Nawi S. F. A. **42.263**
- Mohd Nor F. **42.273**
- Mohindra S. 41.163
- Moiane-Cossa I. 42.184
- Moin M. 41.182
- Molalign H. 43.117
- Monaco A. 42.269
- Monje L. 43.250
- Monokuane S. 42.264
- Monroe-Williams T.-D. 42.228
- Montefiori D. C. 42.131
- Monteiro V. 43.254, 41.222
- Montero P. 42.150
- Montgomery J. 42.029
- Moodambail P. 42.100
- Moodley C. 41.059
- Moogahi S. 42.243, 42.246
- Mooney T. 41.257
- Moore L. S. P. 41.112, 42.010
- Moosavi S. A. A. 42.047
- Moosavian M. **41.075, 41.178**
- Moosazadeh M. 43.243
- Mora-Juárez R. 43.007
- Moraru V. 41.261
- Moreira I. 43.103
- Morel A. 43.244
- Morgan D. **31.001**
- Morillo S. 42.201
- Morita K. 42.085
- Morobe I. 41.168
- Morosetti G. **42.204**
- Morreira R. 42.185
- Morrissey C. 41.252
- Moshime M. 43.213
- Moshime M. 42.060
- Moskovaya T. 41.162
- Motayo B. O. **42.056**
- Mothi S. 42.135
- Moudgil A. D. **43.049, 41.076**
- Mounts T. 41.217, 42.012
- Moureaux A. 42.011
- Mourik M. S. V. 43.089
- Mousavi nasab S. N. 41.250
- Mouton J. W. 41.118
- Moyou Somo R. 42.058, 43.052, 43.053
- Mozaffari Nejad A. S. **41.077**
- Mozumder T. 41.045
- Mpambane D. 42.060
- Mpangane H. 42.060
- Mphahlele J. 43.206, 43.230
- Mphahlele M. J. 42.264
- Mphaka M. R. **43.213**
- Msibi T. 42.264
- Mubiru F. 41.236
- Mudaliar P. P. **43.214**
- Mudavath S. L. **43.050**
- Mudey A. 42.146
- Mudshingkar S. S. **41.078**
- Mudunuri A. **43.119**
- Mueni J. 42.181
- Mugabe P. 42.133
- Mugero C. 43.213
- Mugunthan M. **42.226**
- Muianga A. **41.242**, 43.254, 41.222
- Muinde P. 43.246
- Mukahal M. 42.005
- Mukherjee A. **42.126**, 43.038
- Mukherjee A. 21.003
- Mukhopadhyay B. B. 41.095
- Mukhopadhyay B. 41.091
- Mukhopadhyay C. 41.060, 42.276, **20.001**, 41.254, 41.154
- Mukhopadhyay S. L. 42.218
- Mulay K. 43.133
- Muliyil J. **26.002**
- Müller I. 42.220
- Mullick S. 43.210
- Muloi D. 43.246
- Muloongo K. 42.061
- Mulya Karyanti R. 42.075
- Munagala G. 43.145
- Munawwar A. 43.135
- Munemo E. 41.212



Authors Index

- Mungai M. 42.181
Munoz-Price S. **04.003**
Munusamy E. 41.097
Murayama T. **43.215**
Murhekar M. 42.083, 42.036
Murphy C. 43.140
Murray M. 43.087
Mursalin S. M. **41.243**
Murthy N. S. 43.127
Murthy P. S. R. **41.079**
Muruganantham N. 41.244
Murugananthan A. 43.216
Murugananthan K. **43.216**
Muruganathan K. 43.232
Murugavel K. 42.117, 42.099
Murugesan S. 43.193
Musa B. O. 43.109
Musa W. I. **42.057, 43.261**
Musekiwa A. 42.180
Musenge E. 42.079
Musyoki A. **42.264**
Muthiah Kothandaramnujam S. 21.007, 41.176
Muthuirulandi Sethuvel D. P. 42.002, **41.080**
Muthulakshmi K. 41.224
Muthumani K. **41.244**, 43.228, **14.009**
Muthuraman K. R. 43.082
Mutukuloju J. R. **43.120**
Muwonge C. 42.128
Muyembe J. J. 41.145
Muzah B. 42.079
Muzividzi B. 41.212
Muzyka D. 43.236
Mwamburi C. 42.181
Mwamuye M. M. **35.006**, **43.015**
Mwau M. 42.085
Myles P. R. 42.087
Naaraayan S. A. 42.050
Nabarro L. E. B. **43.121**
Naber K. G. **40.002**
Nachega J. B. 43.097
Nag V. L. 43.116
Nagappa A. 41.089
Nagaraj S. 41.103, **41.081**, 41.229
Nagaraja P. 42.106
Nagasundaram N. **41.155**
Nagelkerke N. 43.012
Nagorny S. 43.069
Naguib M. 41.005
Naicker P. **42.274**
Naik M. M. **41.271**
Nair D. 41.057
Nair S. 42.242
Nair S. R. **43.217**
Naish S. **41.245**
Nakamatsu M. 41.143
Nakamura M. 41.062
Nakibaala G. **41.247, 41.246**, **42.160, 42.161**
Nalam K. 14.007
Nam H. 41.274
Nambi S. 41.164
Nambi S. 41.031
Nanayakkara G. N. **42.127**
Nandanwar N. **43.001**
Nanjundaiah N. **43.051**
Nansseu J. R. N. **42.058**, **43.052, 43.053**
Narain J. P. 43.203
Narain R. 42.143
Narayan C. **41.020**
Narayan Raj B. 41.061
Narayanan S. 21.006
Narayanswamy M. 42.066
Nardi P. 42.249
Narendra A. 42.256
Nareddy S. 42.272, 41.270, 41.269, 43.098
Naseri Z. 43.269, 41.049
Nashibi R. 42.246
Nashibi R. 42.233
Nashibi R. 42.243
Natarajan M. 41.152, **41.082**, 41.070
Nateghi Rostami M. **43.054**, **42.244**
Natesan M. 42.069
Nath G. 43.044, 41.160
Nath P. N. 43.022
Naturinda R. **42.128**
Nava S. 43.250
Naveen S. K. **14.005**
Nawarathna K. 43.175
Nayak D. 41.271
Nayak K. 41.201
Nayak M. K. 42.156, **43.218**
Nayak N. 42.222
Nayak P. **42.205**
Nayak S. 42.146
Nayak S. 21.006, 21.010
Nayar S. 43.228
Nazneen H. 42.082
Ncayiyana J. 43.123
Ncha R. 43.213
Nealon J. **42.011**, 42.075, 41.227
Necsulescu M. 41.261
Neefjes J. 41.160
Neeradi C. 43.110
Negi N. S. 43.078
Negi N. 42.123
Negi S. S. 41.220
Nelson G. 41.033
Nematollahi A. 43.164
Nepesov S. 41.138, 43.063
Nerurkar V. **14.010**
Neumann F. 43.009
Neves I. 42.185
Neves L. 43.254
Newman H. 42.154
Newton P. 41.171
Neza B. 43.066, 42.149
Ng L. C. 43.006
Ng M. L. 43.187
Ngari F. 42.181
Nghiem N. 41.248
Nguenha N. M. C. 42.211
Nguku P. 42.193, 41.132, 41.158, 14.008
Nguyen A. T. **41.248**
Nguyen H. 41.248
Nguyen T. H. 14.004
Nguyen T. A. 14.004
Nguyen L. M. H. 42.012, 41.217
Nguyen Q. V. 42.012
Nguyen T. T. H. 42.012, 41.217
Nguyen Van Vinh C. 14.004, 41.248
Nguyen-Van-Tam J. S. 42.087
Nguyet L. A. 41.259
Ngwarai M. R. **41.156**
Nhan L. N. T. 42.202
Nichols G. J. N. 14.005
Nicholson W. 41.234
Nicol M. P. 41.059, **11.002**, 41.156
Nicolescu G. 41.261, **41.249**
Niesley M. 42.144
Nikookar S. H. 43.243, 41.264, **41.250**
Ninan M. M. **43.122, 41.157**
Nisar I. 41.117, 43.180, 43.181
Nisar M. I. **43.165**
Nisha M. **43.055**
Nishimura S. 41.159
Nixon C. 43.070
Niyogi P. 43.218
Njeru I. 42.085
Njoku O. O. **43.219**
Njuma Libwea J. **42.059**
Nnaji R. N. **41.158**
Nohynek H. 42.059
Noordeen F. 43.235, 43.232, 43.231, 43.216, **43.244**
Nop P. 41.036
Noriega F. 43.162
Nour M. 42.257, 41.219
Nourizadeh M. 41.182
Nourti P. 42.059
Nshioygu M. 43.108
Ntshiqha T. **42.060**, 43.213
Ntshoe G. M. 43.213
Ntuli S. 42.274
Nunn A. 43.125
Nwakanma D. C. 41.181
Nwalor C. I. G. **43.056**
Nwaorgu O. C. 43.034
Nwaorgu O. 43.058
Nwoke B. 43.056
Nwoke B. 43.084, 43.083
Nwokoye N. 41.043
Nyakato V. 42.128
Nyamongo Onkoba W. 41.083
Nyang'wa B.-T. 43.091
Nyasulu P. S. **42.061, 43.123**
Nyasulu P. 42.079
Nyirenda M. 21.002
Nylén S. 35.010, 43.076
Nziramasanga P. 41.212
O'Reilly M. 42.191
O'Ryan M. **24.002**
O-Tipo S. 42.085
Oberoi A. 42.224
Obi L. 41.168
Ochiai L. 42.011
Ochieng J. H. 42.166
Ochoa-Pérez S.-A. 43.007
Ochwoto M. **43.221**
Odeniyi D. 43.166
Odey F. 41.275
Odhiambo Ojwang K. 42.178
Odikamnoro O. 43.059
Odikamnoro O. O. **43.057**
Odongo D. 35.006, 43.015
Oduor J. M. O. 41.083
Ofula V. O. **41.251**
Ogacheke D. 43.083
Ogbonna K. 42.112
Ogbuagu C. N. **43.058**, 42.129
Ogbuagu E. N. **42.129**, 43.058
Ogg G. 43.190, 43.196, 43.197
Ogundipe E. T. **42.265**
Ogunfowokan O. 43.060
Oguz I. 43.030
Oh M. L. H. 41.133
Ohji G. **41.159**
Oka H. 41.180
Okafor F. C. 43.059
Oke Y. 42.139
Oke Y. F. **35.004**
Okeke C. 42.130
Okoh F. N. **43.059**
Okonkwo C. H. **43.060**
Okonkwo R. 42.129
Okoro C. 43.084
Okoye I. C. 43.059
Oksuz L. 41.048
Okullu S. Ö. 43.063
Okumoto S. 41.159
Oladele O. 43.166
Oladimeji A. 42.193, 41.158
Oladokun R. 42.274
Olaiya O. 41.191
Olajubu F. A. **42.206**
Olariu T. R. **43.061**
Olasehinde G. I. **41.179**, 42.141, **42.062**
Olayemi L. O. **43.222**
Olayinka A. 43.109, 41.024, 43.088
Oliveira Junior F. I. 43.103
Olorukooba A. A. **42.130**, 43.149, 42.137, 43.148
Olsen J. 14.002
Olubi O. 41.043
Oluchi O. 43.056
Oludele J. 41.222, 41.242
Olufemi O. T. **41.252**
Olufemi Y. O. 41.252
Olurunshola S. 42.147
Omar E. 42.263
Omidu Y. 43.164
Omidifar N. 41.185
Omondi D. 43.015, 35.006
Omoya F. O. **43.062, 42.245**
Onawale P. 41.033
Oncu S. 43.179
Onditi F. I. **41.083, 35.011**
Oner Y. A. 43.042, 43.256, **43.063**
Ongus J. 41.251
Ono D. **41.180**
Onyancha Z. 42.008



Authors Index

- Onyedibe K. I. 41.275
 Onyejebu N. 43.108
 Onyilo J. 42.139
 Oommen J. 41.255
 Oommen S. 43.191
 Oonyu L. 42.128
 Opal S. **30.003, 37.004**
 Orduña P. **42.266**
 Oriero E. C. **41.181**
 Orikiiriza J. T. 41.236
 Ortakoylu G. 43.136
 Oruganti G. 41.227, 42.095, 42.020
 Osigwe U. 41.158
 Osiowy C. 43.221
 Ossai O. 42.021
 Ostreni V. 43.188
 Ostyn B. 41.186
 Oswal J. 42.109
 Ota Y. 41.147
 Ottenhoff T. H. M. 43.131
 Otter J. A. 42.010
 Ouma Arodi W. 41.083
 Oundo J. 41.251
 Owolabi A. 42.206
 Owusu-Edusei Jr. K. 28.002
 Oyebanji V. O. **43.166**
 Oyugi J. 43.221
 Özakin C. 41.048
 Ozer N. 43.136
 Ozturk R. 41.065
 Pachamuthu B. 42.101
 Pachiappan G. 41.230
 Padanilam X. 43.123
 Padda P. **42.063**
 Padget M. 41.144
 Padhi A. **42.014**
 Padmavathy K. **41.084**
 Padukone S. **43.064**
 Padur Sivaraman R. 42.240
 Page N. 42.203
 Pagliuca A. **05.002**
 Pahwa S. 42.117
 Pak G. D. 42.065
 Pal R. **43.124**
 Pal S. 42.136
 Palani G. 43.228
 Pale M. A. 42.211
 Palewar M. 41.078
 Pallikkuth S. 42.117
 Palmu A. 42.059
 Panda N. 41.189
 Panda S. 43.218
 Pandey C. M. 42.024
 Pandey K. 35.007
 Pandey K. 43.045, 42.156
 Pandey P. K. 43.064
 Pandey R. **43.065**
 Pandey S. 41.040
 Pandeya Y. R. **42.207**
 Pandit T. 41.061
 Panduranga Rao P. 43.159
 Pandya M. 41.126, **41.127**
 Paneerselvam N. **42.131**
 Panigrahi P. **23.003**
 Pant G. R. **42.064**
 Pant S. **41.085**
 Panth R. 42.136
 Pantin-Jackwood M. 43.236
 Panzner U. **42.065**
 Paolazzi G. 43.247
 Papanna M. 42.205
 Papineni P. **43.125**
 Parajuli K. 41.092, 42.076
 Parameshwaran N. 41.152
 Parameswaran A. 42.223
 Paranavitane S. A. 43.197
 Parija S. C. 43.082, 43.178, 43.064, 43.044, 42.116
 Parija S. 41.029, 43.024
 Park J. J. 41.278
 Park J. 42.065
 Parra-Ortega I. 43.007
 Parthasarathy K. **43.126**
 Patel A. E. **43.127**
 Patel N. 42.054
 Patel N. 41.234
 Patel S. 42.068
 Patel T. 42.144
 Patil P. 42.140
 Patil S. 41.228
 Patnaik B. N. 28.001, 43.153
 Patnaik B. 42.205
 Paton N. 43.125
 Patra S. 41.273
 Patterson M. 14.005
 Pattnaik S. 42.183
 Paul D. **41.086**, 41.039, 41.044
 Paul M. 21.005
 Paulraj M. 43.193
 Pavia P. 43.028
 Pearson W. 28.002
 Peddireddy V. **43.128**
 Pedna M. F. 42.247
 Peiris H. 43.190
 Peiris J. S. M. 43.244
 Peiris M. 14.006
 Pennober G. 35.003
 Peralam Yegneswaran P. 42.222
 Perçin D. 41.048
 Perera N. 41.026
 Perera S. 42.259
 Pérez-Torres J. 43.028
 Periasamy S. **42.227**
 Perni N. 41.274
 Perniciaro J. 41.234
 Person M. 41.234
 Perumal N. **41.007**
 Peters R. 43.102
 Peto T. **17.004**
 Petrela R. **43.066**, 42.149
 Petrescu C. 43.061
 Pham N. T. 42.012, 41.217
 Pham T. D. 41.217, 42.012
 Phan Q. 14.004, 41.248
 Phe T. **41.087**
 Phengxay M. 42.191
 Phillips P. 43.125
 Phonemixay O. 41.171
 Phua K. K. 41.135
 Phuangpanom E. 41.171
 Phulpoto A. S. 42.038
 Phyo A. P. **12.002**
 Pica F. 42.249
 Piffer C. 42.204
 Pillai N. 41.194
 Pillay P. **43.067**
 Pinto G. 41.222, 43.254
 Pinto G. 41.242
 Piola P. 41.144
 Pipero P. 41.213, 43.188
 Pisudde P. M. **42.208**
 Pitchai N. 43.244
 Pitisuttiithum P. **03.002**
 Plakhova X. 41.015
 Platts-Mills J. **24.004**
 Poddar S. **42.162**
 Poh B. F. 41.211
 Pokharel P. K. **09.004**
 Pokhrel B. M. 42.076, 41.092
 Pol S. 41.253
 Pollack M. 14.002
 Ponce de Leon S. 42.266
 Pond-Torl S. 43.167, 43.070
 Poojary A. **41.111**
 Poonam S. 43.236
 Poongulali S. 42.110, 42.099, 42.117, 42.105, 42.135, 21.001
 Poorolajal J. 42.121
 Popescu D. 41.261
 Porth J. 42.006
 Potdar G. A. **41.253**
 Poteiko P. 41.046
 Pourpak Z. 41.182
 Pourseif M. M. 43.164
 Prabha D. 43.004
 Prabhu K. 42.258
 Prabhu M. 41.271, 42.258
 Pradeep A. 21.001, 42.110
 Pradhan M. 42.205
 Praharaj A. K. 41.205, 43.211
 Prajapati V. K. 43.065
 Prakasam A. 41.099
 Prakasam A. K. **42.001**
 Prakash A. **09.001**
 Prakash Kumar K. 42.083, 42.082
 Pramina K. **42.066**
 Praneeth M. 43.135
 Prasad A. 41.073
 Prasad J. H. 43.114
 Prasad K. 41.163
 Prasad K. K. **41.014**
 Prasad P. 28.009, **41.280**
 Prasad S. 43.096
 Prasad Baral B. 42.222
 Prasad Tenali S. 42.124
 Pratap C. B. **41.160**
 Prathapan S. 43.197
 Praturi U. 43.158
 Praveen S. 41.084
 Prayitno A. 42.075
 Preka P. 43.188
 Premaratna R. **42.067, 41.088, 13.001, 41.161, 35.005**
 Prieto R. 42.150
 Privor-Dumm L. 41.198
 Priya E. **43.129**
 Priya L. 41.074
 Priyadarisini N. 42.025
 Priyendu A. **41.089**
 Project Team K. 43.079
 Protti D. 42.247
 Pshenichnaya N. **43.069, 43.068, 43.223, 41.162, 43.262, 43.224, 41.239**
 Purnanshi R. 21.005
 Punchihewa C. 43.190
 Punitha J. 41.149
 Purandare B. 42.109, 41.282
 Puranik N. 41.172, 43.171, 43.170
 Puranik P. 41.229
 Purcarea-Ciulacu V. 41.249
 Purisa S. 43.256
 Purkait D. 41.096
 Purnapatre K. P. **28.012**
 Puro A. K. 43.266, 41.096
 Puro K. 43.147
 Purohit P. **42.068**
 Purpari G. 42.190, 43.255
 Purty A. **42.069**
 Putra A. E. 42.171
 Pydigummala J. 43.158
 Qamar F. **11.004**
 Qasimov V. 42.194
 Qato M. 43.188, 41.213
 Qiu L. 42.091
 Qoran I. 43.032
 Queudeville M. 42.220
 Quilici M. L. 41.145
 Qureshi S. 43.165, 43.180
 Rabi Das V. N. 35.007
 Rabini M. 43.247
 Radhakrishnan K. **43.225**
 Radosta M. 42.150, 41.267
 Radotra B. 41.022
 Rafiei A. **42.267, 43.226**
 Raghav P. 42.200
 Raghavendran A. 43.225
 Raghavendhar S. **42.070**
 Raghupathy P. 43.172
 Ragoori V. R. 42.242
 Rahbar M. 41.042
 Rahimi R. 42.263
 Rahman F. 43.022
 Rahoilijaona B. 35.003
 Rahul D. 41.188
 Rai A. 41.001
 Rai M. 43.050, 41.186
 Rai R. P. **41.163**
 Rai S. **41.090**
 Raichur P. A. 41.033, **42.071**
 Raisuddin S. 41.280
 Raj D. K. **43.167, 43.070**
 Rajagopal K. 41.271
 Rajala M. 42.260
 Rajan S. 42.084
 Rajaram D. 43.127
 Rajarethinam J. 43.006
 Rajashree K. 42.082
 Rajendra A. **43.130**
 Rajesh J. 42.020
 Rajkumari N. 43.064
 Rajnala N. 42.111
 Rajnala N. **42.132**
 Raju K. 41.129



Authors Index

- Raju S. 42.256
Rakgants A. 42.203
Rakgole J. N. 43.230
Rakhmanova N. A. 41.239, **41.197**
Rakotomanana F. 35.003
Rakotondramanga J. M. 35.003
Rakshit S. 21.006, **43.131**
Ralan T. H. 41.217
Ram J. 43.202
Ram S. 42.143
Ramachandra R. 41.029
Ramachandran D. 42.069
Ramachandran V. 41.001
Ramachandran V. 42.101
Ramaiah A. **21.006**
Ramakrishnan K. **41.121**
Ramamurthy S. 41.184
Ramapuram J. 42.120
Ramasamy V. 43.154
Ramasubramanian S. 41.176
Ramasubramanian V. 41.164, **37.002**, 41.031
Rambabu A. **42.072**
Ramesh R. **43.132**
Ramesh V. 43.078, **33.003**
Rampal S. 43.012
Ramrao B. 42.083
Rana K. 42.213
Rana S. 42.156
Ranaware P. B. 41.021, 41.019
Rangaiahgari A. 43.264, 42.275, 43.133
Rani C. 43.145
Ranjan A. 43.001, **42.073**
Rao J. **41.091**
Rao M. 41.127, 41.126
Rao P. P. **42.074**
Rao P. V. **41.164**
Rao R. 41.270
Rao S. 41.103
Rao S. N. 42.124, 42.272
Rashid M. 41.129
Rastogi D. N. 43.142
Rastogi S. 28.009, 41.277, 41.280
Ratala D. **43.263**
Rath G. 42.234
Rather A. B. **43.227**
Rathnamma D. 14.001, 42.066
Ratho R. K. 43.229, 43.202, 43.201
Rathor N. 42.199
Ratnamani M. 41.270
Ratnayake P. 43.207
Raut A. A. 41.019, **41.021**
Ravikumar M. 42.083
Rawool D. B. 43.252
Rawson T. M. **41.112**
Ray P. 41.118, 41.058
Ray P. 42.070, 43.239, 43.238
Raymond R. K. C. 41.133
Read J. 42.157
Reddy A. K. **43.133**, **43.264**, 42.275
Reddy D. S. 43.132
Reddy D. Y. V. 43.051
Reddy K. Y. 43.145
Reddy P. S. 42.115
Reddy S. 43.259
Reddy V. 42.074
Rees H. **40.003**
Refai W. **41.012**
Rego S. 41.229
Reijtman V. 43.090
Reju S. 41.258
Reuland E. A. 41.101
Reuschel E. L. 14.009
Reusken C. B. E. M. 42.257, 41.219
Revathi G. **09.003**
Reyes-López A. 43.007
Reynolds G. **42.228**
Rezeki Hadinegoro S. **42.075**
Richards A. 41.233
Riele H. T. 41.160
Rijal B. P. **42.076**, **41.092**
Rijal S. 35.007
Rikhi N. 43.101
Rishikesh K. 42.077
Rispel L. C. 42.180
Ritmeijer K. 35.008
Rivera A. 43.160
Roald B. 43.067
Robinson M. 41.033, 42.071
Rodrigues C. **19.001**, 43.142, 41.183, **11.001**
Rodrigues M. D. L. 42.107
Rodriguez J. 43.102
Rodríguez V. 41.267, 42.150
Rogier C. 35.003
Rogliani P. 42.249
Rogozhin A. 41.046
Rohra S. 41.111
Rojas P. 42.266
Ronnachit A. 43.091
Roointan A. 41.077
Rosa Vieira H. 42.201
Rosanova M. T. 43.090, 42.269
Rose W. 42.278
Rossi C. 41.251
Rostami S. 41.075
Rosy R. C. **41.093**
Roy S. 41.044
Roy S. **41.002**
Rudramurthy S. 41.189
Rula O. 43.236
Runina A. 41.015
Rupali P. 41.157, 43.122, 43.121, 43.130
Ruseva V. V. **43.134**
Ryan A. 42.274
Ryndak M. 41.184
Ryoo S. 41.203
Sa'idu L. 42.057, 43.261
Sabanathan S. 14.004
Sabnis K. 43.130
Sacks D. 35.010, 43.076
Sadanand L. N. R. 42.275
Sadanari H. 43.215
Safaar M. J. 43.226
Saglam H. 42.118
Saha B. 41.095
Saha S. K. **18.003**
Saha T. 28.003, 28.010
Sahai P. 41.060
Sahastrabuddhe S. **38.002**
Sahni R. D. 43.004
Sahoo G. C. 43.045, 42.156
Sahoo P. N. 43.131
Sahr F. 41.236
Sahraei-Rostami F. 41.264
Sahu G. P. 42.165
Sahu S. J. 43.211
Said M. 43.008
Said M. 42.032
Saide M. **09.005**
Saifykhan M. 41.008
Saigal S. R. 43.011
Saighi K. 42.250
Saizu D. 41.249
Sakia U. N. 43.201
Sakthioli M. 41.283
Salami A. 43.166
Sale F. 41.158
Salencia J. J. **42.211**
Salihu M. 35.004
Salmanzadeh S. 42.243, **42.246**, 42.055
Salotra P. 43.078
Samanta B. 43.038
Samaranayake N. **43.071**
Samaranayake T. N. 43.085
Samarasinghe K. 28.008
Sambo J. 42.184
Sambo N. 43.148
Sambri V. **42.247**
Samir S. 42.082
Samo Gudo E. 41.242
Samoei Z. 42.181
Sampath A. **42.229**
Samuel L. 42.135
Samuel R. 42.195
Samuelli M. 42.247
Samutondo C. 42.031
Sancak B. 41.048
Sanchez A. V. 41.267, 42.150
Sandhu R. **42.248**
Sandric I. 41.249
Sang R. 41.251
Sangare A. 43.052, 42.058
Sanjeeva G. 42.125
Sanjukta R. **41.096**, 43.266
Sanjukta R. 43.147
Sankar M. 43.142, 43.079, **43.135**
Sankar R. 41.067
Sankaranarayan S. 42.240
Santiago R. 42.266
Santos A. 42.005
Santoshi M. 41.069
Sapkota S. 41.046
Sapkota G. P. 41.072
Sarrafraz A. 43.104
Sarangan G. **43.228**, 41.244, 43.237, 41.176, 41.258
Saravanakumar S. 42.168, 42.153
Saravanan S. 42.110, 21.001, 42.099, 42.135, 42.117, 42.105
Saravu K. **42.077**, 41.154
Sardesai N. Y. 41.244, 14.009
Sargianou M. **43.265**
Saribas S. **43.136**
Saribas S. 43.063
Saribas S. 43.189, 42.138
Saribas S. 43.199, 41.138
Sarin S. K. 41.273, 42.199
Sarin Y. 42.198
Sarkar P. 28.003, **28.010**
Sarkar S. **43.229**
Sarker S. K. 28.005
Sarki M. 41.158
Sarkis C. 43.090
Sarojini J. 43.095
Sarojini Michael J. 43.121
Sarr I. **41.008**
Sarrafzadeh S. A. **41.182**
Sarathi P. P. 42.208
Sasmono T. 42.075
Sathian B. 42.222
Sathkumara H. 41.214
Satischandra P. 42.218
Satoskar A. 41.012
Sattar S. A. **42.164**, **42.163**
Satyanarayana M. 14.001
Sauer M. **41.198**
Savin E. 41.249
Savini G. 43.255
Saxena S. 43.242
Saxena V. 41.216
Scanu T. 41.160
Schlegel P. 42.220
Schmulson M. 42.266
Schoepp R. 41.251
Schreiter K. 43.009
Schuman R. 43.101
Seal S. **41.165**
Sebastiampillai B. 41.161, 41.088
Sebastian S. **41.113**
Secka F. 41.008
Sehgal R. **43.072**
Sehgal R. 43.048
Sei C. 43.101
Seifert H. **43.137**
Sekaran G. **14.011**
Sekartini R. 42.075
Sekiya N. 41.148
Selabe G. **43.230**
Selvam E. M. 41.074
Semenenko I. 41.197
Sen A. 43.147
Sen A. 41.096, 43.266
Senapati K. 42.145
Senarath U. 41.012
Senaratne T. **43.231**, **43.232**
Sengupta M. 42.145
Sengupta S. 42.162
Sengupta S. **41.166**
Sengvilaipaseuth O. 41.171
Senjovu D. **42.133**
Senthilkumaran S. 43.204
Seo K. 41.147
Seo Y. B. 41.278
Sepulveda N. 43.039



Authors Index

- Seshan V. 21.007
 Sethi G. R. 43.011
 Sethi S. 41.206
 Sethi T. 43.198
 Severin J. 42.170
 Severini F. 42.204
 Sey G. 41.008
 Shadomy S. 41.234
 Shadomy S. V. 41.193
 Shafi H. 41.133
 Shafiq N. 41.118
 Shah F. 43.138
 Shah I. **43.138, 43.139**
 Shah J. 43.140
 Shah N. 41.092, 42.076
 Shah S. K. 42.207
 Shaheen F. A. 43.257
 Shaikh N. **41.183**
 Shailaja V. V. **42.275**
 Shakoor S. 43.165
 Shakuntala I. **43.266**
 Shakuntala I. 41.096
 Shakuntala I. 43.147
 Shalini B. 43.122
 Shampure S. 41.260
 Shandera W. **42.134**
 Shankar C. **41.097**
 Shankar Kumar V. S. **41.283**
 Shanmugam S. 21.006
 Shao J. 14.002
 Sharada R. 42.066, **14.001**
 Sharma A. 42.210
 Sharma A. K. **43.233**
 Sharma A. K. 41.014
 Sharma A. 41.114
 Sharma A. 43.064
 Sharma B. 35.007
 Sharma H. 42.157
 Sharma M. P. 42.208
 Sharma M. **41.118**
 Sharma M. **41.114**
 Sharma N. 41.206
 Sharma N. R. 43.147
 Sharma P. 42.155
 Sharma P. **41.122**
 Sharma P. **42.230**
 Sharma R. 42.200
 Sharma R. 43.145
 Sharma S. **41.022**
 Sharma S. 42.076, 41.092
 Sharma S. **41.184**
 Sharma V. 43.078
 Sharma Joshi M. 43.263
 Sharon L. **43.140**
 Shaskolskiy B. 41.015
 Shaw T. **41.254**
 Sheikh G. A. 43.234
 Sheikh G. A. **43.234**
 Sheikh I. A. 28.010, **28.003**
 Sheikh J. A. 43.257
 Shejpal A. 41.153
 Shen X. 43.106
 Shen Y. **43.141**
 Sheng Y. 43.151
 Shenoy S. 41.068
 Shenoy V. 42.258
 Shepard D. 41.195
 Sher A. **43.073**
 Sherchand J. 42.076, 41.092
 Sherman B. 43.167
 Shet A. 41.229, 42.111,
 41.103, 42.132, 42.125,
 42.124, 41.201, 42.106,
32.002
 Shetty A. 41.183
 Shetty A. K. 42.097, 42.025
 Shetty M. 43.258
 Shewale A. 43.168
 Shi Y. 43.006
 Shibue Y. 41.180
 Shilbe A. S. **42.078**
 Shindano A. B. 43.097
 Shingare R. 43.132
 Shiro K. 42.059
 Shirzadi M. R. 43.248
 Shivekar S. S. 41.074
 Shmaylenko O. 43.223, 43.262
 Shoen C. 43.100
 Shoja S. 41.075
 Shojaee J. 41.250
 Shojaei J. 41.264
 Shokripour M. **41.185**
 Shorr A. **19.003**
 Shrestha K. 41.092
 Shrestha L. B. 41.061
 Shrestha S. **41.098**, 41.027
 Shrimal A. 41.270, 41.269
 Shrivastava A. 42.083, 42.046,
 43.203, 42.063, 42.205
 Shu P.-Y. 42.212
 Shukla V. K. 41.160
 Shwetha H. 42.083
 Shyam I. 41.238
 Sibanda Q. **42.079**
 Sibandze B. 21.009
 Siegrist C.-A. 41.259
 Sileunou I. 43.053, 42.058,
 43.052
 Sigauque B. **09.005**
 Sikkema R. 41.219, 42.257
 Sil A. **28.001**
 Silva J. S. 43.033
 Silva M. C. 43.033
 Silva S. 41.088, 41.161
 Simeoni J. 42.204
 Simhachalam N. 42.020
 Simmerman M. 42.075
 Simoes E. A. F. **41.099**
 Simon A. 43.172
 Singh A. 43.267
 Singh A. K. **41.186**
 Singh A. V. **43.267**
 Singh A. 41.141
 Singh A. 41.198
 Singh A. K. 43.116
 Singh A. K. **43.168**
 Singh B. **41.255, 43.074**
 Singh D. V. 43.242
 Singh D. 43.142
 Singh G. 42.143
 Singh H. **42.165**
 Singh H. S. 43.026
 Singh J. V. 42.024
 Singh J. 43.135
 Singh J. **43.142**
 Singh J. **42.080**
 Singh K. **43.075**
 Singh M. P. 43.049, 41.076
 Singh M. 43.229
 Singh M. 43.202
 Singh M. P. 43.201, 43.229
 Singh N. **28.009**, 41.280
 Singh N. 41.090
 Singh N. **43.076, 35.010**
 Singh O. P. **43.077**, 41.186
 Singh P. P. 43.145
 Singh P. 41.272
 Singh P. P. **43.144, 43.143**
 Singh P. A. 43.229
 Singh R. 42.116
 Singh R. 43.072
 Singh R. **21.003**, 42.123
 Singh R. **43.078**
 Singh S. **43.145**
 Singh S. 43.142
 Singh S. 43.135
 Singh S. **43.079**
 Singh S. 35.002
 Singh T. **41.001**
 Singh T. 41.255
 Singh V. **41.256**
 Singh Z. 42.069
 Singhal R. 43.005, **42.210**
 Singhal S. **41.272**
 Singhi S. 41.206
 Singla L. D. 41.076, 43.049
 Singla M. 43.198
 Singla P. 41.208
 Sinha K. K. 42.262
 Sinha R. **43.080**
 Sinha S. 43.144
 Sinha S. K. 43.233
 Sirekbasan S. 43.189
 Sirisena P. N. 43.232, **43.235**
 Sistla S. 41.131, 41.155,
 41.079, 41.029
 Sithivong N. 42.191
 Sivakumar M. 41.224
 Sivam S. 41.214
 Sivamalar S. 42.099, 42.110,
 42.105, 21.001
 Sivaraj A. 43.126
 Skakni L. 14.006, 42.005
 Skariyachan S. **41.100**
 Skhosana H. 43.161
 Skuhala T. **43.081**
 Slavin M. **05.003**
 Smal E. 42.004
 Smith A. M. 42.274
 Smithsuwan P. **42.081**
 Smok F. 42.152
 Smolinski M. 14.002
 Smout E. M. **41.257**
 Sng J. G. K. 42.159
 Snidevich U. 41.197
 Snyder B. M. 41.099
 Sodha S. 42.046, 42.063
 Soedjatmiko S. 42.075
 Soga T. 41.062
 Sohal P. 41.208
 Sohrabi P. 43.199
 Solodiankin O. 41.046, **43.236**
 Solomon S. S. 42.117, 42.135,
 42.105, 21.001, 42.131,
 42.099, 42.110, 42.101
 Solomon S. 42.105, 21.001
 Solomon S. 42.131
 Solomon S. 42.110
 Solomon S. 42.101
 Solomon S. 42.117, 42.099
 Solomon S. 42.135
 Solomon T. **16.001**
 Soltani F. 42.055, 42.243,
 42.246
 Somaratne K. K. V. N. 43.085
 Sonawane A. 42.014, 41.166,
 43.105
 Sonder G. J. B. **41.284, 41.101**
 Song J.-Y. 41.160
 Songok E. 43.221
 Soni I. 41.067
 Sonkar S. C. **41.187**
 Sonnenberg P. 43.118
 Sood R. 43.135
 Sood R. 41.127
 Sood S. 41.122, 41.057
 Sooka A. 42.274
 Soundravally R. 43.110
 Southlack K. 42.191
 Souza S. A. 43.103
 Sowmya V. 41.279
 Söyletir G. 41.048
 Spaapen R. M. 41.160
 Sree Kalpana M. 42.036,
 42.037
 Sreekalpana M. **42.082,**
42.083
 Sreekumar E. 43.214, 43.217
 Sreenivas V. 41.113
 Sreeramreddy C. **41.199**
 Sreeramaju P. **42.166**
 Sridhar R. 42.159
 Srikantam A. **43.146**
 Srikanth P. 41.244, 21.007,
 43.228, **41.258**, 43.237,
 41.176
 Srinet S. 43.158
 Srinivasan S. 43.129
 Srirama R. 42.135
 Sriskandan S. **01.001**
 Srivastava O. N. 43.050
 Srivastava S. 43.038
 Ssekabira U. 42.133
 Ssekiswa L. 42.128
 Stålsby Lundborg C. 41.114
 Stauffer K. E. 41.193
 Stegny B. 43.236
 Stenos J. 41.235
 Stolte I. G. 41.101
 Strub-Wourgaft N. 35.007
 Su I.-J. 42.202
 Subashini B. **43.004**
 Subashini D. **42.135**
 Subashini K. 41.188
 Subbiah M. **42.268**
 Subramanian S. 43.193
 Subramanian S. **43.237**
 Sudarsanam T. D. 43.004
 Sudarshan M. 41.255



Authors Index

- Sudhaharan S. 41.151, 41.146
 Sudhakar S. B. 41.019, 41.021
 Suleiman Kamara C. 41.236
 Sulieman S. M. **41.102**
 Sunbul M. **42.167**
 Sundar R. 43.126
 Sundar S. 35.010
 Sundar S. 41.186
 Sundar S. 43.077, 43.074
 Sundar S. **33.002**
 Sundar S. 41.255, 43.050
 Sundar S. 43.076
 Sundar S. 43.043
 Sundar S. 41.013
 Sundar S. 43.065
 Sundaramurthy R. **41.188**
 Sundaresan S. **41.103**
 Sundari S. 42.050
 Suneetha L. 42.124
 Suneetha S. 42.124
 Sunyoto T. 35.001, 42.053, 35.007, 35.008
 Sureshkumar D. 42.153, 42.223, 41.164, **42.168**
 Suri D. 41.184
 Surpam R. 41.047
 Suryanarayana V. 14.001
 Suryapranata F. 41.284
 Susanti D. 41.091
 Sutherland C. J. 41.237
 Suzuki K. 41.062
 Swaminathan R. 43.110
 Swaminathan S. 43.212
 Swaminathan S. 21.011, 21.006, **06.001**, **22.001**, 43.142
 Swaminathan S. **30.001**
 Swarup R. 43.264
 Swarup S. 41.190
 Swathi C. **41.104**
 Swathirajan C. 42.135
 Syed Hussain S. I. 42.101
 Syethii M. 42.008
 Syrjänen R. 42.059
 Tadesse M. 43.117
 Taher A. 42.238
 Taherzadeh D. 42.166
 Takuma A. 41.062
 Talaat M. 43.008
 Talat M. 43.050
 Tall A. 42.065
 Talukdar A. 43.038, 42.126
 Tambyah P. A. **36.001**, **37.001**, 42.159
 Tameyi Tatsa J. 42.058, 43.052
 Tamilselvan P. T. **43.082**
 Tan L.V. 41.259
 Tandon M. 41.090
 Taneja I. 41.129
 Taneja N. 41.073, 41.238, 41.223, 41.020
 Taner Z. 41.136, 41.138
 Tankhiwale N. 42.146
 Tantirimudalige M. 43.197
 Tantray V. 42.026
 Taori D. G. 43.142
 Tapparel C. 41.259
 Tarantola A. 41.036
 Tarun B. 42.037
 Tate J. E. **24.001**
 Taurel A.-F. C. 42.075
 Tavella A. 43.247
 Taylor M. 43.067
 Teepruksa P. 42.191
 Tellapragada C. 41.060, 41.254, **42.276**
 Tellis R. 41.003, **41.105**
 Tendo Mpanga J. 42.178
 Tesema T. G. **42.169**
 Thabab M. M. 41.029
 Thai S. 41.087
 Thakare R. 41.067
 Thakkar M. 21.011
 Thakur A. 41.058
 Thakur J. 42.213
 Thakur R. 21.005
 Thakur S. 41.238
 Thapa B. R. 41.020
 Thapa B. R. 41.014
 Thatchinamoorthy G. 41.230
 Theuretzbacher U. **31.002**
 Thevanesam V. 41.214
 Thirumalaikolundusubramaniam P. 43.204, 42.158
 Thirunarayan M. 42.223
 Thiyagarajan Y. **41.106**, **42.003**
 Thoa L. P. K. 42.202
 Thomas G. 41.008
 Thomas K. **02.001**
 Thomas L. **42.277**, 42.278
 Thomas S. 28.006
 Thomas K G. 43.220
 Thuy T.T. 41.259
 Thwaites G. 41.248
 Thwaites L. 14.004
 Thys S. 43.206
 Tigay Z. 43.091
 Tigoi C. 41.251
 Tiku V. R. **43.238**
 Timenetsky M. D. C. S. T. 42.201
 Titus A. **43.268**
 Tivane A. 41.222, 43.254, 42.211
 Tivane A. T. 41.242
 Tiwari P. 42.210, 43.005
 Tiwary P. 43.043
 Tiwary P. **41.013**
 Toda M. **42.085**
 Toh C. Y. 41.211
 Toleman M. 42.254, 42.253, 42.252
 Tomaschek F. 43.137
 Tome T. 41.143
 Topno R. 42.156
 Toprak S. 43.136
 Torabipour M. 41.075
 Torkaman Asadi F. 41.049
 Torkaman Asadi F. **43.269**
 Torres D. 42.150
 Torres J. **06.004**
 Torres-García M. 43.007
 Tran N. T. **41.259**
 Tran T. T. 14.004
 Tran T. 41.248
 Tran V. D. 42.012
 Trehanpati N. 41.273
 Trentini L. 43.247
 Tripathy S. **42.231**
 Tristao F. S. M. 43.033
 Trivedi K. 42.156
 Trovada dos Santos M. D. J. 42.212
 Truong Huu K. 14.004
 Tsai K.-H. **42.212**
 Tseng L.-F. 42.212
 Tshuma N. 42.061
 Tsiredzo R. 21.009
 Tsofo A. 14.008
 Tu C. 42.064
 Tuan H.M. 41.259
 Tuan Soh T. S. 42.263
 Tumanan-Mendoza B. 43.160
 Tumino G. 42.190
 Tunga Babaoglu Ü. 43.256
 Tura G. A. 42.247
 Turan N. 43.189
 Turk Dagi H. 42.189
 Turuk J. 43.211
 Tyagi S. 41.057
 Ubhayawardana N. L. **28.008**
 Udayakiran N. 42.025
 Udayakumar P. 41.017
 Ududec T. 43.061
 Udwardia T. 41.111
 Uechi K. 41.143
 Ufearo S. 42.129
 Ugbene K. 42.034
 Ugen K. 41.244, 14.009
 Ukaga C. N. **43.083**, 43.034, **43.084**
 Ukharov A. 42.194
 Ulziisaikhan G. 43.270
 Uma A. 42.158
 Umadevi P. 41.240
 Umamaheswari K. 42.217
 Umanah T. 43.123
 Umenze F. C. **42.008**
 Ummanni R. 43.132
 Umoh J. U. 41.252
 Upadhyay S. **28.007**
 Urquiza M. 42.150
 Usatkin A. 43.262, 43.223
 Usman A. M. **42.086**
 Usman R. 41.158
 Uthappa C. K. 42.095
 Uthappa C. 42.020
 Uthappa C. K. **42.136**
 Uzim J. 42.034
 Va S. K. 43.193
 Vaidyanathan S. P. 42.268
 Vairo F. 41.236
 Vaite S. 41.194
 Valarmathi S. 41.230
 Valecha D. **42.213**
 Vally S. 43.161
 Valverde V. **42.004**
 Van H.M.T. 41.259
 van Dam A. P. 41.101
 van de Laar T. J. 41.101
 Van Der Westhuizen M. 43.213
 van Doorn H. R. 41.248, 41.259, 14.004
 Van Geertruyden J.-P. 41.181
 van Meijgaarden K. E. 43.131
 Van Schalkwyk C. 21.008
 Vanaabaatar B. **43.270**
 Vandenbroucke-Grauls C. M. 41.101
 Vandepitte W. P. **43.169**
 Vanisree R. **41.167**
 Varghese G. M. 41.149
 Varghese G. M. **13.002**, 42.122
 Varma G. 41.223
 Varma M. 41.270, 41.269
 Varma M. 41.089, 41.235
 Varma V. 42.195
 Varshney A. **43.170**, 41.172, **43.171**
 Vasaiakar S. D. **41.168**
 Vázquez-Flores A. 43.007
 Veeraraghavan B. 41.149, 41.097, 43.004, 42.002, 41.080
 Veeraraghavan B. 42.196
 Veeraraghavan B. 42.001
 Veeraraghavan S. 43.132
 Veeresh B. 42.066
 Veeresh B. 14.001
 Vehid S. 41.136, 43.199, 41.138
 Velásquez G. 43.087
 Velidedeoglu M. 41.136
 Vemu L. 43.258, 43.259, 41.146
 Veng C. 41.087
 Venkat Ramanan P. 42.240
 Venkatachalam I. 42.159
 Venkataramanan R. **41.128**
 Venkatasubramanian S. 42.050
 Venkatesan S. **42.087**
 Venkatesh S. 42.205, 43.203, 42.046, 42.063, 42.083
 Vergese V. P. 43.095
 Verghese V. P. **42.278**, 42.277, **43.172**, 42.270, 41.099
 Vergis J. 43.252
 Verma A. K. **43.239**
 Verma I. 41.184
 Verma N. 43.017
 Verma S. 41.216, **21.004**
 Verma S. 43.038
 Vidhya K.R. 42.063
 Vidyalakshmi K. 41.068
 Viet D.C. 41.259
 Viet H.L. 41.259
 Vijay D. 43.252
 Vijayachari P. 41.244
 Vijayakumar P. 41.019, 41.021
 Vijayakumar R. 41.066
 Vijayalakshmi A. 41.279
 Vijayashree M. 42.082
 Villinger J. 35.006, 43.015
 Vinnakota R. 41.283
 Vise E. **43.147**
 Vishwakarma R. A. 43.145
 Viswanadha S. 43.132
 Vivek K. **41.260**
 Vivek R. 41.201



Authors Index

- Vivekananthan P. 41.224
 Vladimirescu A. **41.261**, 41.249
 Vlieghe E. 41.087
 Volpi A. **42.249**
 Von Seidlein L. **12.003**
 Vongphachanh P. 42.191
 Vongsouvath M. 41.171
 Voorintholt A. 42.170
 Vorobyev D. 41.015
 Vos M. C. **42.170**
 Voss T. G. 14.005
 Voy-Hatter K. 42.166
 Vu N. L. 42.012, 41.217
 Vullo S. 43.255, 42.190
 Vuyisich M. **41.262**
 Vyakarnam A. 21.011, 43.131, 21.010, 21.006
 Vyas A. K. **41.273**
 Wada Kura A. **43.240**
 Wadula J. 43.161
 Wagle P. 42.140
 Wagner A. 42.029, **42.006**
 Wahajuddin M. **41.129**
 Waigankar V. 41.111
 Waldrop G. 42.101
 Walke H. T. 41.193
 Walker D. H. **13.003**
 Wallis R. S. **11.003**
 Walls T. 41.108
 Wamala J. **34.001**
 Wang B. 41.241
 Wang L. 41.252
 Wang W. 43.106
 Wang W. 42.030
 Wang X. 42.030
 Wang X. 42.029
 Wangi Bosila J. **42.088**
 Wanigasinghe J. 43.207
 Wannachart M. 43.169
 Wartel T. 43.162
 Wasserman S. A. **42.232**
 Watson-Jones D. 41.257
 Wattal C. **41.266**, 41.109
 Waturangi D. **42.171**
 Wayesa D. J. 42.078
 Waziri N. E. 14.008
 Weerasekera D. 28.008
 Weerasekera M. 28.008, 42.229
 Weerasingha S. 41.012
 Weiner D. 41.244, 14.009
 Weldegebreal H. H. **42.089**
 Weltman H. 43.140
 Wesangula E. **41.107**, **42.172**
 Wesolowski A. 35.003
 White N. **15.001**
 Wickramasinghe N. 43.196
 Wickramasinghe S. 41.161, 41.088
 Widdowson M.-A. 42.157
 Wieczorek T. **43.009**
 Wiederhold N. **05.001**
 Wiersinga J. **20.003**
 Wierzbna T. F. 42.065
 Wig N. 41.208
 Wijaya H. 41.237
 Wijesooriya H. D. **43.085**
 Wijewickrama A. 43.190, **14.003**
 Wilson A. 42.154
 Wisplinghoff H. 43.137
 Wojno J. 42.274
 Wokorach A. 42.128
 Woldesonbet Z. D. **41.281**, **43.241**, **42.090**
 Wong T. **16.002**
 Wongkumma A. 42.081
 Wood H. 43.194
 Woodall J. 41.263
 Worthy S. 43.102
 Woyessa A. B. 42.078
 Wu D. 43.160
 Wu L.-E. 41.160
 Wulanda I. A. 43.037
 Xiao X. **42.091**
 Xicoténcatl-Cortés J. 43.007
 Xu B. **43.111**, **43.150**, 43.151
 Xu J. 43.150
 Yadati S. R. 43.258, 43.208, 43.259
 Yadav A. 41.061
 Yadav D. K. **41.115**
 Yadav S. 41.115
 Yahaya S. S. **43.149**, **42.137**, 42.130, **43.148**
 Yamada R. 43.215
 Yamaguchi H. 41.062
 Yaman A. 41.048
 Yan F. 43.106
 Yang M. 43.111
 Yang Z. 43.150
 Yanik K. 41.048
 Yanti Y. **42.173**
 Yap G. 43.006
 Yaregal Z. 43.117
 Yarimcam Saglam F. **43.271**
 Yassin K. 42.019
 Yathiraj S. 42.066
 Yeldandi V. 42.095, 42.020
 Yeldandi V. 42.136
 Yeldandi V. **41.274**
 Yembo G. E. 42.078
 Yemisen M. 41.136
 Yen T.-Y. 42.212
 Yenew B. 43.117
 Yeniterzi M. 43.189
 Yeolekar M. E. 43.021, 41.204
 Yigin A. 43.271, 41.032
 Yildiz N. 42.118
 Yilmaz H. 43.189
 Yilmaz Yucel F. 41.065
 Yoganand R. 41.081
 Yoksan S. 43.169
 Yoldas A. 43.271
 Youngster I. **23.002**
 Yousef Alikhani M. 43.269
 Yousefi F. **42.233**
 Yousefi F. 42.246, 42.243, 42.055
 Yousefi H. 43.041
 Yousefi Mashouf R. 41.077
 Yousfi M. **42.250**
 Yuan L. 42.091, 43.151
 Yuan Z. 43.106, 43.111
 Yue-Peng L. 41.199
 Yuill T. **25.004**, **41.263**
 Yuksel P. 43.136, **42.138**, 43.199, 42.118
 Yusuf R. 42.137
 Yusuf R. 42.026
 Zachariah A. 43.114
 Zachariah U. G. 43.225
 Zafurullah S. 42.175
 Zaidi A. **43.086**
 Zaidi A. 43.165, **38.004**
 Zainal Abidin A. S. 42.273
 Zakhharova Y. 41.119
 Zakhhashvili K. 42.194
 Zaki H. 42.019
 Zaman K. **41.189**
 Zambrano B. 43.162
 Zammuto G. 43.255
 Zangeneh M. 42.047
 Zar H. J. 41.059
 Zavalani F. 42.149, 43.066
 Zavalani S. 42.149
 Zhang T. 42.216
 Zhang T. **42.215**, **42.214**
 Zhang X. 43.184
 Zhang X. 42.216, 42.214, 42.215
 Zhang Y. 42.029
 Zhao Q. **43.151**, 42.091
 Zheng K. 43.184
 Zheng Y. 43.111
 Zhou C. 43.111
 Zhou D. 42.052
 Zhou L. 42.214, **42.216**
 Zhou T. 42.215
 Zhuravlev A. 43.262, 43.224, 43.068, 43.223
 Zia A. 41.216, **43.242**
 Ziapour S. P. **43.243**, **41.264**, 41.250
 Zofou D. **41.130**
 Zogu E. 43.188
 Zulu S. G. 43.067
 Zurovac D. 42.085



Faculty Disclosures

In order to assure the highest quality programming, individuals in a position to control conference content are required to disclose relevant financial relationships with any commercial or proprietary entity producing health care goods or services relevant to the content being presented.

THE FOLLOWING SPEAKERS HAVE NO DISCLOSURES.

ABRAHAM Priya (India)	MEHTAR Shaeen (South Africa)
ARJYAL Amit (India)	MENON Vinod (India)
AZIM Tasnin (Bangladesh)	MITREVA Makedonka (USA)
BEARMAN Gonzalo (USA)	MORGAN Daniel (USA)
BURZA Sakib (UK)	MUKHOPADHYAY Chiranjay (India)
CAUDA Roberto (Italy)	NICOL Mark (South Africa)
CHANDY Sujith (India)	PLATTS-MILLS (USA)
CHARANI Esmita (UK)	PRAMARATNA Ranjan (India)
CHU Cindy (Thailand)	PYAE PHYO Aung (Thailand)
COTTER Paul (Ireland)	RAMESH V. (India)
DANCE David (Lao)	REVATHI Gunturu (Kenya)
DAVIES Sally (UK)	SAHASTRABUDDHE Sushant (South Korea)
DE CLERCK (Belgium)	SHET Anita (India)
DESAI ANIta (India)	SRISKANDAN Shiranee (UK)
GALLAGHER Rose (UK)	SUNDAR Shyam (India)
GARRET Denise (USA)	SWAMINATHAN Soumya (India)
GELLBAND Hellen (USA)	TATE Jacqueline (USA)
HAJJEH Rana (USA)	THEURETZBACHER Ursula (Austria)
JACKSON Alan (Canada)	Von SEIDLEIN Lorenz (Thailand)
KUMARASAMY N (India)	WALLIS Robert (South Africa)
LEBLEBICIOGLU Hakan (Turkey)	WALKER David (USA)
MALAVIGE Neelika (Sri Lanka)	WHITE Nicholas (Thailand)
MARTINEZ-MARTINEZ Luis (Spain)	YOUNGSTER Ilan (USA)
	ZAIDI Anita (USA)



Faculty Disclosures

In order to assure the highest quality programming, individuals in a position to control conference content are required to disclose relevant financial relationships with any commercial or proprietary entity producing health care goods or services relevant to the content being presented.

THE FOLLOWING DISCLOSURES ARE REPORTED.

SPEAKER NAME	COMPANY NAME	RELATIONSHIP
AARDAL Christine (Norway)	Merck	Team member research project
	GSK	Team member research project
	Astellas	Team member research project
	AztraZeneca	Team member research project
	Pfizer	Team member research project
	Roche	Team member research project
BLUMBERG Lucille (South Africa)	Sanofi Pasteur	Unrestricted educational grant for vaccinology conference—part of organizing committee
DAGAN Ron (Israel)	Genocea	Scientific consultant
	MeMed	Scientific consultant
	MSD	Research grant, scientific consultant
	GSK	Speaker
	Pfizer	Research grant, scientific consultant, speaker
ISHII Yoshikazu (Japan)	MSD K.K.	Research grant
	Eikem Chemical	Research grant
	Nissui Pharmaceutical	Research grant
	Maruho Co. Ltd	Research grant
	Meiji Seika Pharma Co.	Research grant
LAI Ching Lung (China)	Arrowhead Corp.	Advisory board member
	Gilead Sciences	Consultant/Speaker at Advisory board meeting
KAMARULZAMAN Adeeba (Malaysia)	Merck	Educational grant
	Gilead	Advisory board member
	Roche	Educational grant
	Pfizer	Educational grant
LEO Yee Sin (Singapore)	Tan Tock Seng Hospital	Director, IIDE Clinical Director, CDC Senior Consultant, ID Dept.
LJUNGMAN Per (Sweden)	Astellas	Clinical trial, research grant
	Merck	Clinical trial, research grant
LUZ Kleber (Brazil)	Sanofi-Pasteur	Research grant
	GSK	Research grant
	Takeda	Research grant
MEINTJES Graeme (South Africa)	Sanofi Aventis	Reimbursement for 3 lectures. Attended advisory board meeting but requested NOT to be reimbursed for it.
MENDELSON Marc (South Africa)	MSD	Educational talks Talks on stewardship Travel grant to attend ECCMID
	Pfizer	Advisory panel on pneumococcal conjugate vaccine
	Cipla MediPro	Honorarium for stewardship talk
	Sanofi Pasteur	Travel grants to attend CISTM conference



Faculty Disclosures

In order to assure the highest quality programming, individuals in a position to control conference content are required to disclose relevant financial relationships with any commercial or proprietary entity producing health care goods or services relevant to the content being presented.

THE FOLLOWING DISCLOSURES ARE REPORTED.

SPEAKER NAME	COMPANY NAME	RELATIONSHIP
NABER Kurt (Germany)	Basilea	Research grant, Consultant
	Bionorica	Research grant, Consultant,
	Cubist/MSD	Consultant
	Rosen Pharma	Consultant
	Zambon	Consultant
	Leo Pharma	Consultant, Speaker
	MerLion Pharma	Consultant
OPAL Steven (USA)	Arsanis	Consultant
	Aridis	Consultant
TAMBYAH Paul (Singapore)	Sanofi Pasteur	Research grant
	Fabentech	Research grant
	GSK	Research grant

New feature:
Editor's choice

International Journal of Fundamental and Medical Virology

Intervirology

welcomes your contribution ...

Editor-in-Chief

J.-C. Manuguerra, Paris

Associate Editors

I. Leclercq, Paris

R.C. Medeiros, Belém

Editorial Board

C. Barbezange, Paris

T. Cunningham, Westmead

O. Hino, Tokyo

W.L. Hsu, Taichung

H. Hu, Silver Spring, Md.

Z. Hu, Wuhan

I. Hussein, Cambridge, Mass.

J. Kühn, Münster

U.G. Liebert, Leipzig

K. Moelling, Zürich

J.T. Paweska, Johannesburg

W. Preiser, Tygerberg

G.L. Smith, Cambridge

H. Triki, Tunis

The Editors of *Intervirology* invite the submission of manuscripts on a wide range of topics in fundamental and medical virology. The journal's scope encompasses work on the molecular biology of human and animal viruses, including genome organization and regulation, and the structure and function of viral proteins. The pathogenesis, immunology, diagnosis, epidemiology, prophylaxis and therapy of viral diseases are also considered. Issues publishing original papers alternate with thematic issues, which make timely reviews, research reports and controversy easily accessible to both specialists in the field and those who want to keep track of the latest developments outside their own area of interest.

New feature: Editor's choice

The Editor selects one article from each journal issue for free and full access to users worldwide.

Benefits for Authors

- Cost-effective publishing, i.e. no submission fee and no page charges for papers of 6 or fewer printed pages
- Free online color figures
- Rapid and fair peer-review process
- Full listing in all relevant bibliographic databases (PubMed/MEDLINE, Web of Science, Current Contents etc.)
- Author's choice for open access publishing

Intervirology
2016: Volume 59
6 issues per volume

KARGER



Find out more:
www.karger.com/int

K116221



**International Congress of
Chemotherapy and Infection 2017**
24-27 November 2017

Venue: Taipei International Convention Center

Save the Date

Call for Abstracts Opens November 2016



Sign up for updates @

www.icc2017.tw



REGISTER NOW

34th Annual Meeting of the EUROPEAN SOCIETY FOR PAEDIATRIC INFECTIOUS DISEASES

Organised jointly by ESPID and the ESPID Foundation

BRIGHTON, UK
MAY 10-14, 2016



Meeting Secretariat:
Kenes International
7, rue François-Versonnex C.P. 6053
1211 Geneva 6, Switzerland
Tel: +41 22 908 0488
Fax: +41 22 906 9140
E-mail: espid@kenes.com

espid2016.kenes.com



Brighton 2016

34th Annual Meeting of the European Society
For Paediatric Infectious Diseases



A studio instead of a seat.
It's not business as usual.



Discover the difference of a Business Studio on our A380 and 787 Dreamliner. Eat when you want with menu guidance from our Food & Beverage Manager. Sleep on a large, flat bed, relax with noise-cancelling headsets or work using in-seat connection ports and mobile or Wi-Fi connectivity. The ideal space for work, rest and play.

We are proud to be the international airline partner for the 17th ICID in Hyderabad, India.

الإتihad
ETIHAD
AIRWAYS
ABU DHABI

#Reimagined | etihad.com |



Flying Reimagined



Pneumococcal Disease Prevention: Further Evidence of Success

Friday, March 4, 2016

12:30 – 2:00 PM

Hall 6

AGENDA

12:30 – 12:35 PM

Remarks by Chair

Mark A. Fletcher, MD
Paris, France

PCV Protection of Children: A Story of Immune Response, Serotype by Serotype

12:35 – 1:15 PM

Helping to Protect Against Pneumococcal Disease Across Generations: Public Health Impact of PCVs

Nitin Shah, MD
Mumbai, India

Pneumococcal Vaccination in Older Adults: Where Is the Evidence Leading?

1:15 – 1:35 PM

The Burden of Pneumococcal Pneumonia in Adult Populations: Recognizing an Unmet Need

Rosana Richtmann, MD
São Paulo, Brazil

1:35 – 1:55 PM

Helping to Protect Adults Against Pneumococcal Pneumonia: From Clinical Trials to Vaccine Policy

Charles Feldman, MB Bch, DSc, PhD, FRCP, FCP (SA)
Johannesburg, South Africa

1:55 – 2:00 PM

Summary and Concluding Remarks

Mark A. Fletcher, MD
Paris, France

For the use of a registered medical practitioner, hospital or laboratory

For additional information, please write to:
Pfizer Limited, The Capitali – A Wing 1802, 18th Floor,
Plot No C-70, G-Block, Bandrai – Kirla Complex,
Bandra (East), Mumbai – 400051, India.

Value of Adult Vaccination

Thursday, 3 March 2016

07:45 – 08:45

Meet the Expert
Sponsored by MSD

CHAIR

David Fedson

Formerly, Harry T. Peters, Jr.
Professor of Medicine
University of Virginia School of
Medicine
Sergy Haut, France

FACULTY

John Litt

Associate Professor
Flinders University
Adelaide, Australia

Hyderabad International Convention Centre (HICC)
Room: G.05-06
Hyderabad, India


Chair: David Fedson (France)

AGENDA

07:45 – 07:50	Opening Remarks	David Fedson
---------------	-----------------	--------------

07:50 – 08:20	Herpes Zoster Management	John Litt
---------------	--------------------------	-----------

08:20 – 08:45	Pneumococcal Disease in Adults	David Fedson
---------------	--------------------------------	--------------



Save the date!

October 26-30 • New Orleans, LA • www.idweek.org



IDWeek²⁰¹⁶_{TM}

Advancing Science, Improving Care

Now Accepting Abstracts – Travel Awards up to \$2,500 USD

Member Advanced Registration Opens March 2016

Registration Open to All April 2016

A JOINT MEETING OF



MSD IS COMMITTED TO HELP FIGHT INFECTIOUS DISEASES.



**Please visit the MSD booth to learn more
about our portfolio of products.**

**Before prescribing CANCIDAS, INVANZ or NOXAFIL, please read
the Prescribing Information available at this exhibit.**



Copyright © 2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved.
AINF-1171738-0001 02/16



Better Health, Brighter Future

Vaccines prevent between 2-3 million deaths per year and have greatly reduced the burden of infectious diseases worldwide¹.

Building upon two centuries of healthcare experience in Japan, Takeda's worldclass vaccine team is demonstrating leadership in global vaccine development and delivery. Substantial investments in vaccine R&D aim to tackle the world's most challenging health problems for which vaccines do not currently exist.

With our breadth of expertise and our collective experience, Takeda will always be committed to addressing the world's most pressing public health issues.

¹ WHO Immunization Coverage Fact Sheet <http://www.who.int/mediacentre/factsheets/fs378/en/>



ICID 2016 GSK satellite symposia

Save the dates

Pertussis.

The protection starts with you.

Thursday March 3, 2016

12.30 - 14.15, Hall 6

**Do MMRV combination vaccines
optimise the prevention of measles,
mumps, rubella and varicella?**

Friday March 4, 2016

18.00 - 20.00, Hall 6

Following the successes of vaccination in the 20th Century, we need to be more than ever prepared to support and convey the value of vaccination against measles, mumps, rubella, varicella and pertussis in certain age groups.¹ During recent years there has been a series of outbreaks of pertussis, measles and mumps, mainly due to insufficient vaccine and booster vaccine coverage.^{2,3,4}

The symposium ***“Pertussis. The prevention starts with you”*** will be chaired by Dr Sundaram Balasubramanian, Head of the Department of Pediatrics at Kanchi Kamakoti CHILDS Trust Hospital and Medical Research Foundation, Chennai, India. During a round table discussion the faculty, composed of the GSK experts Dr Anil Dutta, Vice-President & Head, Medical and Clinical - Emerging Markets, Dr Walid Kandeil and Dr Tomas Marcek, Senior Managers Global Medical Affairs for DTP combination vaccines, will address from a global and regional perspective the epidemiology of pertussis, discuss experiences with strategies adopted for optimising pertussis control, as well as recently published data and unmet medical needs.

The GSK symposium ***“Do MMRV combination vaccines optimise the prevention of measles, mumps, rubella and varicella?”*** is designed to tackle some of the burning questions on Measles, Mumps, Rubella and Varicella combination vaccines. Lessons learned all over the world with different MMR/V vaccination schedules will be discussed as well as the safety aspects of combination vaccines. ***New Indian data*** will be presented with **the use of MMRV vaccine for the first time** in a highly endemic measles setting.⁵ The expert faculty consisting of Dr Sanjay Lalwani, Department of Pediatrics, Bharati Vidyapeeth Deemed University, Pune, India, Dr Anil Dutta GSK, Vice-President & Head, Medical and Clinical - Emerging Markets, and Dr Volker Vetter, GSK, Global Medical Affairs Lead for MMRV vaccines will openly discuss different viewpoints.

Upgrade your knowledge on vaccines from the observations, insights and experiences of our expert speakers.

References:

1. Greenwood B. 2014, Phil. Trans. R. Soc. B 369: 20130433; 2. Tan T *et al.* *Pediatr Infect Dis J* 2015; 34: e222-e232. 3. Public trust in vaccines: defining a research agenda, AAAS 2014 ISBN: 0-87724-098-1; 4. Sabbe M *et al.* *Hum Vaccin Immunother* 2016 (epub); 5. Lalwani S *et al.* *BMJ Open* 2015; 5: e007202

Date of preparation: January 2016 VGBU/B00/0001/16a

GlaxoSmithKline Pharmaceuticals Limited, Dr. Annie Besant Road, Worli, Mumbai 400 030 (India).

Please report adverse events with any GSK product to the company at india.pharmacovigilance@gsk.com

© 2016 by GSK Biologicals. All rights reserved.

Welcome to EpiCore

When outbreaks are detected quickly, communities can respond faster, curb epidemic, and save lives.



What is EpiCore?

EpiCore is a new system that finds and reports outbreaks faster than traditional disease surveillance methods alone.

EpiCore draws on the knowledge of a global network of health professionals, and connects it with a secure online networking and reporting platform. By using innovative surveillance techniques, EpiCore enables faster outbreak detection and reporting.



How Does EpiCore Work?

EpiCore links a worldwide network of health professionals to verify information on disease outbreaks.

When evidence of outbreaks is found, local information is requested from EpiCore members. Members are able to quickly provide expertise speeding outbreak verification.



You Can Help!

Support the early detection of outbreaks by becoming an EpiCore member!

By easily responding through a secure online platform, you can share your knowledge to help verify outbreaks in your region.



Become a Member

All health professionals with formal education and training in health, and knowledge of basic principles of epidemiology, infectious disease or related fields are encouraged to apply online.

Join EpiCore and help change the landscape of outbreak detection and reporting! **Learn more or apply online:**
www.epicore.org

Questions? info@epicore.org

EpiCore is a partnership between:



Portez vos blouses...pour la Tunisie

Tunisian Association for Health Promotion



world Federation
of public Health Associations

The First International Congress TUNISIA 2016

The North-South Issues of Public Health in the new Pandemic Situations

March 17th - 18th - 19th 2016

EL Mouradi Hotel

Tozeur (Southern-Tunisian Sahara)

Tunisia



www.atps-tunis.org

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES



Official Publication of the International Society for Infectious Diseases

EDITOR-IN-CHIEF

Eskild Petersen

*Department of Infectious Diseases, Institute of Clinical Medicine
Aarhus University Hospital, Denmark*

IJID provides a source of information relevant to professionals involved in the epidemiology, clinical diagnosis, treatment and control of infectious diseases with particular emphasis placed on those diseases which are most common in under-resourced countries. The journal publishes original clinical and laboratory-based research, together with reports of clinical trials, reviews and some case reports.

Benefits of publishing open access in *IJID*

- Articles are **immediately free** to read by academics, health professionals and the public throughout the world, without restriction
- Authors can choose from a selection of **Creative Commons licenses**, determining how they want their work to be used
- **Competitive** Open Access Publishing Fees
- To help authors **comply with new open access policies and mandates**, Elsevier has established agreements with many funding bodies
- Same standard of **rigorous peer review** by experts in the field
- **Rapid** online publication
- **Community connections** to share your research with your peers around the world

Meet-the-Editors

How to Publish Your Work - Insights From the Editors (*in collaboration with Elsevier*)

Friday, March 4, 2016, 07:45 - 08:45hrs, Room: Hall 2

E. Petersen (Denmark) (editor-in-chief of the *International Journal of Infectious Diseases*)

J. McConnell (United Kingdom) (editor of *The Lancet Infectious Diseases*)

Submit your manuscript online: <http://ees.elsevier.com/ijid>

Full information on publishing your paper open access: www.elsevier.com/openaccess

www.ijidonline.com



Notes

A series of horizontal dotted lines for taking notes, spanning the width of the page.

This image shows a full page of white paper with horizontal dotted lines. The lines are evenly spaced and run across the width of the page, providing a guide for handwriting practice. There are no margins, text, or other markings on the page.



Notes

A series of horizontal dotted lines for taking notes, spanning the width of the page.

128 ~ FINAL PROGRAM



Notes

A series of horizontal dotted lines for taking notes, spanning the width of the page.



Notes

A series of horizontal dotted lines for taking notes, spanning the width of the page.



Notes

A series of horizontal dotted lines for taking notes.



Notes

A series of horizontal dotted lines for taking notes, spanning the width of the page.



Notes

A series of horizontal dotted lines for taking notes.



Notes

A series of horizontal dotted lines for taking notes, spanning the width of the page.

DISCOVER HYDERABAD in Incredible India

HYDERABAD
RAJIV GANDHI
INTERNATIONAL AIRPORT

HICC

Taj Krishna
Hyderabad

HITEX

MARRIOTT
HYDERABAD

TRIDENT
Hyderabad

www.hcvb.co.in



HYDERABAD
CONVENTION VISITORS
BUREAU - INDIA



Telangana
Tourism
It's all in it

TSTDC

HYDERABAD
RAJIV GANDHI
INTERNATIONAL AIRPORT

**HYDERABAD INTERNATIONAL
CONVENTION CENTRE**
Managed by **ACCOR**

HITEX
EXHIBITION CENTER
It all happens here.

MARRIOTT
HYDERABAD

TRIDENT
Hyderabad

THE WESTIN
HYDERABAD
MINDSPACE

TAJ FALAKNUMA PALACE
HYDERABAD

Taj Krishna
Hyderabad

AVASA
HOTELS

KWCONFERENCES

CIMGLOBAL™
www.cimglobal.net

mci



Rachnoutsav Events Pvt. Ltd.
Redefining events to perfection
www.rachnoutsav.com

O2 SPA





The International Meeting on Emerging Diseases (IMED 2016) is organized by the International Society for Infectious Diseases (ISID) and its Program for Monitoring Emerging Diseases (ProMED-mail). Since its inception, IMED has been a summit that unifies our approach to pathogens in the broadest ecological context. Drawing together human and veterinary health specialists, IMED serves as a true One Health forum where those working in diverse specialties and diverse regions can meet, discuss, present and challenge one another with findings and new ideas. While pathogens emerge and mutate, our methodology for detection, surveillance, prevention, control, and treatment also continue to evolve. New approaches to vaccination and isolation the uses of novel data sources and genomics, novel laboratory methods, rapid point-of-care diagnostics, risk communication, political and societal responses to outbreaks have all seen innovation and change that will be explored at IMED 2016.

The deadline for abstract submission will be July 1, 2016.

Target Audience: Physicians, veterinarians and other health care workers and scientists, public health leaders, pharmaceutical and biotechnology industry, journalists, other interested persons including the entire ProMED-mail community.

Planned Session Topics Include:

- Disease Surveillance, Detection, Reporting and Outbreak Modeling
- Ethics of New Methodologies of Disease Surveillance
- Vectorborne and Zoonotic Diseases
- Foodborne and Waterborne Infections
- Infections Related to Travel and Migration of Humans and Animals
- Animal Reservoirs for Emerging Pathogens
- Agents of Bioterrorism/Biological Warfare
- Laboratory Biosafety and Emerging Pathogen Research
- Specific Disease Threats: Pandemic Influenza, Anthrax, *C. difficile*, Q fever, Rift Valley Fever, MERS, West Nile Virus, Zika Virus, Hemorrhagic Fevers, Bluetongue, Chikungunya, TSEs, Healthcare Associated Infections, and Others.
- Antimicrobial Resistance
- Vaccines and Diagnostics for Emerging Diseases
- Submitted Abstracts (Oral and Poster)

International Meeting on Emerging Diseases and Surveillance **Vienna, Austria • November 4–7, 2016**

Meeting Venue: Hilton Hotel, Vienna • Email: info@isid.org • Web site: <http://imed.isid.org>



For further information contact:

International Society for Infectious Diseases

9 Babcock Street, Unit 3 • Brookline, MA 02446 USA • Phone: (617) 277-0551
Fax: (617) 278-9113 • E-mail: info@isid.org • Website: <http://www.isid.org>